

OM protein - protein search, using sw model

Run on: April 8, 2004, 15:30:06 ; Search time 43.3077 Seconds
(without alignments)
71.766 Million cell updates/sec

Title: US-09-787-443A-4
Perfect score: 11
Sequence: 1 AGSAVKLKKKA 11

Scoring table: OLIGO
Gapop 60.0 , Gapext 60.0

Searched: 1586107 seqs, 282547505 residues

Word size : 0

Total number of hits satisfying chosen parameters: 22883

Minimum DB seq length: 11
Maximum DB seq length: 11

Post-processing: Listing first 100 summaries

Database : A_Geneseq_29Jan04:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query		DB	ID	Description
		Match	Length			
1	11	100.0	11	3	AAY88532	Aay88532 NCAM Ig1
2	11	100.0	11	5	ABG69332	Abg69332 Human neu
3	4	36.4	11	1	AAP40439	Aap40439 Sequence
4	4	36.4	11	2	AAR21404	Aar21404 Sequence
5	4	36.4	11	2	AAR35381	Aar35381 Amphiphil
6	4	36.4	11	2	AAR35380	Aar35380 Amphiphil
7	4	36.4	11	2	AAR35364	Aar35364 Amphiphil
8	4	36.4	11	2	AAR36371	Aar36371 Amphiphil
9	4	36.4	11	2	AAR39074	Aar39074 Biologica

10	4	36.4	11	2	AAR33956	Aar33956	Amphiphil
11	4	36.4	11	2	AAR33972	Aar33972	Amphiphil
12	4	36.4	11	2	AAR33973	Aar33973	Amphiphil
13	4	36.4	11	2	AAR31146	Aar31146	C-termina
14	4	36.4	11	2	AAR31163	Aar31163	C-termina
15	4	36.4	11	2	AAR31162	Aar31162	C-termina
16	4	36.4	11	2	AAR45132	Aar45132	Amphiphil
17	4	36.4	11	2	AAR45115	Aar45115	Amphiphil
18	4	36.4	11	2	AAR45133	Aar45133	Amphiphil
19	4	36.4	11	2	AAR45131	Aar45131	Amphiphil
20	4	36.4	11	2	AAR50562	Aar50562	Amphiphil
21	4	36.4	11	2	AAR50546	Aar50546	Amphiphil
22	4	36.4	11	2	AAR50563	Aar50563	Amphiphil
23	4	36.4	11	2	AAR55986	Aar55986	Ion chann
24	4	36.4	11	2	AAR55970	Aar55970	Ion chann
25	4	36.4	11	2	AAR55987	Aar55987	Ion chann
26	4	36.4	11	2	AAR59065	Aar59065	Cancer tr
27	4	36.4	11	2	AAR59048	Aar59048	Cancer tr
28	4	36.4	11	2	AAR59064	Aar59064	Cancer tr
29	4	36.4	11	2	AAR56948	Aar56948	Peptide w
30	4	36.4	11	2	AAR56931	Aar56931	Peptide w
31	4	36.4	11	2	AAR56947	Aar56947	Peptide w
32	4	36.4	11	2	AAR50431	Aar50431	Amphiphil
33	4	36.4	11	2	AAR50448	Aar50448	Amphiphil
34	4	36.4	11	2	AAR50447	Aar50447	Amphiphil
35	4	36.4	11	2	AAR79718	Aar79718	Optimal p
36	4	36.4	11	2	AAW03066	Aaw03066	Polycatio
37	4	36.4	11	2	AAR90267	Aar90267	Ion-chann
38	4	36.4	11	2	AAR90259	Aar90259	Ion-chann
39	4	36.4	11	2	AAR91792	Aar91792	Ion-chann
40	4	36.4	11	2	AAR90260	Aar90260	Ion-chann
41	4	36.4	11	2	AAR91797	Aar91797	Ion-chann
42	4	36.4	11	2	AAR90137	Aar90137	Ion-chann
43	4	36.4	11	2	AAR90266	Aar90266	Ion-chann
44	4	36.4	11	2	AAR90258	Aar90258	Ion-chann
45	4	36.4	11	2	AAR90269	Aar90269	Ion-chann
46	4	36.4	11	2	AAR99096	Aar99096	Magainin-
47	4	36.4	11	2	AAR99123	Aar99123	Magainin-
48	4	36.4	11	2	AAW04041	Aaw04041	Antifunga
49	4	36.4	11	2	AAW39163	Aaw39163	RHAMM bin
50	4	36.4	11	2	AAW44580	Aaw44580	Anti-fung
51	4	36.4	11	2	AAW43762	Aaw43762	Bacterici
52	4	36.4	11	2	AAW65554	Aaw65554	Multiply
53	4	36.4	11	2	AAW66522	Aaw66522	Amphiphil
54	4	36.4	11	2	AAW66523	Aaw66523	Amphiphil
55	4	36.4	11	2	AAW66297	Aaw66297	Amphiphil
56	4	36.4	11	2	AAW66482	Aaw66482	Amphiphil
57	4	36.4	11	2	AAW75190	Aaw75190	Fragment
58	4	36.4	11	2	AAY00557	Aay00557	Antifunga
59	4	36.4	11	2	AAY10749	Aay10749	Peptide u
60	4	36.4	11	2	AAY10769	Aay10769	Peptide u
61	4	36.4	11	2	AAY10785	Aay10785	Peptide u
62	4	36.4	11	2	AAY10780	Aay10780	Peptide u
63	4	36.4	11	2	AAY10750	Aay10750	Peptide u
64	4	36.4	11	2	AAY10766	Aay10766	Peptide u
65	4	36.4	11	2	AAY10733	Aay10733	Peptide u
66	4	36.4	11	2	AAY10751	Aay10751	Peptide u

67	4	36.4	11	2	AA10767	Aa10767	Peptide u
68	4	36.4	11	3	AAB26808	Aab26808	Phosphory
69	4	36.4	11	3	AA88559	Aa88559	NCAM Igl
70	4	36.4	11	3	AA67919	Aa67919	Cyclin co
71	4	36.4	11	3	AA95530	Aa95530	Transacti
72	4	36.4	11	4	AAB65481	Aab65481	Anti-fung
73	4	36.4	11	4	AAU00690	Aau00690	Thymosin
74	4	36.4	11	4	ABP19373	Abp19373	HIV B62 s
75	4	36.4	11	4	ABP13804	Abp13804	HIV A02 s
76	4	36.4	11	4	ABP18275	Abp18275	HIV B58 s
77	4	36.4	11	4	ABP13794	Abp13794	HIV A02 s
78	4	36.4	11	4	ABP13805	Abp13805	HIV A02 s
79	4	36.4	11	4	ABU54031	Abu54031	Human DNA
80	4	36.4	11	5	ABB74780	Abb74780	Nuclear p
81	4	36.4	11	5	ABB74670	Abb74670	Transcrip
82	4	36.4	11	5	ABB74833	Abb74833	Nuclear p
83	4	36.4	11	5	ABB74482	Abb74482	DNA repai
84	4	36.4	11	5	AAU97241	Aau97241	Peptide e
85	4	36.4	11	5	AAE23798	Aae23798	Thymosin-
86	4	36.4	11	5	AAU75185	Aau75185	Amino aci
87	4	36.4	11	5	ABG60826	Abg60826	Hyalauron
88	4	36.4	11	5	AAE24225	Aae24225	Human HIF
89	4	36.4	11	5	ABP55000	Abp55000	Cyclin de
90	4	36.4	11	5	AAE22462	Aae22462	Biologica
91	4	36.4	11	5	AAE22446	Aae22446	Biologica
92	4	36.4	11	5	AAE22464	Aae22464	Biologica
93	4	36.4	11	5	AAE22482	Aae22482	Biologica
94	4	36.4	11	5	AAE22498	Aae22498	Biologica
95	4	36.4	11	5	AAE22480	Aae22480	Biologica
96	4	36.4	11	5	AAE22463	Aae22463	Biologica
97	4	36.4	11	5	AAE22479	Aae22479	Biologica
98	4	36.4	11	5	AAE22493	Aae22493	Biologica
99	4	36.4	11	6	AAE34316	Aae34316	Human ops
100	4	36.4	11	6	ABB99794	Abb99794	Peptide u

ALIGNMENTS

RESULT 1

AA88532

ID AA88532 standard; peptide; 11 AA.

XX

AC AA88532;

XX

DT 07-AUG-2000 (first entry)

XX

DE NCAM Igl binding peptide #4.

XX

KW NCAM; neural cell adhesion molecule; Igl; immunoglobulin domain 1;

KW neurite outgrowth promoter; proliferation; nerve damage; sclerosis;

KW impaired myelination; stroke; Parkinson's disease; memory; schizophrenia;

KW Alzheimer's disease; diabetes mellitus; circadian clock; nephrosis;

KW treatment; prosthetic nerve guide; treatment; nervous system.

XX

OS Synthetic.

XX

PN WO200018801-A2.
XX
PD 06-APR-2000.
XX
PF 23-SEP-1999; 99WO-DK0000500.
XX
PR 29-SEP-1998; 98DK-00001232.
PR 29-APR-1999; 99DK-00000592.
XX
PA (RONN/) RONN L C B.
PA (BOCK/) BOCK E.
PA (HOLM/) HOLM A.
PA (OLSE/) OLSEN M.
PA (OSTE/) OSTERGAARD S.
PA (JENS/) JENSEN P H.
PA (POUL/) POULSEN F M.
PA (SORO/) SOROKA V.
PA (RALE/) RALETS I.
PA (BERE/) BEREZIN V.
XX
PI Ronn LCB, Bock E, Holm A, Olsen M, Ostergaard S, Jensen PH;
PI Poulsen FM, Soroka V, Ralets I, Berezin V;
XX
DR WPI; 2000-293111/25.
XX
PT Compositions that bind neural cell adhesion molecules useful for treating
PT disorders of the nervous system and muscles e.g. Alzheimer's and
PT Parkinson's diseases.
XX
PS Example 4; Page 25; 119pp; English.
XX
CC Neural cell adhesion molecule (NCAM) is a cellular adhesion molecule.
CC NCAM is found in three forms, two of which are transmembrane forms, while
CC the third is attached via a lipid anchor to the cell membrane. All three
CC NCAM forms have an extracellular structure consisting five immunoglobulin
CC domains (Ig domains). The Ig domains are numbered 1 to 5 from the N-
CC terminal. The present sequence represents a peptide which binds to the
CC NCAM Ig1 domain. The peptide can be used in a compound which binds to
CC NCAM-Ig1/Ig2 domains, and is capable of stimulating or promoting neurite
CC outgrowth from NCAM presenting cells, and is also capable of promoting
CC the proliferation of NCAM presenting cells. The compound may be used in
CC the treatment of normal, degenerated or damaged NCAM presenting cells.
CC The compound may in particular be used to treat diseases of the central
CC and peripheral nervous systems such as post operative nerve damage,
CC traumatic nerve damage, impaired myelination of nerve fibres, conditions
CC resulting from a stroke, Parkinson's disease, Alzheimer's disease,
CC dementias, sclerosis, nerve degeneration associated with diabetes
CC mellitus, disorders affecting the circadian clock or neuro-muscular
CC transmission and schizophrenia. Conditions affecting the muscles may also
CC be treated with the compound, such as conditions associated with impaired
CC function of neuromuscular connections (e.g. genetic or traumatic shock or
CC traumatic atrophic muscle disorders). Conditions of the gonads, pancreas
CC (e.g. diabetes mellitus types I and II), kidney (e.g. nephrosis), heart,
CC liver and bowel may also be treated using the compound. The compound is
CC used in a prosthetic nerve guide, and also to stimulate the ability to
CC learn, and to stimulate the memory of a subject
XX

SQ Sequence 11 AA;

Query Match 100.0%; Score 11; DB 3; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.00017;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGSAVKLKKKA 11
| | | | | | | | | |
Db 1 AGSAVKLKKKA 11

RESULT 2

ABG69332

ID ABG69332 standard; peptide; 11 AA.

XX

AC ABG69332;

XX

DT 21-OCT-2002 (first entry)

XX

DE Human neural cell adhesion molecule (NCAM) peptide #4.

XX

KW Human; neural cell adhesion molecule; NCAM; heart muscle cell survival;

KW acute myocardial infarction; central nervous system disorder; stroke;

KW peripheral nervous system disorder; postoperative nerve damage;

KW traumatic nerve damage; spinal cord injury; nerve fibre; schizophrenia;

KW postischaemic damage; multiinfarct dementia; multiple sclerosis;

KW nerve degeneration; diabetes mellitus; neuro-muscular degeneration;

KW Alzheimer's disease; Parkinson's disease;

KW Huntington's disease. atrophic muscle disorder; gonad degeneration;

KW nephrosis.

XX

OS Homo sapiens.

XX

PN WO200247719-A2.

XX

PD 20-JUN-2002.

XX

PF 12-DEC-2001; 2001WO-DK000822.

XX

PR 12-DEC-2000; 2000DK-00001863.

XX

PA (ENKA-) ENKAM PHARM AS.

XX

PI Bock E, Berezin V, Kohler LB;

XX

DR WPI; 2002-583473/62.

XX

PT Use of a compound comprising a peptide of neural cell adhesion molecule,

PT in the preparation of medicament for preventing death of cells presenting

PT NCAM or NCAM ligand and treating central nervous system diseases.

XX

PS Disclosure; Page 15; 57pp; English.

XX

CC The invention relates to use of a compound (I) comprising a peptide which

CC comprises at least 5 contiguous amino acid residues of a sequence of the

CC neural cell adhesion molecule (NCAM), its fragment, variant or its mimic,

CC for the preparation of a medicament for preventing death of cells

CC presenting the NCAM or an NCAM ligand. (I) is useful in the preparation
 CC of a medicament for preventing death of cells presenting the NCAM or an
 CC NCAM ligand. The medicament is for the stimulation of the survival of
 CC heart muscle cells, such as survival after acute myocardial infarction.
 CC The medicament is for the treatment of diseases or conditions of the
 CC central and peripheral nervous system, such as postoperative nerve
 CC damage, traumatic nerve damage, e.g. resulting from spinal cord injury,
 CC impaired myelination of nerve fibres, postischaemic damage, e.g.
 CC resulting from a stroke, multiinfarct dementia, multiple sclerosis, nerve
 CC degeneration associated with diabetes mellitus, neuro-muscular
 CC degeneration, schizophrenia, Alzheimer's disease, Parkinson's disease and
 CC Huntington's disease. The medicament is for the treatment of diseases or
 CC conditions of the muscles including conditions with impaired function of
 CC neuro-muscular connections, such as genetic or traumatic atrophic muscle
 CC disorders, and for the treatment of diseases or conditions of various
 CC organs, such as degenerative conditions of the gonads, pancreas (e.g.
 CC diabetes mellitus type I and II) and kidney (e.g. nephrosis). ABG69329-
 CC ABG69352 represent human NCAM peptides of the invention
 XX
 SQ Sequence 11 AA;

Query Match 100.0%; Score 11; DB 5; Length 11;
 Best Local Similarity 100.0%; Pred. No. 0.00017;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGSAVKLKKKA 11
 |||||
 Db 1 AGSAVKLKKKA 11

RESULT 3

AAP40439

ID AAP40439 standard; peptide; 11 AA.

XX

AC AAP40439;

XX

DT 25-MAR-2003 (revised)

DT 03-OCT-2002 (revised)

DT 14-FEB-1992 (first entry)

XX

DE Sequence of peptide with immunomodulating activity.

XX

KW Immunopotentiator; antimicrobial; antiviral; immunomodulator.

XX

OS Synthetic.

XX

PN EP103858-A.

XX

PD 28-MAR-1984.

XX

PF 16-SEP-1983; 83EP-00109147.

XX

PR 17-SEP-1982; 82JP-00162873.

PR 25-NOV-1982; 82JP-00207335.

XX

PA (FUJI) FUJISAWA PHARM CO LTD.

XX

PI Hashimoto M, Hemmi K;
XX
DR WPI; 1984-083584/14.
XX
PT Penta- to tri-deca:peptide(s) - useful as strong immuno-potentiators esp.
PT against microbes and viruses.
XX
PS Claim 1; Page 82; 87pp; English.
XX
CC The first AA of each claimed peptide is bonded to H and the final AA is
CC bonded to OH. The peptides are useful as antimicrobial and antiviral
CC agents. Dose is 0.1-1000 mg/kg. daily. (Updated on 03-OCT-2002 to add
CC missing OS field.) (Updated on 25-MAR-2003 to correct PA field.)
XX
SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
| | | |
Db 3 KLKK 6

RESULT 4

AAR21404

ID AAR21404 standard; peptide; 11 AA.

XX

AC AAR21404;

XX

DT 25-MAR-2003 (revised)

DT 09-JAN-2003 (revised)

DT 16-MAY-1992 (first entry)

XX

DE Sequence of amphiphilic peptide SEQ ID No. 67 with C-terminal amide, may
DE be acetylated at N-terminus.

XX

KW Amphiphilic peptide; anti-microbial; anti-viral; anti-tumour; spermicide;
KW wound healing; sterilant.

XX

OS Synthetic.

XX

PN W09201462-A.

XX

PD 06-FEB-1992.

XX

PF 19-JUL-1990; 90US-00554422.

XX

PR 19-JUL-1990; 90US-00554422.

PR 08-JUL-1991; 91US-00725331.

XX

PA (SCRI) SCRIPPS RES INST.

XX

PI Houghten RA, Blondelle S;

XX

DR WPI; 1992-064700/08.

XX
PT Method for inhibiting target cell and virus growth - comprises
PT administering amphiphilic peptide compsns, useful for treating viral and
PT phytopathogenic infections, tumours and burns.
XX
PS Disclosure; Page 63; 72pp; English.
XX
CC The peptides of the invention are effective pharmaceuticals having anti-
CC microbial, anti-viral and anti-tumour activity. They are also useful for
CC inhibiting, preventing or destroying the motility of sperm and hence have
CC application in a spermicide preparation. They also have anti-parasitic
CC activity and are useful in wound healing, as preservatives and sterilants
CC and to inhibit growth of phytopathogenic microorganisms. AAR20969 and
CC AAR20970 were published in Houghton and Ostresh, Bio Chromatography, Vol
CC 2, issue 2, page 80-83, 1987. (Updated on 09-JAN-2003 to add missing OS
CC field.) (Updated on 25-MAR-2003 to correct PR field.) (Updated on 25-MAR-
CC 2003 to correct PA field.)
XX
SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
| | | |
Db 3 KLKK 6

RESULT 5
AAR35381

ID AAR35381 standard; peptide; 11 AA.
XX
AC AAR35381;
XX
DT 25-MAR-2003 (revised)
DT 07-JUN-1993 (first entry)
XX
DE Amphiphilic peptide #112 used to treat oral infections.
XX
KW Adverse oral conditions; amphipathic; anti-bacterial; anti-viral;
KW anti-fungal; dental plaque; dental caries; periodontal disease;
KW gingivitis; ionophore; ion-channel forming.
XX
OS Synthetic.
XX
PN WO9301723-A1.
XX
PD 04-FEB-1993.
XX
PF 09-JUL-1992; 92WO-US005757.
XX
PR 25-JUL-1991; 91US-00735070.
XX
PA (MAGA-) MAGAININ PHARM INC.
XX
PI Berkowitz B, Jacob L;

XX
 DR WPI; 1993-058434/07.
 XX
 PT Peptide(s) for prophylaxis and treatment of oral disorders - used for
 PT periodontal disease, plaque, dental caries, gingivitis, etc.
 XX
 PS Claim 2; Page 129; 143pp; English.
 XX
 CC This is a specific example of a highly generic formula covering preferred
 CC amphiphilic peptides for use in preventing or treating adverse oral
 CC conditions. The peptide is an ionophore (i.e. an ion- channel forming
 CC peptide) which has anti-bacterial, anti-viral, anti- fungal activity,
 CC etc. making it suitable for use in oral compositions to treat or prevent
 CC periodontal disease, plaque, dental caries, halitosis and gingivitis. The
 CC anti-bacterial action will also be useful against bacteria associated
 CC with dental implant infections and the peptides can stimulate the healing
 CC of wounds in the oral cavity. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 7 KLKK 10

RESULT 6

AAR35380

ID AAR35380 standard; peptide; 11 AA.

XX

AC AAR35380;

XX

DT 25-MAR-2003 (revised)

DT 07-JUN-1993 (first entry)

XX

DE Amphiphilic peptide #111 used to treat oral infections.

XX

KW Adverse oral conditions; amphipathic; anti-bacterial; anti-viral;

KW anti-fungal; dental plaque; dental caries; periodontal disease;

KW gingivitis; ionophore; ion-channel forming.

XX

OS Synthetic.

XX

PN WO9301723-A1.

XX

PD 04-FEB-1993.

XX

PF 09-JUL-1992; 92WO-US005757.

XX

PR 25-JUL-1991; 91US-00735070.

XX

PA (MAGA-) MAGAININ PHARM INC.

XX

PI Berkowitz B, Jacob L;
 XX
 DR WPI; 1993-058434/07.
 XX
 PT Peptide(s) for prophylaxis and treatment of oral disorders - used for
 PT periodontal disease, plaque, dental caries, gingivitis, etc.
 XX
 PS Claim 2; Page 128; 143pp; English.
 XX
 CC This is a specific example of a highly generic formula covering preferred
 CC amphiphilic peptides for use in preventing or treating adverse oral
 CC conditions. The peptide is an ionophore (i.e. an ion- channel forming
 CC peptide) which has anti-bacterial, anti-viral, anti- fungal activity,
 CC etc. making it suitable for use in oral compositions to treat or prevent
 CC periodontal disease, plaque, dental caries, halitosis and gingivitis. The
 CC anti-bacterial action will also be useful against bacteria associated
 CC with dental implant infections and the peptides can stimulate the healing
 CC of wounds in the oral cavity. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 KLKK 9
 ||||
 Db 7 KLKK 10

RESULT 7

AAR35364

ID AAR35364 standard; peptide; 11 AA.

XX

AC AAR35364;

XX

DT 25-MAR-2003 (revised)

DT 07-JUN-1993 (first entry)

XX

DE Amphiphilic peptide #95 used to treat oral infections.

XX

KW Adverse oral conditions; amphipathic; anti-bacterial; anti-viral;

KW anti-fungal; dental plaque; dental caries; periodontal disease;

KW gingivitis; ionophore; ion-channel forming.

XX

OS Synthetic.

XX

PN WO9301723-A1.

XX

PD 04-FEB-1993.

XX

PF 09-JUL-1992; 92WO-US005757.

XX

PR 25-JUL-1991; 91US-00735070.

XX

PA (MAGA-) MAGAININ PHARM INC.

XX
 PI Berkowitz B, Jacob L;
 XX
 DR WPI; 1993-058434/07.
 XX
 PT Peptide(s) for prophylaxis and treatment of oral disorders - used for
 PT periodontal disease, plaque, dental caries, gingivitis, etc.
 XX
 PS Claim 2; Page 122; 143pp; English.
 XX
 CC This is a specific example of a highly generic formula covering preferred
 CC amphiphilic peptides for use in preventing or treating adverse oral
 CC conditions. The peptide is an ionophore (i.e. an ion- channel forming
 CC peptide) which has anti-bacterial, anti-viral, anti- fungal activity,
 CC etc. making it suitable for use in oral compositions to treat or prevent
 CC periodontal disease, plaque, dental caries, halitosis and gingivitis. The
 CC anti-bacterial action will also be useful against bacteria associated
 CC with dental implant infections and the peptides can stimulate the healing
 CC of wounds in the oral cavity. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 3 KLKK 6

RESULT 8

AAR36371

ID AAR36371 standard; peptide; 11 AA.

XX

AC AAR36371;

XX

DT 25-MAR-2003 (revised)

DT 24-AUG-1993 (first entry)

XX

DE Amphiphilic ion channel forming peptide.

XX

KW Growth; inhibition; antibiotic; fungi; magainin; XPF; PGLa; CPF;

KW tetracycline; pseudomonic acid; neomycin.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 1

FT /note= "may be acylated"

FT Modified-site 11

FT /note= "may be amidated"

XX

PN WO9307892-A1.

XX

PD 29-APR-1993.

XX
 PF 16-OCT-1992; 92WO-US008823.
 XX
 PR 16-OCT-1991; 91US-00778771.
 XX
 PA (CHIL-) CHILDRENS HOSPITAL PHILADELPHIA.
 XX
 PI Zasloff M, Berkowitz B;
 XX
 DR WPI; 1993-152183/18.
 XX
 PT Inhibiting growth of bacteria - by co-administration of antibiotic and
 PT ion channel-forming peptide, e.g. magainin.
 XX
 PS Disclosure; Page 113; 125pp; English.
 XX
 CC The sequence is that of a basic polypeptide of at least 8 hydrophobic
 CC amino acids and at least 8 hydrophilic amino acids. The peptide is
 CC amphiphilic, positively charged and ion channel-forming and may be used
 CC in a compsn. with an antibiotic which is not an ion channel forming
 CC peptide, to inhibit the growth of target cells. The peptide is pref. a
 CC magainin peptide, XPF, PGLa or CPF peptide. The peptide and antibiotic
 CC potentiate each other, i.e. interaction of the peptide with the membranes
 CC of bacterial cells facilitates penetration of the cells by the
 CC antibiotic. The compsn. thus requires less antibiotic and may have
 CC extended range cf. the antibiotic alone. Apart from therapeutic use the
 CC compsns. can be used as preservatives or sterilants. See also AAR36281-
 CC 380. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 3 KLKK 6

RESULT 9

AAR39074

ID AAR39074 standard; peptide; 11 AA.

XX

AC AAR39074;

XX

DT 25-MAR-2003 (revised)

DT 08-NOV-1993 (first entry)

XX

DE Biologically active amphiphilic peptide.

XX

KW Synergistic antimicrobial composition; compsn; chelating agent;

KW combination; preservative; sterilant; animal; plant; infection; control;

KW treatment; prevention; external burns; eye infections.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers
 FT Modified-site 1
 FT /note= "N-terminal may be acetylated"
 FT Modified-site 11
 FT /note= "C-terminal may be amidated"
 XX
 PN WO9311783-A1.
 XX
 PD 24-JUN-1993.
 XX
 PF 03-DEC-1992; 92WO-US010427.
 XX
 PR 09-DEC-1991; 91US-00803629.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Berkowitz B;
 XX
 DR WPI; 1993-213816/26.
 XX
 PT Synergistic antimicrobial compsn. for treating or preventing infection of
 PT burns - contg. amphiphilic peptide or protein e.g. magainin peptide and
 PT chelating agent.
 XX
 PS Example; Page 109; 122pp; English.
 XX
 CC The sequence is that of a biologically active amphiphilic peptide which
 CC is used in a synergistic antimicrobial compsn. with a chelating agent.
 CC The chelating agent potentiates the activity of the peptide by binding
 CC inhibitory Ca/Mg ions and may also increase permeability of the target
 CC cells to the peptide. The compsn. is active against a wide range of
 CC microorganisms (esp. bacteria) and can be used as a preservative or
 CC sterilant, or to control infections in animals or plants. Particular
 CC applications. are to treat/prevent infections of external burns and
 CC treatment of eye infections e.g. where the pathogen is Pseudomonas
 CC aeruginosa, Staphylococcus aureus, Streptococcus or Neisseria
 CC gonorrhoeae. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 3 KLKK 6

RESULT 10
 AAR33956
 ID AAR33956 standard; peptide; 11 AA.
 XX
 AC AAR33956;
 XX
 DT 25-MAR-2003 (revised)
 DT 21-JUL-1993 (first entry)

XX
DE Amphiphilic peptide X10. #1.
XX
KW Hydrophobic; hydrophilic; neutral; X10; ionophore; channel-forming;
KW human; virus; antimicrobial; antiviral; antibacterial; antitumour;
KW antiparasitic; spermicide; preservative; sterilant; disinfectant;
KW wound healing; burn; infection; eye; cysts; spores; trophozoites; plants;
KW contamination.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 1
FT /note= "May be acetylated"
FT Modified-site 11
FT /note= "May be amidated"
XX
PN WO9305802-A1.
XX
PD 01-APR-1993.
XX
PF 04-SEP-1992; 92WO-US007622.
XX
PR 13-SEP-1991; 91US-00760054.
PR 20-APR-1992; 92US-00870960.
XX
PA (MAGA-) MAGAININ PHARM INC.
XX
PI Maloy WL, Kari UP, Williams JI;
XX
DR WPI; 1993-117245/14.
XX
PT New biologically active amphiphilic peptide cpds. - having ion channel-
PT forming properties used for inhibiting growth of target cells, virus or
PT viral-infected cells.
XX
PS Claim 1; Page 23; 46pp; English.
XX
CC The sequences given in AAR33956-59 are examples of biologically active
CC peptides which correspond to the generic sequence; R1-R2-R2-R1-R2-R2-R1-
CC R1-R2-R1-R1 where R1 = a hydrophobic amino acid; and R2 = a basic
CC hydrophilic or neutral hydrophilic amino acid. This basic structure was
CC designated X10. These peptides are ionophores ie. they have channel-
CC forming properties. The peptides can be administered to a host, eg,
CC humans, to inhibit the growth of a target cell, virus or virally infected
CC cell. They can be used as antimicrobial, antiviral agents, antibacterial
CC agents, antitumour agents, antiparasitic agents, and as spermicides. They
CC can be used as preservatives or sterilants or disinfectants. These
CC peptides can also be used to promote or stimulate healing of wounds, to
CC treat and/or prevent prevent skin or burn infections, to prevent or treat
CC eye infections and to kill cysts, spores or trophozoites of infection
CC causing organisms. The peptides may also be administered to plants to
CC prevent or treat microbial, viral or parasitic contamination. (Updated on
CC 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
||||
Db 3 KLKK 6

RESULT 11

AAR33972

ID AAR33972 standard; peptide; 11 AA.

XX

AC AAR33972;

XX

DT 25-MAR-2003 (revised)

DT 21-JUL-1993 (first entry)

XX

DE Amphiphilic peptide (e).

XX

KW Hydrophobic; hydrophilic; neutral; (e); ionophore; channel-forming;

KW human; virus; antimicrobial; antiviral; antibacterial; antitumour;

KW antiparasitic; spermicide; preservative; sterilant; disinfectant;

KW wound healing; burn; infection; eye; cysts; spores; trophozoites; plants;

KW contamination.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 1

FT /note= "May be acetylated"

FT Modified-site 11

FT /note= "May be amidated"

XX

PN WO9305802-A1.

XX

PD 01-APR-1993.

XX

PF 04-SEP-1992; 92WO-US007622.

XX

PR 13-SEP-1991; 91US-00760054.

PR 20-APR-1992; 92US-00870960.

XX

PA (MAGA-) MAGAININ PHARM INC.

XX

PI Maloy WL, Kari UP, Williams JT;

XX

DR WPI; 1993-117245/14.

XX

PT New biologically active amphiphilic peptide cpds. - having ion channel-

PT forming properties used for inhibiting growth of target cells, virus or

PT viral-infected cells.

XX

PS Claim 27; Page 33; 46pp; English.

XX

CC This sequence is an example of a biologically active peptide which

CC corresponds to the generic sequence; R1-R2-R2-R1-R1-R2-R2-R1-R2-R2-R1

CC where R1 = a hydrophobic amino acid; and R2 = a basic hydrophilic or
 CC neutral hydrophilic amino acid. This basic structure was designated (e).
 CC Peptides such as this are ionophores ie. they have channel-forming
 CC properties. The peptides can be administered to a host, eg, humans, to
 CC inhibit the growth of a target cell, virus or virally infected cell. They
 CC can be used as antimicrobial, antiviral agents, antibacterial agents,
 CC antitumour agents, antiparasitic agents, and as spermicides. They can be
 CC used as preservatives or sterilants or disinfectants. These peptides can
 CC also be used to promote or stimulate healing of wounds, to treat and/or
 CC prevent prevent skin or burn infections, to prevent or treat eye
 CC infections and to kill cysts, spores or trophozoites of infection causing
 CC organisms. The peptides may also be administered to plants to prevent or
 CC treat microbial, viral or parasitic contamination. (Updated on 25-MAR-
 CC 2003 to correct PN field.)

XX

SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 7 KLKK 10

RESULT 12

AAR33973

ID AAR33973 standard; peptide; 11 AA.

XX

AC AAR33973;

XX

DT 25-MAR-2003 (revised)

DT 21-JUL-1993 (first entry)

XX

DE Amphiphilic peptide (e), #2.

XX

KW Hydrophobic; hydrophilic; neutral; (e); ionophore; channel-forming;

KW human; virus; antimicrobial; antiviral; antibacterial; antitumour;

KW antiparasitic; spermicide; preservative; sterilant; disinfectant;

KW wound healing; burn; infection; eye; cysts; spores; trophozoites; plants;
 KW contamination.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 1

FT /note= "May be acetylated"

FT Modified-site 11

FT /note= "May be amidated"

XX

PN WO9305802-A1.

XX

PD 01-APR-1993.

XX

PF 04-SEP-1992; 92WO-US007622.

XX

PR 13-SEP-1991; 91US-00760054.
PR 20-APR-1992; 92US-00870960.

XX

PA (MAGA-) MAGAININ PHARM INC.

XX

PI Maloy WL, Kari UP, Williams JI;

XX

DR WPI; 1993-117245/14.

XX

PT New biologically active amphiphilic peptide cpds. - having ion channel-
PT forming properties used for inhibiting growth of target cells, virus or
PT viral-infected cells.

XX

PS Claim 27; Page 33; 46pp; English.

XX

CC This sequence is an example of a biologically active peptide which
CC corresponds to the generic sequence; R1-R2-R2-R1-R1-R2-R2-R1-R2-R1
CC where R1 = a hydrophobic amino acid; and R2 = a basic hydrophilic or
CC neutral hydrophilic amino acid. This basic structure was designated (e).
CC Peptides such as this are ionophores ie. they have channel-forming
CC properties. The peptides can be administered to a host, eg, humans, to
CC inhibit the growth of a target cell, virus or virally infected cell. They
CC can be used as antimicrobial, antiviral agents, antibacterial agents,
CC antitumour agents, antiparasitic agents, and as spermicides. They can be
CC used as preservatives or sterilants or disinfectants. These peptides can
CC also be used to promote or stimulate healing of wounds, to treat and/or
CC prevent prevent skin or burn infections, to prevent or treat eye
CC infections and to kill cysts, spores or trophozoites of infection causing
CC organisms. The peptides may also be administered to plants to prevent or
CC treat microbial, viral or parasitic contamination. (Updated on 25-MAR-
CC 2003 to correct PN field.)

XX

SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 KLKK 9

||||

Db 7 KLKK 10

RESULT 13

AAR31146

ID AAR31146 standard; peptide; 11 AA.

XX

AC AAR31146;

XX

DT 25-MAR-2003 (revised)

DT 10-MAY-1993 (first entry)

XX

DE C-terminal substd. amphiphilic peptide #95.

XX

KW ion-channel forming; ionophore; antibiotic; anti-tumour; anti-virus;
KW wound healing.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 11

FT /note= "Leu-(C=O)-T, T= O-R, NH-NH2, NH-OH or NR'R''; R=

FT opt.substd. 1-10C aliphatic, aromatic or aralkyl gp.; R',

FT R''= H or from one of gps. i and ii; gp.i= 1-10C hydroxy-

FT substd. aliphatic, aromatic or aralkyl gp.; gp.ii= amino-

FT substd. aliphatic, aromatic, aralkyl or alkylaromatic gp.

FT and at least one of R' and R'' = gp.i or gp.ii''"

XX

PN WO9222317-A1.

XX

PD 23-DEC-1992.

XX

PF 01-JUN-1992; 92WO-US004603.

XX

PR 12-JUN-1991; 91US-00713716.

XX

PA (MAGA-) MAGAININ PHARM INC.

XX

PI Maloy WL, Kari UP;

XX

DR WPI; 1993-017904/02.

XX

PT New C-terminal-substd. amphiphilic peptide(s) - for treating bacterial,

PT viral or fungal infections and tumours, also useful as spermicide.

XX

PS Claim 15; Page 107; 124pp; English.

XX

CC This peptide is a preferred example of a highly generic amphiphilic

CC peptide with a C-terminal modification which increases the peptide's

CC biological activity c.f. the unmodified peptide. The preferred C-terminal

CC modification is -(CO)-NHCH2CH2OH or -(CO)-NHCH2CH2NH2. Such substd.

CC peptides may be used for inhibiting the growth of a target cell, virus or

CC virally-infected cell in a host. The peptides have a broad range of

CC potent antibiotic activity, e.g. against gram- negative and gram-positive

CC bacteria, fungi, protozoa and parasites. The peptides can also be used to

CC promote wound healing and treatment of burns. Other preferred amphiphilic

CC peptides include magainins and their analogues, PGLa, XPF, CPF, a

CC cecropin and a sarcotoxin. (Updated on 25-MAR-2003 to correct PN field.)

XX

SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.6e+03;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9

||||

Db 3 KLKK 6

RESULT 14

AAR31163

ID AAR31163 standard; peptide; 11 AA.

XX

AC AAR31163;
 XX
 DT 25-MAR-2003 (revised)
 DT 10-MAY-1993 (first entry)
 XX
 DE C-terminal substd. amphiphilic peptide #112.
 XX
 KW ion-channel forming; ionophore; antibiotic; anti-tumour; anti-virus;
 KW wound healing.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 11
 FT /note= "Leu-(C=O)-T, T= O-R, NH-NH2, NH-OH or NR'R''; R=
 FT opt.substd. 1-10C aliphatic, aromatic or aralkyl gp.; R',
 FT R''= H or from one of gps. i and ii; gp.i= 1-10C hydroxy-
 FT substd. aliphatic, aromatic or aralkyl gp.; gp.ii= amino-
 FT substd. aliphatic, aromatic, aralkyl or alkylaromatic gp.
 FT and at least one of R' and R'' = gp.i or gp.ii'"
 XX
 PN W09222317-A1.
 XX
 PD 23-DEC-1992.
 XX
 PF 01-JUN-1992; 92WO-US004603.
 XX
 PR 12-JUN-1991; 91US-00713716.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Maloy WL, Kari UP;
 XX
 DR WPI; 1993-017904/02.
 XX
 PT New C-terminal-substd. amphiphilic peptide(s) - for treating bacterial,
 PT viral or fungal infections and tumours, also useful as spermicide.
 XX
 PS Claim 21; Page 114; 124pp; English.
 XX
 CC This peptide is a preferred example of a highly generic amphiphilic
 CC peptide with a C-terminal modification which increases the peptide's
 CC biological activity c.f. the unmodified peptide. The preferred C-terminal
 CC modification is -(CO)-NHCH2CH2OH or -(CO)-NHCH2CH2NH2. Such substd.
 CC peptides may be used for inhibiting the growth of a target cell, virus or
 CC virally-infected cell in a host. The peptides have a broad range of
 CC potent antibiotic activity, e.g. against gram- negative and gram-positive
 CC bacteria, fungi, protozoa and parasites. The peptides can also be used to
 CC promote wound healing and treatment of burns. Other preferred amphiphilic
 CC peptides include magainins and their analogues, PGLa, XPF, CPF, a
 CC cecropin and a sarcotoxin. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 KLKK 9
| | | |
Db 7 KLKK 10

RESULT 15

AAR31162

ID AAR31162 standard; peptide; 11 AA.

XX

AC AAR31162;

XX

DT 25-MAR-2003 (revised)

DT 10-MAY-1993 (first entry)

XX

DE C-terminal substd. amphiphilic peptide #111.

XX

KW ion-channel forming; ionophore; antibiotic; anti-tumour; anti-virus;
KW wound healing.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 11

FT /note= "Leu-(C=O)-T, T= O-R, NH-NH2, NH-OH or NR'R''; R=
FT opt.substd. 1-10C aliphatic, aromatic or aralkyl gp.; R',
FT R''= H or from one of gps. i and ii; gp.i= 1-10C hydroxy-
FT substd. aliphatic, aromatic or aralkyl gp.; gp.ii= amino-
FT substd. aliphatic, aromatic, aralkyl or alkylaromatic gp.
FT and at least one of R' and R'' = gp.i or gp.ii''"

XX

PN WO9222317-A1.

XX

PD 23-DEC-1992.

XX

PF 01-JUN-1992; 92WO-US004603.

XX

PR 12-JUN-1991; 91US-00713716.

XX

PA (MAGA-) MAGAININ PHARM INC.

XX

PI Maloy WL, Kari UP;

XX

DR WPI; 1993-017904/02.

XX

PT New C-terminal-substd. amphiphilic peptide(s) - for treating bacterial,
PT viral or fungal infections and tumours, also useful as spermicide.

XX

PS Claim 21; Page 114; 124pp; English.

XX

CC This peptide is a preferred example of a highly generic amphiphilic
CC peptide with a C-terminal modification which increases the peptide's
CC biological activity c.f. the unmodified peptide. The preferred C-terminal
CC modification is -(CO)-NHCH2CH2OH or -(CO)-NHCH2CH2NH2. Such substd.
CC peptides may be used for inhibiting the growth of a target cell, virus or
CC virally-infected cell in a host. The peptides have a broad range of
CC potent antibiotic activity, e.g. against gram- negative and gram-positive

CC bacteria, fungi, protozoa and parasites. The peptides can also be used to
CC promote wound healing and treatment of burns. Other preferred amphiphilic
CC peptides include magainins and their analogues, PGLa, XPF, CPF, a
CC cecropin and a sarcotoxin. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
||||
Db 7 KLKK 10

RESULT 16

AAR45132

ID AAR45132 standard; peptide; 11 AA.

XX

AC AAR45132;

XX

DT 25-MAR-2003 (revised)

DT 28-JUN-1994 (first entry)

XX

DE Amphiphilic peptide for N-terminal lipophilic substitution.

XX

KW Ion channel; magainin; PGLa; XPF; CPF; cecropin; sarcotoxin; amphiphilic;

KW hydrophobic; hydrophilic; lipophilic; growth; inhibition; target cell;

KW virus; virally-infected cell; antimicrobial; antiviral; antitumour;

KW antiparasitic; spermicide; wound healing; burn; infection.

XX

OS Synthetic.

XX

PN WO9324138-A1.

XX

PD 09-DEC-1993.

XX

PF 27-MAY-1993; 93WO-US005192.

XX

PR 01-JUN-1992; 92US-00891201.

XX

PA (MAGA-) MAGAININ PHARM INC.

XX

PI Kari U;

XX

DR WPI; 1993-405419/50.

XX

PT Peptide(s) or proteins with an N-terminal lipophilic substit. - used for
PT inhibiting growth of target cell, virus or virally-infected cell.

XX

PS Disclosure; Page 97-103; 113pp; English.

XX

CC A novel compsn. for inhibiting growth of a target cell, virus or virally-
CC infected cell comprises a peptide of formula T-N(W)-X (I). X is a
CC biologically active amphiphilic ion channel-forming peptide or protein;
CC pref. a magainin peptide, a PGLa peptide, a XPF peptide, a CPF peptide, a

CC cecropin or a sarcotoxin. N is the nitrogen of the N-terminal amino
 CC group. T is a lipophilic moiety; pref. R-CO, where R is a 2-16C
 CC hydrocarbon (alkyl or aromatic or alkylaromatic). T is pref. an octanoyl
 CC group. W is T or hydrogen. Amphiphilic peptides as examples of X are
 CC given in AAR45115-138. The N-terminal substd. peptides and proteins have
 CC increased biological activity as compared with unsubstd. peptides or
 CC proteins or peptides substd. at the N-terminal with an acetyl gp. They
 CC can be used as antimicrobial agents, antiviral agents, antitumour agents,
 CC antiparasitic agents or spermicides and can also exhibit other bioactive
 CC functions. They can also be used in promoting or stimulating wound
 CC healing, for the treatment of external burns and to treat and/or prevent
 CC skin and burn infections or eye infections. (Updated on 25-MAR-2003 to
 CC correct PN field.)

XX

SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 7 KLKK 10

RESULT 17

AAR45115

ID AAR45115 standard; peptide; 11 AA.

XX

AC AAR45115;

XX

DT 25-MAR-2003 (revised)

DT 28-JUN-1994 (first entry)

XX

DE Amphiphilic peptide for N-terminal lipophilic substitution.

XX

KW Ion channel; magainin; PGLa; XPF; CPF; cecropin; sarcotoxin; amphiphilic;
 KW hydrophobic; hydrophilic; lipophilic; growth; inhibition; target cell;
 KW virus; virally-infected cell; antimicrobial; antiviral; antitumour;
 KW antiparasitic; spermicide; wound healing; burn; infection.

XX

OS Synthetic.

XX

PN WO9324138-A1.

XX

PD 09-DEC-1993.

XX

PF 27-MAY-1993; 93WO-US005192.

XX

PR 01-JUN-1992; 92US-00891201.

XX

PA (MAGA-) MAGAININ PHARM INC.

XX

PI Kari U;

XX

DR WPI; 1993-405419/50.

XX

PT Peptide(s) or proteins with an N-terminal lipophilic substit. - used for
PT inhibiting growth of target cell, virus or virally-infected cell.
XX
PS Disclosure; Page 97-103; 113pp; English.
XX
CC A novel compsn. for inhibiting growth of a target cell, virus or virally-
CC infected cell comprises a peptide of formula T-N(W)-X (I). X is a
CC biologically active amphiphilic ion channel-forming peptide or protein;
CC pref. a magainin peptide, a PGLa peptide, a XPF peptide, a CPF peptide, a
CC cecropin or a sarcotoxin. N is the nitrogen of the N-terminal amino
CC group. T is a lipophilic moiety; pref. R-CO, where R is a 2-16C
CC hydrocarbon (alkyl or aromatic or alkylaromatic). T is pref. an octanoyl
CC group. W is T or hydrogen. Amphiphilic peptides as examples of X are
CC given in AAR45115-138. The N-terminal substd. peptides and proteins have
CC increased biological activity as compared with unsubstd. peptides or
CC proteins or peptides substd. at the N-terminal with an acetyl gp. They
CC can be used as antimicrobial agents, antiviral agents, antitumour agents,
CC antiparasitic agents or spermicides and can also exhibit other bioactive
CC functions. They can also be used in promoting or stimulating wound
CC healing, for the treatment of external burns and to treat and/or prevent
CC skin and burn infections or eye infections. (Updated on 25-MAR-2003 to
CC correct PN field.)
XX
SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
| | | |
Db 3 KLKK 6

RESULT 18

AAR45133

ID AAR45133 standard; peptide; 11 AA.

XX

AC AAR45133;

XX

DT 25-MAR-2003 (revised)

DT 28-JUN-1994 (first entry)

XX

DE Amphiphilic peptide for N-terminal lipophilic substitution.

XX

KW Ion channel; magainin; PGLa; XPF; CPF; cecropin; sarcotoxin; amphiphilic;
KW hydrophobic; hydrophilic; lipophilic; growth; inhibition; target cell;
KW virus; virally-infected cell; antimicrobial; antiviral; antitumour;
KW antiparasitic; spermicide; wound healing; burn; infection.

XX

OS Synthetic.

XX

PN WO9324138-A1.

XX

PD 09-DEC-1993.

XX

PF 27-MAY-1993; 93WO-US005192.

XX
 PR 01-JUN-1992; 92US-00891201.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Kari U;
 XX
 DR WPI; 1993-405419/50.
 XX
 PT Peptide(s) or proteins with an N-terminal lipophilic substit. - used for
 PT inhibiting growth of target cell, virus or virally-infected cell.
 XX
 PS Disclosure; Page 97-103; 113pp; English.
 XX
 CC A novel compsn. for inhibiting growth of a target cell, virus or virally-
 CC infected cell comprises a peptide of formula T-N(W)-X (I). X is a
 CC biologically active amphiphilic ion channel-forming peptide or protein;
 CC pref. a magainin peptide, a PGLa peptide, a XPF peptide, a CPF peptide, a
 CC cecropin or a sarcotoxin. N is the nitrogen of the N-terminal amino
 CC group. T is a lipophilic moiety; pref. R-CO, where R is a 2-16C
 CC hydrocarbon (alkyl or aromatic or alkylaromatic). T is pref. an octanoyl
 CC group. W is T or hydrogen. Amphiphilic peptides as examples of X are
 CC given in AAR45115-138. The N-terminal substd. peptides and proteins have
 CC increased biological activity as compared with unsubstd. peptides or
 CC proteins or peptides substd. at the N-terminal with an acetyl gp. They
 CC can be used as antimicrobial agents, antiviral agents, antitumour agents,
 CC antiparasitic agents or spermicides and can also exhibit other bioactive
 CC functions. They can also be used in promoting or stimulating wound
 CC healing, for the treatment of external burns and to treat and/or prevent
 CC skin and burn infections or eye infections. (Updated on 25-MAR-2003 to
 CC correct PN field.)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 3 KLKK 6

RESULT 19

AAR45131

ID AAR45131 standard; peptide; 11 AA.

XX

AC AAR45131;

XX

DT 25-MAR-2003 (revised)

DT 28-JUN-1994 (first entry)

XX

DE Amphiphilic peptide for N-terminal lipophilic substitution.

XX

KW Ion channel; magainin; PGLa; XPF; CPF; cecropin; sarcotoxin; amphiphilic;
 KW hydrophobic; hydrophilic; lipophilic; growth; inhibition; target cell;
 KW virus; virally-infected cell; antimicrobial; antiviral; antitumour;

KW antiparasitic; spermicide; wound healing; burn; infection.
 XX
 OS Synthetic.
 XX
 PN WO9324138-A1.
 XX
 PD 09-DEC-1993.
 XX
 PF 27-MAY-1993; 93WO-US005192.
 XX
 PR 01-JUN-1992; 92US-00891201.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Kari U;
 XX
 DR WPI; 1993-405419/50.
 XX
 PT Peptide(s) or proteins with an N-terminal lipophilic substit. - used for
 PT inhibiting growth of target cell, virus or virally-infected cell.
 XX
 PS Disclosure; Page 97-103; 113pp; English.
 XX
 CC A novel compsn. for inhibiting growth of a target cell, virus or virally-
 CC infected cell comprises a peptide of formula T-N(W)-X (I). X is a
 CC biologically active amphiphilic ion channel-forming peptide or protein;
 CC pref. a magainin peptide, a PGLa peptide, a XPF peptide, a CPF peptide, a
 CC cecropin or a sarcotoxin. N is the nitrogen of the N-terminal amino
 CC group. T is a lipophilic moiety; pref. R-CO, where R is a 2-16C
 CC hydrocarbon (alkyl or aromatic or alkylaromatic). T is pref. an octanoyl
 CC group. W is T or hydrogen. Amphiphilic peptides as examples of X are
 CC given in AAR45115-138. The N-terminal subst. peptides and proteins have
 CC increased biological activity as compared with unsubst. peptides or
 CC proteins or peptides subst. at the N-terminal with an acetyl gp. They
 CC can be used as antimicrobial agents, antiviral agents, antitumour agents,
 CC antiparasitic agents or spermicides and can also exhibit other bioactive
 CC functions. They can also be used in promoting or stimulating wound
 CC healing, for the treatment of external burns and to treat and/or prevent
 CC skin and burn infections or eye infections. (Updated on 25-MAR-2003 to
 CC correct PN field.)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 7 KLKK 10

RESULT 20
 AAR50562
 ID AAR50562 standard; peptide; 11 AA.
 XX
 AC AAR50562;

XX
 DT 25-MAR-2003 (revised)
 DT 18-OCT-1994 (first entry)
 XX
 DE Amphiphilic peptide #111.
 XX
 KW Amphiphilic; ion forming; gynaecological malignancy; magainin; PGLa; XPF;
 KW CPF; cecropin; sarcotoxin; melittin; apidaecin; defensin;
 KW major basic protein; eosinophils; uterine; cervical; cancer;
 KW bacterial permeability increasing protein; ovarian; stage IC.
 XX
 OS Synthetic.
 XX
 PN WO9405313-A1.
 XX
 PD 17-MAR-1994.
 XX
 PF 16-AUG-1993; 93WO-US007798.
 XX
 PR 31-AUG-1992; 92US-00937462.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Jacob LS, Maloy WL, Baker MA;
 XX
 DR WPI; 1994-100851/12.
 XX
 PT Treating gynaecological tumours with amphiphilic peptide(s) - which form
 PT ion channels, e.g. magainin or PGLa peptide(s), partic. for treating
 PT ovarian, uterine or cervical cancers.
 XX
 PS Disclosure; Page 115; 130pp; English.
 XX
 CC The sequences given in AAR50452-568 represent amphiphilic, ion forming
 CC peptides which may be used to treat gynaecological malignancy. These
 CC peptides are based on magainin, PGLa, XPF or CPF, a cecropin, a
 CC sarcotoxin, melittin, an apidaecin, a defensin, major basic protein of
 CC eosinophils or a bacterial permeability increasing protein. These
 CC peptides are esp. used to treat ovarian, esp. stage IC, uterine or
 CC cervical cancers. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 7 KLKK 10

RESULT 21
 AAR50546
 ID AAR50546 standard; peptide; 11 AA.
 XX
 AC AAR50546;

XX
 DT 25-MAR-2003 (revised)
 DT 18-OCT-1994 (first entry)
 XX
 DE Amphiphilic peptide #95.
 XX
 KW Amphiphilic; ion forming; gynaecological malignancy; magainin; PGLa; XPF;
 KW CPF; cecropin; sarcotoxin; melittin; apidaecin; defensin;
 KW major basic protein; eosinophils; uterine; cervical; cancer;
 KW bacterial permeability increasing protein; ovarian; stage IC.
 XX
 OS Synthetic.
 XX
 PN W09405313-A1.
 XX
 PD 17-MAR-1994.
 XX
 PF 16-AUG-1993; 93WO-US007798.
 XX
 PR 31-AUG-1992; 92US-00937462.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Jacob LS, Maloy WL, Baker MA;
 XX
 DR WPI; 1994-100851/12.
 XX
 PT Treating gynaecological tumours with amphiphilic peptide(s) - which form
 PT ion channels, e.g. magainin or PGLa peptide(s), partic. for treating
 PT ovarian, uterine or cervical cancers.
 XX
 PS Disclosure; Page 109; 130pp; English.
 XX
 CC The sequences given in AAR50452-568 represent amphiphilic, ion forming
 CC peptides which may be used to treat gynaecological malignancy. These
 CC peptides are based on magainin, PGLa, XPF or CPF, a cecropin, a
 CC sarcotoxin, melittin, an apidaecin, a defensin, major basic protein of
 CC eosinophils or a bacterial permeability increasing protein. These
 CC peptides are esp. used to treat ovarian, esp. stage IC, uterine or
 CC cervical cancers. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 3 KLKK 6

RESULT 22
 AAR50563
 ID AAR50563 standard; peptide; 11 AA.
 XX
 AC AAR50563;

XX
 DT 25-MAR-2003 (revised)
 DT 18-OCT-1994 (first entry)
 XX
 DE Amphiphillic peptide #112.
 XX
 KW Amphiphilic; ion forming; gynaecological malignancy; magainin; PGLa; XPF;
 KW CPF; cecropin; sarcotoxin; melittin; apidaecin; defensin;
 KW major basic protein; eosinophils; uterine; cervical; cancer;
 KW bacterial permeability increasing protein; ovarian; stage IC.
 XX
 OS Synthetic.
 XX
 PN WO9405313-A1.
 XX
 PD 17-MAR-1994.
 XX
 PF 16-AUG-1993; 93WO-US007798.
 XX
 PR 31-AUG-1992; 92US-00937462.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Jacob LS, Maloy WL, Baker MA;
 XX
 DR WPI; 1994-100851/12.
 XX
 PT Treating gynaecological tumours with amphiphilic peptide(s) - which form
 PT ion channels, e.g. magainin or PGLa peptide(s), partic. for treating
 PT ovarian, uterine or cervical cancers.
 XX
 PS Disclosure; Page 116; 130pp; English.
 XX
 CC The sequences given in AAR50452-568 represent amphiphilic, ion forming
 CC peptides which may be used to treat gynaecological malignancy. These
 CC peptides are based on magainin, PGLa, XPF or CPF, a cecropin, a
 CC sarcotoxin, melittin, an apidaecin, a defensin, major basic protein of
 CC eosinophils or a bacterial permeability increasing protein. These
 CC peptides are esp. used to treat ovarian, esp. stage IC, uterine or
 CC cervical cancers. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 7 KLKK 10

RESULT 23
 AAR55986
 ID AAR55986 standard; peptide; 11 AA.
 XX
 AC AAR55986;

XX
 DT 25-MAR-2003 (revised)
 DT 19-DEC-1994 (first entry)
 XX
 DE Ion channel forming peptide.
 XX
 KW Ion channel forming peptide; tumour; skin disease; malignancy; melanoma;
 KW carcinoma; basal cell; squamous cell; magainin; PGLa; CPF peptides;
 KW cercopins; sarcotoxin; mellitin; apidocin; defensins;
 KW major basic protein; bacteria-permeability increasing protein; perforin.
 XX
 OS Synthetic.
 XX
 PN WO9412206-A1.
 XX
 PD 09-JUN-1994.
 XX
 PF 03-DEC-1993; 93WO-US011885.
 XX
 PR 03-DEC-1992; 92US-00984957.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Jacob LS, Maloy WL;
 XX
 DR WPI; 1994-199965/24.
 XX
 PT Treating skin cancer with ion channel forming peptide(s) - e.g.
 PT magainins, mellitin etc., specifically for treating melanoma.
 XX
 PS Disclosure; Page 120; 136pp; English.
 XX
 CC The peptide is used to treat dermatological malignancies. It may be used
 CC to treat especially melanoma but also basal cell and squamous cell
 CC carcinomas. It can be used together with an ion which also
 CC inhibits/prevents growth of the target cell. Peptides used for such
 CC therapy include magainin, PGLa or CPF peptides; cercopins, sarcotoxins,
 CC mellitin, apidocins, defensins, major basic protein of eosinophils;
 CC bacteria-permeability increasing protein and perforin. See also AAQ55876-
 CC Q55997. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 7 KLKK 10

RESULT 24
 AAR55970
 ID AAR55970 standard; peptide; 11 AA.
 XX
 AC AAR55970;

XX
 DT 25-MAR-2003 (revised)
 DT 19-DEC-1994 (first entry)
 XX
 DE Ion channel forming peptide.
 XX
 KW Ion channel forming peptide; tumour; skin disease; malignancy; melanoma;
 KW carcinoma; basal cell; squamous cell; magainin; PGLa; CPF peptides;
 KW cercopins; sarcotoxin; mellitin; apidocin; defensins;
 KW major basic protein; bacteria-permeability increasing protein; perforin.
 XX
 OS Synthetic.
 XX
 PN WO9412206-A1.
 XX
 PD 09-JUN-1994.
 XX
 PF 03-DEC-1993; 93WO-US011885.
 XX
 PR 03-DEC-1992; 92US-00984957.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Jacob LS, Maloy WL;
 XX
 DR WPI; 1994-199965/24.
 XX
 PT Treating skin cancer with ion channel forming peptide(s) - e.g.
 PT magainins, mellitin etc., specifically for treating melanoma.
 XX
 PS Disclosure; Page 114; 136pp; English.
 XX
 CC The peptide is used to treat dermatological malignancies. It may be used
 CC to treat especially melanoma but also basal cell and squamous cell
 CC carcinomas. It can be used together with an ion which also
 CC inhibits/prevents growth of the target cell. Peptides used for such
 CC therapy include magainin, PGLa or CPF peptides; cercopins, sarcotoxins,
 CC mellitin, apidocins, defensins, major basic protein of eosinophils;
 CC bacteria-permeability increasing protein and perforin. See also AAQ55876-
 CC Q55997. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 3 KLKK 6

RESULT 25
 AAR55987
 ID AAR55987 standard; peptide; 11 AA.
 XX
 AC AAR55987;

XX
 DT 25-MAR-2003 (revised)
 DT 19-DEC-1994 (first entry)
 XX
 DE Ion channel forming peptide.
 XX
 KW Ion channel forming peptide; tumour; skin disease; malignancy; melanoma;
 KW carcinoma; basal cell; squamous cell; magainin; PGLa; CPF peptides;
 KW cercopins; sarcotoxin; mellitin; apidocin; defensins;
 KW major basic protein; bacteria-permeability increasing protein; perforin.
 XX
 OS Synthetic.
 XX
 PN W09412206-A1.
 XX
 PD 09-JUN-1994.
 XX
 PF 03-DEC-1993; 93WO-US011885.
 XX
 PR 03-DEC-1992; 92US-00984957.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Jacob LS, Maloy WL;
 XX
 DR WPI; 1994-199965/24.
 XX
 PT Treating skin cancer with ion channel forming peptide(s) - e.g.
 PT magainins, mellitin etc., specifically for treating melanoma.
 XX
 PS Disclosure; Page 121; 136pp; English.
 XX
 CC The peptide is used to treat dermatological malignancies. It may be used
 CC to treat especially melanoma but also basal cell and squamous cell
 CC carcinomas. It can be used together with an ion which also
 CC inhibits/prevents growth of the target cell. Peptides used for such
 CC therapy include magainin, PGLa or CPF peptides; cercopins, sarcotoxins,
 CC mellitin, apidocins, defensins, major basic protein of eosinophils;
 CC bacteria-permeability increasing protein and perforin. See also AAQ55876-
 CC Q55997. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 7 KLKK 10

RESULT 26
 AAR59065
 ID AAR59065 standard; peptide; 11 AA.
 XX
 AC AAR59065;

XX
 DT 25-MAR-2003 (revised)
 DT 21-APR-1995 (first entry)
 XX
 DE Cancer treating, amphiphilic ion-channel forming peptide.
 XX
 KW Amphiphilic ion-channel forming peptide; cancer treatment;
 KW protease inhibitors.
 XX
 OS Synthetic.
 XX
 PN WO9419369-A1.
 XX
 PD 01-SEP-1994.
 XX
 PF 22-FEB-1994; 94WO-US002121.
 XX
 PR 26-FEB-1993; 93US-00021607.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Herlyn M, Jacob LS, Maloy WL;
 XX
 DR WPI; 1994-294258/36.
 XX
 PT Treating cancerous growths - by administering biologically active
 PT peptide(s) and protease inhibitors.
 XX
 PS Claim 2; Page 106; 124pp; English.
 XX
 CC AAR59060 to AAR59066 are a group of amphiphilic ion-channel forming
 CC peptides conforming to the same generic sequence. Used in combination
 CC with one or more protease inhibitors and other amphiphilic ion-channel
 CC forming peptides or proteins; they are effective in the treatment of
 CC cancerous growths. In particular during surgery and radiation treatment
 CC they may be useful in inhibiting, preventing and/or destroying potential
 CC "loose" malignant cells capable of colonising other sites. (Updated on 25
 CC -MAR-2003 to correct PN field.)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 7 KLKK 10

RESULT 27
 AAR59048
 ID AAR59048 standard; peptide; 11 AA.
 XX
 AC AAR59048;
 XX
 DT 25-MAR-2003 (revised)

DT 21-APR-1995 (first entry)
 XX
 DE Cancer treating, amphiphilic ion-channel forming peptide.
 XX
 KW Amphiphilic ion-channel forming peptide; cancer treatment;
 KW protease inhibitors.
 XX
 OS Synthetic.
 XX
 PN WO9419369-A1.
 XX
 PD 01-SEP-1994.
 XX
 PF 22-FEB-1994; 94WO-US002121.
 XX
 PR 26-FEB-1993; 93US-00021607.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Herlyn M, Jacob LS, Maloy WL;
 XX
 DR WPI; 1994-294258/36.
 XX
 PT Treating cancerous growths - by administering biologically active
 PT peptide(s) and protease inhibitors.
 XX
 PS Claim 2; Page 99; 124pp; English.
 XX
 CC AAR59048 to AAR59051 are a group of amphiphilic ion-channel forming
 CC peptides conforming to the same generic sequence. Used in combination
 CC with one or more protease inhibitors and other amphiphilic ion-channel
 CC forming peptides or proteins; they are effective in the treatment of
 CC cancerous growths. In particular during surgery and radiation treatment
 CC they may be useful in inhibiting, preventing and/or destroying potential
 CC "loose" malignant cells capable of colonising other sites. (Updated on 25
 CC -MAR-2003 to correct PN field.)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 3 KLKK 6

RESULT 28
 AAR59064
 ID AAR59064 standard; peptide; 11 AA.
 XX
 AC AAR59064;
 XX
 DT 25-MAR-2003 (revised)
 DT 21-APR-1995 (first entry)
 XX

DE Cancer treating, amphiphilic ion-channel forming peptide.
 XX
 KW Amphiphilic ion-channel forming peptide; cancer treatment;
 KW protease inhibitors.
 XX
 OS Synthetic.
 XX
 PN W09419369-A1.
 XX
 PD 01-SEP-1994.
 XX
 PF 22-FEB-1994; 94WO-US002121.
 XX
 PR 26-FEB-1993; 93US-00021607.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Herlyn M, Jacob LS, Maloy WL;
 XX
 DR WPI; 1994-294258/36.
 XX
 PT Treating cancerous growths - by administering biologically active
 PT peptide(s) and protease inhibitors.
 XX
 PS Claim 2; Page 106; 124pp; English.
 XX
 CC AAR59060 to AAR59066 are a group of amphiphilic ion-channel forming
 CC peptides conforming to the same generic sequence. Used in combination
 CC with one or more protease inhibitors and other amphiphilic ion-channel
 CC forming peptides or proteins; they are effective in the treatment of
 CC cancerous growths. In particular during surgery and radiation treatment
 CC they may be useful in inhibiting, preventing and/or destroying potential
 CC "loose" malignant cells capable of colonising other sites. (Updated on 25
 CC -MAR-2003 to correct PN field.)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 7 KLKK 10

RESULT 29
 AAR56948
 ID AAR56948 standard; peptide; 11 AA.
 XX
 AC AAR56948;
 XX
 DT 25-MAR-2003 (revised)
 DT 17-MAR-1995 (first entry)
 XX
 DE Peptide which neutralises bacterial endotoxin.
 XX

KW septic shock; bacterial endotoxin; lipopolysaccharide; LPS;
 KW gram negative bacteria; conjugate moiety; septicemia; neutralising;
 KW longer activity; polyvinylpyrrolidone; dextran; hetastarch;
 KW polyvinyl alcohol; ion-channel forming; amphiphilic.
 XX
 OS Synthetic.
 XX
 PN WO9413697-A1.
 XX
 PD 23-JUN-1994.
 XX
 PF 06-DEC-1993; 93WO-US011841.
 XX
 PR 07-DEC-1992; 92US-00987443.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Hendi M, Rao M, Williams TJ;
 XX
 DR WPI; 1994-217804/26.
 XX
 PT New conjugates of bioactive amphiphilic peptide(s) and conjugate moiety -
 PT are useful for treatment of septic shock.
 XX
 PS Disclosure; Page 115; 141pp; English.
 XX
 CC Septic shock is often due to the body's reaction to foreign
 CC lipopolysaccharide (LPS). The compounds of the invention neutralise
 CC bacterial endotoxins without neutralising essential proteins in the
 CC plasma of patients, eg.heparins. They also have longer duration of
 CC activity than unconjugated peptides. In general peptides such as this are
 CC ion-channel forming peptides.The compounds are biologically active
 CC peptides linked to a conjugate moiety, eg. carbohydrates, proteins,
 CC polyvinylpyrrolidone, polyalkylene glycols and polyvinyl alcohols. The
 CC conjugate moiety may be linked at the C- or N-terminal or internally of
 CC the peptide. AAR55591-631 and AAR56879-957 are examples of these peptide-
 CC conjugate moiety compounds (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 7 KLKK 10

RESULT 30
 AAR56931
 ID AAR56931 standard; peptide; 11 AA.
 XX
 AC AAR56931;
 XX
 DT 25-MAR-2003 (revised)
 DT 16-MAR-1995 (first entry)

XX
 DE Peptide which neutralises bacterial endotoxin.
 XX
 KW septic shock; bacterial endotoxin; lipopolysaccharide; LPS;
 KW gram negative bacteria; conjugate moiety; septicemia; neutralising;
 KW longer activity; polyvinylpyrrolidone; dextran; hetastarch;
 KW polyvinyl alcohol; ion-channel forming; amphiphilic.
 XX
 OS Synthetic.
 XX
 PN WO9413697-A1.
 XX
 PD 23-JUN-1994.
 XX
 PF 06-DEC-1993; 93WO-US011841.
 XX
 PR 07-DEC-1992; 92US-00987443.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Hendi M, Rao M, Williams TJ;
 XX
 DR WPI; 1994-217804/26.
 XX
 PT New conjugates of bioactive amphiphilic peptide(s) and conjugate moiety -
 PT are useful for treatment of septic shock.
 XX
 PS Disclosure; Page 108; 141pp; English.
 XX
 CC Septic shock is often due to the body's reaction to foreign
 CC lipopolysaccharide (LPS). The compounds of the invention neutralise
 CC bacterial endotoxins without neutralising essential proteins in the
 CC plasma of patients, eg.heparins. They also have longer duration of
 CC activity than unconjugated peptides. In general peptides such as this are
 CC ion-channel forming peptides.The compounds are biologically active
 CC peptides linked to a conjugate moiety, eg. carbohydrates, proteins,
 CC polyvinylpyrrolidone, polyalkylene glycols and polyvinyl alcohols. The
 CC conjugate moiety may be linked at the C- or N-terminal or internally of
 CC the peptide. AAR55591-631 and AAR56879-957 are examples of these peptide-
 CC conjugate moiety compounds (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 3 KLKK 6

RESULT 31
 AAR56947
 ID AAR56947 standard; peptide; 11 AA.
 XX
 AC AAR56947;

XX
 DT 25-MAR-2003 (revised)
 DT 17-MAR-1995 (first entry)
 XX
 DE Peptide which neutralises bacterial endotoxin.
 XX
 KW septic shock; bacterial endotoxin; lipopolysaccharide; LPS;
 KW gram negative bacteria; conjugate moiety; septicemia; neutralising;
 KW longer activity; polyvinylpyrrolidone; dextran; hetastarch;
 KW polyvinyl alcohol; ion-channel forming; amphiphilic.
 XX
 OS Synthetic.
 XX
 PN WO9413697-A1.
 XX
 PD 23-JUN-1994.
 XX
 PF 06-DEC-1993; 93WO-US011841.
 XX
 PR 07-DEC-1992; 92US-00987443.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Hendi M, Rao M, Williams TJ;
 XX
 DR WPI; 1994-217804/26.
 XX
 PT New conjugates of bioactive amphiphilic peptide(s) and conjugate moiety -
 PT are useful for treatment of septic shock.
 XX
 PS Disclosure; Page 115; 141pp; English.
 XX
 CC Septic shock is often due to the body's reaction to foreign
 CC lipopolysaccharide (LPS). The compounds of the invention neutralise
 CC bacterial endotoxins without neutralising essential proteins in the
 CC plasma of patients, eg.heparins. They also have longer duration of
 CC activity than unconjugated peptides. In general peptides such as this are
 CC ion-channel forming peptides.The compounds are biologically active
 CC peptides linked to a conjugate moiety, eg. carbohydrates, proteins,
 CC polyvinylpyrrolidone, polyalkylene glycols and polyvinyl alcohols. The
 CC conjugate moiety may be linked at the C- or N-terminal or internally of
 CC the peptide. AAR55591-631 and AAR56879-957 are examples of these peptide-
 CC conjugate moiety compounds (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 7 KLKK 10

RESULT 32
 AAR50431

ID AAR50431 standard; peptide; 11 AA.
 XX
 AC AAR50431;
 XX
 DT 25-MAR-2003 (revised)
 DT 17-OCT-1994 (first entry)
 XX
 DE Amphiphilic peptide #96.
 XX
 KW Amphiphilic peptide; aprotic organic solvent; alcohol; antitumour;
 KW antibiotic; antimicrobial; antifungal; antiparasitic; anticancer;
 KW antiviral; human; animal; plant; ion-channel; forming peptide.
 XX
 OS Synthetic.
 XX
 PN WO9405308-A1.
 XX
 PD 17-MAR-1994.
 XX
 PF 13-AUG-1993; 93WO-US007694.
 XX
 PR 28-AUG-1992; 92US-00936504.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Williams JT;
 XX
 DR WPI; 1994-100846/12.
 XX
 PT Purifying amphiphilic protein or peptide by solvent extn. - partic. for
 PT recombinant, ion-channel forming peptide(s) such as magainins, avoids use
 PT of chaotropic agents.
 XX
 PS Disclosure; Page 117; 135pp; English.
 XX
 CC The sequences given in AAR50336-451 are amphiphilic peptides which were
 CC isolated by the method of the invention. A material containing
 CC amphiphilic peptides such as these, was treated with a mixt. of aprotic
 CC organic solvent and alcohol to form a single miscible solution. This
 CC solution was then treated with a aqueous solution to form an aqueous
 CC phase solution containing the peptides and an organic solvent phase, and
 CC the peptides were isolated from the aqueous phase. The isolated peptides
 CC may be useful as antibiotic, antimicrobial, antifungal, antiparasitic,
 CC antitumour, anticancer, and/or antiviral agents for treatment of humans,
 CC animals or plants. These peptides are esp. ion-channel forming peptides
 CC which enable biologically active ions to enter cells. (Updated on 25-MAR-
 CC 2003 to correct PN field.)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 3 KLKK 6

RESULT 33

AAR50448

ID AAR50448 standard; peptide; 11 AA.

XX

AC AAR50448;

XX

DT 25-MAR-2003 (revised)

DT 17-OCT-1994 (first entry)

XX

DE Amphiphilic peptide #113.

XX

KW Amphiphilic peptide; aprotic organic solvent; alcohol; antitumour;

KW antibiotic; antimicrobial; antifungal; antiparasitic; anticancer;

KW antiviral; human; animal; plant; ion-channel; forming peptide.

XX

OS Synthetic.

XX

PN WO9405308-A1.

XX

PD 17-MAR-1994.

XX

PF 13-AUG-1993; 93WO-US007694.

XX

PR 28-AUG-1992; 92US-00936504.

XX

PA (MAGA-) MAGAININ PHARM INC.

XX

PI Williams JI;

XX

DR WPI; 1994-100846/12.

XX

PT Purifying amphiphilic protein or peptide by solvent extn. - partic. for

PT recombinant, ion-channel forming peptide(s) such as magainins, avoids use

PT of chaotropic agents.

XX

PS Disclosure; Page 124; 135pp; English.

XX

CC The sequences given in AAR50336-451 are amphiphilic peptides which were

CC isolated by the method of the invention. A material containing

CC amphiphilic peptides such as these, was treated with a mixt. of aprotic

CC organic solvent and alcohol to form a single miscible solution. This

CC solution was then treated with a aqueous solution to form an aqueous

CC phase solution containing the peptides and an organic solvent phase, and

CC the peptides were isolated from the aqueous phase. The isolated peptides

CC may be useful as antibiotic, antimicrobial, antifungal, antiparasitic,

CC antitumour, anticancer, and/or antiviral agents for treatment of humans,

CC animals or plants. These peptides are esp. ion-channel forming peptides

CC which enable biologically active ions to enter cells. (Updated on 25-MAR-

CC 2003 to correct PN field.)

XX

SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.6e+03;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
Db 7 KLKK 10

RESULT 34

AAR50447

ID AAR50447 standard; peptide; 11 AA.

XX

AC AAR50447;

XX

DT 25-MAR-2003 (revised)

DT 17-OCT-1994 (first entry)

XX

DE Amphiphilic peptide #112.

XX

KW Amphiphilic peptide; aprotic organic solvent; alcohol; antitumour;

KW antibiotic; antimicrobial; antifungal; antiparasitic; anticancer;

KW antiviral; human; animal; plant; ion-channel; forming peptide.

XX

OS Synthetic.

XX

PN WO9405308-A1.

XX

PD 17-MAR-1994.

XX

PF 13-AUG-1993; 93WO-US007694.

XX

PR 28-AUG-1992; 92US-00936504.

XX

PA (MAGA-) MAGAININ PHARM INC.

XX

PI Williams JI;

XX

DR WPI; 1994-100846/12.

XX

PT Purifying amphiphilic protein or peptide by solvent extn. - partic. for
PT recombinant, ion-channel forming peptide(s) such as magainins, avoids use
PT of chaotropic agents.

XX

PS Disclosure; Page 124; 135pp; English.

XX

CC The sequences given in AAR50336-451 are amphiphilic peptides which were
CC isolated by the method of the invention. A material containing
CC amphiphilic peptides such as these, was treated with a mixt. of aprotic
CC organic solvent and alcohol to form a single miscible solution. This
CC solution was then treated with a aqueous solution to form an aqueous
CC phase solution containing the peptides and an organic solvent phase, and
CC the peptides were isolated from the aqueous phase. The isolated peptides
CC may be useful as antibiotic, antimicrobial, antifungal, antiparasitic,
CC antitumour, anticancer, and/or antiviral agents for treatment of humans,
CC animals or plants. These peptides are esp. ion-channel forming peptides
CC which enable biologically active ions to enter cells. (Updated on 25-MAR-
CC 2003 to correct PN field.)

XX

SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
| | | |
Db 7 KLKK 10

RESULT 35

AAR79718

ID AAR79718 standard; peptide; 11 AA.

XX

AC AAR79718;

XX

DT 27-FEB-1996 (first entry)

XX

DE Optimal peptide substrate for cyclin containing kinases.

XX

KW Peptide library; phosphorylation site; protein kinase; substrate;

KW inhibitor; competitor; cellular response; cell cycle control;

KW immune response; transcriptional activation; cell development.

XX

OS Synthetic.

XX

PN WO9518823-A2.

XX

PD 13-JUL-1995.

XX

PF 06-JAN-1995; 95WO-US000147.

XX

PR 07-JAN-1994; 94US-00178570.

XX

PA (BETH-) BETH ISRAEL HOSPITAL ASSOC.

XX

PI Cantley LC, Songyang Z;

XX

DR WPI; 1995-255036/33.

XX

PT Determn.of amino acid sequence of protein kinase phosphorylation site -

PT by phosphorylation of peptide library and sequencing phospho:peptide(s)

PT formed, also new substrates and their analogues for modulating or

PT detecting protein kinase.

XX

PS Example 10; Page 40; 131pp; English.

XX

CC An oriented degenerate peptide library of the amino acid formula AAR79661

CC was constructed to isolate the amino acid sequences at the

CC phosphorylation sites of a protein kinase eg. protein kinase A, cyclin

CC B/p33(cdc2), src family kinases, etc. Peptides which are phosphorylated

CC are isolated and their amino acid sequences are compared to known

CC substrate/inhibitor peptide sequences for that protein kinase. The

CC peptides AAR79718-R79721 are synthetic peptides designed to be optimal

CC substrates for a range of protein kinases. This peptide sequence is

CC designed as a substrate for cyclin containing kinases, e.g cyclin

CC B/p33(cdc2) or cyclin A/p33(CDK2). The isolated peptides can be used to

CC screen cpds. for effects on the protein kinase activity, generate
CC antibodies to identify native kinase substrates, or modulate a variety of
CC cellular responses in which protein kinases are involved eg. cell cycle
CC control, immune response, transcriptional activation or cell development
XX
SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 KKKA 11
||||
Db 8 KKKA 11

RESULT 36

AAW03066

ID AAW03066 standard; peptide; 11 AA.

XX

AC AAW03066;

XX

DT 02-MAR-1997 (first entry)

XX

DE Polycationic polypeptide component of peptide-oligonucleotide conjugate.

XX

KW polycationic polypeptide; polyanionic oligonucleotide; antigene;

KW antisense therapy.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 1

FT /note= "this residue is connected via the thiol group and
FT a linking group to the 5' end of the oligonucleotide
FT AAT01822"

FT Modified-site 11

FT /note= "this residue is connected via the thiol group and
FT a linking group to the 3' end of the oligonucleotide
FT AAT01822"

XX

PN WO9524222-A1.

XX

PD 14-SEP-1995.

XX

PF 07-MAR-1995; 95WO-US002894.

XX

PR 07-MAR-1994; 94US-00207438.

XX

PA (UYNE-) UNIV NEW JERSEY.

XX

PI Stein S, Wei Z, Zhu T, Tung C;

XX

DR WPI; 1995-328105/42.

XX

PT New cyclic conjugate of polycationic polymer and oligo:nucleotide(s) -
PT covalently bonded at each end by crosslinking agent, useful for

PT anti:sense and anti:gene therapy, have strong binding to target and good
PT in-vivo stability.

XX

PS Example; Page 27; 49pp; English.

XX

CC Cyclic polycationic polymer-oligonucleotide conjugates are provided which
CC comprise a polycationic polymer covalently bonded at each end to the 3'
CC and 5' terminal nucleotides of a polyanionic oligonucleotide via a
CC crosslinking agent. Preferably the polycationic polymer is a polypeptide
CC Cys-(LysLeu)2-Lys-(LysLeu)2-Cys (the present sequence) or Cys-(delta-
CC Orn)10-Cys; the polyanionic oligonucleotide is 5'-CATTTCTTTATT-
CC 3'(AAT01822); and each linking group is of formula -CH2CONH- where each -
CC CH2 is attached to the thiol group of each Cys and each NH- is attached
CC to the 5' and 3' terminals respectively of the oligonucleotide. The
CC conjugates can be used for antisense and antigene therapy. They have
CC enhanced stability in-vivo because exonuclease digestion is minimised
CC when both the 3' and 5' termini are blocked; they have enhanced
CC bioavailability because the ability of the oligonucleotide to penetrate
CC through cellular membranes is enhanced when its negative charges are ion-
CC paired; and they have low toxicity because the metabolic degradation
CC products of the conjugates are amino acids and nucleotides

XX

SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.6e+03;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9

||||

Db 3 KLKK 6

RESULT 37

AAR90267

ID AAR90267 standard; peptide; 11 AA.

XX

AC AAR90267;

XX

DT 10-JUL-1996 (first entry)

XX

DE Ion-channel forming peptide #128 with lipophilic N-terminal group.

XX

KW Ion channel forming peptide; lipophilic; N-terminal modification;

KW magainin; inhibition; cell growth; viral replication; ionophore;

KW membrane permeability; antimicrobial; anti-bacterial; antibiotic;

KW anti-fungal; anti-viral; spermicidal; anti-tumour; anti-parasitic.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 1

FT /note= "N-terminal amino group is mono- or di-substd. by

FT lipophilic moiety, esp. octanoyl"

XX

PN W09519370-A1.

XX

PD 20-JUL-1995.
 XX
 PF 18-JAN-1995; 95WO-US000714.
 XX
 PR 18-JAN-1994; 94US-00184462.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Kari U, Williams TJ, McLane M;
 XX
 DR WPI; 1995-263826/34.
 XX
 PT Ion channel-forming amphiphilic peptide(s) with N-terminal lipophilic
 PT gps. - useful e.g. as antiviral, antibacterial, antiparasitic or
 PT antitumour agents.
 XX
 PS Claim 30; Page 113; 139pp; English.
 XX
 CC The present peptide is a specific example corresp. to a highly generic
 CC formula for ion channel forming peptides (ionophores). These ionophores
 CC are known to have a broad range of potent antibiotic activity against
 CC microorganisms including gram-positive and gram-negative bacteria, fungi,
 CC viruses, protozoa and parasites. N-terminal modification (pref. mono-
 CC substn. by octanoyl) to produce an ion-channel forming peptide having a
 CC lipophilic N-terminus increases the biological activity of the peptides
 CC against target cells, viruses and virally-infected cells, compared to
 CC peptides substd. with an acetyl group at the N-terminus. Compositions
 CC comprising the peptides with lipophilic modifications are claimed for
 CC inhibiting growth of a target cell, virus or virally-infected cell
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 7 KLKK 10

RESULT 38

AAR90259

ID AAR90259 standard; peptide; 11 AA.

XX

AC AAR90259;

XX

DT 10-JUL-1996 (first entry)

XX

DE Ion-channel forming peptide #111 with lipophilic N-terminal group.

XX

KW Ion channel forming peptide; lipophilic; N-terminal modification;
 KW magainin; inhibition; cell growth; viral replication; ionophore;
 KW membrane permeability; antimicrobial; anti-bacterial; antibiotic;
 KW anti-fungal; anti-viral; spermicidal; anti-tumour; anti-parasitic.

XX

OS Synthetic.

XX
 FH Key Location/Qualifiers
 FT Modified-site 1
 FT /note= "N-terminal amino group is mono- or di-substd. by
 FT lipophilic moiety, esp. octanoyl"
 XX
 PN WO9519370-A1.
 XX
 PD 20-JUL-1995.
 XX
 PF 18-JAN-1995; 95WO-US000714.
 XX
 PR 18-JAN-1994; 94US-00184462.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Kari U, Williams TJ, Mclane M;
 XX
 DR WPI; 1995-263826/34.
 XX
 PT Ion channel-forming amphiphilic peptide(s) with N-terminal lipophilic
 PT gps. - useful e.g. as antiviral, antibacterial, antiparasitic or
 PT antitumour agents.
 XX
 PS Claim 25; Page 108; 139pp; English.
 XX
 CC The present peptide is a specific example corresp. to a highly generic
 CC formula for ion channel forming peptides (ionophores). These ionophores
 CC are known to have a broad range of potent antibiotic activity against
 CC microorganisms including gram-positive and gram-negative bacteria, fungi,
 CC viruses, protozoa and parasites. N-terminal modification (pref. mono-
 CC substn. by octanoyl) to produce an ion-channel forming peptide having a
 CC lipophilic N-terminus increases the biological activity of the peptides
 CC against target cells, viruses and virally-infected cells, compared to
 CC peptides substd. with an acetyl group at the N-terminus. Compositions
 CC comprising the peptides with lipophilic modifications are claimed for
 CC inhibiting growth of a target cell, virus or virally-infected cell
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 7 KLKK 10

RESULT 39
 AAR91792
 ID AAR91792 standard; peptide; 11 AA.
 XX
 AC AAR91792;
 XX
 DT 11-JUL-1996 (first entry)
 XX

DE Ion-channel forming peptide #141 with lipophilic N-terminal group.
XX
KW Ion channel forming peptide; lipophilic; N-terminal modification;
KW magainin; inhibition; cell growth; viral replication; ionophore;
KW membrane permeability; antimicrobial; anti-bacterial; antibiotic;
KW anti-fungal; anti-viral; spermicidal; anti-tumour; anti-parasitic.

XX
OS Synthetic.

XX
FH Key Location/Qualifiers
FT Modified-site 1
FT /note= "N-terminal amino group is mono-substd. by
FT octanoyl"
FT Modified-site 2
FT /label= Orn
FT Modified-site 11
FT /note= "C-terminal amide"

XX
PN WO9519370-A1.

XX
PD 20-JUL-1995.

XX
PF 18-JAN-1995; 95WO-US000714.

XX
PR 18-JAN-1994; 94US-00184462.

XX
PA (MAGA-) MAGAININ PHARM INC.

XX
PI Kari U, Williams TJ, Mclane M;

XX
DR WPI; 1995-263826/34.

XX
PT Ion channel-forming amphiphilic peptide(s) with N-terminal lipophilic
PT gps. - useful e.g. as antiviral, antibacterial, antiparasitic or
PT antitumour agents.

XX
PS Example 1; Page 116; 139pp; English.

XX
CC Various ion channel forming peptides (ionophores) in C-terminal amide
CC form were modified by N-terminal substn. with a lipophilic group and then
CC tested for activity against S.aureus ATCC 25923 (S), P.aeruginosa ATCC
CC 27853 (P), E.coli ATCC 25922 (E) and C.albicans (C). Results indicated
CC that when a biologically active peptide is substd. with a lipophilic
CC moiety, the peptide has increased activity against a range of
CC microorganisms. Compositions comprising such peptides with lipophilic
CC modifications are claimed for inhibiting growth of a target cell, virus
CC or virally-infected cell. Minimum inhibitory concentrations (in
CC microgram/ml) for the present peptide against S, P, E and C,
CC respectively, were: 4, 4, 8 and 32

XX
SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9

Db ||||
 7 KLKK 10

RESULT 40

AAR90260

ID AAR90260 standard; peptide; 11 AA.

XX

AC AAR90260;

XX

DT 10-JUL-1996 (first entry)

XX

DE Ion-channel forming peptide #112 with lipophilic N-terminal group.

XX

KW Ion channel forming peptide; lipophilic; N-terminal modification;

KW magainin; inhibition; cell growth; viral replication; ionophore;

KW membrane permeability; antimicrobial; anti-bacterial; antibiotic;

KW anti-fungal; anti-viral; spermicidal; anti-tumour; anti-parasitic.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 1

FT /note= "N-terminal amino group is mono- or di-substd. by

FT lipophilic moiety, esp. octanoyl"

XX

PN WO9519370-A1.

XX

PD 20-JUL-1995.

XX

PF 18-JAN-1995; 95WO-US000714.

XX

PR 18-JAN-1994; 94US-00184462.

XX

PA (MAGA-) MAGAININ PHARM INC.

XX

PI Kari U, Williams TJ, McLane M;

XX

DR WPI; 1995-263826/34.

XX

PT Ion channel-forming amphiphilic peptide(s) with N-terminal lipophilic

PT gps. - useful e.g. as antiviral, antibacterial, antiparasitic or

PT antitumour agents.

XX

PS Claim 25; Page 108; 139pp; English.

XX

CC The present peptide is a specific example corresp. to a highly generic
CC formula for ion channel forming peptides (ionophores). These ionophores
CC are known to have a broad range of potent antibiotic activity against
CC microorganisms including gram-positive and gram-negative bacteria, fungi,
CC viruses, protozoa and parasites. N-terminal modification (pref. mono-
CC substn. by octanoyl) to produce an ion-channel forming peptide having a
CC lipophilic N-terminus increases the biological activity of the peptides
CC against target cells, viruses and virally-infected cells, compared to
CC peptides substd. with an acetyl group at the N-terminus. Compositions
CC comprising the peptides with lipophilic modifications are claimed for
CC inhibiting growth of a target cell, virus or virally-infected cell

XX

SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
| | | |
Db 3 KLKK 6

RESULT 41

AAR91797

ID AAR91797 standard; peptide; 11 AA.

XX

AC AAR91797;

XX

DT 11-JUL-1996 (first entry)

XX

DE Ion-channel forming peptide #146 with lipophilic N-terminal group.

XX

KW Ion channel forming peptide; lipophilic; N-terminal modification;
KW magainin; inhibition; cell growth; viral replication; ionophore;
KW membrane permeability; antimicrobial; anti-bacterial; antibiotic;
KW anti-fungal; anti-viral; spermicidal; anti-tumour; anti-parasitic.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 1

FT /note= "N-terminal amino group is mono-substd. by
octanoyl"

FT Modified-site 11

FT /note= "C-terminal amide"

XX

PN WO9519370-A1.

XX

PD 20-JUL-1995.

XX

PF 18-JAN-1995; 95WO-US000714.

XX

PR 18-JAN-1994; 94US-00184462.

XX

PA (MAGA-) MAGAININ PHARM INC.

XX

PI Kari U, Williams TJ, Mclane M;

XX

DR WPI; 1995-263826/34.

XX

PT Ion channel-forming amphiphilic peptide(s) with N-terminal lipophilic
PT gps. - useful e.g. as antiviral, antibacterial, antiparasitic or
PT antitumour agents.

XX

PS Example 1; Page 118; 139pp; English.

XX

CC Various ion channel forming peptides (ionophores) in C-terminal amide

CC form were modified by N-terminal substn. with a lipophilic group and then
 CC tested for activity against S.aureus ATCC 25923 (S), P.aeruginosa ATCC
 CC 27853 (P), E.coli ATCC 25922 (E) and C.albicans (C). Results indicated
 CC that when a biologically active peptide is substd. with a lipophilic
 CC moiety, the peptide has increased activity against a range of
 CC microorganisms. Compositions comprising such peptides with lipophilic
 CC modifications are claimed for inhibiting growth of a target cell, virus
 CC or virally-infected cell. Minimum inhibitory concentrations (in
 CC microgram/ml) for the present peptide against S, P, E and C,
 CC respectively, were: 8, 4, 16 and 32
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 7 KLKK 10

RESULT 42

AAR90137

ID AAR90137 standard; peptide; 11 AA.

XX

AC AAR90137;

XX

DT 10-JUL-1996 (first entry)

XX

DE Ion-channel forming peptide #94 modified by N-terminal lipophilic gp.

XX

KW Ion channel forming peptide; lipophilic; N-terminal modification;

KW magainin; inhibition; cell growth; viral replication; ionophore;

KW membrane permeability; antimicrobial; anti-bacterial; antibiotic;

KW anti-fungal; anti-viral; spermicidal; anti-tumour; anti-parasitic.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 1

FT /note= "N-terminal amino group is mono- or di-substd. by
 FT lipophilic moiety, esp. octanoyl"

XX

PN WO9519370-A1.

XX

PD 20-JUL-1995.

XX

PF 18-JAN-1995; 95WO-US000714.

XX

PR 18-JAN-1994; 94US-00184462.

XX

PA (MAGA-) MAGAININ PHARM INC.

XX

PI Kari U, Williams TJ, Mclane M;

XX

DR WPI; 1995-263826/34.

XX
PT Ion channel-forming amphiphilic peptide(s) with N-terminal lipophilic
PT gps. - useful e.g. as antiviral, antibacterial, antiparasitic or
PT antitumour agents.
XX
PS Claim 23; Page 102; 139pp; English.
XX
CC The present peptide is a specific example corresp. to a highly generic
CC formula for ion channel forming peptides (ionophores). These ionophores
CC are known to have a broad range of potent antibiotic activity against
CC microorganisms including gram-positive and gram-negative bacteria, fungi,
CC viruses, protozoa and parasites. N-terminal modification (pref. mono-
CC substn. by octanoyl) to produce an ion-channel forming peptide having a
CC lipophilic N-terminus increases the biological activity of the peptides
CC against target cells, viruses and virally-infected cells, compared to
CC peptides substd. with an acetyl group at the N-terminus. Compositions
CC comprising the peptides with lipophilic modifications are claimed for
CC inhibiting growth of a target cell, virus or virally-infected cell
XX
SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
||||
Db 3 KLKK 6

RESULT 43

AAR90266

ID AAR90266 standard; peptide; 11 AA.

XX

AC AAR90266;

XX

DT 10-JUL-1996 (first entry)

XX

DE Ion-channel forming peptide #127 with lipophilic N-terminal group.

XX

KW Ion channel forming peptide; lipophilic; N-terminal modification;

KW magainin; inhibition; cell growth; viral replication; ionophore;

KW membrane permeability; antimicrobial; anti-bacterial; antibiotic;

KW anti-fungal; anti-viral; spermicidal; anti-tumour; anti-parasitic.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 1

FT /note= "N-terminal amino group is mono- or di-substd. by

FT lipophilic moiety, esp. octanoyl"

XX

PN WO9519370-A1.

XX

PD 20-JUL-1995.

XX

PF 18-JAN-1995; 95WO-US000714.

XX
 PR 18-JAN-1994; 94US-00184462.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Kari U, Williams TJ, McLane M;
 XX
 DR WPI; 1995-263826/34.
 XX
 PT Ion channel-forming amphiphilic peptide(s) with N-terminal lipophilic
 PT gps. - useful e.g. as antiviral, antibacterial, antiparasitic or
 PT antitumour agents.
 XX
 PS Claim 30; Page 112; 139pp; English.
 XX
 CC The present peptide is a specific example corresp. to a highly generic
 CC formula for ion channel forming peptides (ionophores). These ionophores
 CC are known to have a broad range of potent antibiotic activity against
 CC microorganisms including gram-positive and gram-negative bacteria, fungi,
 CC viruses, protozoa and parasites. N-terminal modification (pref. mono-
 CC substn. by octanoyl) to produce an ion-channel forming peptide having a
 CC lipophilic N-terminus increases the biological activity of the peptides
 CC against target cells, viruses and virally-infected cells, compared to
 CC peptides substd. with an acetyl group at the N-terminus. Compositions
 CC comprising the peptides with lipophilic modifications are claimed for
 CC inhibiting growth of a target cell, virus or virally-infected cell
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 7 KLKK 10

RESULT 44
 AAR90258
 ID AAR90258 standard; peptide; 11 AA.
 XX
 AC AAR90258;
 XX
 DT 10-JUL-1996 (first entry)
 XX
 DE Ion-channel forming peptide #110 with lipophilic N-terminal group.
 XX
 KW Ion channel forming peptide; lipophilic; N-terminal modification;
 KW magainin; inhibition; cell growth; viral replication; ionophore;
 KW membrane permeability; antimicrobial; anti-bacterial; antibiotic;
 KW anti-fungal; anti-viral; spermicidal; anti-tumour; anti-parasitic.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 1

FT /note= "N-terminal amino group is mono- or di-substd. by
FT lipophilic moiety, esp. octanoyl"
XX

PN WO9519370-A1.

XX

PD 20-JUL-1995.

XX

PF 18-JAN-1995; 95WO-US000714.

XX

PR 18-JAN-1994; 94US-00184462.

XX

PA (MAGA-) MAGAININ PHARM INC.

XX

PI Kari U, Williams TJ, Mclane M;

XX

DR WPI; 1995-263826/34.

XX

PT Ion channel-forming amphiphilic peptide(s) with N-terminal lipophilic
PT gps. - useful e.g. as antiviral, antibacterial, antiparasitic or
PT antitumour agents.

XX

PS Claim 25; Page 107; 139pp; English.

XX

CC The present peptide is a specific example corresp. to a highly generic
CC formula for ion channel forming peptides (ionophores). These ionophores
CC are known to have a broad range of potent antibiotic activity against
CC microorganisms including gram-positive and gram-negative bacteria, fungi,
CC viruses, protozoa and parasites. N-terminal modification (pref. mono-
CC substn. by octanoyl) to produce an ion-channel forming peptide having a
CC lipophilic N-terminus increases the biological activity of the peptides
CC against target cells, viruses and virally-infected cells, compared to
CC peptides substd. with an acetyl group at the N-terminus. Compositions
CC comprising the peptides with lipophilic modifications are claimed for
CC inhibiting growth of a target cell, virus or virally-infected cell

XX

SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.6e+03;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9

||||

Db 7 KLKK 10

RESULT 45

AAR90269

ID AAR90269 standard; peptide; 11 AA.

XX

AC AAR90269;

XX

DT 10-JUL-1996 (first entry)

XX

DE Ion-channel forming peptide #130 with lipophilic N-terminal group.

XX

KW Ion channel forming peptide; lipophilic; N-terminal modification;

KW magainin; inhibition; cell growth; viral replication; ionophore;
 KW membrane permeability; antimicrobial; anti-bacterial; antibiotic;
 KW anti-fungal; anti-viral; spermicidal; anti-tumour; anti-parasitic.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 1
 FT /note= "N-terminal amino group is mono- or di-substd. by
 FT lipophilic moiety, esp. octanoyl"
 XX
 PN WO9519370-A1.
 XX
 PD 20-JUL-1995.
 XX
 PF 18-JAN-1995; 95WO-US000714.
 XX
 PR 18-JAN-1994; 94US-00184462.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Kari U, Williams TJ, McLane M;
 XX
 DR WPI; 1995-263826/34.
 XX
 PT Ion channel-forming amphiphilic peptide(s) with N-terminal lipophilic
 PT gps. - useful e.g. as antiviral, antibacterial, antiparasitic or
 PT antitumour agents.
 XX
 PS Claim 34; Page 113; 139pp; English.
 XX
 CC The present peptide is a specific example corresp. to a highly generic
 CC formula for ion channel forming peptides (ionophores). These ionophores
 CC are known to have a broad range of potent antibiotic activity against
 CC microorganisms including gram-positive and gram-negative bacteria, fungi,
 CC viruses, protozoa and parasites. N-terminal modification (pref. mono-
 CC substn. by octanoyl) to produce an ion-channel forming peptide having a
 CC lipophilic N-terminus increases the biological activity of the peptides
 CC against target cells, viruses and virally-infected cells, compared to
 CC peptides substd. with an acetyl group at the N-terminus. Compositions
 CC comprising the peptides with lipophilic modifications are claimed for
 CC inhibiting growth of a target cell, virus or virally-infected cell
 XX
 SQ Sequence 11 AA;

 Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

 Qy 6 KLKK 9
 ||||
 Db 7 KLKK 10

 RESULT 46
 AAR99096
 ID AAR99096 standard; peptide; 11 AA.

XX
 AC AAR99096;
 XX
 DT 28-OCT-1996 (first entry)
 XX
 DE Magainin-derived antimicrobial STD-inhibiting peptide, MSI-591.
 XX
 KW STD; sexually transmitted disease; HIV; human immunodeficiency virus;
 KW herpes simplex virus; HSV; Neisseria gonorrhoeae; Candida; Chlamydia;
 KW magainin; antimicrobial; squalamine.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 1
 FT /label= OTHER
 FT /note= "OCT-Leu, where OCT is undefined in the
 FT specification"
 XX
 PN WO9608270-A2.
 XX
 PD 21-MAR-1996.
 XX
 PF 13-SEP-1995; 95WO-US011675.
 XX
 PR 13-SEP-1994; 94US-00305475.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Jacob L, Zasloff M, Williams T, Bedi G;
 XX
 DR WPI; 1996-179725/18.
 XX
 PT Inhibiting sexually transmitted disease e.g. HIV or herpes simplex - by
 PT administering magainin antimicrobial or squalamine cpd. to inhibit
 PT transmission.
 XX
 PS Claim 9; Page 55; 60pp; English.
 XX
 CC AAR99095-R99107 are antimicrobial, magainin-analogue peptides that may be
 CC used to treat sexually transmitted diseases (STDs) caused by Chlamydia,
 CC HIV, herpes simplex virus, Neisseria gonorrhoeae or Candida infection.
 CC The peptides inhibit STDs by either killing the infectious organism,
 CC impeding the infection mechanism or interrupting the replication cycle of
 CC the organism. Squalamine (an aminosterol host defence molecule of the dog
 CC fish shark Squalus acanthias) and PGLa (a frog antimicrobial peptide)
 CC analogues may also be useful in inhibiting STD infection and transmission
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 7 KLKK 10

RESULT 47

AAR99123

ID AAR99123 standard; peptide; 11 AA.

XX

AC AAR99123;

XX

DT 28-OCT-1996 (first entry)

XX

DE Magainin-derived antimicrobial STD-inhibiting peptide, MSI-591.

XX

KW STD; sexually transmitted disease; HIV; human immunodeficiency virus;

KW herpes simplex virus; HSV; Neisseria gonorrhoeae; Candida; Chlamydia;

KW magainin; antimicrobial; squalamine.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Misc-difference 1

FT /note= "OCT-Leu, where OCT is undefined in the
specification"

FT Modified-site 11

FT /note= "amidated"

XX

PN WO9608270-A2.

XX

PD 21-MAR-1996.

XX

PF 13-SEP-1995; 95WO-US011675.

XX

PR 13-SEP-1994; 94US-00305475.

XX

PA (MAGA-) MAGAININ PHARM INC.

XX

PI Jacob L, Zasloff M, Williams T, Bedi G;

XX

DR WPI; 1996-179725/18.

XX

PT Inhibiting sexually transmitted disease e.g. HIV or herpes simplex - by
PT administering magainin antimicrobial or squalamine cpd. to inhibit
PT transmission.

XX

PS Example 4; Page 39; 60pp; English.

XX

CC AAR99116-R99123 are antimicrobial, magainin-analogue peptides that may be
CC used to treat sexually transmitted diseases (STDs) caused by Chlamydia,
CC HIV, herpes simplex virus, Neisseria gonorrhoeae or Candida infection.

CC The peptides inhibit STDs by either killing the infectious organism,
CC impeding the infection mechanism or interrupting the replication cycle of
CC the organism. Squalamine (an aminosterol host defence molecule of the dog
CC fish shark Squalus acanthias) and PGLa (a frog antimicrobial peptide)
CC analogues may also be useful in inhibiting STD infection and transmission

XX

SQ Sequence 11 AA;

Query Match

36.4%; Score 4; DB 2; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
Db 7 KLKK 10

RESULT 48

AAW04041

ID AAW04041 standard; peptide; 11 AA.

XX

AC AAW04041;

XX

DT 01-NOV-1996 (first entry)

XX

DE Antifungal peptide XMP.350.

XX

KW Antifungal peptide; inhibitor; Domain III; polymorphonuclear leukocyte;
KW bactericidal/permeability-increasing protein; BPI; mammalian; PMN; fungi;
KW neutrophil; replication inhibitor; fungal infection; Aspergillus;
KW Cryptococcus; Candida; C.albicans; C.galabrat; C.krusei; C.lusitaniae;
KW C.parapsilosis; C.tropicalis; therapy.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 11

FT /note= "amidated"

XX

PN WO9608509-A1.

XX

PD 21-MAR-1996.

XX

PF 20-JUL-1995; 95WO-US009262.

XX

PR 15-SEP-1994; 94US-00306473.

PR 13-JAN-1995; 95US-00372105.

XX

PA (XOMA) XOMA CORP.

XX

PI Little RG, Lim E, Fadem MB;

XX

DR WPI; 1996-179900/18.

XX

PT Antifungal peptide(s) derived from Domain III of BPI protein - used in
PT vitro for killing or inhibiting replication of fungi, esp. Candida
PT species.

XX

PS Claim 5; Page 163; 199pp; English.

XX

CC AAW04000-W04160 represent antifungal peptides. These sequences are based
CC on (or derived from) Domain III of the bactericidal/permeability-
CC increasing protein (BPI). BPI is a protein that can be isolated from the
CC granules of mammalian polymorphonuclear leukocytes (PMNs or neutrophils).
CC These antifungal peptides can be used for killing, or inhibiting
CC replication of, fungi in vitro. These sequences can also be used for

CC treatment of a fungal infection involving fungi from the species Candida,
CC Aspergillus and Cryptococcus. The sequences are especially useful for
CC treating C.albicans, C.galabrat, C.krusei, C.lusitaniae, C.parapsilosis
CC and C.tropicalis infections
XX
SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKKK 10
| | | |
Db 8 LKKK 11

RESULT 49

AAW39163

ID AAW39163 standard; peptide; 11 AA.

XX

AC AAW39163;

XX

DT 27-AUG-2003 (revised)

DT 27-APR-1998 (first entry)

XX

DE RHAMM binding domain 1 consensus motif peptide.

XX

KW Hyaluronan receptor; receptor for hyaluronic acid mediated motility;

KW RHAMM; glycosaminoglycan; binding domain; human; mouse; rat; oncogene;

KW growth factor; cell locomotion disorder; treatment; dementia; detection;

KW inflammatory disorder; autoimmune disease; diagnosis; prognosis.

XX

OS Homo sapiens.

OS Mus sp.

OS Rattus sp.

XX

PN WO9738098-A1.

XX

PD 16-OCT-1997.

XX

PF 10-APR-1997; 97WO-CA000240.

XX

PR 10-APR-1996; 96GB-00007441.

XX

PA (UYMA-) UNIV MANITOBA.

PA (MANI-) MANITOBA CANCER TREATMENT & RES FOUND.

XX

PI Turley EA, Entwistle J;

XX

DR WPI; 1997-512715/47.

XX

PT Isolated human receptor for hyaluronic acid mediated motility - used to

PT develop products for treating e.g. tumours, inflammatory disorders,

PT dementia, AIDS, diabetes and auto-immune diseases.

XX

PS Claim 7; Fig 1; 66pp; English.

XX

CC This peptide represents a motif found in a binding domain of human, mouse
 CC and rat hyaluronan receptor corresponding to amino acid position 402-412.
 CC This receptor is also known as the receptor for hyaluronic acid mediated
 CC motility (RHAMM). Hyaluronan is a large glycosaminoglycan that is
 CC ubiquitous in the extracellular matrix and whose synthesis has been
 CC linked to cell migration, growth and transformation. It interacts with
 CC cell surfaces via specific protein receptors, e.g. RHAMM, that mediate
 CC many biological effects. The RHAMM/Hyaluronic acid interaction is
 CC involved in oncogene-and growth factor-mediated cell locomotion. The
 CC products can be used in the treatment of disorders involving cell
 CC locomotion, e.g. tumour invasion, birth defects, acute and chronic
 CC inflammatory disorders, Alzheimer's and other forms of dementia,
 CC including Parkinson's and Huntington's diseases, AIDS, diabetes,
 CC autoimmune diseases, corneal dysplasia and hypertrophies, burns, surgical
 CC incisions and adhesions, strokes and multiple sclerosis. They can also be
 CC used in e.g. CNS and spinal cord regeneration, contraception and in vitro
 CC fertilisation and embryo development. The products can also be used in
 CC detection, diagnosis and prognosis. (Updated on 27-AUG-2003 to correct OS
 CC field.)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 VKLK 8
 ||||
 Db 8 VKLK 11

RESULT 50

AAW44580

ID AAW44580 standard; peptide; 11 AA.

XX

AC AAW44580;

XX

DT 27-APR-1998 (first entry)

XX

DE Anti-fungal peptide #181 based on BPI protein (residues 142-169).

XX

KW Anti-fungal peptide; bactericidal-permeability-increasing protein; BPI;
 KW polymorphonuclear leukocyte; fungicide.

XX

OS Synthetic.

OS Mammalia.

XX

FH Key Location/Qualifiers

FT Modified-site 11

FT /note= "C-terminal amide"

XX

PN W09704008-A1.

XX

PD 06-FEB-1997.

XX

PF 21-MAR-1996; 96WO-US003845.

XX

PR 20-JUL-1995; 95US-00504841.

XX

PA (XOMA) XOMA CORP.

XX

PI Little RG, Lim E, Fadem MB;

XX

DR WPI; 1997-132578/12.

XX

PT Anti-fungal peptide(s) derived from or based on domain III of
PT bactericidal-permeability-increasing protein - are used in vitro or in
PT vivo as fungicides.

XX

PS Claim 1; Page 200; 230pp; English.

XX

CC This is a specifically claimed anti-fungal peptide which is based on
CC domain III (amino acids 142-160) of bactericidal-permeability-increasing
CC protein (BPI), isolated from the granules of mammalian polymorphonuclear
CC leukocytes. It is used in compositions with diluents, carriers or
CC adjuvants to treat fungal infections in patients. It may also be used in
CC vitro to kill or inhibit the replication of fungi, such as in
CC decontaminating fluids and sterilising medical and implant devices

XX

SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.6e+03;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKKK 10

||||

Db 8 LKKK 11

RESULT 51

AAW43762

ID AAW43762 standard; peptide; 11 AA.

XX

AC AAW43762;

XX

DT 20-APR-1998 (first entry)

XX

DE Bactericidal/permeability increasing peptide XMP.350.

XX

KW Bactericidal/permeability increasing peptide; BPI; fusion protein;

KW bacterial infection; fungal infection; endotoxin; heparin; angiogenesis;

KW fungicidal; recombinant DNA; vector.

XX

OS Homo sapiens.

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 11

FT /note= "Amidated"

XX

PN WO9735009-A1.

XX

PD 25-SEP-1997.

XX
 PF 18-MAR-1997; 97WO-US005287.
 XX
 PR 22-MAR-1996; 96US-00621803.
 XX
 PA (XOMA) XOMA CORP.
 XX
 PI Better MD;
 XX
 DR WPI; 1997-480215/44.
 XX
 PT Recombinant production of bactericidal/permeability increasing protein -
 PT by expression as a fusion protein in microbial host cells, then cleaving
 PT the BPI peptide from the carrier.
 XX
 PS Claim 10; Page 130; 186pp; English.
 XX
 CC A new recombinant DNA vector construct has been developed which encodes a
 CC fusion protein and is suitable for introduction into a bacterial host.
 CC The vector comprises: (a) DNA encoding at least one cationic
 CC bactericidal/permeability increasing peptide (BPI), (b) DNA encoding a
 CC carrier protein, and (c) DNA encoding an amino acid (aa) cleavage site
 CC located between (a) and (b). The present sequence represents a
 CC specifically claimed BPI peptide. The peptides have many uses including
 CC the treatment of bacterial and fungal infections. BPI peptides also bind
 CC to endotoxins and heparin, neutralising their effects. The peptides have
 CC further been shown to inhibit angiogenesis (partly due to heparin-binding
 CC activity). The fusion proteins have been found to be expressed in large
 CC amounts without significant proteolysis, and in some cases are actually
 CC secreted from the host cells. This allows the indirect production of anti
 CC -microbial BPI peptides in microbial hosts
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKKK 10
 ||||
 Db 8 LKKK 11

RESULT 52

AAW65554

ID AAW65554 standard; peptide; 11 AA.
 XX
 AC AAW65554;
 XX
 DT 15-OCT-1998 (first entry)
 XX
 DE Multiply branched peptide construct.
 XX
 KW Human immunodeficiency virus; envelope transmembrane glycoprotein; HIV;
 KW multiple branch peptide construction; polylysine core; receptor affinity;
 KW virostatic; MBPC; multiply branched peptide construct.
 XX

OS Synthetic.

OS Human immunodeficiency virus.

XX

FH	Key	Location/Qualifiers
FT	Peptide	1. .7
FT		/label= peptide_derived_from_gp41_of_HIV
FT		/note= "attached to the polylysine core via the alpha
FT		amino group of Lys(8); a second copy of the 7-mer is
FT		linked to Lys(8) via the omega amino group"
FT	Modified-site	8
FT		/note= "Lys(8) is linked to one copy of the gp41-derived
FT		peptide of HIV through the alpha amino group, and two a
FT		second copy of the peptide (not shown) via the omega
FT		group"
FT	Modified-site	9
FT		/note= "the alpha amino group of of Lys(9) forms a
FT		peptide linkage with the carboxyl group of Lys(8); the
FT		omega amino group of Lys(9) forms a peptide bond with a
FT		second Lys residue analogous to Lys(8)"
FT	Modified-site	10
FT		/note= "the alpha amimo group of Lys(10) forms a peptide
FT		linkage with the carboxyl amino group of Lys(9); the
FT		omega amino group of Lys(10) forms a peptide bond with a
FT		second Lys residue analagous to Lys(9)"
FT	Modified-site	11
FT		/label= bAla

XX

PN WO9829443-A1.

XX

PD 09-JUL-1998.

XX

PF 30-DEC-1997; 97WO-EP007334.

XX

PR 31-DEC-1996; 96GB-00027114.

XX

PA (ARME-) ARMEL SA.

XX

PI Mabrouk K, Sabatier J, Rochat H, Van Rietschoten J;

XX

DR WPI; 1998-388041/33.

XX

PT New multiply branched peptide construct - comprises core matrix and many

PT gp41-derived peptide(s) attached, useful for, e.g. treating human immune

PT deficiency virus infection.

XX

PS Disclosure; Page 3; 15pp; English.

XX

CC The invention relates to multiply branched peptide constructs which

CC comprise a core matrix having bonded to it 2-16 peptides each containing

CC the present (RQGY) sequence, preceded by 0-4 amino acids and followed by

CC 2-4 amino acids. The multiply branched peptide constructs are used to

CC treat human immune deficiency virus (HIV) infection (they interfere with

CC HIV-mediated cell fusion). Since the core matrix is hidden by attached

CC peptides, the multiply branched peptide construct is not antigenic. The

CC present sequence represents a multiply branched peptide construct

XX

SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 LKKK 10
||||
Db 7 LKKK 10

RESULT 53

AAW66522

ID AAW66522 standard; peptide; 11 AA.
XX
AC AAW66522;
XX
DT 25-NOV-1998 (first entry)
XX
DE Amphiphilic peptide.
XX
KW magainin; analogue; antimicrobial; antitumour; wound healing; CPF;
KW amphiphilic; XPF peptide.
XX
OS Synthetic.
XX
PN US5792831-A.
XX
PD 11-AUG-1998.
XX
PF 17-NOV-1994; 94US-00343882.
XX
PR 08-FEB-1990; 90US-00476629.
PR 14-MAY-1990; 90US-00522688.
PR 28-APR-1992; 92US-00874685.
PR 05-OCT-1993; 93US-00133740.
XX
PA (MAGA-) MAGAININ PHARM INC.
XX
PI Maloy WL;
XX
DR WPI; 1998-456190/39.
XX
PT Magainin peptide analogues - useful as antimicrobial or antitumour
PT agents, etc.
XX
PS Disclosure; Col 20; 25pp; English.
XX
CC The invention relates to analogues of a magainin I or II, D-form
CC analogues, deletion analogues or related peptides. It also relates to
CC basic polypeptides having at least 16 amino acids, including at least 8
CC hydrophobic amino acids and at least 8 hydrophilic amino acids. The
CC peptides may be used as antimicrobial agents, antiviral agents,
CC antibiotics, antitumour agents, antiparasitic agents, spermicides,
CC preservatives or sterilants, or agents for promoting wound healing. The
CC present sequence represents a specific example of a peptide disclosed in
CC the specification
XX

SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
||||
Db 7 KLKK 10

RESULT 54

AAW66523

ID AAW66523 standard; peptide; 11 AA.

XX

AC AAW66523;

XX

DT 25-NOV-1998 (first entry)

XX

DE Amphiphilic peptide.

XX

KW magainin; analogue; antimicrobial; antitumour; wound healing; CPF;

KW amphiphilic; XPF peptide.

XX

OS Synthetic.

XX

PN US5792831-A.

XX

PD 11-AUG-1998.

XX

PF 17-NOV-1994; 94US-00343882.

XX

PR 08-FEB-1990; 90US-00476629.

PR 14-MAY-1990; 90US-00522688.

PR 28-APR-1992; 92US-00874685.

PR 05-OCT-1993; 93US-00133740.

XX

PA (MAGA-) MAGAININ PHARM INC.

XX

PI Maloy WL;

XX

DR WPI; 1998-456190/39.

XX

PT Magainin peptide analogues - useful as antimicrobial or antitumour agents, etc.

XX

PS Disclosure; Col 20; 25pp; English.

XX

CC The invention relates to analogues of a magainin I or II, D-form
CC analogues, deletion analogues or related peptides. It also relates to
CC basic polypeptides having at least 16 amino acids, including at least 8
CC hydrophobic amino acids and at least 8 hydrophilic amino acids. The
CC peptides may be used as antimicrobial agents, antiviral agents,
CC antibiotics, antitumour agents, antiparasitic agents, spermicides,
CC preservatives or sterilants, or agents for promoting wound healing. The
CC present sequence represents a specific example of a peptide disclosed in
CC the specification

XX
SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
|||
Db 7 KLKK 10

RESULT 55

AAW66297

ID AAW66297 standard; peptide; 11 AA.

XX

AC AAW66297;

XX

DT 25-NOV-1998 (first entry)

XX

DE Amphiphilic peptide containing D-amino acids.

XX

KW magainin; analogue; antimicrobial; antitumour; wound healing.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Misc-difference 1. .14

FT /note= "each amino acid residue which is not a Gly
FT residue is a D-amino acid residue"

XX

PN US5792831-A.

XX

PD 11-AUG-1998.

XX

PF 17-NOV-1994; 94US-00343882.

XX

PR 08-FEB-1990; 90US-00476629.

PR 14-MAY-1990; 90US-00522688.

PR 28-APR-1992; 92US-00874685.

PR 05-OCT-1993; 93US-00133740.

XX

PA (MAGA-) MAGAININ PHARM INC.

XX

PI Maloy WL;

XX

DR WPI; 1998-456190/39.

XX

PT Magainin peptide analogues - useful as antimicrobial or antitumour
PT agents, etc.

XX

PS Example 1; Col 43-44; 25pp; English.

XX

CC The invention relates to analogues of a magainin I peptide of formula:

CC GIGKFLHSAGKFGKAFVGEIMKS or a magainin II peptide of formula:

CC GIGKFLHSAKKFGKAFVGEIMNS, where all amino acids other than Gly are D-amino
CC acids and the analogues are in carboxy- or amide-terminated form.

CC Magainin I or II analogues or related peptides may be used as
CC antimicrobial agents, antiviral agents, antibiotics, antitumour agents,
CC antiparasitic agents, spermicides, preservatives or sterilants, or agents
CC for promoting wound healing. The present sequence is shown in the
CC specification
XX
SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 KLKK 9
| | | |
Db 7 KLKK 10

RESULT 56

AAW66482

ID AAW66482 standard; peptide; 11 AA.

XX

AC AAW66482;

XX

DT 25-NOV-1998 (first entry)

XX

DE Amphiphilic peptide.

XX

KW magainin; analogue; antimicrobial; antitumour; wound healing; CPF;

KW amphiphilic; XPF peptide.

XX

OS Synthetic.

XX

PN US5792831-A.

XX

PD 11-AUG-1998.

XX

PF 17-NOV-1994; 94US-00343882.

XX

PR 08-FEB-1990; 90US-00476629.

PR 14-MAY-1990; 90US-00522688.

PR 28-APR-1992; 92US-00874685.

PR 05-OCT-1993; 93US-00133740.

XX

PA (MAGA-) MAGAININ PHARM INC.

XX

PI Maloy WL;

XX

DR WPI; 1998-456190/39.

XX

PT Magainin peptide analogues - useful as antimicrobial or antitumour
PT agents, etc.

XX

PS Disclosure; Col 17; 25pp; English.

XX

CC The invention relates to analogues of a magainin I or II, D-form
CC analogues, deletion analogues or related peptides. It also relates to
CC basic polypeptides having at least 16 amino acids, including at least 8

CC hydrophobic amino acids and at least 8 hydrophilic amino acids. The
CC peptides may be used as antimicrobial agents, antiviral agents,
CC antibiotics, antitumour agents, antiparasitic agents, spermicides,
CC preservatives or sterilants, or agents for promoting wound healing. The
CC present sequence represents a specific example of a peptide disclosed in
CC the specification

XX

SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9

||||

Db 3 KLKK 6

RESULT 57

AAW75190

ID AAW75190 standard; protein; 11 AA.

XX

AC AAW75190;

XX

DT 25-MAR-2003 (revised)

DT 28-JAN-1999 (first entry)

XX

DE Fragment of human secreted protein encoded by gene 56.

XX

KW Human; secreted protein; fusion protein; gene therapy; protein therapy;
KW diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;
KW developmental abnormality; foetal deficiency; blood; allergy; renal;
KW immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
KW inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;
KW cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
KW osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
KW endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.

XX

OS Homo sapiens.

XX

PN WO9839446-A2.

XX

PD 11-SEP-1998.

XX

PF 06-MAR-1998; 98WO-US004482.

XX

PR 07-MAR-1997; 97US-0038621P.

PR 07-MAR-1997; 97US-0040161P.

PR 07-MAR-1997; 97US-0040162P.

PR 07-MAR-1997; 97US-0040163P.

PR 07-MAR-1997; 97US-0040333P.

PR 07-MAR-1997; 97US-0040334P.

PR 07-MAR-1997; 97US-0040336P.

PR 07-MAR-1997; 97US-0040626P.

PR 11-APR-1997; 97US-0043311P.

PR 11-APR-1997; 97US-0043312P.

PR 11-APR-1997; 97US-0043313P.

PR	11-APR-1997;	97US-0043314P.
PR	11-APR-1997;	97US-0043315P.
PR	11-APR-1997;	97US-0043568P.
PR	11-APR-1997;	97US-0043569P.
PR	11-APR-1997;	97US-0043576P.
PR	11-APR-1997;	97US-0043578P.
PR	11-APR-1997;	97US-0043580P.
PR	11-APR-1997;	97US-0043669P.
PR	11-APR-1997;	97US-0043670P.
PR	11-APR-1997;	97US-0043671P.
PR	11-APR-1997;	97US-0043672P.
PR	11-APR-1997;	97US-0043674P.
PR	23-MAY-1997;	97US-0047492P.
PR	23-MAY-1997;	97US-0047500P.
PR	23-MAY-1997;	97US-0047501P.
PR	23-MAY-1997;	97US-0047502P.
PR	23-MAY-1997;	97US-0047503P.
PR	23-MAY-1997;	97US-0047581P.
PR	23-MAY-1997;	97US-0047582P.
PR	23-MAY-1997;	97US-0047583P.
PR	23-MAY-1997;	97US-0047584P.
PR	23-MAY-1997;	97US-0047585P.
PR	23-MAY-1997;	97US-0047586P.
PR	23-MAY-1997;	97US-0047587P.
PR	23-MAY-1997;	97US-0047588P.
PR	23-MAY-1997;	97US-0047589P.
PR	23-MAY-1997;	97US-0047590P.
PR	23-MAY-1997;	97US-0047592P.
PR	23-MAY-1997;	97US-0047593P.
PR	23-MAY-1997;	97US-0047594P.
PR	23-MAY-1997;	97US-0047595P.
PR	23-MAY-1997;	97US-0047596P.
PR	23-MAY-1997;	97US-0047597P.
PR	23-MAY-1997;	97US-0047598P.
PR	23-MAY-1997;	97US-0047599P.
PR	23-MAY-1997;	97US-0047600P.
PR	23-MAY-1997;	97US-0047601P.
PR	23-MAY-1997;	97US-0047612P.
PR	23-MAY-1997;	97US-0047613P.
PR	23-MAY-1997;	97US-0047614P.
PR	23-MAY-1997;	97US-0047615P.
PR	23-MAY-1997;	97US-0047617P.
PR	23-MAY-1997;	97US-0047618P.
PR	23-MAY-1997;	97US-0047632P.
PR	23-MAY-1997;	97US-0047633P.
PR	06-JUN-1997;	97US-0048964P.
PR	06-JUN-1997;	97US-0048974P.
PR	22-AUG-1997;	97US-0056630P.
PR	22-AUG-1997;	97US-0056631P.
PR	22-AUG-1997;	97US-0056632P.
PR	22-AUG-1997;	97US-0056636P.
PR	22-AUG-1997;	97US-0056637P.
PR	22-AUG-1997;	97US-0056662P.
PR	22-AUG-1997;	97US-0056664P.
PR	22-AUG-1997;	97US-0056845P.
PR	22-AUG-1997;	97US-0056862P.
PR	22-AUG-1997;	97US-0056864P.

PR 22-AUG-1997; 97US-0056872P.
PR 22-AUG-1997; 97US-0056874P.
PR 22-AUG-1997; 97US-0056875P.
PR 22-AUG-1997; 97US-0056876P.
PR 22-AUG-1997; 97US-0056877P.
PR 22-AUG-1997; 97US-0056878P.
PR 22-AUG-1997; 97US-0056879P.
PR 22-AUG-1997; 97US-0056880P.
PR 22-AUG-1997; 97US-0056881P.
PR 22-AUG-1997; 97US-0056882P.
PR 22-AUG-1997; 97US-0056884P.
PR 22-AUG-1997; 97US-0056886P.
PR 22-AUG-1997; 97US-0056887P.
PR 22-AUG-1997; 97US-0056888P.
PR 22-AUG-1997; 97US-0056889P.
PR 22-AUG-1997; 97US-0056892P.
PR 22-AUG-1997; 97US-0056893P.
PR 22-AUG-1997; 97US-0056894P.
PR 22-AUG-1997; 97US-0056903P.
PR 22-AUG-1997; 97US-0056908P.
PR 22-AUG-1997; 97US-0056909P.
PR 22-AUG-1997; 97US-0056910P.
PR 22-AUG-1997; 97US-0056911P.
PR 05-SEP-1997; 97US-0057650P.
PR 05-SEP-1997; 97US-0057761P.

XX

PA (HUMA-) HUMAN GENOME SCI INC.

XX

PI Ruben SM, Rosen CA, Fischer CL, Soppet DR, Carter KC;
PI Bednarik DP, Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM;
PI Ferrie AM, Duan R, Hu J, Florence KA, Olsen HS, Ebner R, Brewer LA;
PI Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;

XX

DR WPI; 1998-609887/51.

XX

PT New isolated human genes and the secreted polypeptides they encode -
PT useful for diagnosis and treatment of e.g. cancers, neurological
PT disorders, immune diseases, inflammation or blood disorders.

XX

PS Disclosure; Page 51; 447pp; English.

XX

CC This sequence represents a fragment of a secreted human protein encoded
CC by the nucleic acid molecule designated Gene 56 (AAV34209). The gene can
CC be used to generate fusion proteins by linking to the gene to a human
CC immunoglobulin Fc portion (e.g. AAV34145) for increasing the stability of
CC the fused protein as compared to the human protein only. The invention
CC relates to 70 novel genes and their fragments (nucleic acid sequences:
CC AAV34154-V34276; amino acid sequences AAW75057-W75179) which are useful
CC for preventing, treating or ameliorating medical conditions e.g. by
CC protein or gene therapy. Also, pathological conditions can be diagnosed
CC by determining the amount of the new polypeptides in a sample or by
CC determining the presence of mutations in the new polynucleotides.
CC Specific uses are described for each of the 70 polynucleotides, based on
CC which tissues they are most highly expressed in (see AAV34154 for
CC described uses). (Updated on 25-MAR-2003 to correct PF field.) (Updated
CC on 25-MAR-2003 to correct PI field.)

XX

SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGSA 4
||||
Db 3 AGSA 6

RESULT 58

AAY00557

ID AAY00557 standard; peptide; 11 AA.

XX

AC AAY00557;

XX

DT 07-MAY-1999 (first entry)

XX

DE Antifungal peptide XMP.350.

XX

KW Antifungal; BPI; bactericidal/permeability increasing protein;

KW Candida infection.

XX

OS Synthetic.

XX

PN US5858974-A.

XX

PD 12-JAN-1999.

XX

PF 21-MAR-1996; 96US-00621259.

XX

PR 20-JUL-1995; 95US-00504841.

XX

PA (XOMA) XOMA CORP.

XX

PI Fadem MB, Lim E, Little RG;

XX

DR WPI; 1999-119956/10.

XX

PT Antifungal peptides - comprising part of bactericidal or permeability-

PT increasing protein sequence or related sequence.

XX

PS Disclosure; Col 179-180; 132pp; English.

XX

CC New peptides are provided which are based on Domain III (amino acids 142-
CC 169) of human bactericidal/permeability-increasing protein (BPI). The
CC peptides all have a C-terminal amide. More particularly, the Claims
CC relate to: (1) a peptide that has an amino acid sequence of human BPI
CC from position 148 to position 161 (KSKVGWLIQLFHKK) and variants of the
CC sequence having antifungal activity; and (2) an antifungal peptide having
CC 6-14 amino acids comprising (a) a core sequence selected from LIQL, IQLF,
CC WLIQL, LIQLF and WLIQLF and (b) one or more cationic amino acids selected
CC from K, R, H, Orn (ornithine) and Dab (diaminobutyric acid) at the N
CC and/or C terminus of the core sequence. The new peptides are used for
CC killing or inhibiting replication of fungi in vitro; and for treating
CC fungal infections in vivo, in particular infections of Candida,

CC Aspergillus or Cryptococcus spp., especially C. albicans, C. krusei, C.
CC lusitaniae, C. parapsilosis or C. tropicalis. The peptide can be
CC administered topically, intravenously, orally or as an aerosol,
CC optionally together with a non-peptide antifungal agent

XX

SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKKK 10

||||

Db 8 LKKK 11

RESULT 59

AAY10749

ID AAY10749 standard; peptide; 11 AA.

XX

AC AAY10749;

XX

DT 11-MAY-1999 (first entry)

XX

DE Peptide used to make biologically active peptides.

XX

KW Sepsis; septic shock; Pseudomonas aeruginosa; cystic fibrosis;
KW antimicrobial; antiviral; antibacterial; antifungal; antitumour;
KW antiparasitic; spermicide; preservative; sterilant; disinfectant;
KW wound healing; burn; skin infection; eye infection; solid tumour;
KW leukaemia; non-small cell lung cancer; adenocarcinoma; plant infection;
KW periodontal disease; plaque; gingivitis; caries; Streptococcus mutans.

XX

OS Synthetic.

XX

PN WO9903488-A2.

XX

PD 28-JAN-1999.

XX

PF 15-JUL-1998; 98WO-US014610.

XX

PR 15-JUL-1997; 97US-00893006.

XX

PA (MAGA-) MAGAININ PHARM INC.

XX

PI Kari UP, Williams TJ, Mclane M;

XX

DR WPI; 1999-131859/11.

XX

PT Treating sepsis or septic shock with N-modified ion-channel forming
PT peptide - or its methane sulphonate derivative of reduced toxicity, also
PT generally useful as antimicrobial and antitumour agents.

XX

PS Example 1; Page 185; 202pp; English.

XX

CC AAY10640-795 represent peptides used in the production of biologically
CC active peptides with reduced toxicity. The biologically active peptides

CC are used to treat sepsis or septic shock, and comprise the formula: T-
CC N(W)-X, where X = biologically active, amphipathic, ion-channel forming
CC peptide or protein; T = lipophilic group; and W = hydrogen or T. The
CC peptides are particularly used to treat infections by Pseudomonas
CC aeruginosa in patients with cystic fibrosis, but more generally as anti-
CC microbial, antiviral, antibacterial, antifungal, antitumour or
CC antiparasitic agents, and also as spermicides, e.g. as preservatives,
CC sterilants, and disinfectants in human and veterinary medicine. They can
CC be used to stimulate wound healing, treat burns and/or skin and burn
CC infections, eye infections, solid tumours or leukaemia (particularly non-
CC small cell lung cancer and adenocarcinoma, including those resistant to
CC other antitumour agents), and also for treatment of infections in plants,
CC and, when formulated in oral hygiene formulations, for treating or
CC preventing periodontal disease, plaque, gingivitis and/or caries
CC (specifically by action on Streptococcus mutans)

XX

SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
| | | |
Db 7 KLKK 10

RESULT 60

AAY10769

ID AAY10769 standard; peptide; 11 AA.

XX

AC AAY10769;

XX

DT 11-MAY-1999 (first entry)

XX

DE Peptide used to make biologically active peptides.

XX

KW Sepsis; septic shock; Pseudomonas aeruginosa; cystic fibrosis;
KW antimicrobial; antiviral; antibacterial; antifungal; antitumour;
KW antiparasitic; spermicide; preservative; sterilant; disinfectant;
KW wound healing; burn; skin infection; eye infection; solid tumour;
KW leukaemia; non-small cell lung cancer; adenocarcinoma; plant infection;
KW periodontal disease; plaque; gingivitis; caries; Streptococcus mutans.

XX

OS Synthetic.

XX

PN WO9903488-A2.

XX

PD 28-JAN-1999.

XX

PF 15-JUL-1998; 98WO-US014610.

XX

PR 15-JUL-1997; 97US-00893006.

XX

PA (MAGA-) MAGAININ PHARM INC.

XX

PI Kari UP, Williams TJ, Mclane M;

XX
 DR WPI; 1999-131859/11.
 XX
 PT Treating sepsis or septic shock with N-modified ion-channel forming
 PT peptide - or its methane sulphonate derivative of reduced toxicity, also
 PT generally useful as antimicrobial and antitumour agents.
 XX
 PS Example 1; Page 192; 202pp; English.
 XX
 CC AAY10640-795 represent peptides used in the production of biologically
 CC active peptides with reduced toxicity. The biologically active peptides
 CC are used to treat sepsis or septic shock, and comprise the formula: T-
 CC N(W)-X, where X = biologically active, amphipathic, ion-channel forming
 CC peptide or protein; T = lipophilic group; and W = hydrogen or T. The
 CC peptides are particularly used to treat infections by Pseudomonas
 CC aeruginosa in patients with cystic fibrosis, but more generally as anti-
 CC microbial, antiviral, antibacterial, antifungal, antitumour or
 CC antiparasitic agents, and also as spermicides, e.g. as preservatives,
 CC sterilants, and disinfectants in human and veterinary medicine. They can
 CC be used to stimulate wound healing, treat burns and/or skin and burn
 CC infections, eye infections, solid tumours or leukaemia (particularly non-
 CC small cell lung cancer and adenocarcinoma, including those resistant to
 CC other antitumour agents), and also for treatment of infections in plants,
 CC and, when formulated in oral hygiene formulations, for treating or
 CC preventing periodontal disease, plaque, gingivitis and/or caries
 CC (specifically by action on Streptococcus mutans)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No: 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 7 KLKK 10

RESULT 61
 AAY10785
 ID AAY10785 standard; peptide; 11 AA.
 XX
 AC AAY10785;
 XX
 DT 11-MAY-1999 (first entry)
 XX
 DE Peptide used to make biologically active peptides.
 XX
 KW Sepsis; septic shock; Pseudomonas aeruginosa; cystic fibrosis;
 KW antimicrobial; antiviral; antibacterial; antifungal; antitumour;
 KW antiparasitic; spermicide; preservative; sterilant; disinfectant;
 KW wound healing; burn; skin infection; eye infection; solid tumour;
 KW leukaemia; non-small cell lung cancer; adenocarcinoma; plant infection;
 KW periodontal disease; plaque; gingivitis; caries; Streptococcus mutans.
 XX
 OS Synthetic.
 XX

PN WO9903488-A2.
 XX
 PD 28-JAN-1999.
 XX
 PF 15-JUL-1998; 98WO-US014610.
 XX
 PR 15-JUL-1997; 97US-00893006.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Kari UP, Williams TJ, Mclane M;
 XX
 DR WPI; 1999-131859/11.
 XX
 PT Treating sepsis or septic shock with N-modified ion-channel forming
 PT peptide - or its methane sulphonate derivative of reduced toxicity, also
 PT generally useful as antimicrobial and antitumour agents.
 XX
 PS Example 1; Page 198; 202pp; English.
 XX
 CC AAY10640-795 represent peptides used in the production of biologically
 CC active peptides with reduced toxicity. The biologically active peptides
 CC are used to treat sepsis or septic shock, and comprise the formula: T-
 CC N(W)-X, where X = biologically active, amphipathic, ion-channel forming
 CC peptide or protein; T = lipophilic group; and W = hydrogen or T. The
 CC peptides are particularly used to treat infections by Pseudomonas
 CC aeruginosa in patients with cystic fibrosis, but more generally as anti-
 CC microbial, antiviral, antibacterial, antifungal, antitumour or
 CC antiparasitic agents, and also as spermicides, e.g. as preservatives,
 CC sterilants, and disinfectants in human and veterinary medicine. They can
 CC be used to stimulate wound healing, treat burns and/or skin and burn
 CC infections, eye infections, solid tumours or leukaemia (particularly non-
 CC small cell lung cancer and adenocarcinoma, including those resistant to
 CC other antitumour agents), and also for treatment of infections in plants,
 CC and, when formulated in oral hygiene formulations, for treating or
 CC preventing periodontal disease, plaque, gingivitis and/or caries
 CC (specifically by action on Streptococcus mutans)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 7 KLKK 10

RESULT 62
 AAY10780
 ID AAY10780 standard; peptide; 11 AA.
 XX
 AC AAY10780;
 XX
 DT 11-MAY-1999 (first entry)
 XX

DE Peptide used to make biologically active peptides.
 XX
 KW Sepsis; septic shock; Pseudomonas aeruginosa; cystic fibrosis;
 KW antimicrobial; antiviral; antibacterial; antifungal; antitumour;
 KW antiparasitic; spermicide; preservative; sterilant; disinfectant;
 KW wound healing; burn; skin infection; eye infection; solid tumour;
 KW leukaemia; non-small cell lung cancer; adenocarcinoma; plant infection;
 KW periodontal disease; plaque; gingivitis; caries; Streptococcus mutans.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 2
 FT /note= "ornithine"
 XX
 PN WO9903488-A2.
 XX
 PD 28-JAN-1999.
 XX
 PF 15-JUL-1998; 98WO-US014610.
 XX
 PR 15-JUL-1997; 97US-00893006.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Kari UP, Williams TJ, Mclane M;
 XX
 DR WPI; 1999-131859/11.
 XX
 PT Treating sepsis or septic shock with N-modified ion-channel forming
 PT peptide - or its methane sulphonate derivative of reduced toxicity, also
 PT generally useful as antimicrobial and antitumour agents.
 XX
 PS Example 1; Page 196; 202pp; English.
 XX
 CC AAY10640-795 represent peptides used in the production of biologically
 CC active peptides with reduced toxicity. The biologically active peptides
 CC are used to treat sepsis or septic shock, and comprise the formula: T-
 CC N(W)-X, where X = biologically active, amphipathic, ion-channel forming
 CC peptide or protein; T = lipophilic group; and W = hydrogen or T. The
 CC peptides are particularly used to treat infections by Pseudomonas
 CC aeruginosa in patients with cystic fibrosis, but more generally as anti-
 CC microbial, antiviral, antibacterial, antifungal, antitumour or
 CC antiparasitic agents, and also as spermicides, e.g. as preservatives,
 CC sterilants, and disinfectants in human and veterinary medicine. They can
 CC be used to stimulate wound healing, treat burns and/or skin and burn
 CC infections, eye infections, solid tumours or leukaemia (particularly non-
 CC small cell lung cancer and adenocarcinoma, including those resistant to
 CC other antitumour agents), and also for treatment of infections in plants,
 CC and, when formulated in oral hygiene formulations, for treating or
 CC preventing periodontal disease, plaque, gingivitis and/or caries
 CC (specifically by action on Streptococcus mutans)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
| | | |
Db 7 KLKK 10

RESULT 63

AAY10750

ID AAY10750 standard; peptide; 11 AA.

XX

AC AAY10750;

XX

DT 11-MAY-1999 (first entry)

XX

DE Peptide used to make biologically active peptides.

XX

KW Sepsis; septic shock; Pseudomonas aeruginosa; cystic fibrosis;

KW antimicrobial; antiviral; antibacterial; antifungal; antitumour;

KW antiparasitic; spermicide; preservative; sterilant; disinfectant;

KW wound healing; burn; skin infection; eye infection; solid tumour;

KW leukaemia; non-small cell lung cancer; adenocarcinoma; plant infection;

KW periodontal disease; plaque; gingivitis; caries; Streptococcus mutans.

XX

OS Synthetic.

XX

PN WO9903488-A2.

XX

PD 28-JAN-1999.

XX

PF 15-JUL-1998; 98WO-US014610.

XX

PR 15-JUL-1997; 97US-00893006.

XX

PA (MAGA-) MAGAININ PHARM INC.

XX

PI Kari UP, Williams TJ, McLane M;

XX

DR WPI; 1999-131859/11.

XX

PT Treating sepsis or septic shock with N-modified ion-channel forming

PT peptide - or its methane sulphonate derivative of reduced toxicity, also

PT generally useful as antimicrobial and antitumour agents.

XX

PS Example 1; Page 186; 202pp; English.

XX

CC AAY10640-795 represent peptides used in the production of biologically
CC active peptides with reduced toxicity. The biologically active peptides

CC are used to treat sepsis or septic shock, and comprise the formula: T-
CC N(W)-X, where X = biologically active, amphipathic, ion-channel forming

CC peptide or protein; T = lipophilic group; and W = hydrogen or T. The

CC peptides are particularly used to treat infections by Pseudomonas

CC aeruginosa in patients with cystic fibrosis, but more generally as anti-

CC microbial, antiviral, antibacterial, antifungal, antitumour or

CC antiparasitic agents, and also as spermicides, e.g. as preservatives,

CC sterilants, and disinfectants in human and veterinary medicine. They can

CC be used to stimulate wound healing, treat burns and/or skin and burn

CC infections, eye infections, solid tumours or leukaemia (particularly non-
CC small cell lung cancer and adenocarcinoma, including those resistant to
CC other antitumour agents), and also for treatment of infections in plants,
CC and, when formulated in oral hygiene formulations, for treating or
CC preventing periodontal disease, plaque, gingivitis and/or caries
CC (specifically by action on Streptococcus mutans)

XX

SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.6e+03;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9

||||

Db 7 KLKK 10

RESULT 64

AAY10766

ID AAY10766 standard; peptide; 11 AA.

XX

AC AAY10766;

XX

DT 11-MAY-1999 (first entry)

XX

DE Peptide used to make biologically active peptides.

XX

KW Sepsis; septic shock; Pseudomonas aeruginosa; cystic fibrosis;

KW antimicrobial; antiviral; antibacterial; antifungal; antitumour;

KW antiparasitic; spermicide; preservative; sterilant; disinfectant;

KW wound healing; burn; skin infection; eye infection; solid tumour;

KW leukaemia; non-small cell lung cancer; adenocarcinoma; plant infection;

KW periodontal disease; plaque; gingivitis; caries; Streptococcus mutans.

XX

OS Synthetic.

XX

PN WO9903488-A2.

XX

PD 28-JAN-1999.

XX

PF 15-JUL-1998; 98WO-US014610.

XX

PR 15-JUL-1997; 97US-00893006.

XX

PA (MAGA-) MAGAININ PHARM INC.

XX

PI Kari UP, Williams TJ, Mclane M;

XX

DR WPI; 1999-131859/11.

XX

PT Treating sepsis or septic shock with N-modified ion-channel forming

PT peptide - or its methane sulphonate derivative of reduced toxicity, also

PT generally useful as antimicrobial and antitumour agents.

XX

PS Example 1; Page 191; 202pp; English.

XX

CC AAY10640-795 represent peptides used in the production of biologically
 CC active peptides with reduced toxicity. The biologically active peptides
 CC are used to treat sepsis or septic shock, and comprise the formula: T-
 CC N(W)-X, where X = biologically active, amphipathic, ion-channel forming
 CC peptide or protein; T = lipophilic group; and W = hydrogen or T. The
 CC peptides are particularly used to treat infections by Pseudomonas
 CC aeruginosa in patients with cystic fibrosis, but more generally as anti-
 CC microbial, antiviral, antibacterial, antifungal, antitumour or
 CC antiparasitic agents, and also as spermicides, e.g. as preservatives,
 CC sterilants, and disinfectants in human and veterinary medicine. They can
 CC be used to stimulate wound healing, treat burns and/or skin and burn
 CC infections, eye infections, solid tumours or leukaemia (particularly non-
 CC small cell lung cancer and adenocarcinoma, including those resistant to
 CC other antitumour agents), and also for treatment of infections in plants,
 CC and, when formulated in oral hygiene formulations, for treating or
 CC preventing periodontal disease, plaque, gingivitis and/or caries
 CC (specifically by action on Streptococcus mutans)

XX

SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 |
 |
 |
 |
 Db 7 KLKK 10

RESULT 65

AAY10733

ID AAY10733 standard; peptide; 11 AA.

XX

AC AAY10733;

XX

DT 11-MAY-1999 (first entry)

XX

DE Peptide used to make biologically active peptides.

XX

KW Sepsis; septic shock; Pseudomonas aeruginosa; cystic fibrosis;
 KW antimicrobial; antiviral; antibacterial; antifungal; antitumour;
 KW antiparasitic; spermicide; preservative; sterilant; disinfectant;
 KW wound healing; burn; skin infection; eye infection; solid tumour;
 KW leukaemia; non-small cell lung cancer; adenocarcinoma; plant infection;
 KW periodontal disease; plaque; gingivitis; caries; Streptococcus mutans.

XX

OS Synthetic.

XX

PN WO9903488-A2.

XX

PD 28-JAN-1999.

XX

PF 15-JUL-1998; 98WO-US014610.

XX

PR 15-JUL-1997; 97US-00893006.

XX

PA (MAGA-) MAGAININ PHARM INC.

XX
 PI Kari UP, Williams TJ, Mclane M;
 XX
 DR WPI; 1999-131859/11.
 XX
 PT Treating sepsis or septic shock with N-modified ion-channel forming
 PT peptide - or its methane sulphonate derivative of reduced toxicity, also
 PT generally useful as antimicrobial and antitumour agents.
 XX
 PS Disclosure; Page 180; 202pp; English.
 XX
 CC AAY10640-795 represent peptides used in the production of biologically
 CC active peptides with reduced toxicity. The biologically active peptides
 CC are used to treat sepsis or septic shock, and comprise the formula: T-
 CC N(W)-X, where X = biologically active, amphipathic, ion-channel forming
 CC peptide or protein; T = lipophilic group; and W = hydrogen or T. The
 CC peptides are particularly used to treat infections by Pseudomonas
 CC aeruginosa in patients with cystic fibrosis, but more generally as anti-
 CC microbial, antiviral, antibacterial, antifungal, antitumour or
 CC antiparasitic agents, and also as spermicides, e.g. as preservatives,
 CC sterilants, and disinfectants in human and veterinary medicine. They can
 CC be used to stimulate wound healing, treat burns and/or skin and burn
 CC infections, eye infections, solid tumours or leukaemia (particularly non-
 CC small cell lung cancer and adenocarcinoma, including those resistant to
 CC other antitumour agents), and also for treatment of infections in plants,
 CC and, when formulated in oral hygiene formulations, for treating or
 CC preventing periodontal disease, plaque, gingivitis and/or caries
 CC (specifically by action on Streptococcus mutans)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 3 KLKK 6

RESULT 66

AAY10751

ID AAY10751 standard; peptide; 11 AA.

XX

AC AAY10751;

XX

DT 11-MAY-1999 (first entry)

XX

DE Peptide used to make biologically active peptides.

XX

KW Sepsis; septic shock; Pseudomonas aeruginosa; cystic fibrosis;
 KW antimicrobial; antiviral; antibacterial; antifungal; antitumour;
 KW antiparasitic; spermicide; preservative; sterilant; disinfectant;
 KW wound healing; burn; skin infection; eye infection; solid tumour;
 KW leukaemia; non-small cell lung cancer; adenocarcinoma; plant infection;
 KW periodontal disease; plaque; gingivitis; caries; Streptococcus mutans.
 XX

OS Synthetic.
 XX
 PN WO9903488-A2.
 XX
 PD 28-JAN-1999.
 XX
 PF 15-JUL-1998; 98WO-US014610.
 XX
 PR 15-JUL-1997; 97US-00893006.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Kari UP, Williams TJ, McLane M;
 XX
 DR WPI; 1999-131859/11.
 XX
 PT Treating sepsis or septic shock with N-modified ion-channel forming
 PT peptide - or its methane sulphonate derivative of reduced toxicity, also
 PT generally useful as antimicrobial and antitumour agents.
 XX
 PS Disclosure; Page 186; 202pp; English.
 XX
 CC AAY10640-795 represent peptides used in the production of biologically
 CC active peptides with reduced toxicity. The biologically active peptides
 CC are used to treat sepsis or septic shock, and comprise the formula: T-
 CC N(W)-X, where X = biologically active, amphipathic, ion-channel forming
 CC peptide or protein; T = lipophilic group; and W = hydrogen or T. The
 CC peptides are particularly used to treat infections by Pseudomonas
 CC aeruginosa in patients with cystic fibrosis, but more generally as anti-
 CC microbial, antiviral, antibacterial, antifungal, antitumour or
 CC antiparasitic agents, and also as spermicides, e.g. as preservatives,
 CC sterilants, and disinfectants in human and veterinary medicine. They can
 CC be used to stimulate wound healing, treat burns and/or skin and burn
 CC infections, eye infections, solid tumours or leukaemia (particularly non-
 CC small cell lung cancer and adenocarcinoma, including those resistant to
 CC other antitumour agents), and also for treatment of infections in plants,
 CC and, when formulated in oral hygiene formulations, for treating or
 CC preventing periodontal disease, plaque, gingivitis and/or caries
 CC (specifically by action on Streptococcus mutans)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 3 KLKK 6

RESULT 67
 AAY10767
 ID AAY10767 standard; peptide; 11 AA.
 XX
 AC AAY10767;
 XX

DT 11-MAY-1999 (first entry)
 XX
 DE Peptide used to make biologically active peptides.
 XX
 KW Sepsis; septic shock; Pseudomonas aeruginosa; cystic fibrosis;
 KW antimicrobial; antiviral; antibacterial; antifungal; antitumour;
 KW antiparasitic; spermicide; preservative; sterilant; disinfectant;
 KW wound healing; burn; skin infection; eye infection; solid tumour;
 KW leukaemia; non-small cell lung cancer; adenocarcinoma; plant infection;
 KW periodontal disease; plaque; gingivitis; caries; Streptococcus mutans.
 XX
 OS Synthetic.
 XX
 PN WO9903488-A2.
 XX
 PD 28-JAN-1999.
 XX
 PF 15-JUL-1998; 98WO-US014610.
 XX
 PR 15-JUL-1997; 97US-00893006.
 XX
 PA (MAGA-) MAGAININ PHARM INC.
 XX
 PI Kari UP, Williams TJ, Mclane M;
 XX
 DR WPI; 1999-131859/11.
 XX
 PT Treating sepsis or septic shock with N-modified ion-channel forming
 PT peptide - or its methane sulphonate derivative of reduced toxicity, also
 PT generally useful as antimicrobial and antitumour agents.
 XX
 PS Example 1; Page 191; 202pp; English.
 XX
 CC AAY10640-795 represent peptides used in the production of biologically
 CC active peptides with reduced toxicity. The biologically active peptides
 CC are used to treat sepsis or septic shock, and comprise the formula: T-
 CC N(W)-X, where X = biologically active, amphipathic, ion-channel forming
 CC peptide or protein; T = lipophilic group; and W = hydrogen or T. The
 CC peptides are particularly used to treat infections by Pseudomonas
 CC aeruginosa in patients with cystic fibrosis, but more generally as anti-
 CC microbial, antiviral, antibacterial, antifungal, antitumour or
 CC antiparasitic agents, and also as spermicides, e.g. as preservatives,
 CC sterilants, and disinfectants in human and veterinary medicine. They can
 CC be used to stimulate wound healing, treat burns and/or skin and burn
 CC infections, eye infections, solid tumours or leukaemia (particularly non-
 CC small cell lung cancer and adenocarcinoma, including those resistant to
 CC other antitumour agents), and also for treatment of infections in plants,
 CC and, when formulated in oral hygiene formulations, for treating or
 CC preventing periodontal disease, plaque, gingivitis and/or caries
 CC (specifically by action on Streptococcus mutans)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
| | | |
Db 7 KLKK 10

RESULT 68

AAB26808

ID AAB26808 standard; peptide; 11 AA.

XX

AC AAB26808;

XX

DT 22-JAN-2001 (first entry)

XX

DE Phosphoryl group acceptor peptide used in CDK2 assay.

XX

KW Pyrrolopyridine derivative; organ transplant rejection; tumour growth;

KW alopecia; thrombocytopaenia; leukopaenia; mucocitis; restenosis;

KW plantar-palmar syndrome; atherosclerosis; rheumatoid arthritis;

KW angiogenesis; cirrhosis; psoriasis; diabetes mellitus; inflammation;

KW neurodegenerative disease; hyperproliferative disorder; cdk2;

KW Alzheimer's disease; viral; fungal; infection; cyclin-dependent kinase 2.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 1

FT /note= "Biotin-aminohexyl-Ala"

XX

PN WO200055159-A2.

XX

PD 21-SEP-2000.

XX

PF 03-MAR-2000; 2000WO-US005583.

XX

PR 04-MAR-1999; 99GB-00004995.

XX

PA (GLAX) GLAXO GROUP LTD.

XX

PI Harris PA, Kuyper LE, Lackey KE, Veal JM;

XX

DR WPI; 2000-594439/56.

XX

PT Pyrrolopyridine derivatives which are kinase inhibitors, useful for

PT treating e.g. organ transplant rejection, tumors, atherosclerosis and

PT rheumatoid arthritis.

XX

PS Disclosure; Page 79; 105pp; English.

XX

CC This invention relates to Pyrrolopyridine derivatives and their salts,

CC esters, amides, carbamates, solvates, polymorphs, hydrates, affinity

CC reagents and/or prodrugs. The pyrrolopyridine derivatives exhibit

CC immunosuppressive, cytostatic, antianaemic, vasotropic,

CC antiarteriosclerotic, antirheumatic, antiarthritic, hepatotropic,

CC nephrotropic, antidiabetic, antipsoriatic, neuroprotective,

CC ophthalmological, keratolytic, virucide, fungicide, and nootropic

CC activity. The derivatives are protein kinase and cyclin-dependent kinase

CC inhibitors. The pyrrolopyridine derivatives are used in the treatment of

CC organ transplant rejection, tumour growth, chemotherapy-induced alopecia,
 CC chemotherapy-induced thrombocytopaenia, chemotherapy-induced leukopaenia,
 CC mucocitis, plantar-palmar syndrome, restenosis, atherosclerosis,
 CC rheumatoid arthritis, angiogenesis, hepatic cirrhosis,
 CC glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis,
 CC thrombotic microangiopathy, glomerulopathy, psoriasis, diabetes mellitus,
 CC inflammation, neurodegenerative disease, macular degeneration, actinic
 CC keratosis, hyperproliferative disorders, Alzheimer's disease and viral or
 CC eukaryotic infection (e.g. fungal diseases). The present sequence
 CC represents a phosphoryl group acceptor peptide used in a cyclin-dependent
 CC kinase 2 (cdk2) assay, to assess the effectiveness of the inhibitors of
 CC the invention
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 3; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KKKA 11
 ||||
 Db 8 KKKA 11

RESULT 69

AAy88559

ID AAY88559 standard; peptide; 11 AA.

XX

AC AAY88559;

XX

DT 07-AUG-2000 (first entry)

XX

DE NCAM Igl binding peptide 114 used as a control peptide.

XX

KW NCAM; neural cell adhesion molecule; Igl; immunoglobulin domain 1;

KW neurite outgrowth promoter; proliferation; nerve damage; sclerosis;

KW impaired myelination; stroke; Parkinson's disease; memory; schizophrenia;

KW Alzheimer's disease; diabetes mellitus; circadian clock; nephrosis;

KW treatment; prosthetic nerve guide; treatment; nervous system.

XX

OS Synthetic.

XX

PN WO200018801-A2.

XX

PD 06-APR-2000.

XX

PF 23-SEP-1999; 99WO-DK000500.

XX

PR 29-SEP-1998; 98DK-00001232.

PR 29-APR-1999; 99DK-00000592.

XX

PA (RONN/) RONN L C B.

PA (BOCK/) BOCK E.

PA (HOLM/) HOLM A.

PA (OLSE/) OLSEN M.

PA (OSTE/) OSTERGAARD S.

PA (JENS/) JENSEN P H.

PA (POUL/) POULSEN F M.
 PA (SORO/) SOROKA V.
 PA (RALE/) RALETS I.
 PA (BERE/) BEREZIN V.
 XX
 PI Ronn LCB, Bock E, Holm A, Olsen M, Ostergaard S, Jensen PH;
 PI Poulsen FM, Soroka V, Ralets I, Berezin V;
 XX
 DR WPI; 2000-293111/25.
 XX
 PT Compositions that bind neural cell adhesion molecules useful for treating
 PT disorders of the nervous system and muscles e.g. Alzheimer's and
 PT Parkinson's diseases.
 XX
 PS Example 5; Fig 7; 119pp; English.
 XX
 CC Neural cell adhesion molecule (NCAM) is a cellular adhesion molecule.
 CC NCAM is found in three forms, two of which are transmembrane forms, while
 CC the third is attached via a lipid anchor to the cell membrane. All three
 CC NCAM forms have an extracellular structure consisting five immunoglobulin
 CC domains (Ig domains). The Ig domains are numbered 1 to 5 from the N-
 CC terminal. The invention relates to a compound containing a peptide which
 CC binds to the NCAM Ig1 domain. The compound binds to NCAM-Ig1/Ig2 domains,
 CC and is capable of stimulating or promoting neurite outgrowth from NCAM
 CC presenting cells, and is also capable of promoting the proliferation of
 CC NCAM presenting cells. The present sequence represents a control peptide
 CC used in the identification of those binding peptides which can be used in
 CC the compound. The compound may be used in the treatment of normal,
 CC degenerated or damaged NCAM presenting cells. The compound may in
 CC particular be used to treat diseases of the central and peripheral
 CC nervous systems such as post operative nerve damage, traumatic nerve
 CC damage, impaired myelination of nerve fibres, conditions resulting from a
 CC stroke, Parkinson's disease, Alzheimer's disease, dementias, sclerosis,
 CC nerve degeneration associated with diabetes mellitus, disorders affecting
 CC the circadian clock or neuro-muscular transmission and schizophrenia.
 CC Conditions affecting the muscles may also be treated with the compound,
 CC such as conditions associated with impaired function of neuromuscular
 CC connections (e.g. genetic or traumatic shock or traumatic atrophic muscle
 CC disorders). Conditions of the gonads, pancreas (e.g. diabetes mellitus
 CC types I and II), kidney (e.g. nephrosis), heart, liver and bowel may also
 CC be treated using the compound. The compound is used in a prosthetic nerve
 CC guide, and also to stimulate the ability to learn, and to stimulate the
 CC memory of a subject
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 3; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KKKA 11
 ||||
 Db 8 KKKA 11

RESULT 70
 AAY67919

ID AAY67919 standard; peptide; 11 AA.
 XX
 AC AAY67919;
 XX
 DT 23-MAR-2000 (first entry)
 XX
 DE Cyclin containing kinase substrate peptide SEQ ID NO:75.
 XX
 KW Protein kinase; phosphorylation site; signal transduction.
 XX
 OS Synthetic.
 XX
 PN US6004757-A.
 XX
 PD 21-DEC-1999.
 XX
 PF 06-JAN-1995; 95US-00369643.
 XX
 PR 07-JAN-1994; 94US-00178570.
 XX
 PA (BETH-) BETH ISRAEL HOSPITAL ASSOC.
 XX
 PI Cantley LC, Songyang Z;
 XX
 DR WPI; 2000-096301/08.
 XX
 PT Peptide substrate for a kinase, useful for determining substrate
 PT specificity.
 XX
 PS Example 10; Col 38; 69pp; English.
 XX
 CC The present invention describes a substrate for lck comprising a 9 amino
 CC acid peptide (I). Also described is a method of inhibiting kinase
 CC activity of lck by contacting it with (I) in vitro. The peptide is useful
 CC for determining substrate specificity of a protein kinase. Information on
 CC the substrate specificity of protein kinases in signal transduction would
 CC provide an insight into signal transduction mechanisms and could allow
 CC for the design of therapeutic agents. The present sequence represents a
 CC peptide used in the exemplification of the present invention
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 3; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KKKA 11
 ||||
 Db 8 KKKA 11

RESULT 71
 AAY95530
 ID AAY95530 standard; peptide; 11 AA.
 XX
 AC AAY95530;
 XX

DT 10-OCT-2000 (first entry)
 XX
 DE Transactivator of transcription (Tat) peptide R52.
 XX
 KW Transactivator of transcription; Tat; HIV; AIDS; Kaposi's sarcoma;
 KW antiviral; virucide; screening; retrovirus; antiretrovirus;
 KW acetamidino saccharide; guanidino saccharide; aminoglycoside; antibiotic;
 KW peptidomimetic.
 XX
 OS Human immunodeficiency virus.
 OS Synthetic.
 XX
 PN WO200039139-A1.
 XX
 PD 06-JUL-2000.
 XX
 PF 28-DEC-1999; 99WO-IL000704.
 XX
 PR 28-DEC-1998; 98IL-00127773.
 XX
 PA (YEDA) YEDA RES & DEV CO LTD.
 XX
 PI Lapidot A, Litovchick A, Evdokimov A;
 XX
 DR WPI; 2000-465729/40.
 XX
 PT Novel peptidomimetic conjugates of saccharides such as aminoglycoside
 PT antibiotics with acetamidino and guanidino compounds useful for treating
 PT HIV-infections, AIDS and AIDS manifestations such as Kaposi's sarcoma.
 XX
 PS Example 10; Page 27; 87pp; English.
 XX
 CC The present sequence is that of the model Tat (transactivator of
 CC transcription) peptide R52. Interaction of the HIV Tat with the
 CC transactivation responsive RNA (TAR) region of the HIV long terminal
 CC repeat regulates viral gene expression, and is an attractive target for
 CC drug design strategies. The invention is based on the discovery that by
 CC combining a carbohydrate skeleton, either a mono- or an oligosaccharide
 CC similar to aminoglycoside antibiotics, with side-chains of variable
 CC length bearing a guanidine moiety or a chemical group with a similar
 CC geometry and/or charge properties resembling peptide side chains, a new
 CC class of peptidomimetic TAR RNA binders is obtained that are anti-HIV
 CC compounds and suppress viral replication by inhibiting transactivation by
 CC Tat as well as by blocking viral entry to cells through chemokine
 CC receptor dependent mechanism. The present Tat peptide and a 31-nucleotide
 CC TAR RNA fragment (see AAA49983) were used in assays to screen for such
 CC compounds, which will be useful as antiviral, particularly
 CC antiretroviral, agents for treatment of HIV infection, AIDS and
 CC manifestations of AIDS, such as Kaposi's sarcoma
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 3; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KKKA 11

Db 8 KKKA 11

RESULT 72

AAB65481

ID AAB65481 standard; peptide; 11 AA.

XX

AC AAB65481;

XX

DT 27-MAR-2001 (first entry)

XX

DE Anti-fungal peptide XMP.350.

XX

KW Human; BPI; antifungal; polymorphonuclear leukocyte; neutrophil;

KW bactericidal/permeability-increasing protein; bactericidal;

KW fungal infection.

XX

OS Homo sapiens.

XX

PN US6156730-A.

XX

PD 05-DEC-2000.

XX

PF 08-JAN-1999; 99US-00227659.

XX

PR 12-MAR-1993; 93US-00030644.

PR 15-JUL-1993; 93US-00093202.

PR 14-JAN-1994; 94US-00183222.

PR 11-MAR-1994; 94US-00209762.

PR 11-JUL-1994; 94US-00273540.

PR 15-SEP-1994; 94US-00306473.

PR 13-JAN-1995; 95US-00372105.

PR 20-JUL-1995; 95US-00504841.

PR 21-MAR-1996; 96US-00621259.

XX

PA (XOMA) XOMA CORP.

XX

PI Lim E, Fadem MB, Little RG;

XX

DR WPI; 2001-090160/10.

XX

PT Novel anti-fungal peptides derived from domain III of

PT bactericidal/permeability-increasing protein useful for killing or

PT inhibiting replication of fungi and for treating fungal infections.

XX

PS Example 2; Col 185-186; 134pp; English.

XX

CC The present invention relates to antifungal peptides (see AAB65301-

CC B65550) derived from Domain III (amino acids 142-169) of

CC bactericidal/permeability-increasing protein (BPI). The present sequence

CC is one such antifungal peptide. BPI is a protein isolated from the

CC granules of mammalian polymorphonuclear leukocytes (PMNs or neutrophils).

CC BPI has potent bactericidal activity against a broad range of gram-

CC negative bacteria. The peptides of the present invention are useful for

CC killing or inhibiting replication of fungi, and treating infections

CC caused by fungus belonging to Candida, Aspergillus, Cryptococcus species

CC such as C.albicans, C.glabrata, C.krusei, C.lusitaniae, C.parapsilosis
CC and C.tropicalis
XX
SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKKK 10
| | | |
Db 8 LKKK 11

RESULT 73

AAU00690

ID AAU00690 standard; protein; 11 AA.

XX

AC AAU00690;

XX

DT 07-SEP-2001 (first entry)

XX

DE Thymosin beta family consensus sequence.

XX

KW Thymosin-beta-10-like protein; ephrin type-A receptor 8-like protein;
KW proteoglycan-like protein; fibromodulin; fibronectin; thymic immune cell;
KW spermatogenesis; male infertility; neoplasia; red blood cell; platelet;
KW small cell lung cancer; GPI-anchored ephrin-A ligand; prostate cancer;
KW neurological disorder; cardiac disorder; vascular disorder; orthopaedic;
KW inflammatory disease; rheumatoid arthritis; connective tissue;
KW congenital muscular dystrophy; chemotherapy; immunotherapy.

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT Misc-difference 6

FT /label= Glu or Asn

FT Misc-difference 8

FT /label= Gln or Glu

XX

PN WO200129217-A2.

XX

PD 26-APR-2001.

XX

PF 13-OCT-2000; 2000WO-US028474.

XX

PR 15-OCT-1999; 99US-0159805P.

PR 18-OCT-1999; 99US-0159992P.

PR 22-OCT-1999; 99US-0160952P.

PR 12-OCT-2000; 2000US-00159805.

XX

PA (CURA-) CURAGEN CORP.

XX

PI Prayaga SK, Taupier RJ, Bandaru R;

XX

DR WPI; 2001-308489/32.

XX

PT New isolated polypeptides, NOV 1-3, having identity to thymosin-beta-10,
PT ephrin type-A receptor 8 and proteoglycans, and polynucleotides, useful
PT for treating male infertility, neurological or cardiac disease or
PT rheumatoid arthritis.
XX
PS Disclosure; Page 5; 102pp; English.
XX
CC The sequence represents a thymosin beta family consensus sequence. The
CC thymosin-beta-10-like protein (NOV1) is a member of the thymosin beta
CC family. NOV1, ephrin type-A receptor 8-like protein (NOV2) and
CC proteoglycan-like proteins (NOV3) may be used in the diagnosis, treatment
CC and prevention of disorders caused by abnormal expression or activity of
CC thymosin-beta-10, ephrin type-A receptor 8 and proteoglycans such as
CC fibromodulin and fibronectin. The polypeptides of the invention are
CC useful in screening for agents that modulate their activity, and in
CC determining predispositions to disorders. NOV1 is useful for treating
CC conditions involving development, differentiation, and activation of
CC thymic immune cells, in pathologies related to spermatogenesis and male
CC infertility, diagnosis of neoplasias, in diseases or pathologies of red
CC blood cells or platelets, in detection of small cell lung cancer. NOV1
CC nucleic acids can be combined in chemo-immunotherapeutical anti-cancer
CC treatments. NOV2 is useful for detecting cells expressing GPI-anchored
CC ephrin-A ligands, as a marker for prostate cancer, and in treating
CC neurological, cardiac and vascular disorders. NOV3 (proteoglycan) nucleic
CC acids and proteins are useful for treating orthopaedic disorders and/or
CC injuries, and inflammatory diseases of connective tissues e.g. rheumatoid
CC arthritis, congenital muscular dystrophies
XX
SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
| | | |
Db 1 KLKK 4

RESULT 74

ABP19373

ID ABP19373 standard; peptide; 11 AA.

XX

AC ABP19373;

XX

DT 11-SEP-2003 (revised)

DT 15-JUL-2002 (first entry)

XX

DE HIV B62 super motif pol peptide #379.

XX

KW HIV; HIV-1; human immunodeficiency virus; env; pol; gag; nef; vpr; vpu;
KW vif; tat; cytotoxic T lymphocyte; CTL; immune response; epitope; antigen;
KW vaccine; HIV infection; immunisation; virucide.

XX

OS Human immunodeficiency virus 1.

XX

PN WO200124810-A1.

XX
 PD 12-APR-2001.
 XX
 PF 05-OCT-2000; 2000WO-US027766.
 XX
 PR 05-OCT-1999; 99US-00412863.
 XX
 PA (EPIM-) EPIMMUNE INC.
 XX
 PI Sette A, Sidney J, Southwood S, Livingston BD, Chesnut R;
 PI Baker DM, Celis E, Kubo RT, Grey HM;
 XX
 DR WPI; 2001-354887/37.
 XX
 PT Vaccine compositions comprising human immunodeficiency virus-1 (HIV-1)
 PT peptide groups, useful for vaccinating against HIV-1.
 XX
 PS Claim 32; Page 265; 448pp; English.
 XX
 CC The present invention describes a composition (I) comprising a prepared
 CC human immunodeficiency virus-1 (HIV-1) group comprising an amino acid
 CC sequence selected from 51 defined amino acid sequences (ABL25347 to
 CC ABP25397). (I) has virucide activity and can be used in vaccines. (I) may
 CC be used for immunising subjects against HIV-1 infections. The use of
 CC group-based vaccines has several advantages over traditional vaccines,
 CC particularly when compared to the use of whole antigens in vaccine
 CC compositions. There is evidence that the immune response to whole
 CC antigens is directed largely toward variable regions of the antigen,
 CC allowing for immune escape due to mutations. The groups for inclusion in
 CC an group-based vaccine may be selected from conserved regions of viral or
 CC tumour-associated antigens, which therefore reduces the likelihood of
 CC escape mutants. Furthermore, immunosuppressive groups that may be present
 CC in whole antigens can be avoided with the use of group-based vaccines. An
 CC additional advantage of an group-based vaccine approach is the ability to
 CC combine selected groups (CTL and HTL), and further, to modify the
 CC composition of the groups, achieving, for example, enhanced
 CC immunogenicity. Accordingly, the immune response can be modulated, as
 CC appropriate, for the target disease. Similar engineering of the response
 CC is not possible with traditional approaches. ABP11501 to ABP25412
 CC represent peptide sequences used in the exemplification of the present
 CC invention. (Updated on 11-SEP-2003 to standardise OS field)
 XX
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 4; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKKK 10
 ||||
 Db 5 LKKK 8

RESULT 75
 ABP13804
 ID ABP13804 standard; peptide; 11 AA.
 XX

AC ABP13804;
XX
DT 11-SEP-2003 (revised)
DT 15-JUL-2002 (first entry)
XX
DE HIV A02 super motif pol peptide #719.
XX
KW HIV; HIV-1; human immunodeficiency virus; env; pol; gag; nef; vpr; vpu;
KW vif; tat; cytotoxic T lymphocyte; CTL; immune response; epitope; antigen;
KW vaccine; HIV infection; immunisation; virucide.
XX
OS Human immunodeficiency virus 1.
XX
PN WO200124810-A1.
XX
PD 12-APR-2001.
XX
PF 05-OCT-2000; 2000WO-US027766.
XX
PR 05-OCT-1999; 99US-00412863.
XX
PA (EPIM-) EPIMMUNE INC.
XX
PI Sette A, Sidney J, Southwood S, Livingston BD, Chesnut R;
PI Baker DM, Celis E, Kubo RT, Grey HM;
XX
DR WPI; 2001-354887/37.
XX
PT Vaccine compositions comprising human immunodeficiency virus-1 (HIV-1)
PT peptide groups, useful for vaccinating against HIV-1.
XX
PS Claim 32; Page 151; 448pp; English.
XX
CC The present invention describes a composition (I) comprising a prepared
CC human immunodeficiency virus-1 (HIV-1) group comprising an amino acid
CC sequence selected from 51 defined amino acid sequences (ABL25347 to
CC ABP25397). (I) has virucide activity and can be used in vaccines. (I) may
CC be used for immunising subjects against HIV-1 infections. The use of
CC group-based vaccines has several advantages over traditional vaccines,
CC particularly when compared to the use of whole antigens in vaccine
CC compositions. There is evidence that the immune response to whole
CC antigens is directed largely toward variable regions of the antigen,
CC allowing for immune escape due to mutations. The groups for inclusion in
CC an group-based vaccine may be selected from conserved regions of viral or
CC tumour-associated antigens, which therefore reduces the likelihood of
CC escape mutants. Furthermore, immunosuppressive groups that may be present
CC in whole antigens can be avoided with the use of group-based vaccines. An
CC additional advantage of an group-based vaccine approach is the ability to
CC combine selected groups (CTL and HTL), and further, to modify the
CC composition of the groups, achieving, for example, enhanced
CC immunogenicity. Accordingly, the immune response can be modulated, as
CC appropriate, for the target disease. Similar engineering of the response
CC is not possible with traditional approaches. ABP11501 to ABP25412
CC represent peptide sequences used in the exemplification of the present
CC invention. (Updated on 11-SEP-2003 to standardise OS field)
XX
SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKKK 10
| | | |
Db 4 LKKK 7

Search completed: April 8, 2004, 15:39:52
Job time : 44.3077 secs

OM protein - protein search, using sw model

Run on: April 8, 2004, 15:30:08 ; Search time 11.3077 Seconds
 (without alignments)
 50.221 Million cell updates/sec

Title: US-09-787-443A-4
 Perfect score: 11
 Sequence: 1 AGSAVKLKKKA 11

Scoring table: OLIGO
 Gapop 60.0 , Gapext 60.0

Searched: 389414 seqs, 51625971 residues

Word size : 0

Total number of hits satisfying chosen parameters: 8542

Minimum DB seq length: 11
 Maximum DB seq length: 11

Post-processing: Listing first 100 summaries

Database : Issued Patents AA:*
 1: /cgn2_6/ptodata/2/iaa/5A_COMB.pep:*
 2: /cgn2_6/ptodata/2/iaa/5B_COMB.pep:*
 3: /cgn2_6/ptodata/2/iaa/6A_COMB.pep:*
 4: /cgn2_6/ptodata/2/iaa/6B_COMB.pep:*
 5: /cgn2_6/ptodata/2/iaa/PCTUS_COMB.pep:*
 6: /cgn2_6/ptodata/2/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	%		DB	ID	Description
		Query Match	Length			
1	4	36.4	11	1	US-07-725-331-67	Sequence 67, Appl
2	4	36.4	11	1	US-08-193-521-1	Sequence 1, Appli
3	4	36.4	11	1	US-08-193-521-17	Sequence 17, Appl
4	4	36.4	11	1	US-08-193-521-18	Sequence 18, Appl
5	4	36.4	11	1	US-08-178-570-75	Sequence 75, Appl
6	4	36.4	11	1	US-08-434-120-95	Sequence 95, Appl
7	4	36.4	11	1	US-08-434-120-111	Sequence 111, App
8	4	36.4	11	1	US-08-434-120-112	Sequence 112, App
9	4	36.4	11	1	US-08-465-325-94	Sequence 94, Appl
10	4	36.4	11	1	US-08-465-325-110	Sequence 110, App
11	4	36.4	11	1	US-08-465-325-111	Sequence 111, App

12	4	36.4	11	1	US-08-465-325-112	Sequence 112, App
13	4	36.4	11	1	US-08-465-325-127	Sequence 127, App
14	4	36.4	11	1	US-08-465-325-128	Sequence 128, App
15	4	36.4	11	1	US-08-465-325-130	Sequence 130, App
16	4	36.4	11	1	US-08-465-325-141	Sequence 141, App
17	4	36.4	11	1	US-08-465-325-146	Sequence 146, App
18	4	36.4	11	1	US-08-343-882-11	Sequence 11, Appl
19	4	36.4	11	2	US-08-621-803-206	Sequence 206, App
20	4	36.4	11	2	US-08-621-259A-181	Sequence 181, App
21	4	36.4	11	3	US-08-369-643-75	Sequence 75, Appl
22	4	36.4	11	3	US-09-217-352-206	Sequence 206, App
23	4	36.4	11	4	US-09-115-737-94	Sequence 94, Appl
24	4	36.4	11	4	US-09-115-737-110	Sequence 110, App
25	4	36.4	11	4	US-09-115-737-111	Sequence 111, App
26	4	36.4	11	4	US-09-115-737-112	Sequence 112, App
27	4	36.4	11	4	US-09-115-737-127	Sequence 127, App
28	4	36.4	11	4	US-09-115-737-128	Sequence 128, App
29	4	36.4	11	4	US-09-115-737-130	Sequence 130, App
30	4	36.4	11	4	US-09-115-737-141	Sequence 141, App
31	4	36.4	11	4	US-09-115-737-146	Sequence 146, App
32	4	36.4	11	4	US-09-148-545-274	Sequence 274, App
33	4	36.4	11	4	US-09-677-664B-181	Sequence 181, App
34	4	36.4	11	5	PCT-US91-05047-67	Sequence 67, Appl
35	4	36.4	11	5	PCT-US95-00147-75	Sequence 75, Appl
36	4	36.4	11	5	PCT-US95-09262-181	Sequence 181, App
37	4	36.4	11	6	5188961-5	Patent No. 5188961
38	3	27.3	11	1	US-07-664-989B-17	Sequence 17, Appl
39	3	27.3	11	1	US-07-830-330-2	Sequence 2, Appli
40	3	27.3	11	1	US-07-914-280-10	Sequence 10, Appl
41	3	27.3	11	1	US-07-914-280-11	Sequence 11, Appl
42	3	27.3	11	1	US-08-049-871-6	Sequence 6, Appli
43	3	27.3	11	1	US-07-819-893-6	Sequence 6, Appli
44	3	27.3	11	1	US-08-029-333-37	Sequence 37, Appl
45	3	27.3	11	1	US-07-694-983-15	Sequence 15, Appl
46	3	27.3	11	1	US-08-116-733-35	Sequence 35, Appl
47	3	27.3	11	1	US-08-218-025A-75	Sequence 75, Appl
48	3	27.3	11	1	US-08-218-025A-163	Sequence 163, App
49	3	27.3	11	1	US-08-280-397-6	Sequence 6, Appli
50	3	27.3	11	1	US-08-378-761A-68	Sequence 68, Appl
51	3	27.3	11	1	US-08-485-286-68	Sequence 68, Appl
52	3	27.3	11	1	US-08-299-249A-13	Sequence 13, Appl
53	3	27.3	11	1	US-08-465-325-131	Sequence 131, App
54	3	27.3	11	1	US-08-465-325-151	Sequence 151, App
55	3	27.3	11	1	US-08-449-207-2	Sequence 2, Appli
56	3	27.3	11	1	US-08-156-552A-17	Sequence 17, Appl
57	3	27.3	11	1	US-08-416-035-8	Sequence 8, Appli
58	3	27.3	11	1	US-08-552-907-16	Sequence 16, Appl
59	3	27.3	11	1	US-08-443-568B-21	Sequence 21, Appl
60	3	27.3	11	1	US-08-542-363-21	Sequence 21, Appl
61	3	27.3	11	1	US-08-248-357C-6	Sequence 6, Appli
62	3	27.3	11	1	US-08-082-269D-2	Sequence 2, Appli
63	3	27.3	11	1	US-08-218-026-50	Sequence 50, Appl
64	3	27.3	11	1	US-08-856-053-17	Sequence 17, Appl
65	3	27.3	11	2	US-08-478-386A-59	Sequence 59, Appl
66	3	27.3	11	2	US-08-653-632-50	Sequence 50, Appl
67	3	27.3	11	2	US-08-292-597-59	Sequence 59, Appl
68	3	27.3	11	2	US-08-456-112B-35	Sequence 35, Appl

69	3	27.3	11	2	US-08-701-124-19	Sequence 19, Appl
70	3	27.3	11	2	US-08-618-696-5	Sequence 5, Appli
71	3	27.3	11	2	US-08-618-696-18	Sequence 18, Appl
72	3	27.3	11	2	US-08-388-653-59	Sequence 59, Appl
73	3	27.3	11	2	US-08-473-985-59	Sequence 59, Appl
74	3	27.3	11	2	US-08-428-257A-54	Sequence 54, Appl
75	3	27.3	11	2	US-08-537-400-31	Sequence 31, Appl
76	3	27.3	11	2	US-08-350-260A-509	Sequence 509, App
77	3	27.3	11	2	US-08-413-708B-3	Sequence 3, Appli
78	3	27.3	11	2	US-08-310-912A-28	Sequence 28, Appl
79	3	27.3	11	2	US-08-483-898-59	Sequence 59, Appl
80	3	27.3	11	3	US-08-105-904B-9	Sequence 9, Appli
81	3	27.3	11	3	US-08-105-904B-21	Sequence 21, Appl
82	3	27.3	11	3	US-09-087-716-59	Sequence 59, Appl
83	3	27.3	11	3	US-08-691-045-16	Sequence 16, Appl
84	3	27.3	11	3	US-09-033-753-5	Sequence 5, Appli
85	3	27.3	11	3	US-09-033-753-18	Sequence 18, Appl
86	3	27.3	11	3	US-08-970-833-8	Sequence 8, Appli
87	3	27.3	11	3	US-09-015-003-5	Sequence 5, Appli
88	3	27.3	11	3	US-09-157-753-59	Sequence 59, Appl
89	3	27.3	11	3	US-09-157-230-59	Sequence 59, Appl
90	3	27.3	11	3	US-09-087-811-59	Sequence 59, Appl
91	3	27.3	11	3	US-09-130-225-19	Sequence 19, Appl
92	3	27.3	11	3	US-09-156-855-59	Sequence 59, Appl
93	3	27.3	11	3	US-09-188-579-77	Sequence 77, Appl
94	3	27.3	11	3	US-08-893-749-17	Sequence 17, Appl
95	3	27.3	11	3	US-08-841-089-28	Sequence 28, Appl
96	3	27.3	11	3	US-09-158-010-59	Sequence 59, Appl
97	3	27.3	11	3	US-09-087-647-59	Sequence 59, Appl
98	3	27.3	11	3	US-08-114-877A-9	Sequence 9, Appli
99	3	27.3	11	3	US-08-114-877A-14	Sequence 14, Appl
100	3	27.3	11	3	US-09-100-089-21	Sequence 21, Appl

ALIGNMENTS

RESULT 1

US-07-725-331-67

; Sequence 67, Application US/07725331

; Patent No. 5294605

; GENERAL INFORMATION:

; APPLICANT: Houghten, Richard

; APPLICANT: Blondelle, Sylvie

; TITLE OF INVENTION: Amphiphilic Peptide Compositions and

; TITLE OF INVENTION: Analogues Thereof

; NUMBER OF SEQUENCES: 68

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Dressler, Goldsmith, Sutker, Shore,

; ADDRESSEE: & Milnamow

; STREET: 180 No. 5294605th Stetson

; CITY: Chicago

; STATE: IL

; COUNTRY: USA

; ZIP: 60601

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

```

;   COMPUTER:  IBM PC compatible
;   OPERATING SYSTEM:  PC-DOS/MS-DOS
;   SOFTWARE:  PatentIn Release #1.24
;   CURRENT APPLICATION DATA:
;   APPLICATION NUMBER:  US/07/725,331
;   FILING DATE:
;   CLASSIFICATION:  514
;   PRIOR APPLICATION DATA:
;   APPLICATION NUMBER:  US 07/554,422
;   FILING DATE:  19-JUL-1990
;   ATTORNEY/AGENT INFORMATION:
;   NAME:  Gamson, Edward P.
;   REGISTRATION NUMBER:  29,381
;   REFERENCE/DOCKET NUMBER:  421250-80
;   TELECOMMUNICATION INFORMATION:
;   TELEPHONE:  3126165418
;   TELEFAX:  3126165460
;   INFORMATION FOR SEQ ID NO:  67:
;   SEQUENCE CHARACTERISTICS:
;   LENGTH:  11 amino acids
;   TYPE:  amino acid
;   STRANDEDNESS:
;   TOPOLOGY:  linear
;   MOLECULE TYPE:  peptide
;   FEATURE:
;   OTHER INFORMATION:  C-terminal amide, may be
;   OTHER INFORMATION:  acetylated at N-terminus.
US-07-725-331-67

```

```

Query Match          36.4%;  Score 4;  DB 1;  Length 11;
Best Local Similarity 100.0%;  Pred. No. 4.7e+02;
Matches      4;  Conservative      0;  Mismatches      0;  Indels      0;  Gaps      0;

```

```

Qy      6 KLKK 9
        ||||
Db      3 KLKK 6

```

RESULT 2

```

US-08-193-521-1
; Sequence 1, Application US/08193521
; Patent No. 5470950
; GENERAL INFORMATION:
;   APPLICANT:  Maloy, W. Lee
;   APPLICANT:  Kari, U. Prasad
;   APPLICANT:  Williams, Jon I.
;   TITLE OF INVENTION:  Biologically Active Peptide
;   TITLE OF INVENTION:  Compositions and Uses Therefor
;   NUMBER OF SEQUENCES:  19
;   CORRESPONDENCE ADDRESS:
;   ADDRESSEE:  Carella, Byrne, Bain, Gilfillan,
;   ADDRESSEE:  Cecchi & Stewart
;   STREET:  6 Becker Farm Road
;   CITY:  Roseland
;   STATE:  New Jersey
;   COUNTRY:  USA
;   ZIP:  07068

```

```

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: DW4.V2
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/193,521
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/870,960
; FILING DATE:
; APPLICATION NUMBER: 07/760,054
; FILING DATE: 13-SEP-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Olstein, Elliot M.
; REGISTRATION NUMBER: 24,025
; REFERENCE/DOCKET NUMBER: 421250-161
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-994-1700
; TELEFAX: 201-994-1744
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; OTHER INFORMATION: May be a C-terminal amide,
; OTHER INFORMATION: and/or may be acetylated at
; OTHER INFORMATION: N-terminus.
US-08-193-521-1

```

```

Query Match          36.4%; Score 4; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches      4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      6 KLKK 9
        ||||
Db      3 KLKK 6

```

RESULT 3

US-08-193-521-17

```

; Sequence 17, Application US/08193521
; Patent No. 5470950
; GENERAL INFORMATION:
; APPLICANT: Maloy, W. Lee
; APPLICANT: Kari, U. Prasad
; APPLICANT: Williams, Jon I.
; TITLE OF INVENTION: Biologically Active Peptide
; TITLE OF INVENTION: Compositions and Uses Therefor
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Carella, Byrne, Bain, Gilfillan,
; ADDRESSEE: Cecchi & Stewart

```

```

; STREET: 6 Becker Farm Road
; CITY: Roseland
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07068
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: DW4.V2
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/193,521
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/870,960
; FILING DATE:
; APPLICATION NUMBER: 07/760,054
; FILING DATE: 13-SEP-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Olstein, Elliot M.
; REGISTRATION NUMBER: 24,025
; REFERENCE/DOCKET NUMBER: 421250-161
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-994-1700
; TELEFAX: 201-994-1744
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; OTHER INFORMATION: May be a C-terminal amide,
; OTHER INFORMATION: and/or may be acetylated at
; OTHER INFORMATION: N-terminus.
US-08-193-521-17

```

```

Query Match          36.4%; Score 4; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches      4; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      6 KLKK 9
        ||||
Db      7 KLKK 10

```

```

RESULT 4
US-08-193-521-18
; Sequence 18, Application US/08193521
; Patent No. 5470950
; GENERAL INFORMATION:
; APPLICANT: Maloy, W. Lee
; APPLICANT: Kari, U. Prasad
; APPLICANT: Williams, Jon I.
; TITLE OF INVENTION: Biologically Active Peptide

```

```

; TITLE OF INVENTION: Compositions and Uses Therefor
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Carella, Byrne, Bain, Gilfillan,
; ADDRESSEE: Cecchi & Stewart
; STREET: 6 Becker Farm Road
; CITY: Roseland
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07068
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: DW4.V2
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/193,521
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/870,960
; FILING DATE:
; APPLICATION NUMBER: 07/760,054
; FILING DATE: 13-SEP-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Olstein, Elliot M.
; REGISTRATION NUMBER: 24,025
; REFERENCE/DOCKET NUMBER: 421250-161
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-994-1700
; TELEFAX: 201-994-1744
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; OTHER INFORMATION: May be a C-terminal amide,
; OTHER INFORMATION: and/or may be acetylated at
; OTHER INFORMATION: N-terminus.
US-08-193-521-18

```

```

Query Match          36.4%; Score 4; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches      4; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      6 KLKK 9
        ||||
Db      7 KLKK 10

```

```

RESULT 5
US-08-178-570-75
; Sequence 75, Application US/08178570
; Patent No. 5532167

```

```

; GENERAL INFORMATION:
; APPLICANT: Lewis C. Cantley
; APPLICANT: Zhou Song yang
; TITLE OF INVENTION: Substrate Specificity of Protein Kinases
; NUMBER OF SEQUENCES: 77
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD
; STREET: 60 STATE STREET, suite 510
; CITY: BOSTON
; STATE: MASSACHUSETTS
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII text
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/178,570
; FILING DATE: JANUARY 7, 1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: DeConti, Giulio A., Jr.
; REGISTRATION NUMBER: 31,503
; REFERENCE/DOCKET NUMBER: BBI-004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 227-7400
; TELEFAX: (617) 227-5941
; INFORMATION FOR SEQ ID NO: 75:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
US-08-178-570-75

```

```

Query Match          36.4%; Score 4; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches      4; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      8 KKKA 11
        ||||
Db      8 KKKA 11

```

```

RESULT 6
US-08-434-120-95
; Sequence 95, Application US/08434120
; Patent No. 5635479
; GENERAL INFORMATION:
; APPLICANT: Baker, Margaret A.
; APPLICANT: Jacob, Leonard S.
; APPLICANT: Maloy, W. Lee
; TITLE OF INVENTION: Treatment of Gynecological
; TITLE OF INVENTION: Malignancies with
; TITLE OF INVENTION: Biologically Active Peptides

```

```

;   NUMBER OF SEQUENCES:  117
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE:  Carella, Byrne, Bain, Gilfillan,
;     ADDRESSEE:  Cecchi & Stewart
;     STREET:    6 Becker Farm Road
;     CITY:     Roseland
;     STATE:    New Jersey
;     COUNTRY:   USA
;     ZIP:      07068
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE:  3.5 inch diskette
;     COMPUTER:    IBM PS/2
;     OPERATING SYSTEM:  PC-DOS
;     SOFTWARE:    DW4.V2
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER:  US/08/434,120
;     FILING DATE:
;     CLASSIFICATION:    514
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER:  US/08/297,950
;     FILING DATE:
;     APPLICATION NUMBER:  US/08/226,108
;     FILING DATE:
;     APPLICATION NUMBER:  US/07/937,462
;     FILING DATE:
;   ATTORNEY/AGENT INFORMATION:
;     NAME:  Olstein, Elliot M.
;     REGISTRATION NUMBER:  24,025
;     REFERENCE/DOCKET NUMBER:  421250-194
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE:  201-994-1700
;     TELEFAX:    201-994-1744
;   INFORMATION FOR SEQ ID NO:  95:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  11 amino acids
;       TYPE:    amino acid
;       STRANDEDNESS:
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  peptide
US-08-434-120-95

```

```

Query Match          36.4%;  Score 4;  DB 1;  Length 11;
Best Local Similarity 100.0%;  Pred. No. 4.7e+02;
Matches      4;  Conservative      0;  Mismatches      0;  Indels      0;  Gaps      0;

```

```

Qy      6 KLKK 9
        ||||
Db      3 KLKK 6

```

```

RESULT 7
US-08-434-120-111
; Sequence 111, Application US/08434120
; Patent No. 5635479
; GENERAL INFORMATION:
;   APPLICANT:  Baker, Margaret A.
;   APPLICANT:  Jacob, Leonard S.

```

```

; APPLICANT: Maloy, W. Lee
; TITLE OF INVENTION: Treatment of Gynecological
; TITLE OF INVENTION: Malignancies with
; TITLE OF INVENTION: Biologically Active Peptides
; NUMBER OF SEQUENCES: 117
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Carella, Byrne, Bain, Gilfillan,
; ADDRESSEE: Cecchi & Stewart
; STREET: 6 Becker Farm Road
; CITY: Roseland
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07068
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: DW4.V2
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/434,120
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/297,950
; FILING DATE:
; APPLICATION NUMBER: US/08/226,108
; FILING DATE:
; APPLICATION NUMBER: US/07/937,462
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Olstein, Elliot M.
; REGISTRATION NUMBER: 24,025
; REFERENCE/DOCKET NUMBER: 421250-194
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-994-1700
; TELEFAX: 201-994-1744
; INFORMATION FOR SEQ ID NO: 111:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-434-120-111

```

```

Query Match          36.4%; Score 4; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches      4; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      6 KLKK 9
        ||||
Db      7 KLKK 10

```

```

RESULT 8
US-08-434-120-112
; Sequence 112, Application US/08434120

```

```

; Patent No. 5635479
; GENERAL INFORMATION:
;   APPLICANT: Baker, Margaret A.
;   APPLICANT: Jacob, Leonard S.
;   APPLICANT: Maloy, W. Lee
;   TITLE OF INVENTION: Treatment of Gynecological
;   TITLE OF INVENTION: Malignancies with
;   TITLE OF INVENTION: Biologically Active Peptides
;   NUMBER OF SEQUENCES: 117
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Carella, Byrne, Bain, Gilfillan,
;     ADDRESSEE: Cecchi & Stewart
;     STREET: 6 Becker Farm Road
;     CITY: Roseland
;     STATE: New Jersey
;     COUNTRY: USA
;     ZIP: 07068
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: 3.5 inch diskette
;     COMPUTER: IBM PS/2
;     OPERATING SYSTEM: PC-DOS
;     SOFTWARE: DW4.V2
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/08/434,120
;     FILING DATE:
;     CLASSIFICATION: 514
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: US/08/297,950
;     FILING DATE:
;     APPLICATION NUMBER: US/08/226,108
;     FILING DATE:
;     APPLICATION NUMBER: US/07/937,462
;     FILING DATE:
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Olstein, Elliot M.
;     REGISTRATION NUMBER: 24,025
;     REFERENCE/DOCKET NUMBER: 421250-194
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: 201-994-1700
;     TELEFAX: 201-994-1744
;   INFORMATION FOR SEQ ID NO: 112:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH: 11 amino acids
;       TYPE: amino acid
;       STRANDEDNESS:
;       TOPOLOGY: linear
;     MOLECULE TYPE: peptide
US-08-434-120-112

```

```

Query Match          36.4%; Score 4; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches      4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      6 KLKK 9
        ||||
Db      7 KLKK 10

```

RESULT 9

US-08-465-325-94

; Sequence 94, Application US/08465325

; Patent No. 5686563

; GENERAL INFORMATION:

; APPLICANT: Magainin Pharmaceuticals Inc.

; APPLICANT: 5110 Campus Drive

; APPLICANT: Plymouth Meeting, PA 19462

; TITLE OF INVENTION: Biologically Active Peptides Having

; TITLE OF INVENTION: N-Terminal Substitutions

; NUMBER OF SEQUENCES: 153

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &

; ADDRESSEE: Dunner

; STREET: 1300 I. Street, N.W. Suite 700

; CITY: Washington

; STATE: D.C.

; COUNTRY: USA

; ZIP: 20005-3315

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/465,325

; FILING DATE: 05-JUN-1995

; CLASSIFICATION: 514

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/184,462

; FILING DATE: 18-JAN-94

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/891,201

; FILING DATE: 01-JUN-92

; ATTORNEY/AGENT INFORMATION:

; NAME: Fordis, Jean B

; REGISTRATION NUMBER: 32,984

; REFERENCE/DOCKET NUMBER: 05387.0021-03000

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (202) 408-4000

; TELEFAX: (202) 408-4400

; INFORMATION FOR SEQ ID NO: 94:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

US-08-465-325-94

Query Match 36.4%; Score 4; DB 1; Length 11;

Best Local Similarity 100.0%; Pred. No. 4.7e+02;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9

||||

Db

3 KLKK 6

RESULT 10

US-08-465-325-110

; Sequence 110, Application US/08465325

; Patent No. 5686563

; GENERAL INFORMATION:

; APPLICANT: Magainin Pharmaceuticals Inc.

; APPLICANT: 5110 Campus Drive

; APPLICANT: Plymouth Meeting, PA 19462

; TITLE OF INVENTION: Biologically Active Peptides Having

; TITLE OF INVENTION: N-Terminal Substitutions

; NUMBER OF SEQUENCES: 153

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &

; ADDRESSEE: Dunner

; STREET: 1300 I. Street, N.W. Suite 700

; CITY: Washington

; STATE: D.C.

; COUNTRY: USA

; ZIP: 20005-3315

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/465,325

; FILING DATE: 05-JUN-1995

; CLASSIFICATION: 514

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/184,462

; FILING DATE: 18-JAN-94

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/891,201

; FILING DATE: 01-JUN-92

; ATTORNEY/AGENT INFORMATION:

; NAME: Fordis, Jean B

; REGISTRATION NUMBER: 32,984

; REFERENCE/DOCKET NUMBER: 05387.0021-03000

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (202) 408-4000

; TELEFAX: (202) 408-4400

; INFORMATION FOR SEQ ID NO: 110:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

US-08-465-325-110

Query Match 36.4%; Score 4; DB 1; Length 11;

Best Local Similarity 100.0%; Pred. No. 4.7e+02;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
Db 7 KLKK 10

RESULT 11

US-08-465-325-111

; Sequence 111, Application US/08465325

; Patent No. 5686563

; GENERAL INFORMATION:

; APPLICANT: Magainin Pharmaceuticals Inc.

; APPLICANT: 5110 Campus Drive

; APPLICANT: Plymouth Meeting, PA 19462

; TITLE OF INVENTION: Biologically Active Peptides Having

; TITLE OF INVENTION: N-Terminal Substitutions

; NUMBER OF SEQUENCES: 153

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &

; ADDRESSEE: Dunner

; STREET: 1300 I. Street, N.W. Suite 700

; CITY: Washington

; STATE: D.C.

; COUNTRY: USA

; ZIP: 20005-3315

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/465,325

; FILING DATE: 05-JUN-1995

; CLASSIFICATION: 514

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/184,462

; FILING DATE: 18-JAN-94

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/891,201

; FILING DATE: 01-JUN-92

; ATTORNEY/AGENT INFORMATION:

; NAME: Fordis, Jean B

; REGISTRATION NUMBER: 32,984

; REFERENCE/DOCKET NUMBER: 05387.0021-03000

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (202) 408-4000

; TELEFAX: (202) 408-4400

; INFORMATION FOR SEQ ID NO: 111:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

US-08-465-325-111

Query Match 36.4%; Score 4; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
| | | |
Db 7 KLKK 10

RESULT 12

US-08-465-325-112

; Sequence 112, Application US/08465325

; Patent No. 5686563

; GENERAL INFORMATION:

; APPLICANT: Magainin Pharmaceuticals Inc.

; APPLICANT: 5110 Campus Drive

; APPLICANT: Plymouth Meeting, PA 19462

; TITLE OF INVENTION: Biologically Active Peptides Having

; TITLE OF INVENTION: N-Terminal Substitutions

; NUMBER OF SEQUENCES: 153

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &

; ADDRESSEE: Dunner

; STREET: 1300 I. Street, N.W. Suite 700

; CITY: Washington

; STATE: D.C.

; COUNTRY: USA

; ZIP: 20005-3315

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/465,325

; FILING DATE: 05-JUN-1995

; CLASSIFICATION: 514

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/184,462

; FILING DATE: 18-JAN-94

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/891,201

; FILING DATE: 01-JUN-92

; ATTORNEY/AGENT INFORMATION:

; NAME: Fordis, Jean B

; REGISTRATION NUMBER: 32,984

; REFERENCE/DOCKET NUMBER: 05387.0021-03000

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (202) 408-4000

; TELEFAX: (202) 408-4400

; INFORMATION FOR SEQ ID NO: 112:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

US-08-465-325-112

Query Match 36.4%; Score 4; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
||||
Db 3 KLKK 6

RESULT 13

US-08-465-325-127

; Sequence 127, Application US/08465325

; Patent No. 5686563

; GENERAL INFORMATION:

; APPLICANT: Magainin Pharmaceuticals Inc.

; APPLICANT: 5110 Campus Drive

; APPLICANT: Plymouth Meeting, PA 19462

; TITLE OF INVENTION: Biologically Active Peptides Having

; TITLE OF INVENTION: N-Terminal Substitutions

; NUMBER OF SEQUENCES: 153

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &

; ADDRESSEE: Dunner

; STREET: 1300 I. Street, N.W. Suite 700

; CITY: Washington

; STATE: D.C.

; COUNTRY: USA

; ZIP: 20005-3315

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/465,325

; FILING DATE: 05-JUN-1995

; CLASSIFICATION: 514

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/184,462

; FILING DATE: 18-JAN-94

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/891,201

; FILING DATE: 01-JUN-92

; ATTORNEY/AGENT INFORMATION:

; NAME: Fordis, Jean B

; REGISTRATION NUMBER: 32,984

; REFERENCE/DOCKET NUMBER: 05387.0021-03000

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (202) 408-4000

; TELEFAX: (202) 408-4400

; INFORMATION FOR SEQ ID NO: 127:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

US-08-465-325-127

Query Match 36.4%; Score 4; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
Db 7 KLKK 10

RESULT 14

US-08-465-325-128

; Sequence 128, Application US/08465325
; Patent No. 5686563
; GENERAL INFORMATION:
; APPLICANT: Magainin Pharmaceuticals Inc.
; APPLICANT: 5110 Campus Drive
; APPLICANT: Plymouth Meeting, PA 19462
; TITLE OF INVENTION: Biologically Active Peptides Having
; TITLE OF INVENTION: N-Terminal Substitutions
; NUMBER OF SEQUENCES: 153
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; ADDRESSEE: Dunner
; STREET: 1300 I. Street, N.W. Suite 700
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/465,325
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/184,462
; FILING DATE: 18-JAN-94
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/891,201
; FILING DATE: 01-JUN-92
; ATTORNEY/AGENT INFORMATION:
; NAME: Fordis, Jean B
; REGISTRATION NUMBER: 32,984
; REFERENCE/DOCKET NUMBER: 05387.0021-03000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4000
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 128:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single

; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-465-325-128

Query Match 36.4%; Score 4; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
| | | |
Db 7 KLKK 10

RESULT 15

US-08-465-325-130

; Sequence 130, Application US/08465325
; Patent No. 5686563
; GENERAL INFORMATION:
; APPLICANT: Magainin Pharmaceuticals Inc.
; APPLICANT: 5110 Campus Drive
; APPLICANT: Plymouth Meeting, PA 19462
; TITLE OF INVENTION: Biologically Active Peptides Having
; TITLE OF INVENTION: N-Terminal Substitutions
; NUMBER OF SEQUENCES: 153
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; ADDRESSEE: Dunner
; STREET: 1300 I. Street, N.W. Suite 700
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/465,325
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/184,462
; FILING DATE: 18-JAN-94
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/891,201
; FILING DATE: 01-JUN-92
; ATTORNEY/AGENT INFORMATION:
; NAME: Fordis, Jean B
; REGISTRATION NUMBER: 32,984
; REFERENCE/DOCKET NUMBER: 05387.0021-03000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4000
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 130:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids

; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-465-325-130

Query Match 36.4%; Score 4; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
| | | |
Db 7 KLKK 10

RESULT 16

US-08-465-325-141

; Sequence 141, Application US/08465325
; Patent No. 5686563
; GENERAL INFORMATION:
; APPLICANT: Magainin Pharmaceuticals Inc.
; APPLICANT: 5110 Campus Drive
; APPLICANT: Plymouth Meeting, PA 19462
; TITLE OF INVENTION: Biologically Active Peptides Having
; TITLE OF INVENTION: N-Terminal Substitutions
; NUMBER OF SEQUENCES: 153
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; ADDRESSEE: Dunner
; STREET: 1300 I. Street, N.W. Suite 700
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/465,325
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/184,462
; FILING DATE: 18-JAN-94
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/891,201
; FILING DATE: 01-JUN-92
; ATTORNEY/AGENT INFORMATION:
; NAME: Fordis, Jean B
; REGISTRATION NUMBER: 32,984
; REFERENCE/DOCKET NUMBER: 05387.0021-03000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4000
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 141:

; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 2
; OTHER INFORMATION: /note= "Xaa=ornithine."
US-08-465-325-141

Query Match 36.4%; Score 4; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
| | | |
Db 7 KLKK 10

RESULT 17

US-08-465-325-146

; Sequence 146, Application US/08465325

; Patent No. 5686563

; GENERAL INFORMATION:

; APPLICANT: Magainin Pharmaceuticals Inc.

; APPLICANT: 5110 Campus Drive

; APPLICANT: Plymouth Meeting, PA 19462

; TITLE OF INVENTION: Biologically Active Peptides Having

; TITLE OF INVENTION: N-Terminal Substitutions

; NUMBER OF SEQUENCES: 153

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &

; ADDRESSEE: Dunner

; STREET: 1300 I. Street, N.W. Suite 700

; CITY: Washington

; STATE: D.C.

; COUNTRY: USA

; ZIP: 20005-3315

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/465,325

; FILING DATE: 05-JUN-1995

; CLASSIFICATION: 514

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/184,462

; FILING DATE: 18-JAN-94

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/891,201

; FILING DATE: 01-JUN-92

; ATTORNEY/AGENT INFORMATION:

; NAME: Fordis, Jean B

; REGISTRATION NUMBER: 32,984
; REFERENCE/DOCKET NUMBER: 05387.0021-03000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4000
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 146:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-465-325-146

Query Match 36.4%; Score 4; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
| | | |
Db 7 KLKK 10

RESULT 18

US-08-343-882-11

; Sequence 11, Application US/08343882
; Patent No. 5792831
; GENERAL INFORMATION:
; APPLICANT: Maloy, W. Lee
; TITLE OF INVENTION: Compositions of and Treatment
; TITLE OF INVENTION: with Biologically Active
; TITLE OF INVENTION: Peptides Having D-amino acid
; TITLE OF INVENTION: residues
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Carella, Byrne, Bain,
; ADDRESSEE: Gilfillan, Cecchi, Stewart &
; ADDRESSEE: Olstein
; STREET: 6 Becker Farm Road
; CITY: Roseland
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07068
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: DW4.V2
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/343,882
; FILING DATE: 17-NOV-1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/133,740
; FILING DATE: 05-OCT-1993
; APPLICATION NUMBER: 07/874,685
; FILING DATE: 28-APR-1992

; APPLICATION NUMBER: 07/522,688
 ; FILING DATE: 14-MAY-1990
 ; APPLICATION NUMBER: 07/476,629
 ; FILING DATE: 08-FEB-1990
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Olstein, Elliot M.
 ; REGISTRATION NUMBER: 24,025
 ; REFERENCE/DOCKET NUMBER: 421250-89
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 201-994-1700
 ; TELEFAX: 201-994-1744
 ; INFORMATION FOR SEQ ID NO: 11:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 11 amino acids
 ; TYPE: amino acid
 ; STRANDEDNESS:
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: peptide
 US-08-343-882-11

Query Match 36.4%; Score 4; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 4.7e+02;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
 ||||
 Db 7 KLKK 10

RESULT 19
 US-08-621-803-206
 ; Sequence 206, Application US/08621803
 ; Patent No. 5851802
 ; GENERAL INFORMATION:
 ; APPLICANT: Better, Marc D.
 ; TITLE OF INVENTION: Methods for Recombinant Microbial Production of
 ; TITLE OF INVENTION: Fusion Proteins and BPI-Derived Peptides
 ; NUMBER OF SEQUENCES: 265
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
 ; STREET: 6300 Sears Tower, 233 South Wacker Drive
 ; CITY: Chicago
 ; STATE: Illinois
 ; COUNTRY: United States of America
 ; ZIP: 60606-6402
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/621,803
 ; FILING DATE: 22-MAR-1996
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Borun, Michael F.
 ; REGISTRATION NUMBER: 25,447
 ; REFERENCE/DOCKET NUMBER: 27129/33199

```

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 206:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: "XMP.350"
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: C-Terminus
; OTHER INFORMATION: /label= Amidation
; OTHER INFORMATION: /note= "The C-Terminus is Amidated."
US-08-621-803-206

```

```

Query Match          36.4%; Score 4; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches      4; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      7 LKKK 10
        ||||
Db      8 LKKK 11

```

```

RESULT 20
US-08-621-259A-181
; Sequence 181, Application US/08621259A
; Patent No. 5858974
; GENERAL INFORMATION:
; APPLICANT: Little II, Roger G
; APPLICANT: Lim, Edward
; APPLICANT: Fadem, Mitchell B.
; TITLE OF INVENTION: Anti-Fungal Peptides
; NUMBER OF SEQUENCES: 252
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: McAndrews, Held & Malloy, Ltd.
; STREET: 500 West Madison Street
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60661
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/621,259A
; FILING DATE: 21-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/504,841
; FILING DATE: 20-JUL-1995

```

```

; ATTORNEY/AGENT INFORMATION:
;   NAME: McNicholas, Janet M.
;   REGISTRATION NUMBER: 32,918
;   REFERENCE/DOCKET NUMBER: 11021US02
; TELECOMMUNICATION INFORMATION:
;   TELEPHONE: 312/707-8889
;   TELEFAX: 312/707-9155
;   TELEX:
; INFORMATION FOR SEQ ID NO: 181:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 11 amino acids
;     TYPE: amino acid
;     TOPOLOGY: linear
;   MOLECULE TYPE: peptide
;   FEATURE:
;     NAME/KEY: misc_feature
;     OTHER INFORMATION: "XMP.350"
;   FEATURE:
;     NAME/KEY: Modified-site
;     LOCATION: C-Terminus
;     OTHER INFORMATION: /label= Amidation
;     OTHER INFORMATION: /note= "The C-Terminus is Amidated."
US-08-621-259A-181

```

```

Query Match          36.4%; Score 4; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches      4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      7 LKKK 10
        ||||
Db      8 LKKK 11

```

RESULT 21

US-08-369-643-75

```

; Sequence 75, Application US/08369643A
; Patent No. 6004757
; GENERAL INFORMATION:
; APPLICANT: Cantley, Lewis C.
; APPLICANT: Songyang, Zhou
; TITLE OF INVENTION: Substrate Specificity of Protein Kinases
; FILE REFERENCE: CNS-001CP
; CURRENT APPLICATION NUMBER: US/08/369,643A
; CURRENT FILING DATE: 1995-01-06
; EARLIER APPLICATION NUMBER: US 08/178,570
; EARLIER FILING DATE: 1994-01-07
; NUMBER OF SEQ ID NOS: 92
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 75
;   LENGTH: 11
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;     OTHER INFORMATION: Description of Artificial Sequence:peptide
;     OTHER INFORMATION: synthesized as a substrate for cyclin containing
;     OTHER INFORMATION: kinases
US-08-369-643-75

```

Query Match 36.4%; Score 4; DB 3; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KKKA 11
||||
Db 8 KKKA 11

RESULT 22

US-09-217-352-206

; Sequence 206, Application US/09217352

; Patent No. 6274344

; GENERAL INFORMATION:

; APPLICANT: Better, Marc D.

; TITLE OF INVENTION: Methods for Recombinant Microbial Production of

; TITLE OF INVENTION: Fusion Proteins and BPI-Derived Peptides

; NUMBER OF SEQUENCES: 265

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun

; STREET: 6300 Sears Tower, 233 South Wacker Drive

; CITY: Chicago

; STATE: Illinois

; COUNTRY: United States of America

; ZIP: 60606-6402

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/217,352

; FILING DATE:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/621,803

; FILING DATE: 22-MAR-1996

; ATTORNEY/AGENT INFORMATION:

; NAME: Borun, Michael F.

; REGISTRATION NUMBER: 25,447

; REFERENCE/DOCKET NUMBER: 27129/33199

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 312/474-6300

; TELEFAX: 312/474-0448

; TELEX: 25-3856

; INFORMATION FOR SEQ ID NO: 206:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

; FEATURE:

; NAME/KEY: misc_feature

; OTHER INFORMATION: "XMP.350"

; FEATURE:

; NAME/KEY: Modified-site

; LOCATION: C-Terminus

; OTHER INFORMATION: /label= Amidation
; OTHER INFORMATION: /note= "The C-Terminus is Amidated."
US-09-217-352-206

Query Match 36.4%; Score 4; DB 3; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKKK 10
| | | |
Db 8 LKKK 11

RESULT 23

US-09-115-737-94

; Sequence 94, Application US/09115737
; Patent No. 6348445

; GENERAL INFORMATION:

; APPLICANT: U. Prasad Kari
; Taffy J. Williams
; Michael McLane

; TITLE OF INVENTION: Biologically Active Peptides With Reduced
; Toxicity in Animals and a Method for Preparing Same

; NUMBER OF SEQUENCES: 156

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; Dunner, L.L.P.

; STREET: 1300 I Street, N.W. Suite 700

; CITY: Washington

; STATE: D.C.

; COUNTRY: USA

; ZIP: 20005-3315

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.3

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/115,737

; FILING DATE: 15-Jul-1998

; CLASSIFICATION: <Unknown>

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/465,330

; FILING DATE: 05-JUN-1995

; APPLICATION NUMBER: 08/184,462

; FILING DATE: 18-JAN-94

; APPLICATION NUMBER: 07/891,201

; FILING DATE: 01-JUN-92

; ATTORNEY/AGENT INFORMATION:

; NAME: Fordis, Jean B

; REGISTRATION NUMBER: 32,984

; REFERENCE/DOCKET NUMBER: 05387.0021-06000

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (202) 408-4000

; TELEFAX: (202) 408-4400

; INFORMATION FOR SEQ ID NO: 94:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 94:
US-09-115-737-94

Query Match 36.4%; Score 4; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 KLKK 9
 ||||
Db 3 KLKK 6

RESULT 24

US-09-115-737-110

; Sequence 110, Application US/09115737
; Patent No. 6348445

; GENERAL INFORMATION:

; APPLICANT: U. Prasad Kari
; Taffy J. Williams
; Michael McLane

; TITLE OF INVENTION: Biologically Active Peptides With Reduced
; Toxicity in Animals and a Method for Preparing Same

; NUMBER OF SEQUENCES: 156

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; Dunner, L.L.P.

; STREET: 1300 I Street, N.W. Suite 700

; CITY: Washington

; STATE: D.C.

; COUNTRY: USA

; ZIP: 20005-3315

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.3

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/115,737

; FILING DATE: 15-Jul-1998

; CLASSIFICATION: <Unknown>

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/465,330

; FILING DATE: 05-JUN-1995

; APPLICATION NUMBER: 08/184,462

; FILING DATE: 18-JAN-94

; APPLICATION NUMBER: 07/891,201

; FILING DATE: 01-JUN-92

; ATTORNEY/AGENT INFORMATION:

; NAME: Fordis, Jean B

; REGISTRATION NUMBER: 32,984

; REFERENCE/DOCKET NUMBER: 05387.0021-06000

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (202) 408-4000
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 110:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 110:
US-09-115-737-110

Query Match 36.4%; Score 4; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
| | | |
Db 7 KLKK 10

RESULT 25

US-09-115-737-111
; Sequence 111, Application US/09115737
; Patent No. 6348445
; GENERAL INFORMATION:
; APPLICANT: U. Prasad Kari
; Taffy J. Williams
; Michael McLane
; TITLE OF INVENTION: Biologically Active Peptides With Reduced
; Toxicity in Animals and a Method for Preparing Same
; NUMBER OF SEQUENCES: 156
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; Dunner, L.L.P.
; STREET: 1300 I Street, N.W. Suite 700
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.3
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/115,737
; FILING DATE: 15-Jul-1998
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/465,330
; FILING DATE: 05-JUN-1995
; APPLICATION NUMBER: 08/184,462
; FILING DATE: 18-JAN-94
; APPLICATION NUMBER: 07/891,201
; FILING DATE: 01-JUN-92
; ATTORNEY/AGENT INFORMATION:

```

;      NAME: Fordis, Jean B
;      REGISTRATION NUMBER: 32,984
;      REFERENCE/DOCKET NUMBER: 05387.0021-06000
;      TELECOMMUNICATION INFORMATION:
;      TELEPHONE: (202) 408-4000
;      TELEFAX: (202) 408-4400
;      INFORMATION FOR SEQ ID NO: 111:
;      SEQUENCE CHARACTERISTICS:
;      LENGTH: 11 amino acids
;      TYPE: amino acid
;      STRANDEDNESS: single
;      TOPOLOGY: linear
;      MOLECULE TYPE: peptide
;      SEQUENCE DESCRIPTION: SEQ ID NO: 111:
US-09-115-737-111

```

```

Query Match          36.4%;  Score 4;  DB 4;  Length 11;
Best Local Similarity 100.0%;  Pred. No. 4.7e+02;
Matches      4;  Conservative      0;  Mismatches      0;  Indels      0;  Gaps      0;

```

```

QY      6 KLKK 9
        ||||
Db      7 KLKK 10

```

RESULT 26

US-09-115-737-112

; Sequence 112, Application US/09115737

; Patent No. 6348445

; GENERAL INFORMATION:

```

;      APPLICANT: U. Prasad Kari
;                  Taffy J. Williams
;                  Michael McLane
;

```

```

;      TITLE OF INVENTION: Biologically Active Peptides With Reduced
;                          Toxicity in Animals and a Method for Preparing Same
;

```

; NUMBER OF SEQUENCES: 156

; CORRESPONDENCE ADDRESS:

```

;      ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
;                  Dunner, L.L.P.
;      STREET: 1300 I Street, N.W. Suite 700
;      CITY: Washington
;      STATE: D.C.
;      COUNTRY: USA
;      ZIP: 20005-3315
;

```

; COMPUTER READABLE FORM:

```

;      MEDIUM TYPE: Floppy disk
;      COMPUTER: IBM PC compatible
;      OPERATING SYSTEM: PC-DOS/MS-DOS
;      SOFTWARE: PatentIn Release #1.0, Version #1.3
;

```

; CURRENT APPLICATION DATA:

```

;      APPLICATION NUMBER: US/09/115,737
;      FILING DATE: 15-Jul-1998
;      CLASSIFICATION: <Unknown>
;

```

; PRIOR APPLICATION DATA:

```

;      APPLICATION NUMBER: 08/465,330
;      FILING DATE: 05-JUN-1995
;      APPLICATION NUMBER: 08/184,462
;

```

```

; FILING DATE: 18-JAN-94
; APPLICATION NUMBER: 07/891,201
; FILING DATE: 01-JUN-92
; ATTORNEY/AGENT INFORMATION:
; NAME: Fordis, Jean B
; REGISTRATION NUMBER: 32,984
; REFERENCE/DOCKET NUMBER: 05387.0021-06000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4000
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 112:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 112:
US-09-115-737-112

```

```

Query Match          36.4%; Score 4; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches      4; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      6 KLKK 9
        ||||
Db      3 KLKK 6

```

RESULT 27

US-09-115-737-127

```

; Sequence 127, Application US/09115737
; Patent No. 6348445

```

GENERAL INFORMATION:

```

; APPLICANT: U. Prasad Kari
;           Taffy J. Williams
;           Michael McLane
; TITLE OF INVENTION: Biologically Active Peptides With Reduced
;                   Toxicity in Animals and a Method for Preparing Same

```

NUMBER OF SEQUENCES: 156

CORRESPONDENCE ADDRESS:

```

; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
;           Dunner, L.L.P.
; STREET: 1300 I Street, N.W. Suite 700
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315

```

COMPUTER READABLE FORM:

```

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.3

```

CURRENT APPLICATION DATA:

```

; APPLICATION NUMBER: US/09/115,737
; FILING DATE: 15-Jul-1998
; CLASSIFICATION: <Unknown>

```

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/465,330
; FILING DATE: 05-JUN-1995
; APPLICATION NUMBER: 08/184,462
; FILING DATE: 18-JAN-94
; APPLICATION NUMBER: 07/891,201
; FILING DATE: 01-JUN-92
; ATTORNEY/AGENT INFORMATION:
; NAME: Fordis, Jean B
; REGISTRATION NUMBER: 32,984
; REFERENCE/DOCKET NUMBER: 05387.0021-06000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4000
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 127:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 127:
US-09-115-737-127

```

```

Query Match          36.4%; Score 4; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches      4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      6 KLKK 9
        ||||
Db      7 KLKK 10

```

RESULT 28

US-09-115-737-128

; Sequence 128, Application US/09115737

; Patent No. 6348445

; GENERAL INFORMATION:

; APPLICANT: U. Prasad Kari

; Taffy J. Williams

; Michael McLane

; TITLE OF INVENTION: Biologically Active Peptides With Reduced
; Toxicity in Animals and a Method for Preparing Same

; NUMBER OF SEQUENCES: 156

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; Dunner, L.L.P.

; STREET: 1300 I Street, N.W. Suite 700

; CITY: Washington

; STATE: D.C.

; COUNTRY: USA

; ZIP: 20005-3315

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.3

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/115,737
; FILING DATE: 15-Jul-1998
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/465,330
; FILING DATE: 05-JUN-1995
; APPLICATION NUMBER: 08/184,462
; FILING DATE: 18-JAN-94
; APPLICATION NUMBER: 07/891,201
; FILING DATE: 01-JUN-92
; ATTORNEY/AGENT INFORMATION:
; NAME: Fordis, Jean B
; REGISTRATION NUMBER: 32,984
; REFERENCE/DOCKET NUMBER: 05387.0021-06000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4000
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 128:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 128:
US-09-115-737-128

```

```

Query Match          36.4%; Score 4; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches      4; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      6 KLKK 9
        ||||
Db      7 KLKK 10

```

RESULT 29

US-09-115-737-130

```

; Sequence 130, Application US/09115737
; Patent No. 6348445

```

GENERAL INFORMATION:

```

; APPLICANT: U. Prasad Kari
;           Taffy J. Williams
;           Michael McLane

```

```

; TITLE OF INVENTION: Biologically Active Peptides With Reduced
;                   Toxicity in Animals and a Method for Preparing Same

```

```

; NUMBER OF SEQUENCES: 156

```

CORRESPONDENCE ADDRESS:

```

; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
;           Dunner, L.L.P.
; STREET: 1300 I Street, N.W. Suite 700
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315

```

```

; COMPUTER READABLE FORM:

```

```

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.3
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/115,737
; FILING DATE: 15-Jul-1998
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/465,330
; FILING DATE: 05-JUN-1995
; APPLICATION NUMBER: 08/184,462
; FILING DATE: 18-JAN-94
; APPLICATION NUMBER: 07/891,201
; FILING DATE: 01-JUN-92
; ATTORNEY/AGENT INFORMATION:
; NAME: Fordis, Jean B
; REGISTRATION NUMBER: 32,984
; REFERENCE/DOCKET NUMBER: 05387.0021-06000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4000
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 130:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 130:
US-09-115-737-130

```

```

Query Match          36.4%; Score 4; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches      4; Conservative    0; Mismatches    0; Indels      0; Gaps      0;

```

```

Qy      6 KLKK 9
        ||||
Db      7 KLKK 10

```

```

RESULT 30
US-09-115-737-141
; Sequence 141, Application US/09115737
; Patent No. 6348445
; GENERAL INFORMATION:
; APPLICANT: U. Prasad Kari
;           Taffy J. Williams
;           Michael McLane
; TITLE OF INVENTION: Biologically Active Peptides With Reduced
;                   Toxicity in Animals and a Method for Preparing Same
; NUMBER OF SEQUENCES: 156
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
;           Dunner, L.L.P.
; STREET: 1300 I Street, N.W. Suite 700
; CITY: Washington

```

```

; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.3
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/115,737
; FILING DATE: 15-Jul-1998
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/465,330
; FILING DATE: 05-JUN-1995
; APPLICATION NUMBER: 08/184,462
; FILING DATE: 18-JAN-94
; APPLICATION NUMBER: 07/891,201
; FILING DATE: 01-JUN-92
; ATTORNEY/AGENT INFORMATION:
; NAME: Fordis, Jean B
; REGISTRATION NUMBER: 32,984
; REFERENCE/DOCKET NUMBER: 05387.0021-06000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4000
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 141:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 2
; OTHER INFORMATION: /note= "Xaa=ornithine."
; SEQUENCE DESCRIPTION: SEQ ID NO: 141:
US-09-115-737-141

```

```

Query Match          36.4%; Score 4; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches      4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      6 KLKK 9
        ||||
Db      7 KLKK 10

```

```

RESULT 31
US-09-115-737-146
; Sequence 146, Application US/09115737
; Patent No. 6348445
; GENERAL INFORMATION:
; APPLICANT: U. Prasad Kari
;           Taffy J. Williams
;           Michael McLane

```

```

; TITLE OF INVENTION: Biologically Active Peptides With Reduced
; Toxicity in Animals and a Method for Preparing Same
;
; NUMBER OF SEQUENCES: 156
;
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; Dunner, L.L.P.
; STREET: 1300 I Street, N.W. Suite 700
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.3
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/115,737
; FILING DATE: 15-Jul-1998
; CLASSIFICATION: <Unknown>
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/465,330
; FILING DATE: 05-JUN-1995
; APPLICATION NUMBER: 08/184,462
; FILING DATE: 18-JAN-94
; APPLICATION NUMBER: 07/891,201
; FILING DATE: 01-JUN-92
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Fordis, Jean B
; REGISTRATION NUMBER: 32,984
; REFERENCE/DOCKET NUMBER: 05387.0021-06000
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4000
; TELEFAX: (202) 408-4400
;
; INFORMATION FOR SEQ ID NO: 146:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 146:
US-09-115-737-146

```

```

Query Match          36.4%; Score 4; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches      4; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      6 KLKK 9
        ||||
Db      7 KLKK 10

```

```

RESULT 32
US-09-148-545-274
; Sequence 274, Application US/09148545
; Patent No. 6590075

```

; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 70 Human Secreted Proteins
; FILE REFERENCE: PZ001P1
; CURRENT APPLICATION NUMBER: US/09/148,545
; CURRENT FILING DATE: 1998-09-04
; EARLIER APPLICATION NUMBER: PCT/US98/04482
; EARLIER FILING DATE: 1998-03-06
; EARLIER APPLICATION NUMBER: 60/040,162
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,333
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/038,621
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,161
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,626
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,334
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,336
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,163
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/047,615
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,600
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,597
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,502
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,633
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,583
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,617
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,618
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,503
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,592
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,581
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,584
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,500
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,587
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,492
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,598
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,613

; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,582
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,596
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,612
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,632
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,601
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/043,580
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,568
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,314
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,569
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,311
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,671
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,674
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,669
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,312
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,313
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,672
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,315
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/048,974
; EARLIER FILING DATE: 1997-06-06
; EARLIER APPLICATION NUMBER: 60/056,886
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,877
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,889
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,893
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,630
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,878
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,662
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,872
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,882
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,637
; EARLIER FILING DATE: 1997-08-22

; EARLIER APPLICATION NUMBER: 60/056,903
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,888
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,879
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,880
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,894
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,911
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,636
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,874
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,910
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,864
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,631
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,845
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,892
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/047,595
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/057,761
; EARLIER FILING DATE: 05-Sep-1997
; EARLIER APPLICATION NUMBER: 60/047,599
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,588
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,585
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,586
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,590
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,594
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,589
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,593
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,614
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/043,578
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,576
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/047,501
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/043,670
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/056,632

```
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,664
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,876
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,881
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,909
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,875
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,862
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,887
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,908
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/048,964
; EARLIER FILING DATE: 1997-06-06
; EARLIER APPLICATION NUMBER: 60/057,650
; EARLIER FILING DATE: 1997-09-05
; EARLIER APPLICATION NUMBER: 60/056,884
; EARLIER FILING DATE: 1997-08-22
; NUMBER OF SEQ ID NOS: 280
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 274
; LENGTH: 11
```

```
Query Match          36.4%; Score 4; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches      4; Conservative      0; Mismatches      0; Indels      0; Gaps      0;
```

```
Qy      1 AGSA 4
        ||||
Db      3 AGSA 6
```

RESULT 33

US-09-677-664B-181

```
; Sequence 181, Application US/09677664B
; Patent No. 6664231
```

GENERAL INFORMATION:

```
; APPLICANT: Little II, Roger G
;           Lim, Edward
;           Fadem, Mitchell B.
; TITLE OF INVENTION: Anti-Fungal Peptides
; NUMBER OF SEQUENCES: 257
; CORRESPONDENCE ADDRESS:
;           ADDRESSEE: McAndrews, Held & Malloy, Ltd.
;           STREET: 500 West Madison Street
;           CITY: Chicago
;           STATE: Illinois
;           COUNTRY: United States of America
;           ZIP: 60661
; COMPUTER READABLE FORM:
;           MEDIUM TYPE: Floppy disk
;           COMPUTER: IBM PC compatible
```

```

;      OPERATING SYSTEM: PC-DOS/MS-DOS
;      SOFTWARE: PatentIn Release #1.0, Version #1.25
;      CURRENT APPLICATION DATA:
;      APPLICATION NUMBER: US/09/677,664B
;      FILING DATE: 07-Mar-2003
;      PRIOR APPLICATION DATA:
;      APPLICATION NUMBER: 09/227,659
;      FILING DATE: 08-Jan-1999
;      ATTORNEY/AGENT INFORMATION:
;      NAME: McNicholas, Janet M.
;      REGISTRATION NUMBER: 32,918
;      REFERENCE/DOCKET NUMBER: 11021US06
;      TELECOMMUNICATION INFORMATION:
;      TELEPHONE: 312/775-8000
;      TELEFAX: 312/775-8100
;      TELEX: <Unknown>
;      INFORMATION FOR SEQ ID NO: 181:
;      SEQUENCE CHARACTERISTICS:
;      LENGTH: 11 amino acids
;      TYPE: amino acid
;      TOPOLOGY: linear
;      MOLECULE TYPE: peptide
;      FEATURE:
;      NAME/KEY: misc_feature
;      OTHER INFORMATION: "XMP.350"
;      FEATURE:
;      NAME/KEY: Modified-site
;      LOCATION: C-Terminus
;      OTHER INFORMATION: /label= Amidation
;      /note= "The C-Terminus is Amidated."
;      SEQUENCE DESCRIPTION: SEQ ID NO: 181:
US-09-677-664B-181

```

```

Query Match          36.4%; Score 4; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches      4; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      7 LKKK 10
        ||||
Db      8 LKKK 11

```

```

RESULT 34
PCT-US91-05047-67
; Sequence 67, Application PC/TUS9105047
; GENERAL INFORMATION:
; APPLICANT: Houghten, Richard
; APPLICANT: Blondelle, Sylvie
; TITLE OF INVENTION: Amphiphilic Peptide Compositions and
; TITLE OF INVENTION: Analogues Thereof
; NUMBER OF SEQUENCES: 68
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dressler, Goldsmith, Sutker, Shore,
; ADDRESSEE: & Milnamow
; STREET: 180 North Stetson
; CITY: Chicago
; STATE: IL

```

```

; COUNTRY: USA
; ZIP: 60601
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.24
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05047
; FILING DATE: 19910717
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/554,422
; FILING DATE: 19-JUL-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Gamson, Edward P.
; REGISTRATION NUMBER: 29,381
; REFERENCE/DOCKET NUMBER: 421250-80
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 3126165418
; TELEFAX: 3126165460
; INFORMATION FOR SEQ ID NO: 67:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: AMINO ACID
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; OTHER INFORMATION: C-terminal amide, may be
; OTHER INFORMATION: acetylated at N-terminus.
PCT-US91-05047-67

```

```

Query Match          36.4%; Score 4; DB 5; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches      4; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      6 KLKK 9
        ||||
Db      3 KLKK 6

```

```

RESULT 35
PCT-US95-00147-75
; Sequence 75, Application PC/TUS9500147
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: Substrate Specificity of Protein Kinases
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD
; STREET: 60 STATE STREET, suite 510
; CITY: BOSTON
; STATE: MASSACHUSETTS
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:

```

```

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII text
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/00147
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/178,570
; FILING DATE: JANUARY 7, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: DeConti, Giulio A., Jr.
; REGISTRATION NUMBER: 31,503
; REFERENCE/DOCKET NUMBER: BBI-004CPPC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 227-7400
; TELEFAX: (617) 227-5941
; INFORMATION FOR SEQ ID NO: 75:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
PCT-US95-00147-75

```

```

Query Match          36.4%; Score 4; DB 5; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches      4; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      8 KKKA 11
        ||||
Db      8 KKKA 11

```

RESULT 36

PCT-US95-09262-181

; Sequence 181, Application PC/TUS9509262

; GENERAL INFORMATION:

; APPLICANT:

; TITLE OF INVENTION: Anti-Fungal Peptides

; NUMBER OF SEQUENCES: 206

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun

; STREET: 6300 Sears Tower, 233 South Wacker Drive

; CITY: Chicago

; STATE: Illinois

; COUNTRY: United States of America

; ZIP: 60606-6402

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: PCT/US95/09262

; FILING DATE:

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/372,105
; FILING DATE: 13-JAN-95
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/306,473
; FILING DATE: 15-SEP-94
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/273,540
; FILING DATE: 11-JUL-94
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/209,762
; FILING DATE: 11-MAR-94
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/183,222
; FILING DATE: 14-JAN-94
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/093,202
; FILING DATE: 15-JUL-93
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/030,644
; FILING DATE: 12-MAR-93
; ATTORNEY/AGENT INFORMATION:
; NAME: Borun, Michael F.
; REGISTRATION NUMBER: 25,447
; REFERENCE/DOCKET NUMBER: 27129/10040
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 181:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: "XMP.350"
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: C-Terminus
; OTHER INFORMATION: /label= Amidation
; OTHER INFORMATION: /note= "The C-Terminus is Amidated"
PCT-US95-09262-181

```

```

Query Match          36.4%; Score 4; DB 5; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches      4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      7 LKKK 10
        ||||
Db      8 LKKK 11

```

```

RESULT 37
5188961-5
;Patent No. 5188961

```

```
; APPLICANT: OVERBYE, KAREN M.;PERO, JANICE;ROBBINS, PHILLIPS W.
; TITLE OF INVENTION: DNA ENCODING A STREPTOMYCES ENDOCHITINASE
;56 SIGNAL PEPTIDE
; NUMBER OF SEQUENCES: 8
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/473,309
; FILING DATE: 01-FEB-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 24,002
; FILING DATE: 10-MAR-1987
;SEQ ID NO:5:
; LENGTH:11
5188961-5
```

```
Query Match          36.4%; Score 4; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches      4; Conservative      0; Mismatches      0; Indels      0; Gaps      0;
```

```
Qy      1 AGSA 4
        ||||
Db      3 AGSA 6
```

RESULT 38

US-07-664-989B-17

```
; Sequence 17, Application US/07664989B
; Patent No. 5223409
; GENERAL INFORMATION:
; APPLICANT: Ladner, Robert Charles
; APPLICANT: Guterman, Sonia Kosow
; APPLICANT: Roberts, Bruce Lindsay
; APPLICANT: Markland, William
; APPLICANT: Ley, Arthur Charles
; APPLICANT: Kent, Rachel Baribault
; TITLE OF INVENTION: Directed Evolution of No. 5223409e1
; TITLE OF INVENTION: Binding Proteins
; NUMBER OF SEQUENCES: 121
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Browdy and Neimark
; STREET: 419 Seventh Street, N.W.
; STREET: Suite 300
; CITY: Washington,
; STATE: DC
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WORDPERFECT 4.2
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/664,989B
; FILING DATE: 19910301
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US89/03731
; FILING DATE: 01-SEP-1989
```

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/487,063
; FILING DATE: 02-MAR-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/240,160
; FILING DATE: 02-SEP-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Cooper, Iver P.
; REGISTRATION NUMBER: 28005
; REFERENCE/DOCKET NUMBER: LADNER 7
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-07-664-989B-17

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches      3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      2 GSA 4
        |||
Db      6 GSA 8

```

```

RESULT 39
US-07-830-330-2
; Sequence 2, Application US/07830330
; Patent No. 5288704
; GENERAL INFORMATION:
; APPLICANT: Ungheri, Domenico
; APPLICANT: Garofano, Luisa
; APPLICANT: Battistini, Carlo
; APPLICANT: Carminati, Paolo
; APPLICANT: Mazue, Guy
; TITLE OF INVENTION: SYNERGISTIC COMPOSITION COMPRISING A
; TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR AND A SULFATED
POLYSACCHARIDE,
; TITLE OF INVENTION: FOR USE AS ANTIVIRAL AGENT
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
; ADDRESSEE: P.C.
; STREET: 1755 Jefferson Davis Highway, Fourth Floor
; CITY: Arlington
; STATE: Virginia
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25

```

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/830,330
; FILING DATE: 19920420
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Oblon, No. 5288704man F.
; REGISTRATION NUMBER: 24,618
; REFERENCE/DOCKET NUMBER: 769-230-0
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)521-4500
; TELEFAX: (703)486-2347
; TELEX: 248855 OPAT UR
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: N-terminal
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
US-07-830-330-2

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      1 AGS 3
      |||
Db      5 AGS 7

```

RESULT 40

US-07-914-280-10

```

; Sequence 10, Application US/07914280
; Patent No. 5304497
; GENERAL INFORMATION:
; APPLICANT: Boyd, Victoria L.
; APPLICANT: Bozzini, MeriLisa
; APPLICANT: Guga, Piotr J.
; APPLICANT: Zon, Gerald
; TITLE OF INVENTION: Method of Forming N-Protected Amino Acid
; TITLE OF INVENTION: Thiohydantoins
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Peter Dehlinger
; STREET: 350 Cambridge Avenue, Suite 300
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94306
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:

```

```

; APPLICATION NUMBER: US/07/914,280
; FILING DATE: 19920715
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Fabian, Gary R.
; REGISTRATION NUMBER: 33,875
; REFERENCE/DOCKET NUMBER: 0550-0025
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 324-0880
; TELEFAX: (415) 324-0960
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; INDIVIDUAL ISOLATE: K11(S)V
US-07-914-280-10

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      3 SAV 5
        |||
Db      9 SAV 11

```

```

RESULT 41
US-07-914-280-11
; Sequence 11, Application US/07914280
; Patent No. 5304497
; GENERAL INFORMATION:
; APPLICANT: Boyd, Victoria L.
; APPLICANT: Bozzini, MeriLisa
; APPLICANT: Guga, Piotr J.
; APPLICANT: Zon, Gerald
; TITLE OF INVENTION: Method of Forming N-Protected Amino Acid
; TITLE OF INVENTION: Thiohydantoins
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Peter Dehlinger
; STREET: 350 Cambridge Avenue, Suite 300
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94306
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/914,280

```

; FILING DATE: 19920715
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Fabian, Gary R.
; REGISTRATION NUMBER: 33,875
; REFERENCE/DOCKET NUMBER: 0550-0025
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 324-0880
; TELEFAX: (415) 324-0960
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; INDIVIDUAL ISOLATE: K12S
US-07-914-280-11

Query Match 27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 SAV 5
|||
Db 9 SAV 11

RESULT 42

US-08-049-871-6

; Sequence 6, Application US/08049871
; Patent No. 5358933
; GENERAL INFORMATION:
; APPLICANT: Porro, Massimo
; TITLE OF INVENTION: Synthetic Peptides for Detoxification
; TITLE OF INVENTION: of Bacterial Endotoxins and for the
; TITLE OF INVENTION: Prevention and Treatment of Septic
; TITLE OF INVENTION: Shock
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hedman, Gibson, Costigan & Hoare
; STREET: 1185 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: DOS
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/049,871
; FILING DATE:
; CLASSIFICATION: 514

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/658,744
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Costigan, James V.
; REGISTRATION NUMBER: 25,669
; REFERENCE/DOCKET NUMBER: 576-001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 302-8989
; TELEFAX: (212) 302-8998
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: circular
US-08-049-871-6

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      7 LKK 9
      |||
Db      8 LKK 10

```

RESULT 43

US-07-819-893-6

```

; Sequence 6, Application US/07819893
; Patent No. 5371186
; GENERAL INFORMATION:
; APPLICANT: Porro, Massimo
; TITLE OF INVENTION: Synthetic Peptides for Detoxification
; TITLE OF INVENTION: of Bacterial Endotoxins and for the
; TITLE OF INVENTION: Prevention and Treatment of Septic
; TITLE OF INVENTION: Shock
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hedman, Gibson, Costigan & Hoare
; STREET: 1185 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: DOS
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/819,893
; FILING DATE: 19920115
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:

```

; NAME: Costigan, James V.
; REGISTRATION NUMBER: 25,669
; REFERENCE/DOCKET NUMBER: 576-002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 302-8989
; TELEFAX: (212) 302-8998
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: circular
US-07-819-893-6

Query Match 27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKK 9
|||
Db 8 LKK 10

RESULT 44
US-08-029-333-37
; Sequence 37, Application US/08029333
; Patent No. 5399667
; GENERAL INFORMATION:
; APPLICANT: Frazier, William A.
; APPLICANT: Kosfeld, Minh D.
; TITLE OF INVENTION: Thrombospondin Receptor Binding Peptides
; NUMBER OF SEQUENCES: 47
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scott J. Meyer, Monsanto Co., A3SG
; STREET: 800 N. Lindbergh Blvd.
; CITY: St. Louis
; STATE: Missouri
; COUNTRY: USA
; ZIP: 63167
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/029,333
; FILING DATE: 19930305
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Meyer, Scott J.
; REGISTRATION NUMBER: 25,275
; REFERENCE/DOCKET NUMBER: 07-24(982)A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (314)694-3117
; TELEFAX: (314)694-5435
; INFORMATION FOR SEQ ID NO: 37:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids

; TYPE: AMINO ACID
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-029-333-37

Query Match 27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 VKL 7
|||
Db 4 VKL 6

RESULT 45

US-07-694-983-15

; Sequence 15, Application US/07694983
; Patent No. 5432260
; GENERAL INFORMATION:
; APPLICANT: Stahl, Philip D.
; TITLE OF INVENTION: HIGH AFFINITY MANNOS RECEPTOR
; TITLE OF INVENTION: LIGANDS
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Irell & Manella
; STREET: 545 Middlefield Road, Suite 200
; CITY: Menlo Park
; STATE: California
; COUNTRY: USA
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/694,983
; FILING DATE: 19910503
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Murashige, Kate H.
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 9500-0039.00
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-327-7250
; TELEFAX: 415-327-2951
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: AMINO ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1

; OTHER INFORMATION: /label= Ac-
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 11
; OTHER INFORMATION: /label= -NH2
US-07-694-983-15

Query Match 27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KKK 10
|||
Db 2 KKK 4

RESULT 46

US-08-116-733-35

; Sequence 35, Application US/08116733
; Patent No. 5516632
; GENERAL INFORMATION:
; APPLICANT: PALKER, Thomas J.
; APPLICANT: HAYNES, Barton F.
; TITLE OF INVENTION: SYNTHETIC PEPTIDES
; NUMBER OF SEQUENCES: 46
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHYE P.C.
; STREET: 1100 NORTH GLEBE ROAD
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/116,733
; FILING DATE: 07-SEP-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: WILSON, MARY J.
; REGISTRATION NUMBER: 32,955
; REFERENCE/DOCKET NUMBER: 1579-33
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
; TELEX: 200797 NIXN UR
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-116-733-35

Query Match 27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 KKA 11
|||
Db 3 KKA 5

RESULT 47

US-08-218-025A-75

; Sequence 75, Application US/08218025A

; Patent No. 5556744

; GENERAL INFORMATION:

; APPLICANT: Weiner, David B.

; APPLICANT: Ugen, Kenneth E.

; APPLICANT: Williams, William V.

; TITLE OF INVENTION: Methods and Compositions for Diagnosing

; TITLE OF INVENTION: and Treating Certain HIV Infected Patients

; NUMBER OF SEQUENCES: 197

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Howson and Howson

; STREET: P.O. Box 457, 321 No. 5556744ristown Road

; CITY: Spring House

; STATE: Pennsylvania

; COUNTRY: U.S.A.

; ZIP: 19477

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/218,025A

; FILING DATE: 24-MAR-1994

; CLASSIFICATION: 424

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 07/891,451

; FILING DATE: 29-MAY-1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Bak, Mary E.

; REGISTRATION NUMBER: 31,215

; REFERENCE/DOCKET NUMBER: WST33A

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (215) 540-9206

; TELEFAX: (215) 540-5818

; INFORMATION FOR SEQ ID NO: 75:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids

; TYPE: amino acid

; TOPOLOGY: unknown

; MOLECULE TYPE: peptide

US-08-218-025A-75

Query Match 27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGS 3
|||
Db 3 AGS 5

RESULT 48

US-08-218-025A-163

; Sequence 163, Application US/08218025A
; Patent No. 5556744
; GENERAL INFORMATION:
; APPLICANT: Weiner, David B.
; APPLICANT: Ugen, Kenneth E.
; APPLICANT: Williams, William V.
; TITLE OF INVENTION: Methods and Compositions for Diagnosing
; TITLE OF INVENTION: and Treating Certain HIV Infected Patients
; NUMBER OF SEQUENCES: 197
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Howson and Howson
; STREET: P.O. Box 457, 321 No. 5556744ristown Road
; CITY: Spring House
; STATE: Pennsylvania
; COUNTRY: U.S.A.
; ZIP: 19477
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/218,025A
; FILING DATE: 24-MAR-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/891,451
; FILING DATE: 29-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Bak, Mary E.
; REGISTRATION NUMBER: 31,215
; REFERENCE/DOCKET NUMBER: WST33A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 540-9206
; TELEFAX: (215) 540-5818
; INFORMATION FOR SEQ ID NO: 163:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
US-08-218-025A-163

Query Match 27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGS 3
|||

Db

8 AGS 10

RESULT 49

US-08-280-397-6

; Sequence 6, Application US/08280397
; Patent No. 5589459
; GENERAL INFORMATION:
; APPLICANT: Porro, Massimo
; TITLE OF INVENTION: Synthetic Peptides for Detoxification
; TITLE OF INVENTION: of Bacterial Endotoxins and for the
; TITLE OF INVENTION: Prevention and Treatment of Septic
; TITLE OF INVENTION: Shock
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hedman, Gibson & Costigan, P.C.
; STREET: 1185 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: DOS
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/280,397
; FILING DATE: 07/26/94
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/819,893
; FILING DATE: 01/16/92
; ATTORNEY/AGENT INFORMATION:
; NAME: Costigan, James V.
; REGISTRATION NUMBER: 25,669
; REFERENCE/DOCKET NUMBER: 576-002A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 302-8989
; TELEFAX: (212) 302-8998
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: circular
US-08-280-397-6

Query Match 27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKK 9
|||
Db 8 LKK 10

RESULT 50

US-08-378-761A-68
; Sequence 68, Application US/08378761A
; Patent No. 5635384
; GENERAL INFORMATION:
; APPLICANT: WALSH, TERENCE A
; APPLICANT: HEY, TIMOTHY D
; APPLICANT: MORGAN, ALICE ER
; TITLE OF INVENTION: RIBOSOME-INACTIVATING PROTEINS, INACTIVE
; TITLE OF INVENTION: PRECURSOR FORMS THEREOF, A PROCESS FOR MAKING A METHOD
OF
; TITLE OF INVENTION: USING
; NUMBER OF SEQUENCES: 81
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ANDREA T. BORUCKI
; STREET: 9330 ZIONSVILLE ROAD
; CITY: INDIANAPOLIS
; STATE: IN
; COUNTRY: US
; ZIP: 46268
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/378,761A
; FILING DATE: 26-JAN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: BORUCKI, ANDREA T
; REGISTRATION NUMBER: 33651
; REFERENCE/DOCKET NUMBER: 38272B
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (317) 337-4846
; INFORMATION FOR SEQ ID NO: 68:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-378-761A-68

Query Match 27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 KKA 11
|||
Db 3 KKA 5

RESULT 51
US-08-485-286-68
; Sequence 68, Application US/08485286
; Patent No. 5646026
; Patent No. 5646026 5646119

```

; GENERAL INFORMATION:
; APPLICANT: WALSH, TERENCE A
; APPLICANT: HEY, TIMOTHY D
; APPLICANT: MORGAN, ALICE ER
; TITLE OF INVENTION: RIBOSOME-INACTIVATING PROTEINS, INACTIVE
; TITLE OF INVENTION: PRECURSOR FORMS THEREOF, A PROCESS FOR MAKING A METHOD
OF
; TITLE OF INVENTION: USING
; NUMBER OF SEQUENCES: 81
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ANDREA T. BORUCKI
; STREET: 9330 ZIONSVILLE ROAD
; CITY: INDIANAPOLIS
; STATE: IN
; COUNTRY: US
; ZIP: 46268
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/485,286
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/378761
; FILING DATE: 26-JAN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: BORUCKI, ANDREA T
; REGISTRATION NUMBER: 33651
; REFERENCE/DOCKET NUMBER: 38272B
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (317) 337-4846
; INFORMATION FOR SEQ ID NO: 68:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-485-286-68

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      9 KKA 11
      |||
Db      3 KKA 5

```

```

RESULT 52
US-08-299-249A-13
; Sequence 13, Application US/08299249A
; Patent No. 5650267
; GENERAL INFORMATION:

```

```

; APPLICANT: RAY, Bryan L.; and
; APPLICANT: LIN, Edmund C.C.
; TITLE OF INVENTION: Method Of Detecting Compounds
; TITLE OF INVENTION: Utilizing Genetically Modified
; TITLE OF INVENTION: Lambdoid Bacteriophage
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HALE and DORR
; STREET: 60 State Street
; CITY: Boston
; STATE: MA
; COUNTRY: U.S.A.
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/299,249A
; FILING DATE: 31-AUG-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/053,865
; FILING DATE: 27-APR-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Kerner, Ann-Louise
; REGISTRATION NUMBER: 33,523
; REFERENCE/DOCKET NUMBER: SYZ-011FWC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/526-6000
; TELEFAX: 617/526-5000
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
US-08-299-249A-13

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches      3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 AGS 3
      |||
Db      3 AGS 5

```

```

RESULT 53
US-08-465-325-131
; Sequence 131, Application US/08465325
; Patent No. 5686563
; GENERAL INFORMATION:

```

```

; APPLICANT: Magainin Pharmaceuticals Inc.
; APPLICANT: 5110 Campus Drive
; APPLICANT: Plymouth Meeting, PA 19462
; TITLE OF INVENTION: Biologically Active Peptides Having
; TITLE OF INVENTION: N-Terminal Substitutions
; NUMBER OF SEQUENCES: 153
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; ADDRESSEE: Dunner
; STREET: 1300 I. Street, N.W. Suite 700
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/465,325
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/184,462
; FILING DATE: 18-JAN-94
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/891,201
; FILING DATE: 01-JUN-92
; ATTORNEY/AGENT INFORMATION:
; NAME: Fordis, Jean B
; REGISTRATION NUMBER: 32,984
; REFERENCE/DOCKET NUMBER: 05387.0021-03000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4000
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 131:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-465-325-131

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      7 LKK 9
      |||
Db      1 LKK 3

```

```

RESULT 54
US-08-465-325-151
; Sequence 151, Application US/08465325

```

```

; Patent No. 5686563
; GENERAL INFORMATION:
;   APPLICANT: Magainin Pharmaceuticals Inc.
;   APPLICANT: 5110 Campus Drive
;   APPLICANT: Plymouth Meeting, PA 19462
;   TITLE OF INVENTION: Biologically Active Peptides Having
;   TITLE OF INVENTION: N-Terminal Substitutions
;   NUMBER OF SEQUENCES: 153
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
;     ADDRESSEE: Dunner
;     STREET: 1300 I. Street, N.W. Suite 700
;     CITY: Washington
;     STATE: D.C.
;     COUNTRY: USA
;     ZIP: 20005-3315
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: Floppy disk
;     COMPUTER: IBM PC compatible
;     OPERATING SYSTEM: PC-DOS/MS-DOS
;     SOFTWARE: PatentIn Release #1.0, Version #1.25
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/08/465,325
;     FILING DATE: 05-JUN-1995
;     CLASSIFICATION: 514
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: 08/184,462
;     FILING DATE: 18-JAN-94
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: 07/891,201
;     FILING DATE: 01-JUN-92
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Fordis, Jean B
;     REGISTRATION NUMBER: 32,984
;     REFERENCE/DOCKET NUMBER: 05387.0021-03000
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: (202) 408-4000
;     TELEFAX: (202) 408-4400
;   INFORMATION FOR SEQ ID NO: 151:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH: 11 amino acids
;       TYPE: amino acid
;       STRANDEDNESS: single
;       TOPOLOGY: linear
;     MOLECULE TYPE: peptide
US-08-465-325-151

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      7 LKK 9
      |||
Db      1 LKK 3

```

RESULT 55

US-08-449-207-2
; Sequence 2, Application US/08449207
; Patent No. 5714313
; GENERAL INFORMATION:
; APPLICANT: Garfinkel, David J.
; APPLICANT: Nissley, Dwight V.
; APPLICANT: Curcio, Joan M.
; APPLICANT: Strathern, Jeffrey N.
; TITLE OF INVENTION: SIMPLE METHOD FOR DETECTING INHIBITORS
; TITLE OF INVENTION: OF RETROVIRAL REPLICATION
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NEEDLE & ROSENBERG, P.C.
; STREET: Suite 1200, 127 Peachtree Street
; CITY: Atlanta
; STATE: GA
; COUNTRY: U.S.A.
; ZIP: 30303-1811
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/449,207
; FILING DATE: 24-MAY-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Selby, Elizabeth
; REGISTRATION NUMBER: 38,298
; REFERENCE/DOCKET NUMBER: 14014.0144
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (404) 688-0770
; TELEFAX: (404) 688-9880
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: not relevant
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-449-207-2

Query Match 27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 AVK 6
|||
Db 6 AVK 8

RESULT 56
US-08-156-552A-17
; Sequence 17, Application US/08156552A
; Patent No. 5726155
; GENERAL INFORMATION:

```

; APPLICANT: Bokoch, Gary M
; APPLICANT: Curnutte, John T
; TITLE OF INVENTION: REGULATION OF OXIDATIVE BURST USING
; TITLE OF INVENTION: LMWG-DERIVED PEPTIDES AND ANALOGS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: The Scripps Research Institute, Office of
; ADDRESSEE: Patent Counsel
; STREET: 10666 No. 5726155th Torrey Pines Road, TPC 8
; CITY: La Jolla
; STATE: CA
; COUNTRY: USA
; ZIP: 92037
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/156,552A
; FILING DATE: 15-NOV-1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,944
; FILING DATE: 02-AUG-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Logan, April C.
; REGISTRATION NUMBER: 33,950
; REFERENCE/DOCKET NUMBER: SCRF 281.1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-554-2937
; TELEFAX: 619-554-6312
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-156-552A-17

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      6 KLK 8
      |||
Db      2 KLK 4

```

```

RESULT 57
US-08-416-035-8
; Sequence 8, Application US/08416035
; Patent No. 5739278
; GENERAL INFORMATION:
; APPLICANT: Daum, Gunter
; APPLICANT: Cool, Deborah E.
; APPLICANT: Fischer, Edmond H.

```

```

; TITLE OF INVENTION: Methods and Compositions for Protein
; TITLE OF INVENTION: Tyrosine Phosphatases
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/416,035
; FILING DATE: 30-MAR-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/059,949
; FILING DATE: 10-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Sharkey, Richard G.
; REGISTRATION NUMBER: 32,629
; REFERENCE/DOCKET NUMBER: 940010.531
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; TELEX: 3723836
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-416-035-8

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      8 KKK 10
      |||
Db      9 KKK 11

```

RESULT 58

US-08-552-907-16

```

; Sequence 16, Application US/08552907
; Patent No. 5744299
; GENERAL INFORMATION:
; APPLICANT: Henrickson, Kelly J.
; APPLICANT: Fan, Jiang (n.m.i.)
; TITLE OF INVENTION: HUMAN PARAINFLUENZA VIRUS-1 ASSAY
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:

```

; ADDRESSEE: Quarles & Brady
 ; STREET: 411 East Wisconsin Avenue
 ; CITY: Milwaukee
 ; STATE: Wisconsin
 ; COUNTRY: U.S.A.
 ; ZIP: 53202-4497
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/552,907
 ; FILING DATE:
 ; CLASSIFICATION: 435
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Baker, Jean C.
 ; REGISTRATION NUMBER: 35,433
 ; REFERENCE/DOCKET NUMBER: 650053.91037
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (414) 277-5000
 ; TELEFAX: (414) 271-3552
 ; INFORMATION FOR SEQ ID NO: 16:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 11 amino acids
 ; TYPE: amino acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: peptide
 US-08-552-907-16

Query Match 27.3%; Score 3; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 4.4e+03;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKK 9
 |||
 Db 2 LKK 4

RESULT 59
 US-08-443-568B-21
 ; Sequence 21, Application US/08443568B
 ; Patent No. 5759807
 ; GENERAL INFORMATION:
 ; APPLICANT: Breece, Tim
 ; APPLICANT: Hayenga, Kirk
 ; APPLICANT: Rindersknecht, Ernst
 ; APPLICANT: Vandlen, Richard
 ; APPLICANT: Daniel, Yansura
 ; TITLE OF INVENTION: Process for Producing Relaxin
 ; NUMBER OF SEQUENCES: 47
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Pennie & Edmonds LLP
 ; STREET: 1155 Avenue of the Americas
 ; CITY: New York
 ; STATE: New York

```

; COUNTRY: U.S.A.
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/443,568B
; FILING DATE: 22-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/080,354
; FILING DATE: 21-JUNE-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Abrams, Samuel B.
; REGISTRATION NUMBER: 30,605
; REFERENCE/DOCKET NUMBER: 7842-037
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-493-4935
; TELEFAX: 650-493-5556
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
US-08-443-568B-21

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      7 LKK 9
      |||
Db      9 LKK 11

```

```

RESULT 60
US-08-542-363-21
; Sequence 21, Application US/08542363
; Patent No. 5770421
; GENERAL INFORMATION:
; APPLICANT: Morris, Stephan W.
; APPLICANT: Look, A. Thomas
; TITLE OF INVENTION: ALK Protein Tyrosine Kinase/Receptor and
; TITLE OF INVENTION: Ligands Thereof
; NUMBER OF SEQUENCES: 43
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
; STREET: 1100 New York Avenue, N.W., Suite 600
; CITY: Washington
; STATE: DC
; COUNTRY: USA

```

```

;      ZIP: 20005
;      COMPUTER READABLE FORM:
;      MEDIUM TYPE: Floppy disk
;      COMPUTER: IBM PC compatible
;      OPERATING SYSTEM: PC-DOS/MS-DOS
;      SOFTWARE: PatentIn Release #1.0, Version #1.30
;      CURRENT APPLICATION DATA:
;      APPLICATION NUMBER: US/08/542,363
;      FILING DATE: 12-OCT-1995
;      CLASSIFICATION: 435
;      ATTORNEY/AGENT INFORMATION:
;      NAME: Fox, Samuel L.
;      REGISTRATION NUMBER: 30,353
;      REFERENCE/DOCKET NUMBER: 0656.0400001/SLF/GKT
;      TELECOMMUNICATION INFORMATION:
;      TELEPHONE: 202-371-2600
;      TELEFAX: 202-371-2540
;      INFORMATION FOR SEQ ID NO: 21:
;      SEQUENCE CHARACTERISTICS:
;      LENGTH: 11 amino acids
;      TYPE: amino acid
;      STRANDEDNESS: single
;      TOPOLOGY: linear
;      MOLECULE TYPE: peptide
US-08-542-363-21

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      4 AVK 6
      |||
Db      5 AVK 7

```

```

RESULT 61
US-08-248-357C-6
; Sequence 6, Application US/08248357C
; Patent No. 5773225
; GENERAL INFORMATION:
; APPLICANT: Luban, Jeremy
; APPLICANT: Goff, Stephen P.
; TITLE OF INVENTION: Screening Method for the Identification of
Compou
; TITLE OF INVENTION: Formation
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooper & Dunham LLP
; STREET: 1185 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS

```

```

;   SOFTWARE: PatentIn Release #1.0, Version #1.30
;   CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: US/08/248,357C
;   FILING DATE: 24-MAY-1994
;   CLASSIFICATION: 435
;   ATTORNEY/AGENT INFORMATION:
;   NAME: White, John P.
;   REGISTRATION NUMBER: 28,678
;   REFERENCE/DOCKET NUMBER: 44010
;   TELECOMMUNICATION INFORMATION:
;   TELEPHONE: 212-278-0400
;   TELEFAX: 212-391-0525
;   INFORMATION FOR SEQ ID NO: 6:
;   SEQUENCE CHARACTERISTICS:
;   LENGTH: 11 amino acids
;   TYPE: amino acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
;   MOLECULE TYPE: amino acid
US-08-248-357C-6

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches      3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 AGS 3
      |||
Db      7 AGS 9

```

RESULT 62

US-08-082-269D-2

```

; Sequence 2, Application US/08082269D
; Patent No. 5773227

```

; GENERAL INFORMATION:

```

;   APPLICANT: Kuhn, Michael
;   APPLICANT: Meyer, Tobias
;   APPLICANT: Allbritton, Nancy
;   TITLE OF INVENTION: Bifunctional Chelating Polysaccharides
;   NUMBER OF SEQUENCES: 9
;   CORRESPONDENCE ADDRESS:
;   ADDRESSEE: Molecular Probes, Inc.
;   STREET: 4849 Pitchford Avenue
;   CITY: Eugene
;   STATE: Oregon
;   COUNTRY: USA
;   ZIP: 97402-9144

```

; COMPUTER READABLE FORM:

```

;   MEDIUM TYPE: Diskette, 3.5 inch
;   COMPUTER: IBM
;   OPERATING SYSTEM: MS-DOS 6.2
;   SOFTWARE: Text Editor
;   CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: US/08/082,269D
;   FILING DATE: 23-June-1993
;   CLASSIFICATION: 435
;   ATTORNEY/AGENT INFORMATION:

```

```

; NAME: Helfenstein, Allegra J.
; REGISTRATION NUMBER: 34,179
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (503)465-8300
; TELEFAX: (503)344-6504
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 AMINO ACIDS
; TYPE: Amino Acid
; TOPOLOGY: Linear
; MOLECULE TYPE: Peptide
; HYPOTHETICAL: no
; FRAGMENT TYPE:
; PUBLICATION INFORMATION:
; AUTHORS: Chelsky, Daniel, Ralph, Rebecca and Jonak, Gerald
; TITLE: Sequence Requirements for Synthetic Peptide-Mediated
Translocation to the
; Patent No. 5773227
; JOURNAL: Molecular and Cellular Biology
; VOLUME: 9
; ISSUE: 6
; PAGES: 2487-2492
; DATE: 1989
US-08-082-269D-2

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches    3; Conservative    0; Mismatches    0; Indels    0; Gaps    0;

```

```

Qy      8 KKK 10
      |||
Db      5 KKK 7

```

RESULT 63

US-08-218-026-50

```

; Sequence 50, Application US/08218026
; Patent No. 5786324

```

; GENERAL INFORMATION:

```

; APPLICANT: Gray, Beulah
; APPLICANT: Haseman, Judith R.
; APPLICANT: Mayo, Kevin
; TITLE OF INVENTION: Synthetic Peptides with Bactericidal
; TITLE OF INVENTION: Activity and Endotoxin Neutralizing Activity for Gram
; TITLE OF INVENTION: Negative Bacteria and Methods for Their Use
; NUMBER OF SEQUENCES: 60
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merchant & Gould
; STREET: 3100 No. 5786324west Center
; CITY: Minneapolis
; STATE: MN
; COUNTRY: USA
; ZIP: 55402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS

```

```

;   SOFTWARE: PatentIn Release #1.0, Version #1.25
;   CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: US/08/218,026
;   FILING DATE: 24-MAR-1994
;   CLASSIFICATION: 514
;   ATTORNEY/AGENT INFORMATION:
;   NAME: Kowalchyk, Katherine M.
;   REGISTRATION NUMBER: 36,848
;   REFERENCE/DOCKET NUMBER: 600.286US01
;   TELECOMMUNICATION INFORMATION:
;   TELEPHONE: 612-332-5300
;   TELEFAX: 612-332-9081
;   INFORMATION FOR SEQ ID NO: 50:
;   SEQUENCE CHARACTERISTICS:
;   LENGTH: 11 amino acids
;   TYPE: amino acid
;   TOPOLOGY: circular
;   MOLECULE TYPE: peptide
US-08-218-026-50

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      7 LKK 9
      |||
Db      8 LKK 10

```

```

RESULT 64
US-08-856-053-17
; Sequence 17, Application US/08856053
; Patent No. 5807827
; GENERAL INFORMATION:
;   APPLICANT: Lee, Nancy M.
;   APPLICANT: Loh, Horace H.
;   APPLICANT: Takemori, Akira E.
;   TITLE OF INVENTION: DES-TYR DYNORPHIN ANALOGUES
;   NUMBER OF SEQUENCES: 23
;   CORRESPONDENCE ADDRESS:
;   ADDRESSEE: Majestic, Parsons, Siebert & Hsue
;   STREET: Four Embarcadero Center, Suite 1450
;   CITY: San Francisco
;   STATE: California
;   COUNTRY: U.S.A.
;   ZIP: 94111-4121
;   COMPUTER READABLE FORM:
;   MEDIUM TYPE: Floppy disk
;   COMPUTER: IBM PC compatible
;   OPERATING SYSTEM: PC-DOS/MS-DOS
;   SOFTWARE: PatentIn Release #1.0, Version #1.25
;   CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: US/08/856,053
;   FILING DATE:
;   CLASSIFICATION: 514
;   PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: US 07/897,920

```

```

; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Siebert, J. Suzanne
; REGISTRATION NUMBER: 28,758
; REFERENCE/DOCKET NUMBER: 2995.1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 362-5556
; TELEFAX: (415) 362-5418
; TELEX: 278638 MGPS
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: porcine
US-08-856-053-17

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      6 KLK 8
        |||
Db      9 KLK 11

```

RESULT 65

```

US-08-478-386A-59
; Sequence 59, Application US/08478386A
; Patent No. 5830462
; GENERAL INFORMATION:
; APPLICANT: Crabtree, Gerald R.
; APPLICANT: Schreiber, Stuart L.
; APPLICANT: Spencer, David M.
; APPLICANT: Wandless, Thomas J.
; APPLICANT: Belshaw, Peter
; TITLE OF INVENTION: REGULATED TRANSCRIPTION OF TARGETED
; TITLE OF INVENTION: GENES AND OTHER BIOLOGICAL EVENTS
; NUMBER OF SEQUENCES: 81
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARIAD Pharmaceuticals, Inc.
; STREET: 26 Landsdowne Street
; CITY: Cambridge
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02139
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC/DOS/MS/DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/478,386A

```

```

; FILING DATE: 07/JUN/1995
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Figg, E. Anthony
; REGISTRATION NUMBER: 27,195
; REFERENCE/DOCKET NUMBER: 2054-114A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 783-6040
; TELEFAX: (202) 783-6031
; INFORMATION FOR SEQ ID NO: 59:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..11
; OTHER INFORMATION: /note= "Translation product of SEQ ID
; OTHER INFORMATION: NOS:58 and 60."
US-08-478-386A-59

```

```

Query Match          27.3%; Score 3; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches      3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      8 KKK 10
        |||
Db      4 KKK 6

```

RESULT 66

US-08-653-632-50

```

; Sequence 50, Application US/08653632
; Patent No. 5830860
; GENERAL INFORMATION:
; APPLICANT: GRAY, Beulah
; APPLICANT: HASEMAN, Judith R.
; APPLICANT: MAYO, Kevin
; TITLE OF INVENTION: PEPTIDES WITH BACTERICIDAL AND ENDOTOXIN NEUTRALIZING
; NUMBER OF SEQUENCES: 66
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merchant, Gould, Smith, Edell, Welter & Schmidt
; STREET: 3100 No. 5830860west Center, 90 South Seventh St
; CITY: Minneapolis
; STATE: MN
; COUNTRY: USA
; ZIP: 55402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/653,632
; FILING DATE: 24-MAY-1996
; CLASSIFICATION: 514

```

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/218026
; FILING DATE: 24-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Kettelberger, Denise M
; REGISTRATION NUMBER: 33,924
; REFERENCE/DOCKET NUMBER: 600.286US11
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 612/371-5268
; TELEFAX: 612/332-9081
; TELEX:
; INFORMATION FOR SEQ ID NO: 50:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:

```

US-08-653-632-50

```

Query Match          27.3%; Score 3; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches      3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      7 LKK 9
        |||
Db      8 LKK 10

```

RESULT 67

US-08-292-597-59

```

; Sequence 59, Application US/08292597
; Patent No. 5834266
; GENERAL INFORMATION:
; APPLICANT: Gerald R. Crabtree
; APPLICANT: Schreiber, Stuart L.
; APPLICANT: Spencer, David M.
; APPLICANT: Wandless, Thomas J.
; APPLICANT: Belshaw, Peter
; TITLE OF INVENTION: Regulated Apoptosis
; NUMBER OF SEQUENCES: 81
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARIAD Pharmaceuticals, Inc.
; STREET: 26 Landsdowne Street
; CITY: Cambridge
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02139
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC/DOS/MS/DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25

```

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,597
; FILING DATE: 18/AUG/1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Figg, E. Anthony
; REGISTRATION NUMBER: 27,195
; REFERENCE/DOCKET NUMBER: 2054-108A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 783-6040
; TELEFAX: (202) 783-6031
; INFORMATION FOR SEQ ID NO: 59:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..11
; OTHER INFORMATION: /note= "Translation product of SEQ
; OTHER INFORMATION: ID NOS:58 and 60."
US-08-292-597-59

```

```

Query Match          27.3%; Score 3; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      8 KKK 10
      |||
Db      4 KKK 6

```

```

RESULT 68
US-08-456-112B-35
; Sequence 35, Application US/08456112B
; Patent No. 5834430
; GENERAL INFORMATION:
; APPLICANT: Porro, Massimo
; TITLE OF INVENTION: POTENTIATION OF ANTIBIOTICS
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hedman, Gibson & Costigan
; STREET: 1185 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: LEADING EDGE 486
; OPERATING SYSTEM: DOS
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:

```

```

; APPLICATION NUMBER: US/08/456,112B
; FILING DATE: May 31, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Costigan, James V.
; REGISTRATION NUMBER: 25,669
; REFERENCE/DOCKET NUMBER: 576-004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 302-8989
; TELEFAX: (212) 302-8998
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: circular
US-08-456-112B-35

```

```

Query Match          27.3%; Score 3; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches      3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      7 LKK 9
        |||
Db      8 LKK 10

```

RESULT 69

US-08-701-124-19

```

; Sequence 19, Application US/08701124
; Patent No. 5846782
; GENERAL INFORMATION:
; APPLICANT: Wickham, Thomas J.
; APPLICANT: Roelvink, Petrus W.
; APPLICANT: Kovesdi, Imre
; TITLE OF INVENTION: TARGETING ADENOVIRUS WITH USE OF
; TITLE OF INVENTION: CONSTRAINED PEPTIDE MOTIFS
; NUMBER OF SEQUENCES: 80
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Leydig, Voit & Mayer, Ltd.
; STREET: Two Prudential Plaza - 49th Floor
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60601
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/701,124
; FILING DATE: 21-AUG-1996
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:

```

; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-701-124-19

Query Match 27.3%; Score 3; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KKK 10
|||
Db 3 KKK 5

RESULT 70

US-08-618-696-5

; Sequence 5, Application US/08618696
; Patent No. 5861475
; GENERAL INFORMATION:
; APPLICANT: COOPER, Jr., J. ALLEN D.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE
; TITLE OF INVENTION: INHIBITION OF PHAGOCYTES
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARNOLD, WHITE & DURKEE
; STREET: P.O. BOX 4433
; CITY: HOUSTON
; STATE: TEXAS
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: FLOPPY DISK
; COMPUTER: IBM PC COMPATIBLE
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/618,696
; FILING DATE: 20-MAR-1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/995,269
; FILING DATE: 12/21/92
; ATTORNEY/AGENT INFORMATION:
; NAME: PARKER, DAVID L.
; REGISTRATION NUMBER: 32,165
; REFERENCE/DOCKET NUMBER: UOAB:002/PAR
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512-320-7200
; TELEFAX: 512-474-7577
; TELEX: NOT APPLICABLE
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acid residues
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-08-618-696-5

Query Match 27.3%; Score 3; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GSA 4
|||
Db 3 GSA 5

RESULT 71

US-08-618-696-18

; Sequence 18, Application US/08618696
; Patent No. 5861475
; GENERAL INFORMATION:
; APPLICANT: COOPER, Jr., J. ALLEN D.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE
; TITLE OF INVENTION: INHIBITION OF PHAGOCYTES
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARNOLD, WHITE & DURKEE
; STREET: P.O. BOX 4433
; CITY: HOUSTON
; STATE: TEXAS
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: FLOPPY DISK
; COMPUTER: IBM PC COMPATIBLE
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/618,696
; FILING DATE: 20-MAR-1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/995,269
; FILING DATE: 12/21/92
; ATTORNEY/AGENT INFORMATION:
; NAME: PARKER, DAVID L.
; REGISTRATION NUMBER: 32,165
; REFERENCE/DOCKET NUMBER: UOAB:002/PAR
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512-320-7200
; TELEFAX: 512-474-7577
; TELEX: NOT APPLICABLE
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acid residues
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-08-618-696-18

Query Match 27.3%; Score 3; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;

Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GSA 4
|||
Db 3 GSA 5

RESULT 72

US-08-388-653-59

; Sequence 59, Application US/08388653

; Patent No. 5869337

; GENERAL INFORMATION:

; APPLICANT: Crabtree, Gerald R.

; APPLICANT: Schreiber, Stuart L.

; APPLICANT: Spencer, David M.

; APPLICANT: Wandless, Thomas J.

; APPLICANT: Belshaw, Peter

; TITLE OF INVENTION: REGULATED TRANSCRIPTION OF TARGETED

; TITLE OF INVENTION: GENES AND OTHER BIOLOGICAL EVENTS

; NUMBER OF SEQUENCES: 81

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: ARIAD Pharmaceuticals, Inc.

; STREET: 26 Landsdowne Street

; CITY: Cambridge

; STATE: Massachusetts

; COUNTRY: USA

; ZIP: 02139

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC/DOS/MS/DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/388,653

; FILING DATE: 14-FEB-1995

; CLASSIFICATION: 514

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/478,386

; FILING DATE: 07-JUN-1995

; ATTORNEY/AGENT INFORMATION:

; NAME: Figg, E. Anthony

; REGISTRATION NUMBER: 27,195

; REFERENCE/DOCKET NUMBER: 2054-114A

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (202) 783-6040

; TELEFAX: (202) 783-6031

; INFORMATION FOR SEQ ID NO: 59:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; FEATURE:

; NAME/KEY: Peptide

; LOCATION: 1..11

; OTHER INFORMATION: /note= "Translation product of SEQ ID

; OTHER INFORMATION: NOS:58 and 60."

US-08-388-653-59

Query Match 27.3%; Score 3; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KKK 10
|||
Db 4 KKK 6

RESULT 73

US-08-473-985-59

; Sequence 59, Application US/08473985

; Patent No. 5871753

; GENERAL INFORMATION:

; APPLICANT: Crabtree, Gerald R.

; APPLICANT: Schreiber, Stuart L.

; APPLICANT: Spencer, David M.

; APPLICANT: Wandless, Thomas J.

; APPLICANT: Belshaw, Peter

; APPLICANT: Ho, Steffan

; TITLE OF INVENTION: Regulated Transcription of Targeted Genes and

; TITLE OF INVENTION: Other Biological Events

; NUMBER OF SEQUENCES: 66

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Campbell and Flores

; STREET: 4370 La Jolla Village Drive, Suite 700

; CITY: San Diego

; STATE: California

; COUNTRY: USA

; ZIP: 92122

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/473,985

; FILING DATE:

; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/179,748

; FILING DATE: 07-JAN-1994

; ATTORNEY/AGENT INFORMATION:

; NAME: Campbell, Cathryn A.

; REGISTRATION NUMBER: 31,815

; REFERENCE/DOCKET NUMBER: P-SU 9863

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (619) 535-9001

; TELEFAX: (619) 535-8949

; INFORMATION FOR SEQ ID NO: 59:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..11
; OTHER INFORMATION: /note= "Translation product of SEQ
; OTHER INFORMATION: ID NOS:58 and 60."
US-08-473-985-59

Query Match 27.3%; Score 3; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KKK 10
|||
Db 4 KKK 6

RESULT 74

US-08-428-257A-54

; Sequence 54, Application US/08428257A
; Patent No. 5885808

; GENERAL INFORMATION:

; APPLICANT: Spooner, Robert A.
; APPLICANT: Epenetos, A.A.
; TITLE OF INVENTION: Compounds to target cells
; NUMBER OF SEQUENCES: 80
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Jules E. Goldberg
; STREET: 261 Madison Avenue
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10016-2391

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/428,257A
; FILING DATE: 07/05/95
; CLASSIFICATION: 514

; INFORMATION FOR SEQ ID NO: 54:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein

US-08-428-257A-54

Query Match 27.3%; Score 3; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.4e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKK 9
|||
Db 2 LKK 4

RESULT 75

US-08-537-400-31

; Sequence 31, Application US/08537400

; Patent No. 5939301

; GENERAL INFORMATION:

; APPLICANT:

; TITLE OF INVENTION: Cloned DNA Polymerases From Thermotoga

; TITLE OF INVENTION: neapolitana And Mutants Thereof

; NUMBER OF SEQUENCES: 37

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

; STREET: 1100 New York Avenue, N.W., Suite 600

; CITY: Washington

; STATE: DC

; COUNTRY: USA

; ZIP: 20005

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.30

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/537,400

; FILING DATE: 02-OCT-1995

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/316,423

; FILING DATE: 30-SEP-1994

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/370,190

; FILING DATE: 09-JAN-1995

; ATTORNEY/AGENT INFORMATION:

; NAME: Esmond, Robert W.

; REGISTRATION NUMBER: 32,893

; REFERENCE/DOCKET NUMBER: 0942.2800002

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 202-371-2600

; TELEFAX: 202-371-2540

; INFORMATION FOR SEQ ID NO: 31:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: protein

US-08-537-400-31

Query Match 27.3%; Score 3; DB 2; Length 11;

Best Local Similarity 100.0%; Pred. No. 4.4e+03;

Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKK 9

|||

Db 6 LKK 8

Search completed: April 8, 2004, 15:52:08
Job time : 13.3077 secs

OM protein - protein search, using sw model

Run on: April 8, 2004, 15:30:07 ; Search time 8.61538 Seconds
 (without alignments)
 122.816 Million cell updates/sec

Title: US-09-787-443A-4
 Perfect score: 11
 Sequence: 1 AGSAVKLKKKA 11

Scoring table: OLIGO
 Gapop 60.0 , Gapext 60.0

Searched: 283366 seqs, 96191526 residues

Word size : 0

Total number of hits satisfying chosen parameters: 226

Minimum DB seq length: 11
 Maximum DB seq length: 11

Post-processing: Listing first 100 summaries

Database : PIR_78:*
 1: pirl:*
 2: pir2:*
 3: pir3:*
 4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query		DB	ID	Description
		Match	Length			
1	3	27.3	11	2	A44755	20alpha-hydroxyste
2	3	27.3	11	2	S33519	probable secreted
3	3	27.3	11	2	D57789	gallbladder stone
4	3	27.3	11	2	PH0941	T-cell receptor be
5	3	27.3	11	2	PU0034	dextranucrase (EC
6	2	18.2	11	1	LFTWWE	probable trpEG lea
7	2	18.2	11	2	S66196	alcohol dehydrogen
8	2	18.2	11	2	A33917	dihydroorotase (EC
9	2	18.2	11	2	A38841	rhodopsin homolog
10	2	18.2	11	2	YHRT	morphogenetic neur
11	2	18.2	11	2	YHHU	morphogenetic neur
12	2	18.2	11	2	YHBO	morphogenetic neur
13	2	18.2	11	2	YHXA	morphogenetic neur

14	2	18.2	11	2	YHJFHY	morphogenetic neur
15	2	18.2	11	2	B26744	megascoliakinin -
16	2	18.2	11	2	S42449	ant1 protein - pha
17	2	18.2	11	2	A58502	38K kidney stone p
18	2	18.2	11	2	F58501	43.5K bile stone p
19	2	18.2	11	2	JQ0395	hypothetical prote
20	2	18.2	11	2	S66606	quinoline 2-oxidor
21	2	18.2	11	2	S58244	pyrroloquinoline q
22	2	18.2	11	2	B43669	hypothetical prote
23	2	18.2	11	2	E41476	probable antigen 5
24	2	18.2	11	2	S70338	napin small chain
25	2	18.2	11	2	S19775	wound-induced prot
26	2	18.2	11	2	A38590	transforming prote
27	2	18.2	11	2	A34135	DNA-binding protei
28	2	18.2	11	2	A61512	variant surface gl
29	2	18.2	11	2	S43626	cytochrome-c oxida
30	2	18.2	11	2	D42965	talin - chicken (f
31	2	18.2	11	2	S21727	gamma-interferon-i
32	2	18.2	11	2	PT0287	Ig heavy chain CRD
33	2	18.2	11	2	S57575	T cell receptor V-
34	2	18.2	11	2	S51732	T-cell receptor al
35	2	18.2	11	2	A32428	amine oxidase (cop
36	2	18.2	11	2	A61483	pyridoxal kinase (
37	2	18.2	11	2	PD0442	NIPSNAP2 protein -
38	2	18.2	11	2	PN0044	protein kinase C i
39	2	18.2	11	2	PT0209	T-cell receptor al
40	2	18.2	11	2	PT0218	T-cell receptor be
41	2	18.2	11	2	D41946	T-cell receptor ga
42	2	18.2	11	2	B41946	T-cell receptor ga
43	2	18.2	11	2	C38887	T-cell receptor ga
44	2	18.2	11	2	I41946	T-cell receptor ga
45	2	18.2	11	2	A49037	TcR gamma V-J regi
46	2	18.2	11	2	B49037	TcR gamma V-J regi
47	2	18.2	11	2	C49037	TcR gamma V-J regi
48	2	18.2	11	2	PD0441	translation elonga
49	2	18.2	11	2	S65377	cytochrome-c oxida
50	2	18.2	11	2	S09349	microtubule-associ
51	2	18.2	11	2	S18385	NADP-cytochrome P4
52	2	18.2	11	2	S78422	ribosomal protein
53	2	18.2	11	2	PH0939	T-cell receptor be
54	2	18.2	11	2	PH0940	T-cell receptor be
55	2	18.2	11	2	PH0947	T-cell receptor be
56	2	18.2	11	2	PC2254	cytochrome P450 3A
57	2	18.2	11	2	A34243	H-hyosophorin - Ja
58	2	18.2	11	2	H84082	hypothetical prote
59	2	18.2	11	4	I52708	ELAV-like neuronal
60	2	18.2	11	4	I54081	retinoic acid rece
61	1	9.1	11	1	XAVIBH	bradykinin-potenti
62	1	9.1	11	1	XASNBA	bradykinin-potenti
63	1	9.1	11	1	ECLQ2M	tachykinin II - mi
64	1	9.1	11	1	SPHO	substance P - hors
65	1	9.1	11	1	EOOCC	eledoisin - curled
66	1	9.1	11	1	A60654	substance P - guin
67	1	9.1	11	1	EOOC	eledoisin - musky
68	1	9.1	11	1	GMROL	leucosulfakinin -
69	1	9.1	11	2	G42762	proteasome endopep
70	1	9.1	11	2	S68392	H+-transporting tw

71	1	9.1	11	2	B49164	chromogranin-B - r
72	1	9.1	11	2	JN0023	substance P - chic
73	1	9.1	11	2	S32575	ribosomal protein
74	1	9.1	11	2	A40693	transgelin - sheep
75	1	9.1	11	2	PQ0682	photosystem I 17.5
76	1	9.1	11	2	S00616	parasporal crystal
77	1	9.1	11	2	C53652	rhlR protein - Pse
78	1	9.1	11	2	S09074	cytochrome P450-4b
79	1	9.1	11	2	A57458	gene Gax protein -
80	1	9.1	11	2	A26930	ermG leader peptid
81	1	9.1	11	2	D60409	kassinin-like pept
82	1	9.1	11	2	F60409	substance P-like p
83	1	9.1	11	2	E60409	substance P-like p
84	1	9.1	11	2	A61365	phyllokinin - Rohd
85	1	9.1	11	2	S23308	substance P - rain
86	1	9.1	11	2	S23306	substance P - Atla
87	1	9.1	11	2	B60409	kassinin-like pept
88	1	9.1	11	2	C60409	kassinin-like pept
89	1	9.1	11	2	S07203	uperolein - frog (
90	1	9.1	11	2	S07207	Crinia-angiotensin
91	1	9.1	11	2	S07201	physalaemin - frog
92	1	9.1	11	2	A61033	ranatachykinin A -
93	1	9.1	11	2	D61033	ranatachykinin D -
94	1	9.1	11	2	B58501	24K kidney and bla
95	1	9.1	11	2	D58502	27K bile and gallb
96	1	9.1	11	2	C58501	42K bile stone pro
97	1	9.1	11	2	PQ0231	beta-glucosidase (
98	1	9.1	11	2	S04875	nifS protein - Bra
99	1	9.1	11	2	I41138	acetyl ornithine d
100	1	9.1	11	2	S42587	celF protein - Esc

ALIGNMENTS

RESULT 1

A44755

20alpha-hydroxysteroid dehydrogenase (EC 1.1.1.149) - Clostridium scindens
(fragment)

C;Species: Clostridium scindens

C;Date: 12-Mar-1993 #sequence_revision 12-Mar-1993 #text_change 17-Mar-1999

C;Accession: A44755

R;Krafft, A.E.; Hylemon, P.B.

J. Bacteriol. 171, 2925-2932, 1989

A;Title: Purification and characterization of a novel form of 20alpha-hydroxysteroid dehydrogenase from Clostridium scindens.

A;Reference number: A44755; MUID:89255043; PMID:2722736

A;Accession: A44755

A;Molecule type: protein

A;Residues: 1-11 <KRA>

C;Comment: This enzyme was purified to homogeneity and shown to have 20alpha-hydroxysteroid dehydrogenase activity in the presence of NADH or NADPH. The enzyme as purified lacked glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity although the fragment shows near identify to known GAPDH sequences.

C;Keywords: homotetramer; NAD; NADP; oxidoreductase

Query Match

27.3%; Score 3; DB 2; Length 11;

Best Local Similarity 100.0%; Pred. No. 4.3e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 AVK 6
|||
Db 1 AVK 3

RESULT 2

S33519

probable secreted protein - *Acholeplasma laidlawii* (fragment)

C;Species: *Acholeplasma laidlawii*

C;Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 22-Oct-1999

C;Accession: S33519

R;Boyer, M.J.; Jarhede, T.K.; Tegman, V.; Wieslander, A.

submitted to the EMBL Data Library, June 1993

A;Description: Sequence regions from *Acholeplasma laidlawii* which restore export of beta-lactamase in *Escherichia coli*.

A;Reference number: S33518

A;Accession: S33519

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-11 <BOY>

A;Cross-references: EMBL:Z22875; NID:g311706; PIDN:CAA80495.1; PID:g311708

Query Match 27.3%; Score 3; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.3e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLK 8
|||
Db 3 KLK 5

RESULT 3

D57789

gallbladder stone matrix protein, 14.5K - human (fragment)

C;Species: *Homo sapiens* (man)

C;Date: 23-Feb-1996 #sequence_revision 23-Feb-1996 #text_change 23-Feb-1996

C;Accession: D57789

R;Binette, J.P.; Binette, M.B.

submitted to the Protein Sequence Database, February 1996

A;Description: The proteins of gallbladder stones.

A;Reference number: A57789

A;Accession: D57789

A;Status: preliminary

A;Molecule type: protein

A;Residues: 1-11 <BIN>

Query Match 27.3%; Score 3; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.3e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGS 3
|||
Db 7 AGS 9

RESULT 4

PH0941

T-cell receptor beta chain V-D-J region (clone 12) - rat (fragment)

C;Species: Rattus norvegicus (Norway rat)

C;Date: 09-Oct-1992 #sequence_revision 09-Oct-1992 #text_change 30-May-1997

C;Accession: PH0941

R;Gold, D.P.; Offner, H.; Sun, D.; Wiley, S.; Vandenbark, A.A.; Wilson, D.B.

J. Exp. Med. 174, 1467-1476, 1991

A;Title: Analysis of T cell receptor beta chains in Lewis rats with experimental allergic encephalomyelitis: conserved complementarity determining region 3.

A;Reference number: PH0891; MUID:92078857; PMID:1836012

A;Accession: PH0941

A;Molecule type: mRNA

A;Residues: 1-11 <GOL>

A;Experimental source: complete Freund's adjuvant-immunized lymph node

C;Keywords: T-cell receptor

Query Match 27.3%; Score 3; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.3e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SAV 5

|||

Db 4 SAV 6

RESULT 5

PU0034

dextranucrase (EC 2.4.1.5) - Streptococcus bovis (fragment)

C;Species: Streptococcus bovis

C;Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 18-Sep-1996

C;Accession: PU0034

R;Uezono, Y.; Tsumori, H.; Mukasa, H.

submitted to JIPID, October 1993

A;Description: Purification and properties of glucosyltransferase synthesizing 1,6-alpha-D-glucan from Streptococcus bovis.

A;Reference number: PU0034

A;Accession: PU0034

A;Molecule type: protein

A;Residues: 1-11 <UEZ>

A;Experimental source: ATCC 9809

C;Keywords: glycosyltransferase; hexosyltransferase

Query Match 27.3%; Score 3; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4.3e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SAV 5

|||

Db 4 SAV 6

RESULT 6

LFTWWE

probable trpEG leader peptide - Thermus aquaticus

C;Species: Thermus aquaticus

C;Date: 30-Jun-1991 #sequence_revision 30-Jun-1991 #text_change 16-Jul-1999
 C;Accession: S03315
 R;Sato, S.; Nakada, Y.; Kanaya, S.; Tanaka, T.
 Biochim. Biophys. Acta 950, 303-312, 1988
 A;Title: Molecular cloning and nucleotide sequence of *Thermus thermophilus* HB8 trpE and trpG.
 A;Reference number: S03315; MUID:89000781; PMID:2844259
 A;Accession: S03315
 A;Molecule type: DNA
 A;Residues: 1-11 <SAT>
 A;Cross-references: EMBL:X07744; NID:g48261; PIDN:CAA30565.1; PID:g48262
 A;Note: the source is designated as *Thermus thermophilus* HB8
 C;Genetics:
 A;Gene: trpL
 C;Superfamily: probable trpEG leader peptide

Query Match 18.2%; Score 2; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 4e+04;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SA 4
 ||
 Db 5 SA 6

RESULT 7

S66196

alcohol dehydrogenase (EC 1.1.1.1) class III high affinity form - cod (*Gadus* sp.) (fragment)

C;Species: *Gadus* sp. (cod)

C;Date: 14-Feb-1997 #sequence_revision 13-Mar-1997 #text_change 12-Jun-1998

C;Accession: S66196

R;Hjelmqvist, L.; Hackett, M.; Shafqat, J.; Danielsson, O.; Iida, J.; Hendrickson, R.C.; Michel, H.; Shabanowitz, J.; Hunt, D.F.; Joernvall, H. FEBS Lett. 367, 237-240, 1995

A;Title: Multiplicity of N-terminal structures of medium-chain alcohol dehydrogenases. Mass-spectrometric analysis of plant, lower vertebrate and higher vertebrate class I, II, and III forms of the enzyme.

A;Reference number: S66191; MUID:95331382; PMID:7607314

A;Accession: S66196

A;Molecule type: protein

A;Residues: 1-11 <HJE>

C;Superfamily: alcohol dehydrogenase; long-chain alcohol dehydrogenase homology

C;Keywords: alcohol metabolism; NAD; oxidoreductase

Query Match 18.2%; Score 2; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 4e+04;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 AV 5
 ||
 Db 7 AV 8

RESULT 8

A33917

dihydroorotase (EC 3.5.2.3) - Chinese hamster (fragment)

C;Species: Cricetulus griseus (Chinese hamster)
 C;Date: 09-Mar-1990 #sequence_revision 09-Mar-1990 #text_change 07-Nov-1997
 C;Accession: A33917
 R;Simmer, J.P.; Kelly, R.E.; Scully, J.L.; Grayson, D.R.; Rinker Jr., A.G.; Bergh, S.T.; Evans, D.R.
 Proc. Natl. Acad. Sci. U.S.A. 86, 4382-4386, 1989
 A;Title: Mammalian aspartate transcarbamylase (ATCase): sequence of the ATCase domain and interdomain linker in the CAD multifunctional polypeptide and properties of the isolated domain.
 A;Reference number: A33917; MUID:89282776; PMID:2543974
 A;Accession: A33917
 A;Status: preliminary
 A;Molecule type: mRNA
 A;Residues: 1-11 <SIM>
 A;Cross-references: GB:M23652
 C;Superfamily: rudimentary enzyme; aspartate/ornithine carbamoyltransferase homology; Bacillus dihydroorotase homology; biotin carboxylase homology; carbamoyl-phosphate synthase (ammonia) homology; carbamoyl-phosphate synthase (glutamine-hydrolyzing) large chain homology; carbamoyl-phosphate synthase (glutamine-hydrolyzing) small chain homology; trpG homology
 C;Keywords: hydrolase

Query Match 18.2%; Score 2; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 4e+04;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 VK 6
 ||
 Db 6 VK 7

RESULT 9

A38841
 rhodopsin homolog - squid (Watasenia scintillans) (fragment)
 N;Alternate names: visual pigment protein
 C;Species: Watasenia scintillans (sparkling enope)
 C;Date: 17-Jul-1992 #sequence_revision 17-Jul-1992 #text_change 31-Oct-1997
 C;Accession: A38841
 R;Seidou, M.; Kubota, I.; Hiraki, K.; Kito, Y.
 Biochim. Biophys. Acta 957, 318-321, 1988
 A;Title: Amino acid sequence of the retinal binding site of squid visual pigment.
 A;Reference number: PT0063; MUID:89051045; PMID:3191148
 A;Accession: A38841
 A;Molecule type: protein
 A;Residues: 1-11 <SEI>
 C;Superfamily: vertebrate rhodopsin
 C;Keywords: chromoprotein; retinal
 F;3/Binding site: retinal (Lys) (covalent) #status experimental

Query Match 18.2%; Score 2; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 4e+04;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SA 4
 ||
 Db 5 SA 6

RESULT 10

YHRT

morphogenetic neuropeptide - rat

C;Species: Rattus norvegicus (Norway rat)

C;Date: 20-Jun-2000 #sequence_revision 20-Jun-2000 #text_change 20-Jun-2000

C;Accession: A01427

R;Bodenmuller, H.; Schaller, H.C.

Nature 293, 579-580, 1981

A;Title: Conserved amino acid sequence of a neuropeptide, the head activator, from coelenterates to humans.

A;Reference number: A93266; MUID:82035850; PMID:7290191

A;Accession: A01427

A;Molecule type: protein

A;Residues: 1-11 <BOD>

R;Birrr, C.; Zachmann, B.; Bodenmuller, H.; Schaller, H.C.

FEBS Lett. 131, 317-321, 1981

A;Title: Synthesis of a new neuropeptide, the head activator from hydra.

A;Reference number: A91296; MUID:82050803; PMID:7297679

A;Contents: annotation; synthesis

A;Note: the synthetic peptide was identical with the natural peptide in chemical structure and biological activity

C;Comment: This peptide was first isolated from nerve cells of hydra and was called head activator by the authors, because it induced head-specific growth and differentiation in this animal. It has been found in mammalian intestine and hypothalamus.

C;Superfamily: unassigned animal peptides

C;Keywords: growth factor; hormone; hypothalamus; intestine; neuropeptide; pyroglutamic acid

F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental

Query Match 18.2%; Score 2; DB 2; Length 11;

Best Local Similarity 100.0%; Pred. No. 4e+04;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3

||

Db 5 GS 6

RESULT 11

YHHU

morphogenetic neuropeptide - human

C;Species: Homo sapiens (man)

C;Date: 20-Jun-2000 #sequence_revision 20-Jun-2000 #text_change 20-Jun-2000

C;Accession: B01427; A01427

R;Bodenmuller, H.; Schaller, H.C.

Nature 293, 579-580, 1981

A;Title: Conserved amino acid sequence of a neuropeptide, the head activator, from coelenterates to humans.

A;Reference number: A93266; MUID:82035850; PMID:7290191

A;Accession: B01427

A;Molecule type: protein

A;Residues: 1-11 <BOD>

R;Birrr, C.; Zachmann, B.; Bodenmuller, H.; Schaller, H.C.

FEBS Lett. 131, 317-321, 1981

A;Title: Synthesis of a new neuropeptide, the head activator from hydra.
A;Reference number: A91296; MUID:82050803; PMID:7297679
A;Contents: annotation; synthesis
A;Note: the synthetic peptide was identical with the natural peptide in chemical structure and biological activity
C;Comment: This peptide was first isolated from nerve cells of hydra and was called head activator because it induced head-specific growth and differentiation in this animal. It has been found in mammalian intestine and hypothalamus.
C;Superfamily: unassigned animal peptides
C;Keywords: blocked amino end; growth factor; hormone; hypothalamus; intestine; neuropeptide
F;1/Modified site: blocked amino end (Gln) (probably pyrrolidone carboxylic acid) #status experimental

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3
||
Db 5 GS 6

RESULT 12

YHBO

morphogenetic neuropeptide - bovine

C;Species: Bos primigenius taurus (cattle)

C;Date: 20-Jun-2000 #sequence_revision 20-Jun-2000 #text_change 20-Jun-2000

C;Accession: C01427; A01427

R;Bodenmuller, H.; Schaller, H.C.

Nature 293, 579-580, 1981

A;Title: Conserved amino acid sequence of a neuropeptide, the head activator, from coelenterates to humans.

A;Reference number: A93266; MUID:82035850; PMID:7290191

A;Accession: C01427

A;Molecule type: protein

A;Residues: 1-11 <BOD>

R;Birrr, C.; Zachmann, B.; Bodenmuller, H.; Schaller, H.C.

FEBS Lett. 131, 317-321, 1981

A;Title: Synthesis of a new neuropeptide, the head activator from hydra.

A;Reference number: A91296; MUID:82050803; PMID:7297679

A;Contents: annotation; synthesis

A;Note: the synthetic peptide was identical with the natural peptide in chemical structure and biological activity

C;Comment: This peptide was first isolated from nerve cells of hydra and was called head activator because it induced head-specific growth and differentiation in this animal. It has been found in mammalian intestine and hypothalamus.

C;Superfamily: unassigned animal peptides

C;Keywords: blocked amino end; growth factor; hormone; hypothalamus; intestine; neuropeptide

F;1/Modified site: blocked amino end (Gln) (probably pyrrolidone carboxylic acid) #status experimental

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3
||
Db 5 GS 6

RESULT 13

YHXAE

morphogenetic neuropeptide - sea anemone (*Anthopleura elegantissima*)

N;Alternate names: head activator

C;Species: *Anthopleura elegantissima*

C;Date: 20-Jun-2000 #sequence_revision 20-Jun-2000 #text_change 20-Jun-2000

C;Accession: A93900; A01427

R;Schaller, H.C.; Bodenmuller, H.

Proc. Natl. Acad. Sci. U.S.A. 78, 7000-7004, 1981

A;Title: Isolation and amino acid sequence of a morphogenetic peptide from hydra.

A;Reference number: A93900

A;Accession: A93900

A;Molecule type: protein

A;Residues: 1-11 <SCH>

R;Birrr, C.; Zachmann, B.; Bodenmuller, H.; Schaller, H.C.

FEBS Lett. 131, 317-321, 1981

A;Title: Synthesis of a new neuropeptide, the head activator from hydra.

A;Reference number: A91296; MUID:82050803; PMID:7297679

A;Contents: annotation; synthesis

A;Note: the synthetic peptide was identical with the natural peptide in chemical structure and biological activity

C;Comment: This peptide was first isolated from nerve cells of hydra and was called head activator because it induced head-specific growth and differentiation in this animal. It has also been found in mammalian intestine and hypothalamus.

C;Superfamily: unassigned animal peptides

C;Keywords: growth factor; hormone; neuropeptide; pyroglutamic acid

F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental

Query Match 18.2%; Score 2; DB 2; Length 11;

Best Local Similarity 100.0%; Pred. No. 4e+04;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3
||
Db 5 GS 6

RESULT 14

YHJFHY

morphogenetic neuropeptide - *Hydra attenuata*

N;Alternate names: head activator

C;Species: *Hydra attenuata*

C;Date: 20-Jun-2000 #sequence_revision 20-Jun-2000 #text_change 20-Jun-2000

C;Accession: B93900; A01427

R;Schaller, H.C.; Bodenmuller, H.

Proc. Natl. Acad. Sci. U.S.A. 78, 7000-7004, 1981

A;Title: Isolation and amino acid sequence of a morphogenetic peptide from hydra.

A;Reference number: A93900
 A;Accession: B93900
 A;Molecule type: protein
 A;Residues: 1-11 <SCH>
 R;Birrr, C.; Zachmann, B.; Bodenmuller, H.; Schaller, H.C.
 FEBS Lett. 131, 317-321, 1981
 A;Title: Synthesis of a new neuropeptide, the head activator from hydra.
 A;Reference number: A91296; MUID:82050803; PMID:7297679
 A;Contents: annotation; synthesis
 A;Note: the synthetic peptide was identical with the natural peptide in chemical structure and biological activity
 C;Comment: This peptide was first isolated from nerve cells of hydra and was called head activator because it induced head-specific growth and differentiation in this animal. It has also been found in mammalian intestine and hypothalamus.
 C;Superfamily: unassigned animal peptides
 C;Keywords: growth factor; hormone; neuropeptide; pyroglutamic acid
 F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental

Query Match 18.2%; Score 2; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 4e+04;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3
 ||
 Db 5 GS 6

RESULT 15

B26744

megascoliakinin - garden dagger wasp

N;Alternate names: 6-Thr-bradykinin-Lys-Ala

C;Species: Megascolia flavifrons (garden dagger wasp)

C;Date: 08-Mar-1989 #sequence_revision 08-Mar-1989 #text_change 18-Aug-2000

C;Accession: B26744; A28609

R;Yasuhara, T.; Mantel, P.; Nakajima, T.; Piek, T.

Toxicon 25, 527-535, 1987

A;Title: Two kinins isolated from an extract of the venom reservoirs of the solitary wasp Megascolia flavifrons.

A;Reference number: A94322; MUID:87293024; PMID:3617088

A;Accession: B26744

A;Molecule type: protein

A;Residues: 1-11 <YAS>

R;Nakajima, T.; Piek, T.; Yashuara, T.; Mantel, P.

Toxicon 26, 34, 1988

A;Title: Two kinins isolated from the venom of Megascolia flavifrons.

A;Reference number: A28609

A;Accession: A28609

A;Molecule type: protein

A;Residues: 1-11 <NAK>

C;Superfamily: unassigned animal peptides

C;Keywords: bradykinin; presynaptic neurotoxin; venom

Query Match 18.2%; Score 2; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 4e+04;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 KA 11
||
Db 10 KA 11

RESULT 16

S42449

ant1 protein - phage P7

C;Species: phage P7

C;Date: 07-Sep-1994 #sequence_revision 26-May-1995 #text_change 08-Oct-1999

C;Accession: S42449

R;Citron, M.; Schuster, H.

Cell 62, 591-598, 1990

A;Title: The c4 repressors of bacteriophages P1 and P7 are antisense RNAs.

A;Reference number: S42448; MUID:90335968; PMID:1696181

A;Accession: S42449

A;Status: preliminary; translation not shown

A;Molecule type: DNA

A;Residues: 1-11 <CIT>

A;Cross-references: EMBL:M35139; NID:g215705; PIDN:AAA32437.1; PID:g215707

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KK 9
||
Db 2 KK 3

RESULT 17

A58502

38K kidney stone protein - unidentified bacterium (fragment)

C;Species: unidentified bacterium

C;Date: 07-Feb-1997 #sequence_revision 07-Feb-1997 #text_change 10-Jul-1998

C;Accession: A58502

R;Binette, J.P.; Binette, M.B.

submitted to the Protein Sequence Database, October 1996

A;Description: The proteins of kidney and gallbladder stones.

A;Reference number: A58501

A;Accession: A58502

A;Status: preliminary

A;Molecule type: protein

A;Residues: 1-11 <BIN>

A;Experimental source: human kidney stone containing Ca ox.mono and dihyd, 1% struvite, CaPO4 carbonate & hydrox., and 4% protein

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AG 2
||
Db 6 AG 7

RESULT 18

F58501
 43.5K bile stone protein - unidentified bacterium (fragment)
 C;Species: unidentified bacterium
 C;Date: 07-Feb-1997 #sequence_revision 07-Feb-1997 #text_change 10-Jul-1998
 C;Accession: F58501
 R;Binette, J.P.; Binette, M.B.
 submitted to the Protein Sequence Database, October 1996
 A;Description: The proteins of kidney and gallbladder stones.
 A;Reference number: A58501
 A;Accession: F58501
 A;Status: preliminary
 A;Molecule type: protein
 A;Residues: 1-11 <BIN>
 A;Experimental source: human bile with stones
 A;Note: 6-Asn and 8-Ala were also found

Query Match 18.2%; Score 2; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 4e+04;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 VK 6
 ||
 Db 2 VK 3

RESULT 19

JQ0395
 hypothetical protein (nodB 3' region) - Azorhizobium caulinodans
 N;Alternate names: hypothetical 1.4K protein
 C;Species: Azorhizobium caulinodans
 A;Note: host Sesbania rostrata
 C;Date: 07-Sep-1990 #sequence_revision 07-Sep-1990 #text_change 03-Feb-1994
 C;Accession: JQ0395
 R;Goethals, K.; Gao, M.; Tomekpe, K.; Van Montagu, M.; Holsters, M.
 Mol. Gen. Genet. 219, 289-298, 1989
 A;Title: Common nodABC genes in Nod locus 1 of Azorhizobium caulinodans:
 nucleotide sequence and plant-inducible expression.
 A;Reference number: JQ0393; MUID:90136519; PMID:2615763
 A;Accession: JQ0395
 A;Molecule type: DNA
 A;Residues: 1-11 <GOE>
 A;Cross-references: GB:L18897
 A;Experimental source: strain ORS571

Query Match 18.2%; Score 2; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 4e+04;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KK 9
 ||
 Db 6 KK 7

RESULT 20

S66606
 quinoline 2-oxidoreductase alpha chain - Comamonas testosteroni (fragment)
 C;Species: Comamonas testosteroni

C;Date: 15-Feb-1997 #sequence_revision 13-Mar-1997 #text_change 17-Mar-1999
C;Accession: S66606
R;Schach, S.; Tshisuaka, B.; Fetzner, S.; Lingens, F.
Eur. J. Biochem. 232, 536-544, 1995
A;Title: Quinoline 2-oxidoreductase and 2-oxo-1,2-dihydroquinoline 5,6-dioxygenase from *Comamonas testosteroni* 63. The first two enzymes in quinoline and 3-methylquinoline degradation.
A;Reference number: S66606; MUID:96035889; PMID:7556204
A;Accession: S66606
A;Molecule type: protein
A;Residues: 1-11 <SCH>
A;Experimental source: strain 63

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LK 8
||
Db 8 LK 9

RESULT 21

S58244
pyrroloquinoline quinone synthesis C - *Pseudomonas fluorescens* (fragment)
C;Species: *Pseudomonas fluorescens*
C;Date: 13-Jan-1996 #sequence_revision 01-Mar-1996 #text_change 08-Oct-1999
C;Accession: S58244
R;Schnider, U.; Keel, C.; Defago, G.; Haas, D.
submitted to the EMBL Data Library, May 1995
A;Description: Tn5-directed cloning of pqq genes from *Pseudomonas fluorescens* CHA0: their involvement in the production of the antibiotic pyoluteorin.
A;Reference number: S58239
A;Accession: S58244
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-11 <SCH>
A;Cross-references: EMBL:X87299; NID:g929799; PIDN:CAA60734.1; PID:g929806

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SA 4
||
Db 7 SA 8

RESULT 22

B43669
hypothetical protein (rhdA 5' region) - *Synechococcus* sp. (fragment)
C;Species: *Synechococcus* sp.
C;Date: 03-Mar-1993 #sequence_revision 03-Mar-1993 #text_change 30-Sep-1993
C;Accession: B43669
R;Laudenbach, D.E.; Ehrhardt, D.; Green, L.; Grossman, A.
J. Bacteriol. 173, 2751-2760, 1991

A;Title: Isolation and characterization of a sulfur-regulated gene encoding a periplasmically localized protein with sequence similarity to rhodanese.
A;Reference number: A43669; MUID:91210163; PMID:1708376
A;Accession: B43669
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-11 <LAU>
A;Cross-references: GB:M65244

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SA 4
||
Db 4 SA 5

RESULT 23

E41476

probable antigen 5 - Mycobacterium leprae (fragment)

C;Species: Mycobacterium leprae

C;Date: 10-Apr-1992 #sequence_revision 10-Apr-1992 #text_change 18-Jun-1993

C;Accession: E41476

R;Hartskeerl, R.A.; van Rens, R.M.; Stabel, L.F.E.M.; de Wit, M.Y.L.; Klatser, P.R.

Infect. Immun. 58, 2821-2827, 1990

A;Title: Selection and characterization of recombinant clones that produce Mycobacterium leprae antigens recognized by antibodies in sera from household contacts of leprosy patients.

A;Reference number: A41476; MUID:90354041; PMID:1696931

A;Accession: E41476

A;Status: preliminary; not compared with conceptual translation

A;Molecule type: DNA

A;Residues: 1-11 <HAR>

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3
||
Db 1 GS 2

RESULT 24

S70338

napin small chain S3A - Swedish turnip (fragment)

C;Species: Brassica napus var. rapifera (Swedish turnip, rutabaga)

C;Date: 19-Mar-1998 #sequence_revision 17-Apr-1998 #text_change 07-May-1999

C;Accession: S70338

R;Neumann, G.M.; Condrón, R.; Thomas, I.; Polya, G.M.

Biochim. Biophys. Acta 1295, 23-33, 1996

A;Title: Purification and sequencing of multiple forms of Brassica napus seed napin small chains that are calmodulin antagonists and substrates for plant calcium-dependent protein kinase.

A;Reference number: S70336; MUID:96283790; PMID:8679670

A;Accession: S70338
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-11 <NEU>

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3
||
Db 6 GS 7

RESULT 25

S19775

wound-induced protein - tomato (fragment)

C;Species: Lycopersicon esculentum (tomato)

C;Date: 30-Jun-1992 #sequence_revision 30-Jun-1992 #text_change 09-Sep-1997

C;Accession: S19775

R;Parsons, B.L.

submitted to the EMBL Data Library, May 1991

A;Reference number: S19773

A;Accession: S19775

A;Molecule type: mRNA

A;Residues: 1-11 <PAR>

A;Cross-references: EMBL:X59884; NID:g19323; PID:g19324

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KK 9
||
Db 5 KK 6

RESULT 26

A38590

transforming protein (Ddras) - slime mold (Dictyostelium discoideum) (fragment)

C;Species: Dictyostelium discoideum

C;Date: 18-Oct-1991 #sequence_revision 18-Oct-1991 #text_change 30-Sep-1993

C;Accession: A38590

R;Esch, R.K.; Firtel, R.A.

Genes Dev. 5, 9-21, 1991

A;Title: cAMP and cell sorting control the spatial expression of a developmentally essential cell-type-specific ras gene in Dictyostelium.

A;Reference number: A38590; MUID:91115102; PMID:1703508

A;Accession: A38590

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-11 <ESC>

A;Cross-references: GB:Z11804; GB:K02114; GB:X58190

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KL 7
 ||
Db 5 KL 6

RESULT 27

A34135

DNA-binding protein p - Crithidia fasciculata mitochondrion (fragment)
C;Species: mitochondrion Crithidia fasciculata
C;Date: 30-Sep-1991 #sequence_revision 30-Sep-1991 #text_change 07-Dec-1999
C;Accession: A34135
R;Tittawella, I.
FEBS Lett. 260, 57-61, 1990
A;Title: Kinetoplast DNA-aggregating proteins from the parasitic protozoan Crithidia fasciculata.
A;Reference number: A34135
A;Accession: A34135
A;Molecule type: protein
A;Residues: 1-11 <TIT>
C;Genetics:
A;Genome: mitochondrion
A;Genetic code: SGC6
C;Keywords: mitochondrion

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SA 4
 ||
Db 5 SA 6

RESULT 28

A61512

variant surface glycoprotein MITat 1.7 - Trypanosoma brucei (fragment)
C;Species: Trypanosoma brucei
C;Date: 28-Oct-1994 #sequence_revision 28-Oct-1994 #text_change 07-May-1999
C;Accession: A61512
R;Holder, A.A.; Cross, G.A.M.
Mol. Biochem. Parasitol. 2, 135-150, 1981
A;Title: Glycopeptides from variant surface glycoproteins of Trypanosoma brucei. C-terminal location of antigenically cross-reacting carbohydrate moieties.
A;Reference number: A61512; MUID:81172836; PMID:6163983
A;Accession: A61512
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-11 <HOL>
C;Keywords: glycoprotein

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3
 ||

Db 10 GS 11

RESULT 29

S43626

cytochrome-c oxidase (EC 1.9.3.1) chain Vb-H - trout (fragment)

C;Species: Salmo sp. (trout)

C;Date: 19-Mar-1997 #sequence_revision 01-Aug-1997 #text_change 02-Jul-1998

C;Accession: S43626

R;Freund, R.; Kadenbach, B.

Eur. J. Biochem. 221, 1111-1116, 1994

A;Title: Identification of tissue-specific isoforms for subunits Vb and VIIa of cytochrome c oxidase isolated from rainbow trout.

A;Reference number: S43624; MUID:94237150; PMID:8181469

A;Accession: S43626

A;Status: preliminary

A;Molecule type: protein

A;Residues: 1-11 <FRE>

C;Keywords: electron transfer; membrane-associated complex; oxidoreductase; respiratory chain; transmembrane protein

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LK 8

||

Db 3 LK 4

RESULT 30

D42965

talin - chicken (fragment)

C;Species: Gallus gallus (chicken)

C;Date: 05-Jan-1996 #sequence_revision 05-Jan-1996 #text_change 05-Jan-1996

C;Accession: D42965

R;Hagmann, J.; Grob, M.; Burger, M.M.

J. Biol. Chem. 267, 14424-14428, 1992

A;Title: The cytoskeletal protein talin is O-glycosylated.

A;Reference number: A42965; MUID:92332560; PMID:1629228

A;Accession: D42965

A;Status: preliminary

A;Molecule type: protein

A;Residues: 1-11 <HAG>

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AG 2

||

Db 9 AG 10

RESULT 31

S21727

gamma-interferon-induced protein IP-30 precursor - human (fragment)

C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 13-Mar-1997 #text_change 13-Mar-1997
C;Accession: S21727
R;Wei, M.L.; Cresswell, P.
Nature 356, 443-446, 1992
A;Title: HLA-A2 molecules in an antigen-processing mutant cell contain signal
sequence-derived peptides.
A;Reference number: S21727; MUID:92212461; PMID:1557127
A;Accession: S21727
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-11 <WEI>

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 AV 5
||
Db 9 AV 10

RESULT 32

PT0287

Ig heavy chain CRD3 region (clone 4-103) - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 16-Aug-1996

C;Accession: PT0287

R;Yamada, M.; Wasserman, R.; Reichard, B.A.; Shane, S.; Caton, A.J.; Rovera, G.
J. Exp. Med. 173, 395-407, 1991

A;Title: Preferential utilization of specific immunoglobulin heavy chain
diversity and joining segments in adult human peripheral blood B lymphocytes.

A;Reference number: PT0222; MUID:91108337; PMID:1899102

A;Accession: PT0287

A;Molecule type: DNA

A;Residues: 1-11 <YAM>

A;Experimental source: B lymphocyte

C;Keywords: heterotetramer; immunoglobulin

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AG 2
||
Db 4 AG 5

RESULT 33

S57575

T cell receptor V-J junctional alpha chain region - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 19-Oct-1995 #sequence_revision 17-Nov-1995 #text_change 05-Nov-1999

C;Accession: S57575

R;Burrows, S.R.; Silins, S.L.; Moss, D.J.; Khanna, R.; Misko, I.S.; Argaet, V.P.
submitted to the EMBL Data Library, June 1995

A;Description: T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background MHC antigen.
A;Reference number: S57494
A;Accession: S57575
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-11 <BUR>
A;Cross-references: EMBL:Z49953; NID:g887510; PIDN:CAA90224.1; PID:g887511
C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KL 7
||
Db 7 KL 8

RESULT 34

S51732

T-cell receptor alpha chain joining region - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 07-May-1995 #sequence_revision 01-Sep-1995 #text_change 05-Nov-1999

C;Accession: S51732

R;Durinovic-Bello, I.; Steinle, A.; Ziegler, A.G.; Schendel, D.J.

submitted to the EMBL Data Library, November 1993

A;Reference number: S51732

A;Accession: S51732

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-11 <DUR>

A;Cross-references: EMBL:Z28343; NID:g607116; PIDN:CAA82197.1; PID:g607117

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KL 7
||
Db 8 KL 9

RESULT 35

A32428

amine oxidase (copper-containing) (EC 1.4.3.6) - pig (fragment)

C;Species: Sus scrofa domestica (domestic pig)

C;Date: 12-Oct-1989 #sequence_revision 31-Dec-1993 #text_change 06-Sep-1996

C;Accession: A32428

R;van der Meer, R.A.; van Wassenaar, P.D.; van Brouwershaven, J.H.; Duine, J.A.

Biochem. Biophys. Res. Commun. 159, 726-733, 1989

A;Title: Primary structure of a pyrroloquinoline quinone (PQQ) containing peptide isolated from porcine kidney diamine oxidase.

A;Reference number: A32428; MUID:89193662; PMID:2539124

A;Accession: A32428

A;Molecule type: protein

A;Residues: 1-7,'K',9-11 <VAN>

A;Note: the modified residue thought by the authors to be pyrroloquinoline quinone covalently bound to lysine is probably a topaquinone modified tyrosine

C;Keywords: oxidoreductase; quinoprotein; topaquinone

F;8/Modified site: topaquinone (Tyr) #status predicted

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 AV 5
||
Db 4 AV 5

RESULT 36

A61483

pyridoxal kinase (EC 2.7.1.35) - sheep (fragment)

C;Species: Ovis orientalis aries, Ovis ammon aries (domestic sheep)

C;Date: 07-Oct-1994 #sequence_revision 07-Oct-1994 #text_change 07-Oct-1994

C;Accession: A61483

R;Churchich, J.E.

J. Protein Chem. 9, 613-621, 1990

A;Title: Cleavage of pyridoxal kinase into two structural domains: kinetics of proteolysis monitored by emission anisotropy.

A;Reference number: A61483; MUID:91197387; PMID:2085386

A;Accession: A61483

A;Status: preliminary

A;Molecule type: protein

A;Residues: 1-11 <CHU>

C;Keywords: homodimer; phosphotransferase

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SA 4
||
Db 3 SA 4

RESULT 37

PD0442

NIPSNAP2 protein - mouse (fragment)

C;Species: Mus musculus (house mouse)

C;Date: 05-Feb-1999 #sequence_revision 05-Feb-1999 #text_change 05-Feb-1999

C;Accession: PD0442

R;Kawakami, T.; Uchida, T.; Sakai, T.; Kamo, M.; Morimasa, T.; Tsugita, A.
submitted to JIPID, August 1998

A;Description: Proteome analysis of mouse brain.

A;Reference number: PD0441

A;Contents: Striatum

A;Accession: PD0442

A;Molecule type: protein

A;Residues: 1-11 <KAW>

Query Match 18.2%; Score 2; DB 2; Length 11;

Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LK 8
||
Db 6 LK 7

RESULT 38

PN0044

protein kinase C inhibitor I - mouse (fragment)

C;Species: Mus musculus (house mouse)

C;Date: 29-Oct-1997 #sequence_revision 29-Oct-1997 #text_change 23-Jan-1998

C;Accession: PN0044

R;Kato, H.

Kawasaki Igakkaishi 22, 245-259, 1996

A;Title: Analysis of proteins isolated by two dimensional electrophoresis of mouse neuroblastoma cells.

A;Reference number: PN0041

A;Accession: PN0044

A;Molecule type: protein

A;Residues: 1-11 <KAT>

A;Experimental source: neuroblastoma cell

C;Comment: The molecular mass is 13,900 and the pI is 6.36. The amino-terminus is blocked.

C;Keywords: brain

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 KA 11
||
Db 1 KA 2

RESULT 39

PT0209

T-cell receptor alpha chain V-J region (4-1-L.6) - mouse (fragment)

C;Species: Mus musculus (house mouse)

C;Date: 31-Dec-1991 #sequence_revision 31-Dec-1991 #text_change 30-May-1997

C;Accession: PT0209

R;Nakano, N.; Kikutani, H.; Nishimoto, H.; Kishimoto, T.

J. Exp. Med. 173, 1091-1097, 1991

A;Title: T cell receptor V gene usage of islet beta cell-reactive T cells is not restricted in non-obese diabetic mice.

A;Reference number: PT0209; MUID:91217621; PMID:1902501

A;Accession: PT0209

A;Molecule type: mRNA

A;Residues: 1-11 <NAK>

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3

9 GS 10

Db

RESULT 40

PT0218

T-cell receptor beta chain V-J region (7-10-D.3) - mouse (fragment)

C;Species: Mus musculus (house mouse)

C;Date: 31-Dec-1991 #sequence revision 31-Dec-1991 #text_change 30-May-1997

C;Accession: PT0218

R; Nakano, N.; Kikutani, H.; Nishimoto, H.; Kishimoto, T.

J. Exp. Med. 173, 1091-1097, 1991

A;Title: T cell receptor V gene usage of islet beta cell-reactive T cells is not restricted in non-obese diabetic mice.

A;Reference number: PT0209; MUID:91217621; PMID:1902501

A;Accession: PT0218

A;Molecule type: mRNA

A;Residues: 1-11 <NAK>

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AG 2

11

Db 3 AG 4

RESULT 41

D41946

T-cell receptor gamma chain (1a.4) - mouse (fragment)

C;Species: Mus musculus (house mouse)

C;Date: 03-Feb-1994 #sequence revision 03-Feb-1994 #text_change 07-May-1999

C;Accession: D41946

R; Whetsell, M.; Mosley, R.L.; Whetsell, L.; Schaefer, F.V.; Miller, K.S.; Klein, J.R.

Mol. Cell. Biol. 11, 5902-5909, 1991

A;Title: Rearrangement and junctional-site sequence analyses of T-cell receptor gamma genes in intestinal intraepithelial lymphocytes from murine athymic chimeras.

A;Reference number: A41946; MUID:92049316; PMID:1658619

A;Accession: D41946

A;Status: preliminary; not compared with conceptual translation

A;Molecule type: DNA

A;Residues: 1-11 <WHE>

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 AV 5

1

Db 3 AV 4

RESULT 42

B41946

T-cell receptor gamma chain (1t.57) - mouse (fragment)

C;Species: Mus musculus (house mouse)

C;Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 07-May-1999

C;Accession: B41946

R;Whetsell, M.; Mosley, R.L.; Whetsell, L.; Schaefer, F.V.; Miller, K.S.; Klein, J.R.

Mol. Cell. Biol. 11, 5902-5909, 1991

A;Title: Rearrangement and junctional-site sequence analyses of T-cell receptor gamma genes in intestinal intraepithelial lymphocytes from murine athymic chimeras.

A;Reference number: A41946; MUID:92049316; PMID:1658619

A;Accession: B41946

A;Status: preliminary; not compared with conceptual translation

A;Molecule type: DNA

A;Residues: 1-11 <WHE>

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 AV 5
||
Db 3 AV 4

RESULT 43

C38887

T-cell receptor gamma chain (5a.3) - mouse (fragment)

C;Species: Mus musculus (house mouse)

C;Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 07-May-1999

C;Accession: C38887

R;Whetsell, M.; Mosley, R.L.; Whetsell, L.; Schaefer, F.V.; Miller, K.S.; Klein, J.R.

Mol. Cell. Biol. 11, 5902-5909, 1991

A;Title: Rearrangement and junctional-site sequence analyses of T-cell receptor gamma genes in intestinal intraepithelial lymphocytes from murine athymic chimeras.

A;Reference number: A41946; MUID:92049316; PMID:1658619

A;Accession: C38887

A;Status: preliminary; not compared with conceptual translation

A;Molecule type: DNA

A;Residues: 1-11 <WHE>

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AG 2
||
Db 4 AG 5

RESULT 44

I41946

T-cell receptor gamma chain (5t.1) - mouse (fragment)

C;Species: Mus musculus (house mouse)

C;Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 07-May-1999

C;Accession: I41946

R;Whetsell, M.; Mosley, R.L.; Whetsell, L.; Schaefer, F.V.; Miller, K.S.; Klein, J.R.

Mol. Cell. Biol. 11, 5902-5909, 1991

A;Title: Rearrangement and junctional-site sequence analyses of T-cell receptor gamma genes in intestinal intraepithelial lymphocytes from murine athymic chimeras.

A;Reference number: A41946; MUID:92049316; PMID:1658619

A;Accession: I41946

A;Status: preliminary; not compared with conceptual translation

A;Molecule type: DNA

A;Residues: 1-11 <WHE>

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AG 2
||
Db 4 AG 5

RESULT 45

A49037

TcR gamma V-J region - mouse (fragment)

C;Species: Mus musculus (house mouse)

C;Date: 21-Jan-1994 #sequence_revision 18-Nov-1994 #text_change 05-Nov-1999

C;Accession: A49037

R;Ezquerro, A.; Wilde, D.B.; McConnell, T.J.; Sturmhofel, K.; Valas, R.B.; Shevach, E.M.; Coligan, J.E.

Eur. J. Immunol. 22, 491-498, 1992

A;Title: Mouse autoreactive gamma/delta T cells. II. Molecular characterization of the T cell receptor.

A;Reference number: A49037; MUID:92164730; PMID:1311262

A;Accession: A49037

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-11 <EZQ>

A;Cross-references: GB:S90637; NID:g246288; PIDN:AAB21547.1; PID:g246289

A;Experimental source: dendritic epidermal T-cell lines

A;Note: sequence extracted from NCBI backbone (NCBIN:90637, NCBIP:90641)

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 AV 5
||
Db 2 AV 3

RESULT 46

B49037

TcR gamma V-J region - mouse (fragment)

C;Species: Mus musculus (house mouse)

C;Date: 21-Jan-1994 #sequence_revision 18-Nov-1994 #text_change 05-Nov-1999

C;Accession: B49037

R;Ezquerra, A.; Wilde, D.B.; McConnell, T.J.; Sturmhofel, K.; Valas, R.B.; Shevach, E.M.; Coligan, J.E.

Eur. J. Immunol. 22, 491-498, 1992

A;Title: Mouse autoreactive gamma/delta T cells. II. Molecular characterization of the T cell receptor.

A;Reference number: A49037; MUID:92164730; PMID:1311262

A;Accession: B49037

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-11 <EZQ>

A;Cross-references: GB:S90638; NID:g246290; PIDN:AAB21548.1; PID:g246291

A;Experimental source: dendritic epidermal T-cell lines

A;Note: sequence extracted from NCBI backbone (NCBIN:90638, NCBIP:90644)

Query Match 18.2%; Score 2; DB 2; Length 11;

Best Local Similarity 100.0%; Pred. No. 4e+04;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 AV 5

||

Db 2 AV 3

RESULT 47

C49037

TcR gamma V-J region - mouse (fragment)

C;Species: Mus musculus (house mouse)

C;Date: 21-Jan-1994 #sequence_revision 18-Nov-1994 #text_change 05-Nov-1999

C;Accession: C49037

R;Ezquerra, A.; Wilde, D.B.; McConnell, T.J.; Sturmhofel, K.; Valas, R.B.; Shevach, E.M.; Coligan, J.E.

Eur. J. Immunol. 22, 491-498, 1992

A;Title: Mouse autoreactive gamma/delta T cells. II. Molecular characterization of the T cell receptor.

A;Reference number: A49037; MUID:92164730; PMID:1311262

A;Accession: C49037

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-11 <EZQ>

A;Cross-references: GB:S90639; NID:g246292; PIDN:AAB21549.1; PID:g246293

A;Experimental source: dendritic epidermal T-cell lines

A;Note: sequence extracted from NCBI backbone (NCBIN:90639, NCBIP:90645)

Query Match 18.2%; Score 2; DB 2; Length 11;

Best Local Similarity 100.0%; Pred. No. 4e+04;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 AV 5

||

Db 2 AV 3

RESULT 48

PD0441

translation elongation factor TU-like protein P43, mitochondrial - mouse
(fragment)

C;Species: Mus musculus (house mouse)

C;Date: 21-Aug-1998 #sequence_revision 21-Aug-1998 #text_change 21-Aug-1998

C;Accession: PD0441

R;Kawakami, T.; Uchida, T.; Sakai, T.; Kamo, M.; Morimasa, T.; Tsugita, A.
submitted to JIPID, August 1998

A;Description: Proteome analysis of mouse brain.

A;Reference number: PD0441

A;Accession: PD0441

A;Molecule type: protein

A;Residues: 1-11 <KAW>

A;Experimental source: striatum

C;Keywords: mitochondrion

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KK 9

||

Db 5 KK 6

RESULT 49

S65377

cytochrome-c oxidase (EC 1.9.3.1) chain VIa-H, cardiac - rat (fragment)

C;Species: Rattus norvegicus (Norway rat)

C;Date: 28-Oct-1996 #sequence_revision 13-Mar-1997 #text_change 16-Jul-1999

C;Accession: S65377

R;Schaeffer, H.; Noack, H.; Halangk, W.; Brandt, U.; von Jagow, G.

Eur. J. Biochem. 230, 235-241, 1995

A;Title: Cytochrome-c oxidase in developing rat heart. Enzymic properties and
amino-terminal sequences suggest identity of the fetal heart and the adult liver
isoform.

A;Reference number: S65372; MUID:95324529; PMID:7601105

A;Accession: S65377

A;Status: preliminary

A;Molecule type: protein

A;Residues: 1-11 <SCH>

C;Keywords: cardiac muscle; heart; oxidoreductase

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AG 2

||

Db 10 AG 11

RESULT 50

S09349

microtubule-associated protein MAP2 - rat (fragment)

C;Species: Rattus norvegicus (Norway rat)

C;Date: 19-Mar-1997 #sequence_revision 29-Aug-1997 #text_change 21-Nov-1998
C;Accession: S09349
R;Papandrikopoulou, A.; Doll, T.; Tucker, R.P.; Garner, C.C.; Matus, A.
Nature 340, 650-652, 1989
A;Title: Embryonic MAP2 lacks the cross-linking sidearm sequences and dendritic
targeting signal of adult MAP2.
A;Reference number: S09349; MUID:89365159; PMID:2770869
A;Accession: S09349
A;Status: not compared with conceptual translation
A;Molecule type: mRNA
A;Residues: 1-11 <PAP>
C;Genetics:
A;Gene: MAP2

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SA 4
||
Db 10 SA 11

RESULT 51
S18385
NADP-cytochrome P450 reductase-related protein - rat (fragment)
C;Species: Rattus norvegicus (Norway rat)
C;Date: 22-Nov-1993 #sequence_revision 12-Apr-1996 #text_change 07-Feb-1997
C;Accession: S18385
R;Nadler, S.G.; Strobel, H.W.
Arch. Biochem. Biophys. 290, 277-284, 1991
A;Title: Identification and characterization of an NADPH-cytochrome P450
reductase derived peptide involved in binding to cytochrome P450.
A;Reference number: S18385; MUID:92027739; PMID:1929397
A;Accession: S18385
A;Molecule type: protein
A;Residues: 1-11 <NAD>
C;Keywords: NADP

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SA 4
||
Db 3 SA 4

RESULT 52
S78422
ribosomal protein RS20, mitochondrial [validated] - rat (tentative sequence)
(fragment)
C;Species: Rattus norvegicus (Norway rat)
C;Date: 25-Feb-1998 #sequence_revision 13-Mar-1998 #text_change 21-Jul-2000
C;Accession: S78422
R;Goldschmidt-Reisin, S.; Graack, H.R.
submitted to the Protein Sequence Database, February 1998

A;Reference number: S78411
A;Accession: S78422
A;Molecule type: protein
A;Residues: 1-11 <GOL>
A;Note: the protein is designated as mitochondrial ribosomal protein S20
C;Keywords: mitochondrion; protein biosynthesis; ribosome

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 KA 11
||
Db 10 KA 11

RESULT 53

PH0939

T-cell receptor beta chain V-D-J region (clone 10) - rat (fragment)

C;Species: Rattus norvegicus (Norway rat)

C;Date: 09-Oct-1992 #sequence_revision 09-Oct-1992 #text_change 30-May-1997

C;Accession: PH0939

R;Gold, D.P.; Offner, H.; Sun, D.; Wiley, S.; Vandenbark, A.A.; Wilson, D.B.
J. Exp. Med. 174, 1467-1476, 1991

A;Title: Analysis of T cell receptor beta chains in Lewis rats with experimental
allergic encephalomyelitis: conserved complementarity determining region 3.

A;Reference number: PH0891; MUID:92078857; PMID:1836012

A;Accession: PH0939

A;Molecule type: mRNA

A;Residues: 1-11 <GOL>

A;Experimental source: complete Freund's adjuvant-immunized lymph node

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LK 8
||
Db 8 LK 9

RESULT 54

PH0940

T-cell receptor beta chain V-D-J region (clone 11) - rat (fragment)

C;Species: Rattus norvegicus (Norway rat)

C;Date: 09-Oct-1992 #sequence_revision 09-Oct-1992 #text_change 30-May-1997

C;Accession: PH0940

R;Gold, D.P.; Offner, H.; Sun, D.; Wiley, S.; Vandenbark, A.A.; Wilson, D.B.
J. Exp. Med. 174, 1467-1476, 1991

A;Title: Analysis of T cell receptor beta chains in Lewis rats with experimental
allergic encephalomyelitis: conserved complementarity determining region 3.

A;Reference number: PH0891; MUID:92078857; PMID:1836012

A;Accession: PH0940

A;Molecule type: mRNA

A;Residues: 1-11 <GOL>

A;Experimental source: complete Freund's adjuvant-immunized lymph node

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SA 4

||

Db 7 SA 8

RESULT 55

PH0947

T-cell receptor beta chain V-D-J region (clone A2) - rat (fragment)

C;Species: Rattus norvegicus (Norway rat)

C;Date: 09-Oct-1992 #sequence_revision 09-Oct-1992 #text_change 30-May-1997

C;Accession: PH0947

R;Gold, D.P.; Offner, H.; Sun, D.; Wiley, S.; Vandenbark, A.A.; Wilson, D.B.

J. Exp. Med. 174, 1467-1476, 1991

A;Title: Analysis of T cell receptor beta chains in Lewis rats with experimental allergic encephalomyelitis: conserved complementarity determining region 3.

A;Reference number: PH0891; MUID:92078857; PMID:1836012

A;Accession: PH0947

A;Molecule type: mRNA

A;Residues: 1-11 <GOL>

A;Experimental source: myelin basic protein fragment-reactive T-cell, recovered from experimentally induced allergic encephalomyelitis

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3

||

Db 8 GS 9

RESULT 56

PC2254

cytochrome P450 3A - savannah baboon (fragment)

C;Species: Papio hamadryas doguera (savannah baboon)

C;Date: 24-Feb-1995 #sequence_revision 24-Feb-1995 #text_change 19-May-2000

C;Accession: PC2254

R;Ohmori, S.; Kudo, S.; Nakasa, H.; Horie, T.; Kitada, M.

Biol. Pharm. Bull. 17, 1584-1588, 1994

A;Title: Purification and characterization of cytochrome P450 3A enzyme from hepatic microsomes of untreated Doguera baboons.

A;Reference number: PC2254; MUID:95253110; PMID:7735199

A;Accession: PC2254

A;Molecule type: protein

A;Residues: 1-11 <OHM>

A;Experimental source: liver

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 AV 5
||
Db 8 AV 9

RESULT 57

A34243

H-hyosophorin - Japanese flounder (fragment)

C;Species: *Paralichthys olivaceus* (Japanese flounder)

C;Date: 07-Sep-1990 #sequence_revision 07-Sep-1990 #text_change 12-Feb-1999

C;Accession: A34243

R;Seko, A.; Kitajima, K.; Iwasaki, M.; Inoue, S.; Inoue, Y.

J. Biol. Chem. 264, 15922-15929, 1989

A;Title: Structural studies of fertilization-associated carbohydrate-rich glycoproteins (Hyosophorin) isolated from the fertilized and unfertilized eggs of flounder, *Paralichthys olivaceus*. Presence of a novel penta-antennary N-linked glycan chain in the tandem repeating glycopeptide unit of hyosophorin.

A;Reference number: A34243; MUID:89380184; PMID:2777771

A;Accession: A34243

A;Molecule type: protein

A;Residues: 1-11 <SEK>

A;Note: 3-Ala, 4-Ala, 5-Pro or Gln, and 6-Val were also found

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3
||
Db 2 GS 3

RESULT 58

H84082

hypothetical protein BH3464 [imported] - *Bacillus halodurans* (strain C-125)

C;Species: *Bacillus halodurans*

C;Date: 01-Dec-2000 #sequence_revision 01-Dec-2000 #text_change 15-Jun-2001

C;Accession: H84082

R;Takami, H.; Nakasone, K.; Takaki, Y.; Maeno, G.; Sasaki, R.; Masui, N.; Fuji, F.; Hirama, C.; Nakamura, Y.; Ogasawara, N.; Kuhara, S.; Horikoshi, K.

Nucleic Acids Res. 28, 4317-4331, 2000

A;Title: Complete genome sequence of the alkaliphilic bacterium *Bacillus halodurans* and genomic sequence comparison with *Bacillus subtilis*.

A;Reference number: A83650; MUID:20512582; PMID:11058132

A;Accession: H84082

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-11 <STO>

A;Cross-references: GB:AP001518; GB:BA000004; NID:g10175792; PIDN:BAB07183.1; GSPDB:GN00137

A;Experimental source: strain C-125

C;Genetics:

A;Gene: BH3464

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 VK 6
||
Db 3 VK 4

RESULT 59

I52708

ELAV-like neuronal protein 1, truncated splice form - human

N;Alternate names: Drosophila ELAV(embryonic lethal, abnormal vision)-like 4; Hu antigen D; paraneoplastic encephalomyelitis antigen

C;Species: Homo sapiens (man)

C;Date: 18-Aug-2000 #sequence_revision 18-Aug-2000 #text_change 18-Aug-2000

C;Accession: I52708

R;Sekido, Y.; Bader, S.A.; Carbone, D.P.; Johnson, B.E.; Minna, J.D.
Cancer Res. 54, 4988-4992, 1994

A;Title: Molecular analysis of the HuD gene encoding a paraneoplastic encephalomyelitis antigen in human lung cancer cell lines.

A;Reference number: I52708; MUID:94349312; PMID:8069866

A;Accession: I52708

A;Status: translated from GB/EMBL/DDBJ

A;Molecule type: mRNA

A;Residues: 1-11 <SEK>

A;Cross-references: GB:S73887; NID:g688242; PIDN:AAD14142.1; PID:g4261842

C;Comment: This abnormal peptide is expressed. For the long splice form, see PIR:I38726.

C;Genetics:

A;Gene: GDB:ELAVL4; HUD; PNEM

A;Cross-references: GDB:141875; OMIM:168360

A;Map position: 1p36-1p36

C;Keywords: alternative splicing

Query Match 18.2%; Score 2; DB 4; Length 11;

Best Local Similarity 100.0%; Pred. No. 4e+04;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LK 8
||
Db 8 LK 9

RESULT 60

I54081

retinoic acid receptor alpha, exon 3 (mistranslated) - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 04-Jun-1999 #sequence_revision 04-Jun-1999 #text_change 28-Jun-1999

C;Accession: I54081

R;Dong, S.; Geng, J.P.; Tong, J.H.; Wu, Y.; Cai, J.R.; Sun, G.L.; Chen, S.R.; Wang, Z.Y.; Larsen, C.J.; Berger, R.

Genes Chromosomes Cancer 6, 133-139, 1993

A;Title: Breakpoint clusters of the PML gene in acute promyelocytic leukemia: primary structure of the reciprocal products of the PML-RARA gene in a patient with t(15;17).

A;Reference number: I54081; MUID:93222087; PMID:7682097

A;Accession: I54081

A;Status: translated from GB/EMBL/DDBJ

A;Molecule type: DNA
A;Residues: 1-11 <DON>
A;Cross-references: GB:S57794; NID:g299073; PIDN:AAD13888.1; PID:g4261588
A;Note: the translation is from an incorrect reading frame
C;Genetics:
A;Gene: GDB:RARA
A;Cross-references: GDB:120337; OMIM:180240
A;Map position: 17q12-17q12

Query Match 18.2%; Score 2; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 4e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 AV 5
||
Db 7 AV 8

RESULT 61

XAVIBH

bradykinin-potentiating peptide - halys viper

N;Alternate names: BPP

C;Species: Agkistrodon halys (halys viper)

C;Date: 30-Sep-1988 #sequence_revision 30-Sep-1988 #text_change 05-Aug-1994

C;Accession: JC0002

R;Chi, C.W.; Wang, S.Z.; Xu, L.G.; Wang, M.Y.; Lo, S.S.; Huang, W.D.

Peptides 6, 339-342, 1985

A;Title: Structure-function studies on the bradykinin potentiating peptide from Chinese snake venom (Agkistrodon halys Pallas).

A;Reference number: JC0002; MUID:86177022; PMID:3008123

A;Accession: JC0002

A;Molecule type: protein

A;Residues: 1-11 <CHI>

C;Comment: Because this peptide both inhibits the activity of the angiotensin-converting enzyme and enhances the action of bradykinin, it is an antihypertensive agent.

C;Superfamily: bradykinin-potentiating peptide

C;Keywords: angiotensin-converting enzyme inhibitor; antihypertensive; bradykinin; pyroglutamic acid; venom

F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 G 2
|
Db 2 G 2

RESULT 62

XASNBA

bradykinin-potentiating peptide B - mamushi

C;Species: Agkistrodon blomhoffi (mamushi)

C;Date: 13-Jul-1981 #sequence_revision 13-Jul-1981 #text_change 08-Dec-1995

C;Accession: A01254

R;Kato, H.; Suzuki, T.

Proc. Jpn. Acad. 46, 176-181, 1970

A;Reference number: A01254

A;Accession: A01254

A;Molecule type: protein

A;Residues: 1-11 <KAT>

A;Note: the sequence of the natural peptide was confirmed by the synthesis and analysis of a peptide having the identical structure and biological properties

C;Superfamily: bradykinin-potentiating peptide

C;Keywords: angiotensin-converting enzyme inhibitor; bradykinin; pyroglutamic acid; venom

F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 G 2

|

Db 2 G 2

RESULT 63

ECLQ2M

tachykinin II - migratory locust

C;Species: Locusta migratoria (migratory locust)

C;Date: 31-Dec-1991 #sequence_revision 31-Dec-1991 #text_change 08-Dec-1995

C;Accession: S08266

R;Schoofs, L.; Holman, G.M.; Hayes, T.K.; Nachman, R.J.; de Loof, A.

FEBS Lett. 261, 397-401, 1990

A;Title: Locustatachykinin I and II, two novel insect neuropeptides with homology to peptides of the vertebrate tachykinin family.

A;Reference number: S08265; MUID:90184489; PMID:2311766

A;Accession: S08266

A;Molecule type: protein

A;Residues: 1-11 <SCH>

C;Superfamily: tachykinin

C;Keywords: amidated carboxyl end; neuropeptide; tachykinin

F;11/Modified site: amidated carboxyl end (Arg) #status experimental

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 A 1

|

Db 1 A 1

RESULT 64

SPHO

substance P - horse

C;Species: Equus caballus (domestic horse)

C;Date: 23-Oct-1981 #sequence_revision 23-Oct-1981 #text_change 23-Aug-1996

C;Accession: A01558

R;Studer, R.O.; Trzeciak, A.; Lergier, W.

Helv. Chim. Acta 56, 860-866, 1973

A;Title: Isolierung und Aminosaeuresequenz von Substanz P aus Pferdedarm.

A;Reference number: A01558
A;Accession: A01558
A;Molecule type: protein
A;Residues: 1-11 <STU>
C;Superfamily: substance P precursor
C;Keywords: amidated carboxyl end; hormone
F;11/Modified site: amidated carboxyl end (Met) #status experimental

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 K 6
|
Db 3 K 3

RESULT 65

EOOCC

eledoisin - curled octopus

C;Species: Eledone cirrosa, Ozaena cirrosa (curled octopus)

C;Date: 31-Dec-1991 #sequence_revision 31-Dec-1991 #text_change 20-Mar-1998

C;Accession: B01561; A01561

R;Anastasi, A.; Erspamer, V.

Arch. Biochem. Biophys. 101, 56-65, 1963

A;Title: The isolation and amino acid sequence of eledoisin, the active endecapeptide of the posterior salivary glands of Eledone.

A;Reference number: A01561

A;Accession: B01561

A;Molecule type: protein

A;Residues: 1-11 <ANA>

C;Superfamily: substance P precursor

C;Keywords: amidated carboxyl end; hormone; pyroglutamic acid; salivary gland; secretagogue; vasodilator; venom

F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental

F;11/Modified site: amidated carboxyl end (Met) #status experimental

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 S 3
|
Db 3 S 3

RESULT 66

A60654

substance P - guinea pig

C;Species: Cavia porcellus (guinea pig)

C;Date: 14-May-1993 #sequence_revision 27-Jun-1994 #text_change 08-Dec-1995

C;Accession: A60654

R;Murphy, R.

Neuropeptides 14, 105-110, 1989

A;Title: Primary amino acid sequence of guinea-pig substance P.

A;Reference number: A60654; MUID:90044685; PMID:2478925

A;Accession: A60654

A;Molecule type: protein
A;Residues: 1-11 <MUR>
C;Superfamily: substance P precursor
C;Keywords: amidated carboxyl end; neuropeptide; tachykinin
F;11/Modified site: amidated carboxyl end (Met) #status experimental

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 K 6
|
Db 3 K 3

RESULT 67

EOOC

eledoisin - musky octopus

C;Species: Eledone moschata, Ozaena moschata (musky octopus)

C;Date: 13-Jul-1981 #sequence_revision 13-Jul-1981 #text_change 20-Mar-1998

C;Accession: A01561

R;Anastasi, A.; Erspamer, V.

Arch. Biochem. Biophys. 101, 56-65, 1963

A;Title: The isolation and amino acid sequence of eledoisin, the active endecapeptide of the posterior salivary glands of Eledone.

A;Reference number: A01561

A;Accession: A01561

A;Molecule type: protein

A;Residues: 1-11 <ANA>

C;Superfamily: substance P precursor

C;Keywords: amidated carboxyl end; hormone; pyroglutamic acid; salivary gland; secretagogue; vasodilator; venom

F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental

F;11/Modified site: amidated carboxyl end (Met) #status experimental

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 S 3
|
Db 3 S 3

RESULT 68

GMROL

leucosulfakinin - Madeira cockroach

N;Alternate names: LSK

C;Species: Leucophaea maderae (Madeira cockroach)

C;Date: 17-Mar-1987 #sequence_revision 17-Mar-1987 #text_change 13-Sep-1996

C;Accession: A01622

R;Nachman, R.J.; Holman, G.M.; Haddon, W.F.; Ling, N.

Science 234, 71-73, 1986

A;Title: Leucosulfakinin, a sulfated insect neuropeptide with homology to gastrin and cholecystokinin.

A;Reference number: A01622; MUID:86315858; PMID:3749893

A;Accession: A01622

A;Molecule type: protein
A;Residues: 1-11 <NAC>
C;Superfamily: gastrin
C;Keywords: amidated carboxyl end; hormone; sulfoprotein
F;6/Binding site: sulfate (Tyr) (covalent) #status experimental
F;11/Modified site: amidated carboxyl end (Phe) #status experimental

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 G 2
|
Db 7 G 7

RESULT 69

G42762

proteasome endopeptidase complex (EC 3.4.25.1) subunit 13 - bovine (fragment)

C;Species: Bos primigenius taurus (cattle)

C;Date: 04-Mar-1993 #sequence_revision 18-Nov-1994 #text_change 17-Feb-2003

C;Accession: G42762

R;Dick, L.R.; Moomaw, C.R.; Pramanik, B.C.; DeMartino, G.N.; Slaughter, C.A.
Biochemistry 31, 7347-7355, 1992

A;Title: Identification and localization of a cysteinyl residue critical for the
trypsin-like catalytic activity of the proteasome.

A;Reference number: A42762; MUID:92378961; PMID:1510924

A;Accession: G42762

A;Status: preliminary

A;Molecule type: protein

A;Residues: 1-11 <DIC>

A;Note: sequence extracted from NCBI backbone (NCBIP:112176)

C;Superfamily: multicatalytic endopeptidase complex chain C9

C;Keywords: hydrolase

Query Match 9.1%; Score 1; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 V 5
|
Db 2 V 2

RESULT 70

S68392

H+-transporting two-sector ATPase (EC 3.6.3.14) chain I - Chlamydomonas
reinhardtii chloroplast (fragment)

N;Alternate names: ATP synthase chain I

C;Species: chloroplast Chlamydomonas reinhardtii

C;Date: 04-Dec-1997 #sequence_revision 12-Dec-1997 #text_change 03-Jun-2002

C;Accession: S68392

R;Fiedler, H.R.; Schmid, R.; Leu, S.; Shavit, N.; Strotmann, H.
FEBS Lett. 377, 163-166, 1995

A;Title: Isolation of CF(0)CF(1) from Chlamydomonas reinhardtii cw15 and the N-
terminal amino acid sequences of the CF(0)CF(1) subunits.

A;Reference number: S68388; MUID:96128220; PMID:8543042

A;Accession: S68392
A;Molecule type: protein
A;Residues: 1-11 <FIE>
A;Experimental source: strain CW15
C;Genetics:
A;Genome: chloroplast
C;Superfamily: H⁺-transporting ATP synthase protein 6
C;Keywords: ATP biosynthesis; chloroplast; hydrolase; membrane-associated complex; thylakoid

Query Match 9.1%; Score 1; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 V 5
|
Db 2 V 2

RESULT 71

B49164

chromogranin-B - rat (fragment)

C;Species: Rattus norvegicus (Norway rat)

C;Date: 19-Dec-1993 #sequence_revision 18-Nov-1994 #text_change 31-Oct-1997

C;Accession: B49164

R;Nielsen, E.; Welinder, B.S.; Madsen, O.D.

Endocrinology 129, 3147-3156, 1991

A;Title: Chromogranin-B, a putative precursor of eight novel rat glucagonoma peptides through processing at mono-, di-, or tribasic residues.

A;Reference number: A49164; MUID:92063871; PMID:1954895

A;Accession: B49164

A;Status: preliminary

A;Molecule type: protein

A;Residues: 1-11 <NIE>

A;Note: sequence extracted from NCBI backbone (NCBIP:66370)

C;Superfamily: chromogranin B precursor

Query Match 9.1%; Score 1; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 S 3
|
Db 3 S 3

RESULT 72

JN0023

substance P - chicken

C;Species: Gallus gallus (chicken)

C;Date: 07-Sep-1990 #sequence_revision 07-Sep-1990 #text_change 11-Jul-1997

C;Accession: JN0023

R;Conlon, J.M.; Katsoulis, S.; Schmidt, W.E.; Thim, L.

Regul. Pept. 20, 171-180, 1988

A;Title: [Arg3]substance P and neurokinin A from chicken small intestine.

A;Reference number: JN0023; MUID:88204263; PMID:2452461

A;Accession: JN0023

A;Molecule type: protein
A;Residues: 1-11 <CON>
C;Superfamily: substance P precursor
C;Keywords: amidated carboxyl end; tachykinin
F;11/Modified site: amidated carboxyl end (Met) #status predicted

Query Match 9.1%; Score 1; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 G 2
|
Db 9 G 9

RESULT 73

S32575

ribosomal protein S2, plastid - squawroot plastid (fragment)

C;Species: plastid Conopholis americana (squawroot)

C;Date: 19-Mar-1997 #sequence_revision 25-Apr-1997 #text_change 13-Aug-1999

C;Accession: S32575

R;Taylor, G.W.; Wolfe, K.H.; Morden, C.W.; dePamphilis, C.W.; Palmer, J.D.

Curr. Genet. 20, 515-518, 1991

A;Title: Lack of a functional plastid tRNA(Cys) gene is associated with loss of photosynthesis in a lineage of parasitic plants.

A;Reference number: S32575; MUID:92145776; PMID:1723664

A;Accession: S32575

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-11 <TAY>

A;Cross-references: EMBL:X64567; NID:g11275; PIDN:CAA45868.1; PID:g11276

C;Genetics:

A;Gene: rps2

A;Genome: plastid

C;Superfamily: Escherichia coli ribosomal protein S2

C;Keywords: plastid; protein biosynthesis; ribosome

Query Match 9.1%; Score 1; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 L 7
|
Db 10 L 10

RESULT 74

A40693

transgelin - sheep (fragment)

C;Species: Ovis orientalis aries, Ovis ammon aries (domestic sheep)

C;Date: 03-May-1994 #sequence_revision 03-May-1994 #text_change 31-Oct-1997

C;Accession: A40693

R;Shapland, C.; Hsuan, J.J.; Totty, N.F.; Lawson, D.

J. Cell Biol. 121, 1065-1073, 1993

A;Title: Purification and properties of transgelin: a transformation and shape change sensitive actin-gelling protein.

A;Reference number: A40693; MUID:93273790; PMID:8501116

A;Accession: A40693
A;Molecule type: protein
A;Residues: 1-11 <SHA>
A;Experimental source: aorta
C;Comment: This protein gels actin and is down regulated by transformation or loss of cell adherence in culture.
C;Superfamily: smooth muscle protein SM22; calponin repeat homology; smooth muscle protein SM22 homology
C;Keywords: actin binding; cytoskeleton

Query Match 9.1%; Score 1; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 K 6
|
Db 1 K 1

RESULT 75

PQ0682

photosystem I 17.5K D2 chain - common tobacco (fragment)

C;Species: *Nicotiana tabacum* (common tobacco)

C;Date: 19-May-1994 #sequence_revision 19-May-1994 #text_change 17-Mar-1999

C;Accession: PQ0682

R;Obokata, J.; Mikami, K.; Hayashida, N.; Nakamura, M.; Sugiura, M.

Plant Physiol. 102, 1259-1267, 1993

A;Title: Molecular heterogeneity of photosystem I. psaD, psaE, psaF, psaH and psaL are all present in isoforms in *Nicotiana* spp.

A;Reference number: PQ0667; MUID:94105345; PMID:8278548

A;Accession: PQ0682

A;Molecule type: protein

A;Residues: 1-11 <OBO>

C;Superfamily: photosystem I chain II

C;Keywords: chloroplast; photosynthesis; photosystem I; thylakoid

Query Match 9.1%; Score 1; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 A 1
|
Db 1 A 1

Search completed: April 8, 2004, 15:49:25

Job time : 8.61538 secs

OM protein - protein search, using sw model

Run on: April 8, 2004, 15:47:33 ; Search time 30.3077 Seconds
(without alignments)
95.432 Million cell updates/sec

Title: US-09-787-443A-4
Perfect score: 11
Sequence: 1 AGSAVKLKKKA 11

Scoring table: OLIGO
Gapop 60.0 , Gapext 60.0

Searched: 1073127 seqs, 262937947 residues

Word size : 0

Total number of hits satisfying chosen parameters: 9223

Minimum DB seq length: 11
Maximum DB seq length: 11

Post-processing: Listing first 100 summaries

Database : Published Applications_AA:*

- 1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep:*
- 2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep:*
- 3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep:*
- 4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep:*
- 5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep:*
- 6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep:*
- 7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep:*
- 8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep:*
- 9: /cgn2_6/ptodata/1/pubpaa/US09A_PUBCOMB.pep:*
- 10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep:*
- 11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep:*
- 12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep:*
- 13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep:*
- 14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep:*
- 15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep:*
- 16: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep:*
- 17: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep:*
- 18: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result		Query				Description
No.	Score	Match	Length	DB	ID	

1	5	45.5	11	12	US-10-653-595-458	Sequence 458, App
2	4	36.4	11	9	US-09-828-592-10	Sequence 10, Appl
3	4	36.4	11	9	US-09-765-527-206	Sequence 206, App
4	4	36.4	11	9	US-09-881-490-181	Sequence 181, App
5	4	36.4	11	9	US-09-981-876-274	Sequence 274, App
6	4	36.4	11	10	US-09-148-545-274	Sequence 274, App
7	4	36.4	11	10	US-09-876-904A-246	Sequence 246, App
8	4	36.4	11	10	US-09-876-904A-434	Sequence 434, App
9	4	36.4	11	10	US-09-876-904A-544	Sequence 544, App
10	4	36.4	11	10	US-09-876-904A-597	Sequence 597, App
11	4	36.4	11	10	US-09-852-910-162	Sequence 162, App
12	4	36.4	11	10	US-09-852-910-251	Sequence 251, App
13	4	36.4	11	10	US-09-978-309A-30	Sequence 30, Appl
14	4	36.4	11	14	US-10-281-478-89	Sequence 89, Appl
15	4	36.4	11	14	US-10-281-478-127	Sequence 127, App
16	4	36.4	11	15	US-10-137-867-340	Sequence 340, App
17	4	36.4	11	15	US-10-205-647A-1	Sequence 1, Appli
18	4	36.4	11	15	US-10-411-336A-162	Sequence 162, App
19	4	36.4	11	15	US-10-411-336A-251	Sequence 251, App
20	3	27.3	11	9	US-09-739-907-108	Sequence 108, App
21	3	27.3	11	9	US-09-827-949-21	Sequence 21, Appl
22	3	27.3	11	9	US-09-865-578-6	Sequence 6, Appli
23	3	27.3	11	9	US-09-124-280A-35	Sequence 35, Appl
24	3	27.3	11	9	US-09-030-619-55	Sequence 55, Appl
25	3	27.3	11	9	US-09-030-619-56	Sequence 56, Appl
26	3	27.3	11	9	US-09-030-619-78	Sequence 78, Appl
27	3	27.3	11	9	US-09-030-619-79	Sequence 79, Appl
28	3	27.3	11	9	US-09-030-619-113	Sequence 113, App
29	3	27.3	11	9	US-09-030-619-114	Sequence 114, App
30	3	27.3	11	9	US-09-484-704-16	Sequence 16, Appl
31	3	27.3	11	9	US-09-766-412-40	Sequence 40, Appl
32	3	27.3	11	9	US-09-734-520-55	Sequence 55, Appl
33	3	27.3	11	9	US-09-734-520-65	Sequence 65, Appl
34	3	27.3	11	9	US-09-734-520-68	Sequence 68, Appl
35	3	27.3	11	9	US-09-734-520-72	Sequence 72, Appl
36	3	27.3	11	9	US-09-984-056-45	Sequence 45, Appl
37	3	27.3	11	9	US-09-957-674-1	Sequence 1, Appli
38	3	27.3	11	9	US-09-966-871-10	Sequence 10, Appl
39	3	27.3	11	9	US-09-988-842-23	Sequence 23, Appl
40	3	27.3	11	9	US-09-766-353A-20	Sequence 20, Appl
41	3	27.3	11	9	US-09-867-852-28	Sequence 28, Appl
42	3	27.3	11	9	US-09-781-988-17	Sequence 17, Appl
43	3	27.3	11	9	US-09-969-192-19	Sequence 19, Appl
44	3	27.3	11	9	US-09-984-057-45	Sequence 45, Appl
45	3	27.3	11	9	US-09-846-352-1	Sequence 1, Appli
46	3	27.3	11	9	US-09-805-301-5	Sequence 5, Appli
47	3	27.3	11	9	US-09-805-301-43	Sequence 43, Appl
48	3	27.3	11	9	US-09-805-301-99	Sequence 99, Appl
49	3	27.3	11	9	US-09-017-743C-121	Sequence 121, App
50	3	27.3	11	10	US-09-999-724-76	Sequence 76, Appl
51	3	27.3	11	10	US-09-229-173-41	Sequence 41, Appl
52	3	27.3	11	10	US-09-259-658-44	Sequence 44, Appl
53	3	27.3	11	10	US-09-906-393A-5	Sequence 5, Appli
54	3	27.3	11	10	US-09-882-291-55	Sequence 55, Appl
55	3	27.3	11	10	US-09-882-291-64	Sequence 64, Appl
56	3	27.3	11	10	US-09-929-266-2	Sequence 2, Appli

57	3	27.3	11	10	US-09-929-266-4	Sequence 4, Appli
58	3	27.3	11	10	US-09-929-266-7	Sequence 7, Appli
59	3	27.3	11	10	US-09-929-266-8	Sequence 8, Appli
60	3	27.3	11	10	US-09-929-266-27	Sequence 27, Appl
61	3	27.3	11	10	US-09-876-904A-25	Sequence 25, Appl
62	3	27.3	11	10	US-09-876-904A-77	Sequence 77, Appl
63	3	27.3	11	10	US-09-876-904A-113	Sequence 113, App
64	3	27.3	11	10	US-09-876-904A-273	Sequence 273, App
65	3	27.3	11	10	US-09-876-904A-354	Sequence 354, App
66	3	27.3	11	10	US-09-876-904A-362	Sequence 362, App
67	3	27.3	11	10	US-09-876-904A-363	Sequence 363, App
68	3	27.3	11	10	US-09-876-904A-364	Sequence 364, App
69	3	27.3	11	10	US-09-876-904A-373	Sequence 373, App
70	3	27.3	11	10	US-09-876-904A-542	Sequence 542, App
71	3	27.3	11	10	US-09-876-904A-591	Sequence 591, App
72	3	27.3	11	10	US-09-876-904A-622	Sequence 622, App
73	3	27.3	11	10	US-09-820-053A-126	Sequence 126, App
74	3	27.3	11	10	US-09-820-053A-127	Sequence 127, App
75	3	27.3	11	10	US-09-820-053A-132	Sequence 132, App
76	3	27.3	11	10	US-09-820-053A-137	Sequence 137, App
77	3	27.3	11	10	US-09-820-053A-140	Sequence 140, App
78	3	27.3	11	10	US-09-820-053A-141	Sequence 141, App
79	3	27.3	11	10	US-09-852-910-6	Sequence 6, Appli
80	3	27.3	11	10	US-09-852-910-51	Sequence 51, Appl
81	3	27.3	11	10	US-09-852-910-53	Sequence 53, Appl
82	3	27.3	11	10	US-09-852-910-60	Sequence 60, Appl
83	3	27.3	11	10	US-09-852-910-64	Sequence 64, Appl
84	3	27.3	11	10	US-09-852-910-89	Sequence 89, Appl
85	3	27.3	11	10	US-09-852-910-103	Sequence 103, App
86	3	27.3	11	10	US-09-852-910-184	Sequence 184, App
87	3	27.3	11	10	US-09-852-910-243	Sequence 243, App
88	3	27.3	11	10	US-09-852-910-263	Sequence 263, App
89	3	27.3	11	10	US-09-893-878-17	Sequence 17, Appl
90	3	27.3	11	10	US-09-791-524-15	Sequence 15, Appl
91	3	27.3	11	10	US-09-854-248-20	Sequence 20, Appl
92	3	27.3	11	10	US-09-940-316B-43	Sequence 43, Appl
93	3	27.3	11	10	US-09-933-767-903	Sequence 903, App
94	3	27.3	11	11	US-09-077-439A-16	Sequence 16, Appl
95	3	27.3	11	11	US-09-896-095-17	Sequence 17, Appl
96	3	27.3	11	11	US-09-938-671-108	Sequence 108, App
97	3	27.3	11	12	US-10-462-452-120	Sequence 120, App
98	3	27.3	11	12	US-10-462-452-145	Sequence 145, App
99	3	27.3	11	12	US-10-462-452-170	Sequence 170, App
100	3	27.3	11	12	US-10-462-452-181	Sequence 181, App

ALIGNMENTS

RESULT 1

US-10-653-595-458

; Sequence 458, Application US/10653595

; Publication No. US20040048304A1

; GENERAL INFORMATION:

; APPLICANT: Ruben et. al.

; TITLE OF INVENTION: 95 Human secreted proteins

; FILE REFERENCE: PZ027P1C1

```

; CURRENT APPLICATION NUMBER: US/10/653,595
; CURRENT FILING DATE: 2003-09-03
; PRIOR APPLICATION NUMBER: US 09/397945
; PRIOR FILING DATE: 1999-09-17
; PRIOR APPLICATION NUMBER: PCT/US99/05804
; PRIOR FILING DATE: 1999-03-18
; PRIOR APPLICATION NUMBER: 60/078,566
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/078,576
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/078,573
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/078,574
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/078,579
; PRIOR FILING DATE: 1998-03-19
; PRIOR APPLICATION NUMBER: 60/080,314
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/080,312
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/078,578
; PRIOR FILING DATE: 1998-03-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 470
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 458
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-653-595-458

```

```

Query Match          45.5%; Score 5; DB 12; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches      5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      7 LKKKA 11
        |||||
Db      6 LKKKA 10

```

RESULT 2

US-09-828-592-10

```

; Sequence 10, Application US/09828592
; Patent No. US20010055591A1
; GENERAL INFORMATION:
; APPLICANT: Walston, Timothy
; APPLICANT: Cooper, Scott
; APPLICANT: Revzaie, Alireza
; TITLE OF INVENTION: ANTITHROMBIN H-HELIX MUTANTS
; FILE REFERENCE: 7869.10USU1
; CURRENT APPLICATION NUMBER: US/09/828,592
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: 60/195,872
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10

```

; LENGTH: 11
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-828-592-10

Query Match 36.4%; Score 4; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
||||
Db 7 KLKK 10

RESULT 3

US-09-765-527-206

; Sequence 206, Application US/09765527
; Patent No. US20020006638A1
; GENERAL INFORMATION:
; APPLICANT: Better, Marc D.
; TITLE OF INVENTION: Methods for Recombinant Microbial Production of
; Fusion Proteins and BPI-Derived Peptides
; NUMBER OF SEQUENCES: 265
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/765,527
; FILING DATE: 18-Jan-2001
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/621,803
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Borun, Michael F.
; REGISTRATION NUMBER: 25,447
; REFERENCE/DOCKET NUMBER: 27129/33199
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 206:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; NAME/KEY: misc_feature

```

;         OTHER INFORMATION:  "XMP.350"
;
;   FEATURE:
;
;         NAME/KEY:  Modified-site
;         LOCATION:  C-Terminus
;         OTHER INFORMATION:  /label= Amidation
;         /note= "The C-Terminus is Amidated."
;
;   SEQUENCE DESCRIPTION:  SEQ ID NO: 206:
US-09-765-527-206

```

```

Query Match          36.4%;  Score 4;  DB 9;  Length 11;
Best Local Similarity 100.0%;  Pred. No. 1.7e+03;
Matches      4;  Conservative      0;  Mismatches      0;  Indels      0;  Gaps      0;

```

```

Qy          7 LKKK 10
             ||||
Db          8 LKKK 11

```

RESULT 4

```

US-09-881-490-181
; Sequence 181, Application US/09881490
; Patent No. US20020077298A1
;   GENERAL INFORMATION:
;
;     APPLICANT: Little II, Roger G.
;               Lim, Edward
;               Fadem, Mitchell B.
;
;   TITLE OF INVENTION: Anti-Fungal Peptides
;
;   NUMBER OF SEQUENCES: 211
;
;   CORRESPONDENCE ADDRESS:
;
;     ADDRESSEE: McAndrews, Held & Malloy, Ltd.
;     STREET: 500 West Madison Street, 34th FloorDrive
;     CITY: Chicago
;     STATE: Illinois
;     COUNTRY: United States of America
;     ZIP: 60661
;
;   COMPUTER READABLE FORM:
;
;     MEDIUM TYPE: Floppy disk
;     COMPUTER: IBM PC compatible
;     OPERATING SYSTEM: PC-DOS/MS-DOS
;     SOFTWARE: PatentIn Release #1.0, Version #1.25
;
;   CURRENT APPLICATION DATA:
;
;     APPLICATION NUMBER: US/09/881,490
;     FILING DATE: 14-Jun-2001
;
;   PRIOR APPLICATION DATA:
;
;     APPLICATION NUMBER: 09/119,858
;     FILING DATE: <Unknown>
;
;     APPLICATION NUMBER: 08/372,105
;     FILING DATE: 13-JAN-95
;
;     APPLICATION NUMBER: 08/306,473
;     FILING DATE: 15-SEP-94
;
;     APPLICATION NUMBER: 08/273,540
;     FILING DATE: 11-JUL-94
;
;     APPLICATION NUMBER: 08/209,762
;     FILING DATE: 11-MAR-94
;
;     APPLICATION NUMBER: 08/183,222
;     FILING DATE: 14-JAN-94
;
;     APPLICATION NUMBER: 08/093,202

```

```

; FILING DATE: 15-JUL-93
; APPLICATION NUMBER: 08/030,644
; FILING DATE: 12-MAR-93
; ATTORNEY/AGENT INFORMATION:
; NAME: McNicholas, Janet M.
; REGISTRATION NUMBER: 32,918
; REFERENCE/DOCKET NUMBER: 100-238/11021US01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/707-8889
; TELEFAX: 312/707-9155
; TELEX: 650 388-1248
; INFORMATION FOR SEQ ID NO: 181:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: "XMP.350"
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: C-Terminus
; OTHER INFORMATION: /label= Amidation
; /note= "The C-Terminus is Amidated"
; SEQUENCE DESCRIPTION: SEQ ID NO: 181:
US-09-881-490-181

```

```

Query Match          36.4%; Score 4; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches      4; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      7 LKKK 10
        ||||
Db      8 LKKK 11

```

RESULT 5

```

US-09-981-876-274
; Sequence 274, Application US/09981876
; Patent No. US20020164669A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 70 Human Secreted Proteins
; FILE REFERENCE: PZ001P1
; CURRENT APPLICATION NUMBER: US/09/981,876
; CURRENT FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: 09/148,545
; PRIOR FILING DATE: 1998-09-04
; PRIOR APPLICATION NUMBER: 60/040,162
; PRIOR FILING DATE: 1997-03-07
; PRIOR APPLICATION NUMBER: 60/040,333
; PRIOR FILING DATE: 1997-03-07
; PRIOR APPLICATION NUMBER: 60/038,621
; PRIOR FILING DATE: 1997-03-07
; PRIOR APPLICATION NUMBER: 60/040,161
; PRIOR FILING DATE: 1997-03-07

```

; PRIOR APPLICATION NUMBER: 60/040,626
; PRIOR FILING DATE: 1997-03-07
; PRIOR APPLICATION NUMBER: 60/040,334
; PRIOR FILING DATE: 1997-03-07
; PRIOR APPLICATION NUMBER: 60/040,336
; PRIOR FILING DATE: 1997-03-07
; PRIOR APPLICATION NUMBER: 60/040,163
; PRIOR FILING DATE: 1997-03-07
; PRIOR APPLICATION NUMBER: 60/047,615
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,600
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,597
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,502
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,633
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,583
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,617
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,618
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,503
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,592
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,581
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,584
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,500
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,587
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,492
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,598
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,613
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,582
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,596
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,612
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,632
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,601
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/043,580
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,568
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,314

; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,569
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,311
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,671
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,674
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,669
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,312
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,313
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,672
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,315
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/048,974
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/056,886
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,877
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,889
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,893
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,630
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,878
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,662
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,872
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,882
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,637
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,903
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,888
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,879
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,880
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,894
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,911
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,636
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,874
; PRIOR FILING DATE: 1997-08-22

; PRIOR APPLICATION NUMBER: 60/056,910
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,864
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,631
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,845
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,892
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/047,595
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/057,761
; PRIOR FILING DATE: 05-Sep-1997
; PRIOR APPLICATION NUMBER: 60/047,599
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,588
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,585
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,586
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,590
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,594
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,589
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,593
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,614
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/043,578
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,576
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/047,501
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/043,670
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/056,632
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,664
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,876
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,881
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,909
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,875
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,862
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,887
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,908

; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/048,964
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/057,650
; PRIOR FILING DATE: 1997-09-05
; PRIOR APPLICATION NUMBER: 60/056,884
; PRIOR FILING DATE: 1997-08-22
; NUMBER OF SEQ ID NOS: 280
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 274
; LENGTH: 11

Query Match 36.4%; Score 4; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGSA 4
||||
Db 3 AGSA 6

RESULT 6

US-09-148-545-274

; Sequence 274, Application US/09148545
; Publication No. US20030027132A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 70 Human Secreted Proteins
; FILE REFERENCE: PZ001P1
; CURRENT APPLICATION NUMBER: US/09/148,545
; CURRENT FILING DATE: 1998-09-04
; EARLIER APPLICATION NUMBER: PCT/US98/04482
; EARLIER FILING DATE: 1998-03-06
; EARLIER APPLICATION NUMBER: 60/040,162
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,333
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/038,621
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,161
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,626
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,334
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,336
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,163
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/047,615
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,600
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,597
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,502
; EARLIER FILING DATE: 1997-05-23

; EARLIER APPLICATION NUMBER: 60/047,633
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,583
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,617
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,618
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,503
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,592
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,581
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,584
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,500
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,587
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,492
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,598
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,613
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,582
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,596
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,612
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,632
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,601
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/043,580
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,568
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,314
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,569
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,311
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,671
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,674
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,669
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,312
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,313
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,672

; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,315
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/048,974
; EARLIER FILING DATE: 1997-06-06
; EARLIER APPLICATION NUMBER: 60/056,886
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,877
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,889
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,893
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,630
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,878
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,662
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,872
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,882
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,637
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,903
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,888
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,879
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,880
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,894
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,911
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,636
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,874
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,910
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,864
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,631
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,845
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,892
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/047,595
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/057,761
; EARLIER FILING DATE: 05-Sep-1997
; EARLIER APPLICATION NUMBER: 60/047,599
; EARLIER FILING DATE: 1997-05-23

```

; EARLIER APPLICATION NUMBER: 60/047,588
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,585
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,586
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,590
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,594
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,589
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,593
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,614
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/043,578
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,576
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/047,501
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/043,670
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/056,632
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,664
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,876
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,881
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,909
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,875
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,862
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,887
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,908
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/048,964
; EARLIER FILING DATE: 1997-06-06
; EARLIER APPLICATION NUMBER: 60/057,650
; EARLIER FILING DATE: 1997-09-05
; EARLIER APPLICATION NUMBER: 60/056,884
; EARLIER FILING DATE: 1997-08-22
; NUMBER OF SEQ ID NOS: 280
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 274
; LENGTH: 11

```

```

Query Match          36.4%; Score 4; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches      4; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

Qy 1 AGSA 4
||||
Db 3 AGSA 6

RESULT 7

US-09-876-904A-246

; Sequence 246, Application US/09876904A
; Publication No. US20030072794A1
; GENERAL INFORMATION:
; APPLICANT: BOULIKAS, TENI
; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND
THERAPEUTIC
; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC
PEPTIDE
; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES
; FILE REFERENCE: TB-2002.00
; CURRENT APPLICATION NUMBER: US/09/876,904A
; CURRENT FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/210,925
; PRIOR FILING DATE: 2000-06-09
; NUMBER OF SEQ ID NOS: 629
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 246
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: mismatch repair peptide
US-09-876-904A-246

Query Match 36.4%; Score 4; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
||||
Db 5 KLKK 8

RESULT 8

US-09-876-904A-434

; Sequence 434, Application US/09876904A
; Publication No. US20030072794A1
; GENERAL INFORMATION:
; APPLICANT: BOULIKAS, TENI
; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND
THERAPEUTIC
; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC
PEPTIDE
; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES
; FILE REFERENCE: TB-2002.00
; CURRENT APPLICATION NUMBER: US/09/876,904A
; CURRENT FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/210,925
; PRIOR FILING DATE: 2000-06-09
; NUMBER OF SEQ ID NOS: 629

; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 434
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Drosophila sp.
; FEATURE:
; OTHER INFORMATION: Drosophila ultrabiothorax protein (from the
; OTHER INFORMATION: conserved 61 amino acid homeodomain segment only).
US-09-876-904A-434

Query Match 36.4%; Score 4; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
||||
Db 6 KLKK 9

RESULT 9

US-09-876-904A-544
; Sequence 544, Application US/09876904A
; Publication No. US20030072794A1
; GENERAL INFORMATION:
; APPLICANT: BOULIKAS, TENI
; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND
THERAPEUTIC
; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC
PEPTIDE
; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES
; FILE REFERENCE: TB-2002.00
; CURRENT APPLICATION NUMBER: US/09/876,904A
; CURRENT FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/210,925
; PRIOR FILING DATE: 2000-06-09
; NUMBER OF SEQ ID NOS: 629
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 544
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Rattus sp.
; FEATURE:
; OTHER INFORMATION: Rat L17 ribosomal protein (184 aas).
US-09-876-904A-544

Query Match 36.4%; Score 4; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLKK 9
||||
Db 8 KLKK 11

RESULT 10

US-09-876-904A-597
; Sequence 597, Application US/09876904A

; Publication No. US20030072794A1
; GENERAL INFORMATION:
; APPLICANT: BOULIKAS, TENI
; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND
THERAPEUTIC
; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC
PEPTIDE
; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES
; FILE REFERENCE: TB-2002.00
; CURRENT APPLICATION NUMBER: US/09/876,904A
; CURRENT FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/210,925
; PRIOR FILING DATE: 2000-06-09
; NUMBER OF SEQ ID NOS: 629
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 597
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Parechinus angulosus
; FEATURE:
; OTHER INFORMATION: Sea urchin Parechinus angulosus sperm H1 (248 aa).
US-09-876-904A-597

Query Match 36.4%; Score 4; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KKKA 11
| | | |
Db 8 KKKA 11

RESULT 11
US-09-852-910-162
; Sequence 162, Application US/09852910
; Publication No. US20030096297A1
; GENERAL INFORMATION:
; APPLICANT: Hamm, Heidi
; APPLICANT: Gilchrist, Annette
; TITLE OF INVENTION: Method For Identifying Inhibitors of G Protein Coupled
Receptor Signaling
; FILE REFERENCE: 2661-101
; CURRENT APPLICATION NUMBER: US/09/852,910
; CURRENT FILING DATE: 2001-09-18
; PRIOR APPLICATION NUMBER: US 60/275,472
; PRIOR FILING DATE: 2001-03-14
; NUMBER OF SEQ ID NOS: 271
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 162
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(11)
; OTHER INFORMATION: G alpha t library pepetide
US-09-852-910-162

Query Match 36.4%; Score 4; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 VKLK 8
||||
Db 3 VKLK 6

RESULT 12

US-09-852-910-251

; Sequence 251, Application US/09852910
; Publication No. US20030096297A1
; GENERAL INFORMATION:
; APPLICANT: Hamm, Heidi
; APPLICANT: Gilchrist, Annette
; TITLE OF INVENTION: Method For Identifying Inhibitors of G Protein Coupled
Receptor Signaling
; FILE REFERENCE: 2661-101
; CURRENT APPLICATION NUMBER: US/09/852,910
; CURRENT FILING DATE: 2001-09-18
; PRIOR APPLICATION NUMBER: US 60/275,472
; PRIOR FILING DATE: 2001-03-14
; NUMBER OF SEQ ID NOS: 271
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 251
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(11)
; OTHER INFORMATION: G11 library peptide
US-09-852-910-251

Query Match 36.4%; Score 4; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 VKLK 8
||||
Db 3 VKLK 6

RESULT 13

US-09-978-309A-30

; Sequence 30, Application US/09978309A
; Publication No. US20030100490A1
; GENERAL INFORMATION:
; APPLICANT: Cruz, Tony
; APPLICANT: Pastrak, Aleksandra
; APPLICANT: Turley, Eva A.
; TITLE OF INVENTION: Compositions and Methods for Treating Cellular Response
to
; TITLE OF INVENTION: Injury and Other Proliferating Cell Disorders Regulated
by

```
; TITLE OF INVENTION: Hyaladherin and Hyaluronans
; FILE REFERENCE: 033352-010
; CURRENT APPLICATION NUMBER: US/09/978,309A
; CURRENT FILING DATE: 2002-04-04
; PRIOR APPLICATION NUMBER: US 09/685,010
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/541,522
; PRIOR FILING DATE: 2000-04-03
; PRIOR APPLICATION NUMBER: US 60/127,457
; PRIOR FILING DATE: 1999-04-01
; NUMBER OF SEQ ID NOS: 84
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 30
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Peptide composition that binds a hyalauronan
US-09-978-309A-30
```

```
Query Match          36.4%; Score 4; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches      4; Conservative      0; Mismatches      0; Indels      0; Gaps      0;
```

```
Qy      5 VKLK 8
        ||||
Db      8 VKLK 11
```

```
RESULT 14
US-10-281-478-89
; Sequence 89, Application US/10281478
; Publication No. US20030108959A1
; GENERAL INFORMATION:
; APPLICANT: Immunex Corporation
; APPLICANT: Johnson, Richard S.
; APPLICANT: Guo, Lin
; APPLICANT: Mahimkar, Rajeev M.
; APPLICANT: Peschon, Jacques J.
; APPLICANT: Black, Roy A.
; TITLE OF INVENTION: TREATING DISEASES MEDIATED BY METALLOPROTEASE-SHED
PROTEINS
; FILE REFERENCE: 3327-A
; CURRENT APPLICATION NUMBER: US/10/281,478
; CURRENT FILING DATE: 2002-10-25
; NUMBER OF SEQ ID NOS: 158
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 89
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: peptide
; FEATURE:
; NAME/KEY: MOD_RES
; LOCATION: (2)..(2)
; OTHER INFORMATION: alkylated cysteine
```

; FEATURE:
; NAME/KEY: MOD_RES
; LOCATION: (10)..(10)
; OTHER INFORMATION: alkylated cysteine
US-10-281-478-89

Query Match 36.4%; Score 4; DB 14; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GSAV 5
||||
Db 5 GSAV 8

RESULT 15

US-10-281-478-127

; Sequence 127, Application US/10281478
; Publication No. US20030108959A1
; GENERAL INFORMATION:
; APPLICANT: Immunex Corporation
; APPLICANT: Johnson, Richard S.
; APPLICANT: Guo, Lin
; APPLICANT: Mahimkar, Rajeev M.
; APPLICANT: Peschon, Jacques J.
; APPLICANT: Black, Roy A.
; TITLE OF INVENTION: TREATING DISEASES MEDIATED BY METALLOPROTEASE-SHED
PROTEINS
; FILE REFERENCE: 3327-A
; CURRENT APPLICATION NUMBER: US/10/281,478
; CURRENT FILING DATE: 2002-10-25
; NUMBER OF SEQ ID NOS: 158
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 127
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: peptide
; FEATURE:
; NAME/KEY: MOD_RES
; LOCATION: (2)..(2)
; OTHER INFORMATION: alkylated cysteine
; FEATURE:
; NAME/KEY: MOD_RES
; LOCATION: (10)..(10)
; OTHER INFORMATION: alkylated cysteine
US-10-281-478-127

Query Match 36.4%; Score 4; DB 14; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GSAV 5
||||
Db 5 GSAV 8

RESULT 16

US-10-137-867-340

; Sequence 340, Application US/10137867
 ; Publication No. US20030207349A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; TITLE OF INVENTION: ACIDS ENCODING THE SAME
 ; FILE REFERENCE: P3330R1C146
 ; CURRENT APPLICATION NUMBER: US/10/137,867
 ; CURRENT FILING DATE: 2002-05-03
 ; Prior Application removed - See Palm or File Wrapper
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 340
 ; LENGTH: 386
 ; TYPE: PRT
 ; ORGANISM: Homo Sapien

US-10-137-867-340

Query Match 36.4%; Score 4; DB 15; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.7e+03;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGSA 4
 ||||
 Db 4 AGSA 7

RESULT 17

US-10-205-647A-1

; Sequence 1, Application US/10205647A
 ; Publication No. US20040010812A1
 ; GENERAL INFORMATION:
 ; APPLICANT: University of Manitoba
 ; APPLICANT: Manitoba Cancer Treatment and Research Foundation
 ; APPLICANT: TURLEY, Eva A.
 ; APPLICANT: ENTWISTLE, Joycelyn
 ; TITLE OF INVENTION: HUMAN HYALURONAN RECEPTOR
 ; NUMBER OF SEQUENCES: 52
 ; CORRESPONDENCE ADDRESS:

```

; STREET: 181 Freedman Crescent, Room 361
; CITY: Winnipeg
; STATE: Manitoba
; COUNTRY: Canada
; ZIP: R3T 5V4
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/205,647A
; FILING DATE: 23-JULY-2002
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: WO PCT/CA97/00240
; FILING DATE: 10-APR-1996
; APPLICATION NUMBER: GB 9607441.4
; FILING DATE: 10
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-10-205-647A-1

```

```

Query Match          36.4%; Score 4; DB 15; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches      4; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      5 VKLK 8
        ||||
Db      8 VKLK 11

```

```

RESULT 18
US-10-411-336A-162
; Sequence 162, Application US/10411336A
; Publication No. US20040018558A1
; GENERAL INFORMATION:
; APPLICANT: GILCHRIST, ANNETTE
; APPLICANT: HAMM, HEIDI
; TITLE OF INVENTION: METHOD FOR IDENTIFYING MODULATORS OF G PROTEIN COUPLED
RECEPTOR
; TITLE OF INVENTION: SIGNALING
; FILE REFERENCE: 2661-102
; CURRENT APPLICATION NUMBER: US/10/411,336A
; CURRENT FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: US 09/852910
; PRIOR FILING DATE: 2001-05-11
; PRIOR APPLICATION NUMBER: US 60/275472
; PRIOR FILING DATE: 2001-03-14
; NUMBER OF SEQ ID NOS: 273
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 162
; LENGTH: 11

```

; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: G alpha t library pepetide
US-10-411-336A-162

Query Match 36.4%; Score 4; DB 15; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 VKLK 8
||||
Db 3 VKLK 6

RESULT 19

US-10-411-336A-251
; Sequence 251, Application US/10411336A
; Publication No. US20040018558A1
; GENERAL INFORMATION:
; APPLICANT: GILCHRIST, ANNETTE
; APPLICANT: HAMM, HEIDI
; TITLE OF INVENTION: METHOD FOR IDENTIFYING MODULATORS OF G PROTEIN COUPLED
RECEPTOR
; TITLE OF INVENTION: SIGNALING
; FILE REFERENCE: 2661-102
; CURRENT APPLICATION NUMBER: US/10/411,336A
; CURRENT FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: US 09/852910
; PRIOR FILING DATE: 2001-05-11
; PRIOR APPLICATION NUMBER: US 60/275472
; PRIOR FILING DATE: 2001-03-14
; NUMBER OF SEQ ID NOS: 273
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 251
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: G11 library peptide
US-10-411-336A-251

Query Match 36.4%; Score 4; DB 15; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 VKLK 8
||||
Db 3 VKLK 6

RESULT 20

US-09-739-907-108
; Sequence 108, Application US/09739907
; Patent No. US20010012889A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.

; TITLE OF INVENTION: 36 Human Secreted Proteins
; FILE REFERENCE: PZ022P1
; CURRENT APPLICATION NUMBER: US/09/739,907
; CURRENT FILING DATE: 2000-12-20
; PRIOR APPLICATION NUMBER: 09/348,457
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: 60/070,567
; PRIOR FILING DATE: 1998-01-07
; PRIOR APPLICATION NUMBER: 60/070,692
; PRIOR FILING DATE: 1998-01-07
; PRIOR APPLICATION NUMBER: 60/070,704
; PRIOR FILING DATE: 1998-01-07
; PRIOR APPLICATION NUMBER: 60/070,658
; PRIOR FILING DATE: 1998-01-07
; NUMBER OF SEQ ID NOS: 196
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 108
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-739-907-108

Query Match 27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGS 3
|||
Db 1 AGS 3

RESULT 21

US-09-827-949-21
; Sequence 21, Application US/09827949
; Patent No. US20010021505A1
; GENERAL INFORMATION:
; APPLICANT: Morris, Stephan W.
; APPLICANT: Look, A. Thomas
; TITLE OF INVENTION: ALK Protein Tyrosine Kinase/Receptor and Ligands Thereof
; FILE REFERENCE: 0656.0400004
; CURRENT APPLICATION NUMBER: US/09/827,949
; CURRENT FILING DATE: 2001-04-09
; PRIOR APPLICATION NUMBER: US 09/670,827
; PRIOR FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US 09/100,089
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: US 08/542,363
; PRIOR FILING DATE: 1995-10-12
; PRIOR APPLICATION NUMBER: US 08/160,861
; PRIOR FILING DATE: 1993-12-03
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 21
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-827-949-21

Query Match 27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 AVK 6
|||
Db 5 AVK 7

RESULT 22

US-09-865-578-6

; Sequence 6, Application US/09865578

; Patent No. US20010034433A1

; GENERAL INFORMATION:

; APPLICANT: E. MARTIN, SPENCER

; TITLE OF INVENTION: HUMAN SOMATOMEDIAN CARRIER PROTEIN SUBUNITS

; TITLE OF INVENTION: AND PROCESS FOR PRODUCING THEM; RECOMBINANT DNA
MOLECULES,

; TITLE OF INVENTION: HOSTS, PROCESSES AND HUMAN SOMATOMEDIAN CARRIER PROTEIN-
LIKE

; TITLE OF INVENTION: POLYPEPTIDES

; FILE REFERENCE: 057491/0680

; CURRENT APPLICATION NUMBER: US/09/865,578

; CURRENT FILING DATE: 2001-05-29

; PRIOR APPLICATION NUMBER: 09/397,192

; PRIOR FILING DATE: 1999-09-16

; PRIOR APPLICATION NUMBER: 09/162,118

; PRIOR FILING DATE: 1998-09-28

; PRIOR APPLICATION NUMBER: 08/923,860

; PRIOR FILING DATE: 1997-09-03

; PRIOR APPLICATION NUMBER: 08/706,755

; PRIOR FILING DATE: 1996-09-03

; PRIOR APPLICATION NUMBER: 08/437,407

; PRIOR FILING DATE: 1995-05-12

; PRIOR APPLICATION NUMBER: 08/320,123

; PRIOR FILING DATE: 1994-10-07

; PRIOR APPLICATION NUMBER: 08/043,039

; PRIOR FILING DATE: 1993-04-05

; PRIOR APPLICATION NUMBER: 07/763,481

; PRIOR FILING DATE: 1991-09-20

; PRIOR APPLICATION NUMBER: 07/290,250

; PRIOR FILING DATE: 1988-12-22

; PRIOR APPLICATION NUMBER: 07/170,022

; PRIOR FILING DATE: 1988-03-31

; PRIOR APPLICATION NUMBER: 07/034,885

; PRIOR FILING DATE: 1987-04-06

; NUMBER OF SEQ ID NOS: 14

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 6

; LENGTH: 11

; TYPE: PRT

; ORGANISM: Homo sapiens

; FEATURE:

; NAME/KEY: MOD_RES

; LOCATION: (5)

; OTHER INFORMATION: Ala or Gly

US-09-865-578-6

Query Match 27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SAV 5
|||
Db 7 SAV 9

RESULT 23

US-09-124-280A-35

; Sequence 35, Application US/09124280A
; Patent No. US20020034520A1
; GENERAL INFORMATION:
; APPLICANT: Porro, Massimo
; TITLE OF INVENTION: VACCINES FOR PREVENTION OF GRAM-
; TITLE OF INVENTION: NEGATIVE BACTERIAL INFECTIONS AND ENDOTOXIN RELATED
DISEASES
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hedman, Gibson & Costigan
; STREET: 1185 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: DOS
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/124,280A
; FILING DATE: July 29,1998
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Costigan, James V.
; REGISTRATION NUMBER: 25,669
; REFERENCE/DOCKET NUMBER: 576-008
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 302-8989
; TELEFAX: (212) 302-8998
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: circular
US-09-124-280A-35

Query Match 27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKK 9
|||
Db 8 LKK 10

RESULT 24

US-09-030-619-55

; Sequence 55, Application US/09030619B
; Patent No. US20020035061A1
; GENERAL INFORMATION:
; APPLICANT: Krieger, Timothy J.
; APPLICANT: Taylor, Robert
; APPLICANT: Erfle, Douglas
; APPLICANT: Fraser, Janet R.
; APPLICANT: West, Michael H.P.
; APPLICANT: McNicol, Patricia J.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING
; TITLE OF INVENTION: INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN
COMBINATION
; TITLE OF INVENTION: WITH ANTIBIOTICS
; FILE REFERENCE: 660081.406
; CURRENT APPLICATION NUMBER: US/09/030,619B
; CURRENT FILING DATE: 1998-02-25
; NUMBER OF SEQ ID NOS: 232
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 55
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Indolicidin Analogue
US-09-030-619-55

Query Match 27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKK 9
|||
Db 2 LKK 4

RESULT 25

US-09-030-619-56

; Sequence 56, Application US/09030619B
; Patent No. US20020035061A1
; GENERAL INFORMATION:
; APPLICANT: Krieger, Timothy J.
; APPLICANT: Taylor, Robert
; APPLICANT: Erfle, Douglas
; APPLICANT: Fraser, Janet R.
; APPLICANT: West, Michael H.P.
; APPLICANT: McNicol, Patricia J.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING
; TITLE OF INVENTION: INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN
COMBINATION

; TITLE OF INVENTION: WITH ANTIBIOTICS
; FILE REFERENCE: 660081.406
; CURRENT APPLICATION NUMBER: US/09/030,619B
; CURRENT FILING DATE: 1998-02-25
; NUMBER OF SEQ ID NOS: 232
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 56
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Indolicidin Analogue
US-09-030-619-56

Query Match 27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKK 9
|||
Db 2 LKK 4

RESULT 26

US-09-030-619-78

; Sequence 78, Application US/09030619B
; Patent No. US20020035061A1

; GENERAL INFORMATION:

; APPLICANT: Krieger, Timothy J.
; APPLICANT: Taylor, Robert
; APPLICANT: Erfle, Douglas
; APPLICANT: Fraser, Janet R.
; APPLICANT: West, Michael H.P.
; APPLICANT: McNicol, Patricia J.

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING
; TITLE OF INVENTION: INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN
COMBINATION

; TITLE OF INVENTION: WITH ANTIBIOTICS
; FILE REFERENCE: 660081.406
; CURRENT APPLICATION NUMBER: US/09/030,619B
; CURRENT FILING DATE: 1998-02-25
; NUMBER OF SEQ ID NOS: 232
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 78
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Indolicidin Analogue
US-09-030-619-78

Query Match 27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKK 9
|||

Db 2 LKK 4

RESULT 27

US-09-030-619-79

; Sequence 79, Application US/09030619B

; Patent No. US20020035061A1

; GENERAL INFORMATION:

; APPLICANT: Krieger, Timothy J.

; APPLICANT: Taylor, Robert

; APPLICANT: Erfle, Douglas

; APPLICANT: Fraser, Janet R.

; APPLICANT: West, Michael H.P.

; APPLICANT: McNicol, Patricia J.

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING

; TITLE OF INVENTION: INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION

; TITLE OF INVENTION: WITH ANTIBIOTICS

; FILE REFERENCE: 660081.406

; CURRENT APPLICATION NUMBER: US/09/030,619B

; CURRENT FILING DATE: 1998-02-25

; NUMBER OF SEQ ID NOS: 232

; SOFTWARE: FastSEQ for Windows Version 3.0

; SEQ ID NO 79

; LENGTH: 11

; TYPE: PRT

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Indolicidin Analogue

US-09-030-619-79

Query Match 27.3%; Score 3; DB 9; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.5e+04;

Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKK 9

|||

Db 2 LKK 4

RESULT 28

US-09-030-619-113

; Sequence 113, Application US/09030619B

; Patent No. US20020035061A1

; GENERAL INFORMATION:

; APPLICANT: Krieger, Timothy J.

; APPLICANT: Taylor, Robert

; APPLICANT: Erfle, Douglas

; APPLICANT: Fraser, Janet R.

; APPLICANT: West, Michael H.P.

; APPLICANT: McNicol, Patricia J.

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING

; TITLE OF INVENTION: INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION

; TITLE OF INVENTION: WITH ANTIBIOTICS

; FILE REFERENCE: 660081.406

; CURRENT APPLICATION NUMBER: US/09/030,619B

; CURRENT FILING DATE: 1998-02-25
; NUMBER OF SEQ ID NOS: 232
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 113
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cationic Peptide Analogue
US-09-030-619-113

Query Match 27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKK 9
|||
Db 2 LKK 4

RESULT 29

US-09-030-619-114

; Sequence 114, Application US/09030619B
; Patent No. US20020035061A1
; GENERAL INFORMATION:
; APPLICANT: Krieger, Timothy J.
; APPLICANT: Taylor, Robert
; APPLICANT: Erfle, Douglas
; APPLICANT: Fraser, Janet R.
; APPLICANT: West, Michael H.P.
; APPLICANT: McNicol, Patricia J.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING
; TITLE OF INVENTION: INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN
COMBINATION
; TITLE OF INVENTION: WITH ANTIBIOTICS
; FILE REFERENCE: 660081.406
; CURRENT APPLICATION NUMBER: US/09/030,619B
; CURRENT FILING DATE: 1998-02-25
; NUMBER OF SEQ ID NOS: 232
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 114
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cationic Peptide Analogue
US-09-030-619-114

Query Match 27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKK 9
|||
Db 2 LKK 4

RESULT 30

US-09-484-704-16

; Sequence 16, Application US/09484704
 ; Patent No. US20020081567A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Henrickson, Kelly J.
 ; APPLICANT: Fan, Jiang (n.m.i.)
 ; TITLE OF INVENTION: VIRUS ASSAY METHOD
 ; NUMBER OF SEQUENCES: 65
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Quarles & Brady
 ; STREET: 411 East Wisconsin Avenue
 ; CITY: Milwaukee
 ; STATE: Wisconsin
 ; COUNTRY: U.S.A.
 ; ZIP: 53202-4497
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/484,704
 ; FILING DATE:
 ; CLASSIFICATION:
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Baker, Jean C.
 ; REGISTRATION NUMBER: 35,433
 ; REFERENCE/DOCKET NUMBER: 650053.91126
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (414) 277-5000
 ; TELEFAX: (414) 271-3552
 ; INFORMATION FOR SEQ ID NO: 16:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 11 amino acids
 ; TYPE: amino acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: peptide

US-09-484-704-16

Query Match 27.3%; Score 3; DB 9; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+04;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKK 9
 |||
 Db 2 LKK 4

RESULT 31

US-09-766-412-40

; Sequence 40, Application US/09766412
 ; Patent No. US20020103129A1
 ; GENERAL INFORMATION:
 ; APPLICANT: GE, Ruowen et al.

```
; TITLE OF INVENTION: SMALL PEPTIDES HAVING ANTI-ANGIOGENIC AND ENDOTHELIAL
CELL INHIBITION
; TITLE OF INVENTION: ACTIVITY
; FILE REFERENCE: 1781-0215P
; CURRENT APPLICATION NUMBER: US/09/766,412
; CURRENT FILING DATE: 2001-01-11
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 40
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Mammalian
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: hFLT2-11
US-09-766-412-40
```

```
Query Match          27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;
```

```
Qy      7 LKK 9
      |||
Db      6 LKK 8
```

RESULT 32

US-09-734-520-55

```
; Sequence 55, Application US/09734520
; Patent No. US20020115173A1
; GENERAL INFORMATION:
; APPLICANT: Ben-Sasson, Shmuel
; TITLE OF INVENTION: SHORT PEPTIDES FROM THE A-REGION OF
; TITLE OF INVENTION: PROTEIN KINASES WHICH SELECTIVELY MODULATE PROTEIN
KINASE
; TITLE OF INVENTION: ACTIVITY
; FILE REFERENCE: 1242.2003-000
; CURRENT APPLICATION NUMBER: US/09/734,520
; CURRENT FILING DATE: 2000-12-11
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 55
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: plx1
; NAME/KEY: MYRISTATE
; LOCATION: (1)...(0)
; NAME/KEY: AMIDATION
; LOCATION: (0)...(11)
US-09-734-520-55
```

```
Query Match          27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;
```

Qy 5 VKL 7
|||
Db 9 VKL 11

RESULT 33

US-09-734-520-65

; Sequence 65, Application US/09734520
; Patent No. US20020115173A1
; GENERAL INFORMATION:
; APPLICANT: Ben-Sasson, Shmuel
; TITLE OF INVENTION: SHORT PEPTIDES FROM THE A-REGION OF
; TITLE OF INVENTION: PROTEIN KINASES WHICH SELECTIVELY MODULATE PROTEIN
KINASE
; TITLE OF INVENTION: ACTIVITY
; FILE REFERENCE: 1242.2003-000
; CURRENT APPLICATION NUMBER: US/09/734,520
; CURRENT FILING DATE: 2000-12-11
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 65
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Fyn
; NAME/KEY: MYRISTATE
; LOCATION: (1)...(0)
; NAME/KEY: AMIDATION
; LOCATION: (0)...(11)
US-09-734-520-65

Query Match 27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLK 8
|||
Db 2 KLK 4

RESULT 34

US-09-734-520-68

; Sequence 68, Application US/09734520
; Patent No. US20020115173A1
; GENERAL INFORMATION:
; APPLICANT: Ben-Sasson, Shmuel
; TITLE OF INVENTION: SHORT PEPTIDES FROM THE A-REGION OF
; TITLE OF INVENTION: PROTEIN KINASES WHICH SELECTIVELY MODULATE PROTEIN
KINASE
; TITLE OF INVENTION: ACTIVITY
; FILE REFERENCE: 1242.2003-000
; CURRENT APPLICATION NUMBER: US/09/734,520
; CURRENT FILING DATE: 2000-12-11
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 68

; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Hck
; NAME/KEY: MYRISTATE
; LOCATION: (1)...(0)
; NAME/KEY: AMIDATION
; LOCATION: (0)...(11)
US-09-734-520-68

Query Match 27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 VKL 7
|||
Db 9 VKL 11

RESULT 35
US-09-734-520-72
; Sequence 72, Application US/09734520
; Patent No. US20020115173A1
; GENERAL INFORMATION:
; APPLICANT: Ben-Sasson, Shmuel
; TITLE OF INVENTION: SHORT PEPTIDES FROM THE A-REGION OF
; TITLE OF INVENTION: PROTEIN KINASES WHICH SELECTIVELY MODULATE PROTEIN
KINASE
; TITLE OF INVENTION: ACTIVITY
; FILE REFERENCE: 1242.2003-000
; CURRENT APPLICATION NUMBER: US/09/734,520
; CURRENT FILING DATE: 2000-12-11
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 72
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Fak
; NAME/KEY: MYRISTATE
; LOCATION: (1)...(0)
; NAME/KEY: AMIDATION
; LOCATION: (0)...(11)
US-09-734-520-72

Query Match 27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 VKL 7
|||
Db 9 VKL 11

RESULT 36

US-09-984-056-45
; Sequence 45, Application US/09984056
; Patent No. US20020120106A1
; GENERAL INFORMATION:
; APPLICANT: BOGOCH, SAMUEL
; APPLICANT: BOGOCH, ELENORE S.
; TITLE OF INVENTION: ANTHRAX AND SMALL POX REPLIKINS AND METHODS OF USE
; FILE REFERENCE: 09425-46903
; CURRENT APPLICATION NUMBER: US/09/984,056
; CURRENT FILING DATE: 2001-10-26
; PRIOR APPLICATION NUMBER: 60/303,396
; PRIOR FILING DATE: 2001-07-09
; PRIOR APPLICATION NUMBER: 60/278,761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: 09/146,755
; PRIOR FILING DATE: 1998-09-04
; PRIOR APPLICATION NUMBER: 09/817,144
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: 08/198,139
; PRIOR FILING DATE: 1994-02-17
; NUMBER OF SEQ ID NOS: 103
; SOFTWARE: PatentIn 2.1
; SEQ ID NO 45
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Arabidopsis thaliana
US-09-984-056-45

Query Match 27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 KKA 11
|||
Db 8 KKA 10

RESULT 37

US-09-957-674-1
; Sequence 1, Application US/09957674
; Patent No. US20020120948A1
; GENERAL INFORMATION:
; APPLICANT: Medical Research Council
; TITLE OF INVENTION: Methods for Expressing Gene Products
; FILE REFERENCE: 18396/2072
; CURRENT APPLICATION NUMBER: US/09/957,674
; CURRENT FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: GB990736
; PRIOR FILING DATE: 1999-03-30
; PRIOR APPLICATION NUMBER: PCT/GB00/01225
; PRIOR FILING DATE: 2000-03-30
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Sperm Whale

US-09-957-674-1

Query Match 27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKK 9
|||
Db 9 LKK 11

RESULT 38

US-09-966-871-10

; Sequence 10, Application US/09966871
; Patent No. US20020127539A1
; GENERAL INFORMATION:
; APPLICANT: Kopin, Alan S.
; TITLE OF INVENTION: Assays for Identifying Receptors Having
; TITLE OF INVENTION: Alterations in Signaling
; FILE REFERENCE: 00398/512002
; CURRENT APPLICATION NUMBER: US/09/966,871
; CURRENT FILING DATE: 2001-09-28
; PRIOR APPLICATION NUMBER: US 60/236,302
; PRIOR FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US 60/288,644
; PRIOR FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 87
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-966-871-10

Query Match 27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 KKA 11
|||
Db 3 KKA 5

RESULT 39

US-09-988-842-23

; Sequence 23, Application US/09988842
; Patent No. US20020143105A1
; GENERAL INFORMATION:
; APPLICANT: Johansson, Jan
; TITLE OF INVENTION: DISCORDANT HELIX STABILIZATION FOR PREVENTION
; TITLE OF INVENTION: OF AMYLOID FORMATION
; FILE REFERENCE: 12125-002001
; CURRENT APPLICATION NUMBER: US/09/988,842
; CURRENT FILING DATE: 2001-11-19
; PRIOR APPLICATION NUMBER: US 60/251,662
; PRIOR FILING DATE: 2000-12-06
; PRIOR APPLICATION NUMBER: US 60/253,695

; PRIOR FILING DATE: 2000-11-20
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetically generated peptide
US-09-988-842-23

Query Match 27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GSA 4
|||
Db 8 GSA 10

RESULT 40

US-09-766-353A-20
; Sequence 20, Application US/09766353A
; Patent No. US20020146406A1
; GENERAL INFORMATION:
; APPLICANT: Regents of the University of Minnesota
; APPLICANT: Mayo, Kevin H.
; TITLE OF INVENTION: POLYPEPTIDES WITH THERAPEUTIC ACTIVITY AND METHODS OF
; TITLE OF INVENTION: USE
; FILE REFERENCE: 110.01120101
; CURRENT APPLICATION NUMBER: US/09/766,353A
; CURRENT FILING DATE: 2001-01-19
; PRIOR APPLICATION NUMBER: 60/177,255
; PRIOR FILING DATE: 2000-01-20
; PRIOR APPLICATION NUMBER: 60/210,297
; PRIOR FILING DATE: 2000-06-08
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:artificially
synthesized peptide
US-09-766-353A-20

Query Match 27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLK 8
|||
Db 1 KLK 3

RESULT 41

US-09-867-852-28
 ; Sequence 28, Application US/09867852
 ; Patent No. US20020147324A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ausubel, Frederick M.
 ; APPLICANT: Staskawicz, Brian J.
 ; APPLICANT: Brent, Andrew F.
 ; APPLICANT: Dahlbeck, Douglas
 ; APPLICANT: Katagiri, Fumiaki
 ; APPLICANT: Kunkel, Barbara N.
 ; APPLICANT: Mindrinos, Michael N.
 ; APPLICANT: Yu, Guo-Liang
 ; TITLE OF INVENTION: RPS2 GENE FAMILY, PRIMERS, PROBES, AND
 ; TITLE OF INVENTION: DETECTION METHODS
 ; FILE REFERENCE: 00786/254002
 ; CURRENT APPLICATION NUMBER: US/09/867,852
 ; CURRENT FILING DATE: 2001-05-29
 ; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 09/301,085
 ; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-28
 ; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 08/310,912
 ; PRIOR FILING DATE: EARLIER FILING DATE: 1994-09-22
 ; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 08/227,360
 ; PRIOR FILING DATE: EARLIER FILING DATE: 1994-04-13
 ; NUMBER OF SEQ ID NOS: 208
 ; SOFTWARE: FastSEQ for Windows Version 4.0
 ; SEQ ID NO 28
 ; LENGTH: 11
 ; TYPE: PRT
 ; ORGANISM: Arabidopsis thaliana
 US-09-867-852-28

Query Match 27.3%; Score 3; DB 9; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+04;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGS 3
 |||
 Db 6 AGS 8

RESULT 42
 US-09-781-988-17
 ; Sequence 17, Application US/09781988
 ; Patent No. US20020150881A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ladner, Robert Charles
 ; Guterman, Sonia Kosow
 ; Roberts, Bruce Lindsay
 ; Markland, William
 ; Ley, Arthur Charles
 ; Kent, Rachel Baribault
 ; TITLE OF INVENTION: Directed Evolution of No. US20020150881A1e1
 ; Binding Proteins
 ; NUMBER OF SEQUENCES: 121
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Browdy and Neimark
 ; STREET: 419 Seventh Street, N.W.

```

;           Suite 300
;       CITY: Washington,
;       STATE: DC
;       COUNTRY: USA
;       ZIP: 20004
;
;   COMPUTER READABLE FORM:
;       MEDIUM TYPE: Floppy disk
;       COMPUTER: IBM PC compatible
;       OPERATING SYSTEM: PC-DOS/MS-DOS
;       SOFTWARE: WORDPERFECT 4.2
;
;   CURRENT APPLICATION DATA:
;       APPLICATION NUMBER: US/09/781,988
;       FILING DATE: 14-Feb-2001
;       CLASSIFICATION: <Unknown>
;
;   PRIOR APPLICATION DATA:
;       APPLICATION NUMBER: 07/664,989
;       FILING DATE: <Unknown>
;       APPLICATION NUMBER: 07/487,063
;       FILING DATE: 02-MAR-1990
;       APPLICATION NUMBER: 07/240,160
;       FILING DATE: 02-SEP-1988
;
;   ATTORNEY/AGENT INFORMATION:
;       NAME: Cooper, Iver P.
;       REGISTRATION NUMBER: 28005
;       REFERENCE/DOCKET NUMBER: LADNER 7
;
;   TELECOMMUNICATION INFORMATION:
;       TELEPHONE: 202-628-5197
;       TELEFAX: 202-737-3528
;
;   INFORMATION FOR SEQ ID NO: 17:
;       SEQUENCE CHARACTERISTICS:
;           LENGTH: 11 amino acids
;           TYPE: amino acid
;           TOPOLOGY: linear
;       MOLECULE TYPE: protein
;       SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-09-781-988-17

```

```

Query Match          27.3%;  Score 3;  DB 9;  Length 11;
Best Local Similarity 100.0%;  Pred. No. 1.5e+04;
Matches      3;  Conservative    0;  Mismatches    0;  Indels      0;  Gaps      0;

```

```

Qy      2 GSA 4
      |||
Db      6 GSA 8

```

RESULT 43

US-09-969-192-19

```

; Sequence 19, Application US/09969192
; Patent No. US20020151027A1

```

GENERAL INFORMATION:

```

;   APPLICANT: WICKHAM, THOMAS J.
;               ROELVINK, PETRUS W.
;               KOVESDI, IMRE
;
;   TITLE OF INVENTION: TARGETING ADENOVIRUS WITH USE OF
;                       CONSTRAINED PEPTIDE MOTIFS
;
;   NUMBER OF SEQUENCES: 80

```

```

;      CORRESPONDENCE ADDRESS:
;      ADDRESSEE: Leydig, Voit & Mayer, Ltd.
;      STREET: Two Prudential Plaza - 49th Floor
;      CITY: Chicago
;      STATE: Illinois
;      COUNTRY: USA
;      ZIP: 60601
;      COMPUTER READABLE FORM:
;      MEDIUM TYPE: Floppy disk
;      COMPUTER: IBM PC compatible
;      OPERATING SYSTEM: PC-DOS/MS-DOS
;      SOFTWARE: PatentIn Release #1.0, Version #1.30
;      CURRENT APPLICATION DATA:
;      APPLICATION NUMBER: US/09/969,192
;      FILING DATE: 01-Oct-2001
;      PRIOR APPLICATION DATA:
;      APPLICATION NUMBER: US 9-455061
;      FILING DATE: 06-DEC-1999
;      APPLICATION NUMBER: US 9-130225
;      FILING DATE: 06-AUG-1998
;      APPLICATION NUMBER: US 8-701124
;      FILING DATE: 21-AUG-1996
;      ATTORNEY/AGENT INFORMATION:
;      NAME: Hefner, M. Daniel
;      REGISTRATION NUMBER: 41,826
;      REFERENCE/DOCKET NUMBER: 213564
;      INFORMATION FOR SEQ ID NO: 19:
;      SEQUENCE CHARACTERISTICS:
;      LENGTH: 11 amino acids
;      TYPE: amino acid
;      TOPOLOGY: linear
;      MOLECULE TYPE: peptide
;      SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-09-969-192-19

```

```

Query Match          27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      8 KKK 10
      |||
Db      3 KKK 5

```

```

RESULT 44
US-09-984-057-45
; Sequence 45, Application US/09984057
; Patent No. US20020151677A1
; GENERAL INFORMATION:
; APPLICANT: BOGOCH, SAMUEL
; APPLICANT: BOGOCH, ELENORE S.
; TITLE OF INVENTION: REPLIKINS AND METHODS OF IDENTIFYING
; TITLE OF INVENTION: REPLIKIN-CONTAINING SEQUENCES
; FILE REFERENCE: 09425-46902
; CURRENT APPLICATION NUMBER: US/09/984,057
; CURRENT FILING DATE: 2001-10-26
; PRIOR APPLICATION NUMBER: 60/303,396

```

; PRIOR FILING DATE: 2001-07-09
; PRIOR APPLICATION NUMBER: 60/278,761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: 09/146,755
; PRIOR FILING DATE: 1998-09-04
; PRIOR APPLICATION NUMBER: 09/817,144
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: 08/198,139
; PRIOR FILING DATE: 1994-02-17
; NUMBER OF SEQ ID NOS: 90
; SOFTWARE: PatentIn 2.1
; SEQ ID NO 45
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Arabidopsis thaliana
US-09-984-057-45

Query Match 27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 KKA 11
|||
Db 8 KKA 10

RESULT 45

US-09-846-352-1

; Sequence 1, Application US/09846352
; Patent No. US20020161187A1
; GENERAL INFORMATION:
; APPLICANT: Jackowski, George
; TITLE OF INVENTION: Biopolymer Marker Indicative of Disease State Having A
Molecular Weight
; TITLE OF INVENTION: of 1097
; TITLE OF INVENTION: Daltons
; FILE REFERENCE: 2132.027
; CURRENT APPLICATION NUMBER: US/09/846,352
; CURRENT FILING DATE: 2001-04-30
; NUMBER OF SEQ ID NOS: 1
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-846-352-1

Query Match 27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SAV 5
|||
Db 7 SAV 9

RESULT 46

US-09-805-301-5

; Sequence 5, Application US/09805301
; Patent No. US20020173456A1
; GENERAL INFORMATION:
; APPLICANT: Smith, Louis C.
; Sparrow, James T.
; Hauer, Jochen
; Mims, Martha P.
; TITLE OF INVENTION: LIPOPHILIC PEPTIDES FOR
; MACROMOLECULE DELIVERY
; NUMBER OF SEQUENCES: 139
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 6.0
; SOFTWARE: Word Perfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/805,301
; FILING DATE: 12-Mar-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/584,043
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 217/189
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 5:

US-09-805-301-5

Query Match 27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KKK 10
|||
Db 1 KKK 3

RESULT 47

US-09-805-301-43

; Sequence 43, Application US/09805301

; Patent No. US20020173456A1

; GENERAL INFORMATION:

; APPLICANT: Smith, Louis C.

; Sparrow, James T.

; Hauer, Jochen

; Mims, Martha P.

; TITLE OF INVENTION: LIPOPHILIC PEPTIDES FOR
; MACROMOLECULE DELIVERY

; NUMBER OF SEQUENCES: 139

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; Suite 4700

; CITY: Los Angeles

; STATE: California

; COUNTRY: U.S.A.

; ZIP: 90071-2066

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; storage

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C. DOS 6.0

; SOFTWARE: Word Perfect 6.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/805,301

; FILING DATE: 12-Mar-2001

; CLASSIFICATION: <Unknown>

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/584,043

; FILING DATE: <Unknown>

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard J.

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 217/189

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 43:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

; FEATURE:

; OTHER INFORMATION: "Xaa" stands for any naturally
; occurring amino acid and
; analogues thereof.

; SEQUENCE DESCRIPTION: SEQ ID NO: 43:

US-09-805-301-43

Query Match 27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KKK 10
|||
Db 1 KKK 3

RESULT 48

US-09-805-301-99

; Sequence 99, Application US/09805301

; Patent No. US20020173456A1

; GENERAL INFORMATION:

; APPLICANT: Smith, Louis C.
; Sparrow, James T.
; Hauer, Jochen
; Mims, Martha P.

; TITLE OF INVENTION: LIPOPHILIC PEPTIDES FOR
; MACROMOLECULE DELIVERY

; NUMBER OF SEQUENCES: 139

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 6.0
; SOFTWARE: Word Perfect 6.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/805,301
; FILING DATE: 12-Mar-2001
; CLASSIFICATION: <Unknown>

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/584,043
; FILING DATE: <Unknown>

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 217/189

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 99:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear

; MOLECULE TYPE: peptide

; SEQUENCE DESCRIPTION: SEQ ID NO: 99:
US-09-805-301-99

Query Match 27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KKK 10
|||
Db 1 KKK 3

RESULT 49

US-09-017-743C-121

; Sequence 121, Application US/09017743C

; Patent No. US20020177694A1

; GENERAL INFORMATION:

; APPLICANT: Sette, Alessandro

; Sidney, John

; Southwood, Scott

; TITLE OF INVENTION: HLA Binding Peptides and Their
Uses

; NUMBER OF SEQUENCES: 146

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Townsend and Townsend and Crew LLP

; STREET: Two Embarcadero Center, Eighth Floor

; CITY: San Francisco

; STATE: CA

; COUNTRY: USA

; ZIP: 94111-3834

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: DOS

; SOFTWARE: FastSEQ for Windows Version 2.0

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/017,743C

; FILING DATE: 03-Feb-1998

; CLASSIFICATION: <Unknown>

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/590,298

; FILING DATE: 23-JAN-1996

; ATTORNEY/AGENT INFORMATION:

; NAME: Parent, Annette S.

; REGISTRATION NUMBER: 42,058

; REFERENCE/DOCKET NUMBER: 018623-008050US

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 415-576-0200

; TELEFAX: 415-576-0300

; TELEX: <Unknown>

; INFORMATION FOR SEQ ID NO: 121:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

; SEQUENCE DESCRIPTION: SEQ ID NO: 121:
US-09-017-743C-121

Query Match 27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SAV 5
|||
Db 8 SAV 10

RESULT 50

US-09-999-724-76

; Sequence 76, Application US/09999724
; Publication No. US20030022355A1
; GENERAL INFORMATION:
; APPLICANT: WICKHAM, THOMAS J.
; APPLICANT: KOVESDI, IMRE
; APPLICANT: BROUGH, DOUGLAS E.
; TITLE OF INVENTION: VECTORS AND METHODS FOR GENE TRANSFER
; FILE REFERENCE: 212960
; CURRENT APPLICATION NUMBER: US/09/999,724
; CURRENT FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 09/101,751
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: WO 96US19150
; PRIOR FILING DATE: 1996-11-27
; PRIOR APPLICATION NUMBER: US 08/700,846
; PRIOR FILING DATE: 1996-08-21
; PRIOR APPLICATION NUMBER: US 08/701,124
; PRIOR FILING DATE: 1996-08-21
; PRIOR APPLICATION NUMBER: US 08/563,368
; PRIOR FILING DATE: 1995-11-28
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 76
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-999-724-76

Query Match 27.3%; Score 3; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KKK 10
|||
Db 3 KKK 5

RESULT 51

US-09-229-173-41

; Sequence 41, Application US/09229173
; Publication No. US20030027296A1

```

; GENERAL INFORMATION:
;   APPLICANT: Chatterjee, Deb K.
;   TITLE OF INVENTION: Cloned DNA Polymerases from Thermotoga
;   TITLE OF INVENTION: maritima and Mutants Thereof
;   NUMBER OF SEQUENCES: 47
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: STERNE, KESSLER, GOLDSTEIN & FOX, P.L.L.C.
;     STREET: 1100 New York Ave., N.W., Suite 600
;     CITY: Washington
;     STATE: DC
;     COUNTRY: USA
;     ZIP: 20005-3934
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: Floppy disk
;     COMPUTER: IBM PC compatible
;     OPERATING SYSTEM: PC-DOS/MS-DOS
;     SOFTWARE: PatentIn Release #1.0, Version #1.30
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/09/229,173
;     FILING DATE: 13-JAN-1999
;     CLASSIFICATION: 435
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: US 08/706,702
;     FILING DATE: 06-SEP-1996
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: US 08/689,807
;     FILING DATE: 14-AUG-1996
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: US 08/537,400
;     FILING DATE: 02-OCT-1995
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: US 08/576,759
;     FILING DATE: 21-DEC-1995
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: US 08/537,397
;     FILING DATE: 02-OCT-1995
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: US 08/525,057
;     FILING DATE: 08-SEP-1995
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Millonig, Robert C.
;     REGISTRATION NUMBER: 34,395
;     REFERENCE/DOCKET NUMBER: 0942.2800008
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: 202-371-2600
;     TELEFAX: 202-371-2540
;   INFORMATION FOR SEQ ID NO: 41:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH: 11 amino acids
;       TYPE: amino acid
;       STRANDEDNESS: single
;       TOPOLOGY: not relevant
;     MOLECULE TYPE: peptide
US-09-229-173-41

```

```

Query Match          27.3%; Score 3; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;

```

Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKK 9
|||
Db 6 LKK 8

RESULT 52

US-09-259-658-44

; Sequence 44, Application US/09259658

; Publication No. US20030032054A1

; GENERAL INFORMATION:

; APPLICANT: Colyer

; APPLICANT: Craig

; APPLICANT: Maschio

; APPLICANT: Mezna

; TITLE OF INVENTION: Compositions And Methods For Monitoring The

; TITLE OF INVENTION: Modification State Of A Pair Of Polypeptides

; FILE REFERENCE: colyer 4256/79245

; CURRENT APPLICATION NUMBER: US/09/259,658

; CURRENT FILING DATE: 1999-02-26

; NUMBER OF SEQ ID NOS: 59

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 44

; LENGTH: 11

; TYPE: PRT

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence:Synthetic

; OTHER INFORMATION: peptide based upon p67srf glycosylation acceptor

; OTHER INFORMATION: site.

US-09-259-658-44

Query Match 27.3%; Score 3; DB 10; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.5e+04;

Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SAV 5
|||
Db 1 SAV 3

RESULT 53

US-09-906-393A-5

; Sequence 5, Application US/09906393A

; Publication No. US20030039970A1

; GENERAL INFORMATION:

; APPLICANT: Wang, Zhou

; APPLICANT: Xiao, Wuhan

; TITLE OF INVENTION: METHOD OF PROGNOSING CANCER AND THE PROTEINS INVOLVED

; FILE REFERENCE: 1720-1-001CIP

; CURRENT APPLICATION NUMBER: US/09/906,393A

; CURRENT FILING DATE: 2001-07-16

; PRIOR APPLICATION NUMBER: 60/218,761

; PRIOR FILING DATE: 2000-07-17

; NUMBER OF SEQ ID NOS: 36

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 5
; LENGTH: 11
; TYPE: PRT
; ORGANISM: homo sapiens
US-09-906-393A-5

Query Match 27.3%; Score 3; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 VKL 7
|||
Db 6 VKL 8

RESULT 54
US-09-882-291-55
; Sequence 55, Application US/09882291
; Publication No. US20030040472A1
; GENERAL INFORMATION:
; APPLICANT: Zealand Pharmaceuticals A/S
; TITLE OF INVENTION: No. US20030040472A1el Peptide Conjugates
; FILE REFERENCE: 007-2001
; CURRENT APPLICATION NUMBER: US/09/882,291
; CURRENT FILING DATE: 2001-06-15
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 55
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic peptide
sequence
US-09-882-291-55

Query Match 27.3%; Score 3; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KKK 10
|||
Db 6 KKK 8

RESULT 55
US-09-882-291-64
; Sequence 64, Application US/09882291
; Publication No. US20030040472A1
; GENERAL INFORMATION:
; APPLICANT: Zealand Pharmaceuticals A/S
; TITLE OF INVENTION: No. US20030040472A1el Peptide Conjugates
; FILE REFERENCE: 007-2001
; CURRENT APPLICATION NUMBER: US/09/882,291
; CURRENT FILING DATE: 2001-06-15
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 64
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic peptide
sequence
US-09-882-291-64

Query Match 27.3%; Score 3; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KKK 10
|||
Db 6 KKK 8

RESULT 56

US-09-929-266-2
; Sequence 2, Application US/09929266
; Publication No. US20030045694A1
; GENERAL INFORMATION:
; APPLICANT: Brian T. Chait
; APPLICANT: Darin R. Latimer
; APPLICANT: Paul M. Lizardi
; APPLICANT: Eric R. Kershner
; APPLICANT: Jon S. Morrow
; APPLICANT: Matthew E. Roth
; APPLICANT: Martin J. Mattessich
; APPLICANT: Kevin J. McConnell
; TITLE OF INVENTION: ULTRA-SENSITIVE DETECTION SYSTEMS
; FILE REFERENCE: 01173.0003U2
; CURRENT APPLICATION NUMBER: US/09/929,266
; CURRENT FILING DATE: 2001-08-13
; PRIOR APPLICATION NUMBER: 60/224,939
; PRIOR FILING DATE: 2000-08-11
; PRIOR APPLICATION NUMBER: 60/283,498
; PRIOR FILING DATE: 2000-04-12
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence; No.
US20030045694A1=synthetic
; OTHER INFORMATION: construct
US-09-929-266-2

Query Match 27.3%; Score 3; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGS 3
|||

Db 1 AGS 3

RESULT 57

US-09-929-266-4

; Sequence 4, Application US/09929266
; Publication No. US20030045694A1
; GENERAL INFORMATION:
; APPLICANT: Brian T. Chait
; APPLICANT: Darin R. Latimer
; APPLICANT: Paul M. Lizardi
; APPLICANT: Eric R. Kershner
; APPLICANT: Jon S. Morrow
; APPLICANT: Matthew E. Roth
; APPLICANT: Martin J. Mattessich
; APPLICANT: Kevin J. McConnell
; TITLE OF INVENTION: ULTRA-SENSITIVE DETECTION SYSTEMS
; FILE REFERENCE: 01173.0003U2
; CURRENT APPLICATION NUMBER: US/09/929,266
; CURRENT FILING DATE: 2001-08-13
; PRIOR APPLICATION NUMBER: 60/224,939
; PRIOR FILING DATE: 2000-08-11
; PRIOR APPLICATION NUMBER: 60/283,498
; PRIOR FILING DATE: 2000-04-12
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence; No.
US20030045694A1=synthetic
; OTHER INFORMATION: construct
US-09-929-266-4

Query Match 27.3%; Score 3; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGS 3
|||
Db 1 AGS 3

RESULT 58

US-09-929-266-7

; Sequence 7, Application US/09929266
; Publication No. US20030045694A1
; GENERAL INFORMATION:
; APPLICANT: Brian T. Chait
; APPLICANT: Darin R. Latimer
; APPLICANT: Paul M. Lizardi
; APPLICANT: Eric R. Kershner
; APPLICANT: Jon S. Morrow
; APPLICANT: Matthew E. Roth
; APPLICANT: Martin J. Mattessich

```
; APPLICANT: Kevin J. McConnell
; TITLE OF INVENTION: ULTRA-SENSITIVE DETECTION SYSTEMS
; FILE REFERENCE: 01173.0003U2
; CURRENT APPLICATION NUMBER: US/09/929,266
; CURRENT FILING DATE: 2001-08-13
; PRIOR APPLICATION NUMBER: 60/224,939
; PRIOR FILING DATE: 2000-08-11
; PRIOR APPLICATION NUMBER: 60/283,498
; PRIOR FILING DATE: 2000-04-12
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence; No.
US20030045694A1=synthetic
; OTHER INFORMATION: construct
US-09-929-266-7
```

```
Query Match          27.3%; Score 3; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;
```

```
Qy          1 AGS 3
            |||
Db          1 AGS 3
```

RESULT 59

```
US-09-929-266-8
; Sequence 8, Application US/09929266
; Publication No. US20030045694A1
; GENERAL INFORMATION:
; APPLICANT: Brian T. Chait
; APPLICANT: Darin R. Latimer
; APPLICANT: Paul M. Lizardi
; APPLICANT: Eric R. Kershner
; APPLICANT: Jon S. Morrow
; APPLICANT: Matthew E. Roth
; APPLICANT: Martin J. Mattessich
; APPLICANT: Kevin J. McConnell
; TITLE OF INVENTION: ULTRA-SENSITIVE DETECTION SYSTEMS
; FILE REFERENCE: 01173.0003U2
; CURRENT APPLICATION NUMBER: US/09/929,266
; CURRENT FILING DATE: 2001-08-13
; PRIOR APPLICATION NUMBER: 60/224,939
; PRIOR FILING DATE: 2000-08-11
; PRIOR APPLICATION NUMBER: 60/283,498
; PRIOR FILING DATE: 2000-04-12
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
```

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence; No.
US20030045694A1=synthetic
; OTHER INFORMATION: construct
US-09-929-266-8

Query Match 27.3%; Score 3; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGS 3
|||
Db 7 AGS 9

RESULT 60

US-09-929-266-27

; Sequence 27, Application US/09929266
; Publication No. US20030045694A1
; GENERAL INFORMATION:
; APPLICANT: Brian T. Chait
; APPLICANT: Darin R. Latimer
; APPLICANT: Paul M. Lizardi
; APPLICANT: Eric R. Kershner
; APPLICANT: Jon S. Morrow
; APPLICANT: Matthew E. Roth
; APPLICANT: Martin J. Mattessich
; APPLICANT: Kevin J. McConnell
; TITLE OF INVENTION: ULTRA-SENSITIVE DETECTION SYSTEMS
; FILE REFERENCE: 01173.0003U2
; CURRENT APPLICATION NUMBER: US/09/929,266
; CURRENT FILING DATE: 2001-08-13
; PRIOR APPLICATION NUMBER: 60/224,939
; PRIOR FILING DATE: 2000-08-11
; PRIOR APPLICATION NUMBER: 60/283,498
; PRIOR FILING DATE: 2000-04-12
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 27
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence; No.
US20030045694A1=synthetic
; OTHER INFORMATION: construct
US-09-929-266-27

Query Match 27.3%; Score 3; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGS 3
|||
Db 1 AGS 3

RESULT 61

US-09-876-904A-25

; Sequence 25, Application US/09876904A
 ; Publication No. US20030072794A1
 ; GENERAL INFORMATION:
 ; APPLICANT: BOULIKAS, TENI
 ; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND THERAPEUTIC
 ; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC PEPTIDE
 ; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES
 ; FILE REFERENCE: TB-2002.00
 ; CURRENT APPLICATION NUMBER: US/09/876,904A
 ; CURRENT FILING DATE: 2001-06-08
 ; PRIOR APPLICATION NUMBER: US 60/210,925
 ; PRIOR FILING DATE: 2000-06-09
 ; NUMBER OF SEQ ID NOS: 629
 ; SOFTWARE: PatentIn Ver. 2.1
 ; SEQ ID NO 25
 ; LENGTH: 11
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic SV40 large T
 ; OTHER INFORMATION: protein
 US-09-876-904A-25

Query Match 27.3%; Score 3; DB 10; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+04;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KKK 10
 |||
 Db 5 KKK 7

RESULT 62

US-09-876-904A-77

; Sequence 77, Application US/09876904A
 ; Publication No. US20030072794A1
 ; GENERAL INFORMATION:
 ; APPLICANT: BOULIKAS, TENI
 ; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND THERAPEUTIC
 ; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC PEPTIDE
 ; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES
 ; FILE REFERENCE: TB-2002.00
 ; CURRENT APPLICATION NUMBER: US/09/876,904A
 ; CURRENT FILING DATE: 2001-06-08
 ; PRIOR APPLICATION NUMBER: US 60/210,925
 ; PRIOR FILING DATE: 2000-06-09
 ; NUMBER OF SEQ ID NOS: 629
 ; SOFTWARE: PatentIn Ver. 2.1
 ; SEQ ID NO 77
 ; LENGTH: 11

; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
crosslinked
; OTHER INFORMATION: to bovine serum albumin
US-09-876-904A-77

Query Match 27.3%; Score 3; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KKK 10
|||
Db 6 KKK 8

RESULT 63

US-09-876-904A-113
; Sequence 113, Application US/09876904A
; Publication No. US20030072794A1
; GENERAL INFORMATION:
; APPLICANT: BOULIKAS, TENI
; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND
THERAPEUTIC
; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC
PEPTIDE
; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES
; FILE REFERENCE: TB-2002.00
; CURRENT APPLICATION NUMBER: US/09/876,904A
; CURRENT FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/210,925
; PRIOR FILING DATE: 2000-06-09
; NUMBER OF SEQ ID NOS: 629
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 113
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic c-Myc and
HIV
; OTHER INFORMATION: Tat NLSs
US-09-876-904A-113

Query Match 27.3%; Score 3; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 VKL 7
|||
Db 3 VKL 5

RESULT 64

US-09-876-904A-273
; Sequence 273, Application US/09876904A

```

; Publication No. US20030072794A1
; GENERAL INFORMATION:
; APPLICANT: BOULIKAS, TENI
; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND
THERAPEUTIC
; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC
PEPTIDE
; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES
; FILE REFERENCE: TB-2002.00
; CURRENT APPLICATION NUMBER: US/09/876,904A
; CURRENT FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/210,925
; PRIOR FILING DATE: 2000-06-09
; NUMBER OF SEQ ID NOS: 629
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 273
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Drosophila sp.
; FEATURE:
; OTHER INFORMATION: Recombination repair protein 1
US-09-876-904A-273

```

```

Query Match          27.3%; Score 3; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      8 KKK 10
      |||
Db      6 KKK 8

```

```

RESULT 65
US-09-876-904A-354
; Sequence 354, Application US/09876904A
; Publication No. US20030072794A1
; GENERAL INFORMATION:
; APPLICANT: BOULIKAS, TENI
; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND
THERAPEUTIC
; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC
PEPTIDE
; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES
; FILE REFERENCE: TB-2002.00
; CURRENT APPLICATION NUMBER: US/09/876,904A
; CURRENT FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/210,925
; PRIOR FILING DATE: 2000-06-09
; NUMBER OF SEQ ID NOS: 629
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 354
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Human ATF-3 (in basic region that binds DNA)
US-09-876-904A-354

```

Query Match 27.3%; Score 3; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KKK 10
|||
Db 6 KKK 8

RESULT 66

US-09-876-904A-362

; Sequence 362, Application US/09876904A
; Publication No. US20030072794A1
; GENERAL INFORMATION:
; APPLICANT: BOULIKAS, TENI
; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND
THERAPEUTIC
; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC
PEPTIDE
; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES
; FILE REFERENCE: TB-2002.00
; CURRENT APPLICATION NUMBER: US/09/876,904A
; CURRENT FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/210,925
; PRIOR FILING DATE: 2000-06-09
; NUMBER OF SEQ ID NOS: 629
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 362
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Mus sp.
; FEATURE:
; OTHER INFORMATION: Murine LEF-1.
US-09-876-904A-362

Query Match 27.3%; Score 3; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KKK 10
|||
Db 2 KKK 4

RESULT 67

US-09-876-904A-363

; Sequence 363, Application US/09876904A
; Publication No. US20030072794A1
; GENERAL INFORMATION:
; APPLICANT: BOULIKAS, TENI
; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND
THERAPEUTIC
; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC
PEPTIDE
; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES
; FILE REFERENCE: TB-2002.00

; CURRENT APPLICATION NUMBER: US/09/876,904A
; CURRENT FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/210,925
; PRIOR FILING DATE: 2000-06-09
; NUMBER OF SEQ ID NOS: 629
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 363
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Human TCF-1 alpha.
US-09-876-904A-363

Query Match 27.3%; Score 3; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KKK 10
|||
Db 2 KKK 4

RESULT 68

US-09-876-904A-364

; Sequence 364, Application US/09876904A
; Publication No. US20030072794A1
; GENERAL INFORMATION:
; APPLICANT: BOULIKAS, TENI
; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND
THERAPEUTIC
; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC
PEPTIDE
; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES
; FILE REFERENCE: TB-2002.00
; CURRENT APPLICATION NUMBER: US/09/876,904A
; CURRENT FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/210,925
; PRIOR FILING DATE: 2000-06-09
; NUMBER OF SEQ ID NOS: 629
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 364
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Human TCF-1
US-09-876-904A-364

Query Match 27.3%; Score 3; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KKK 10
|||
Db 2 KKK 4

RESULT 69

US-09-876-904A-373

; Sequence 373, Application US/09876904A
 ; Publication No. US20030072794A1
 ; GENERAL INFORMATION:
 ; APPLICANT: BOULIKAS, TENI
 ; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND THERAPEUTIC
 ; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC PEPTIDE
 ; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES
 ; FILE REFERENCE: TB-2002.00
 ; CURRENT APPLICATION NUMBER: US/09/876,904A
 ; CURRENT FILING DATE: 2001-06-08
 ; PRIOR APPLICATION NUMBER: US 60/210,925
 ; PRIOR FILING DATE: 2000-06-09
 ; NUMBER OF SEQ ID NOS: 629
 ; SOFTWARE: PatentIn Ver. 2.1
 ; SEQ ID NO 373
 ; LENGTH: 11
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; FEATURE:
 ; OTHER INFORMATION: MBP-1 (class I MHC enhancer binding protein
 ; OTHER INFORMATION: 1) mw 200 kD.
 US-09-876-904A-373

Query Match 27.3%; Score 3; DB 10; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+04;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KKK 10
 |||
 Db 3 KKK 5

RESULT 70

US-09-876-904A-542

; Sequence 542, Application US/09876904A
 ; Publication No. US20030072794A1
 ; GENERAL INFORMATION:
 ; APPLICANT: BOULIKAS, TENI
 ; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND THERAPEUTIC
 ; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC PEPTIDE
 ; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES
 ; FILE REFERENCE: TB-2002.00
 ; CURRENT APPLICATION NUMBER: US/09/876,904A
 ; CURRENT FILING DATE: 2001-06-08
 ; PRIOR APPLICATION NUMBER: US 60/210,925
 ; PRIOR FILING DATE: 2000-06-09
 ; NUMBER OF SEQ ID NOS: 629
 ; SOFTWARE: PatentIn Ver. 2.1
 ; SEQ ID NO 542
 ; LENGTH: 11

; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Human S6 ribosomal protein (homologous to yeast
; OTHER INFORMATION: S10).
US-09-876-904A-542

Query Match 27.3%; Score 3; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKK 9
|||
Db 1 LKK 3

RESULT 71

US-09-876-904A-591
; Sequence 591, Application US/09876904A
; Publication No. US20030072794A1
; GENERAL INFORMATION:
; APPLICANT: BOULIKAS, TENI
; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND
THERAPEUTIC
; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC
PEPTIDE
; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES
; FILE REFERENCE: TB-2002.00
; CURRENT APPLICATION NUMBER: US/09/876,904A
; CURRENT FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/210,925
; PRIOR FILING DATE: 2000-06-09
; NUMBER OF SEQ ID NOS: 629
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 591
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Trout testis H1 (194
aa).
US-09-876-904A-591

Query Match 27.3%; Score 3; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 KKA 11
|||
Db 6 KKA 8

RESULT 72

US-09-876-904A-622
; Sequence 622, Application US/09876904A
; Publication No. US20030072794A1
; GENERAL INFORMATION:

; APPLICANT: BOULIKAS, TENI
 ; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND
 THERAPEUTIC
 ; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC
 PEPTIDE
 ; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES
 ; FILE REFERENCE: TB-2002.00
 ; CURRENT APPLICATION NUMBER: US/09/876,904A
 ; CURRENT FILING DATE: 2001-06-08
 ; PRIOR APPLICATION NUMBER: US 60/210,925
 ; PRIOR FILING DATE: 2000-06-09
 ; NUMBER OF SEQ ID NOS: 629
 ; SOFTWARE: PatentIn Ver. 2.1
 ; SEQ ID NO 622
 ; LENGTH: 11
 ; TYPE: PRT
 ; ORGANISM: Unknown Organism
 ; FEATURE:
 ; OTHER INFORMATION: Description of Unknown Organism: Trout testis H6 (60 aa).
 US-09-876-904A-622

Query Match 27.3%; Score 3; DB 10; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+04;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 KKA 11
 |||
 Db 3 KKA 5

RESULT 73
 US-09-820-053A-126
 ; Sequence 126, Application US/09820053A
 ; Publication No. US20030083243A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Owen, Donald R.
 ; TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES
 ; FILE REFERENCE: HELX027
 ; CURRENT APPLICATION NUMBER: US/09/820,053A
 ; CURRENT FILING DATE: 2001-03-28
 ; NUMBER OF SEQ ID NOS: 165
 ; SOFTWARE: PatentIn Ver. 2.1
 ; SEQ ID NO 126
 ; LENGTH: 11
 ; TYPE: PRT
 ; ORGANISM: ARTIFICIAL SEQUENCE
 ; FEATURE:
 ; OTHER INFORMATION: SYNTHETIC SEQUENCE
 ; NAME/KEY: MOD_RES
 ; LOCATION: (11)
 ; OTHER INFORMATION: AMIDATION
 US-09-820-053A-126

Query Match 27.3%; Score 3; DB 10; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+04;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKK 9
| | |
Db 8 LKK 10

RESULT 74

US-09-820-053A-127
; Sequence 127, Application US/09820053A
; Publication No. US20030083243A1
; GENERAL INFORMATION:
; APPLICANT: Owen, Donald R.
; TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES
; FILE REFERENCE: HELX027
; CURRENT APPLICATION NUMBER: US/09/820,053A
; CURRENT FILING DATE: 2001-03-28
; NUMBER OF SEQ ID NOS: 165
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 127
; LENGTH: 11
; TYPE: PRT
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: SYNTHETIC SEQUENCE
; NAME/KEY: MOD_RES
; LOCATION: (11)
; OTHER INFORMATION: AMIDATION
US-09-820-053A-127

Query Match 27.3%; Score 3; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKK 9
| | |
Db 7 LKK 9

RESULT 75

US-09-820-053A-132
; Sequence 132, Application US/09820053A
; Publication No. US20030083243A1
; GENERAL INFORMATION:
; APPLICANT: Owen, Donald R.
; TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES
; FILE REFERENCE: HELX027
; CURRENT APPLICATION NUMBER: US/09/820,053A
; CURRENT FILING DATE: 2001-03-28
; NUMBER OF SEQ ID NOS: 165
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 132
; LENGTH: 11
; TYPE: PRT
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: SYNTHETIC SEQUENCE
; NAME/KEY: MOD_RES
; LOCATION: (11)

; OTHER INFORMATION: AMIDATION
US-09-820-053A-132

Query Match 27.3%; Score 3; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKK 9
|||
Db 7 LKK 9

Search completed: April 8, 2004, 16:35:34
Job time : 31.3077 secs

OM protein - protein search, using sw model

Run on: April 8, 2004, 15:30:07 ; Search time 27.7692 Seconds
(without alignments)
124.984 Million cell updates/sec

Title: US-09-787-443A-4
Perfect score: 11
Sequence: 1 AGSAVKLKKKA 11

Scoring table: OLIGO
Gapop 60.0 , Gapext 60.0

Searched: 1017041 seqs, 315518202 residues

Word size : 0

Total number of hits satisfying chosen parameters: 460

Minimum DB seq length: 11
Maximum DB seq length: 11

Post-processing: Listing first 100 summaries

Database : SPTREMBL 25:*
1: sp_archaea:*
2: sp_bacteria:*
3: sp_fungi:*
4: sp_human:*
5: sp_invertebrate:*
6: sp_mammal:*
7: sp_mhc:*
8: sp_organelle:*
9: sp_phage:*
10: sp_plant:*
11: sp_rodent:*
12: sp_virus:*
13: sp_vertebrate:*
14: sp_unclassified:*
15: sp_rvirus:*
16: sp_bacteriap:*
17: sp_archeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

%
Result Query
No. Score Match Length DB ID Description

1	3	27.3	11	2	Q9S618	Q9s618	prochloroco
2	3	27.3	11	2	Q44090	Q44090	acholeplasm
3	3	27.3	11	3	Q9HDR9	Q9hdr9	aspergillus
4	3	27.3	11	3	O43131	O43131	aspergillus
5	3	27.3	11	3	Q9HDR8	Q9hdr8	aspergillus
6	3	27.3	11	3	Q9HDR7	Q9hdr7	aspergillus
7	3	27.3	11	3	O42762	O42762	aspergillus
8	3	27.3	11	3	O43130	O43130	aspergillus
9	3	27.3	11	3	Q9HDS3	Q9hds3	aspergillus
10	3	27.3	11	5	Q86D32	Q86d32	trypanosoma
11	3	27.3	11	5	Q86D31	Q86d31	trypanosoma
12	3	27.3	11	7	O77908	O77908	oreochromis
13	3	27.3	11	11	Q9QXM6	Q9qxm6	mus musculus
14	2	18.2	11	2	O68237	O68237	borrelia bu
15	2	18.2	11	2	Q9R790	Q9r790	borrelia ga
16	2	18.2	11	2	Q8RKN1	Q8rkn1	escherichia
17	2	18.2	11	2	Q9L4F7	Q9l4f7	bacillus ce
18	2	18.2	11	2	Q8L2T4	Q8l2t4	neisseria m
19	2	18.2	11	2	Q9R5P3	Q9r5p3	serratia ma
20	2	18.2	11	2	P77404	P77404	escherichia
21	2	18.2	11	2	Q93RM6	Q93rm6	staphylococ
22	2	18.2	11	2	P71228	P71228	escherichia
23	2	18.2	11	2	Q9K332	Q9k332	staphylococ
24	2	18.2	11	2	Q9RFZ2	Q9rfz2	mycoplasma
25	2	18.2	11	2	P95518	P95518	pasteurella
26	2	18.2	11	2	Q47604	Q47604	escherichia
27	2	18.2	11	2	Q44237	Q44237	anabaena sp
28	2	18.2	11	2	Q9R872	Q9r872	escherichia
29	2	18.2	11	2	Q9R446	Q9r446	neisseria g
30	2	18.2	11	2	Q8GMU3	Q8gmu3	acinetobact
31	2	18.2	11	2	Q8GL24	Q8gl24	borrelia bu
32	2	18.2	11	2	Q8GL19	Q8gl19	borrelia bu
33	2	18.2	11	2	P83537	P83537	lactobacill
34	2	18.2	11	2	Q47569	Q47569	escherichia
35	2	18.2	11	2	Q7WUL8	Q7wul8	pseudomonas
36	2	18.2	11	3	O42763	O42763	aspergillus
37	2	18.2	11	3	Q9UR95	Q9ur95	pichia angu
38	2	18.2	11	3	Q9HFN8	Q9hfn8	candida rug
39	2	18.2	11	3	Q9URG1	Q9urg1	neurospora
40	2	18.2	11	3	O60005	O60005	aspergillus
41	2	18.2	11	3	O60007	O60007	emerella
42	2	18.2	11	3	O60192	O60192	aspergillus
43	2	18.2	11	3	O60006	O60006	aspergillus
44	2	18.2	11	4	Q9Y3G2	Q9y3g2	homo sapien
45	2	18.2	11	4	O60761	O60761	homo sapien
46	2	18.2	11	4	Q9H4H5	Q9h4h5	homo sapien
47	2	18.2	11	4	Q15997	Q15997	homo sapien
48	2	18.2	11	4	Q9UCP5	Q9ucp5	homo sapien
49	2	18.2	11	4	Q16234	Q16234	homo sapien
50	2	18.2	11	4	Q9C057	Q9c057	homo sapien
51	2	18.2	11	4	Q8NFN9	Q8nfn9	homo sapien
52	2	18.2	11	4	Q8NI03	Q8ni03	homo sapien
53	2	18.2	11	4	Q8TDA8	Q8tda8	homo sapien
54	2	18.2	11	4	Q9UC46	Q9uc46	homo sapien
55	2	18.2	11	4	Q9UH72	Q9uh72	homo sapien
56	2	18.2	11	5	Q26092	Q26092	pisaster oc
57	2	18.2	11	5	P82698	P82698	leucophaea

58	2	18.2	11	5	P82699	P82699	leucophaea
59	2	18.2	11	5	P82700	P82700	leucophaea
60	2	18.2	11	5	Q95PX6	Q95px6	caenorhabdi
61	2	18.2	11	6	Q9BDC8	Q9bdc8	pongo pygma
62	2	18.2	11	6	Q95J20	Q95j20	eulemur ful
63	2	18.2	11	6	Q9XSP7	Q9xsp7	pygathrix n
64	2	18.2	11	6	Q9TTQ0	Q9ttq0	gorilla gor
65	2	18.2	11	6	Q9XSP2	Q9xsp2	hylobates s
66	2	18.2	11	6	Q9BDQ9	Q9bdq9	gorilla gor
67	2	18.2	11	6	Q95NB6	Q95nb6	eulemur ful
68	2	18.2	11	6	Q9XSP5	Q9xsp5	pan troglod
69	2	18.2	11	6	Q95J19	Q95j19	eulemur ful
70	2	18.2	11	6	Q9TQS0	Q9tqs0	bos taurus
71	2	18.2	11	6	Q9BDD0	Q9bdd0	pan troglod
72	2	18.2	11	6	Q9XSP8	Q9xsp8	presbytis j
73	2	18.2	11	6	Q9XSP6	Q9xsp6	pongo pygma
74	2	18.2	11	6	Q9BDC9	Q9bdc9	pan paniscu
75	2	18.2	11	6	Q9XSQ4	Q9xsq4	gorilla gor
76	2	18.2	11	7	O77898	O77898	oreochromis
77	2	18.2	11	7	O77914	O77914	oreochromis
78	2	18.2	11	7	O78119	O78119	oreochromis
79	2	18.2	11	7	O78118	O78118	oreochromis
80	2	18.2	11	7	O77892	O77892	oreochromis
81	2	18.2	11	7	O77880	O77880	oreochromis
82	2	18.2	11	7	O77895	O77895	oreochromis
83	2	18.2	11	7	O78120	O78120	oreochromis
84	2	18.2	11	7	O77906	O77906	oreochromis
85	2	18.2	11	7	O77896	O77896	oreochromis
86	2	18.2	11	7	O77893	O77893	oreochromis
87	2	18.2	11	7	O77913	O77913	oreochromis
88	2	18.2	11	7	O77894	O77894	oreochromis
89	2	18.2	11	7	O77907	O77907	oreochromis
90	2	18.2	11	7	O77897	O77897	oreochromis
91	2	18.2	11	7	Q7YP62	Q7yp62	homo sapien
92	2	18.2	11	8	Q8HGX5	Q8hgx5	rhabdothamn
93	2	18.2	11	8	Q7YKC6	Q7ykc6	ribes cereu
94	2	18.2	11	8	Q7YKA6	Q7yka6	itea ilicif
95	2	18.2	11	8	Q7YK19	Q7yk19	pseudosaman
96	2	18.2	11	8	Q7YK05	Q7yk05	acacia roem
97	2	18.2	11	8	Q7YK03	Q7yk03	acacia schw
98	2	18.2	11	9	Q38415	Q38415	bacteriopha
99	2	18.2	11	9	Q9T0R6	Q9t0r6	bacteriopha
100	2	18.2	11	9	Q37925	Q37925	bacteriopha

ALIGNMENTS

RESULT 1

Q9S618

ID Q9S618 PRELIMINARY; PRT; 11 AA.

AC Q9S618;

DT 01-MAY-2000 (TrEMBLrel. 13, Created)

DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)

DT 01-MAY-2000 (TrEMBLrel. 13, Last annotation update)

DE Cytochrome b6/f complex subunit IV (Fragment).

GN PETD.

OS Prochlorococcus sp.
 OC Bacteria; Cyanobacteria; Prochlorophytes; Prochlorococcaceae;
 OC Prochlorococcus.
 OX NCBI_TaxID=1220;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Urbach E., Chisholm S.W.;
 RT "Genetic diversity in Prochlorococcus populations flow cytometrically
 RT sorted from the Sargasso Sea and Gulf Stream.";
 RL Limnol. Oceanog. 43:1615-1630(1998).
 DR EMBL; AF070132; AAD20740.1; -.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1297 MW; 5CC38013B7633337 CRC64;

Query Match 27.3%; Score 3; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+04;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LKK 9
 |||
 Db 4 LKK 6

RESULT 2

Q44090
 ID Q44090 PRELIMINARY; PRT; 11 AA.
 AC Q44090;
 DT 01-NOV-1996 (TrEMBLrel. 01, Created)
 DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE Hypothetical export segment (Fragment).
 OS Acholeplasma laidlawii.
 OC Bacteria; Firmicutes; Mollicutes; Acholeplasmatales;
 OC Acholeplasmataceae; Acholeplasma.
 OX NCBI_TaxID=2148;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=A-EF22;
 RA Boyer M.J., Jarhede T.K., Tegman V., Wieslander A.;
 RT "Sequence regions from Acholeplasma laidlawii which restore export of
 RT beta-lactamase in Escherichia coli.";
 RL Submitted (JUN-1993) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; Z22875; CAA80495.1; -.
 DR PIR; S33519; S33519.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1234 MW; 5C9D2AE8A682C337 CRC64;

Query Match 27.3%; Score 3; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+04;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KKK 8
 |||
 Db 3 KKK 5

RESULT 3

Q9HDR9

ID Q9HDR9 PRELIMINARY; PRT; 11 AA.
AC Q9HDR9;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-MAR-2001 (TrEMBLrel. 16, Last annotation update)
DE TrpC polyprotein (Fragment).
GN TRPC.
OS *Aspergillus oryzae*.
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
OC Eurotiales; Trichocomaceae; mitosporic Trichocomaceae; *Aspergillus*.
OX NCBI_TaxID=5062;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=NRRL 448;
RA Geiser D.M., Dorner J.W., Horn B.W., Taylor J.W.;
RT "The phylogenetics of mycotoxin and sclerotium production in
RT *Aspergillus flavus* and *Aspergillus oryzae*."
RL Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
DR EMBL; AF261875; AAG16149.1; -.
KW Polyprotein.
FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1139 MW; 8FBEEBD3BAE72AB5 CRC64;

Query Match 27.3%; Score 3; DB 3; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGS 3
|||
Db 2 AGS 4

RESULT 4

O43131

ID O43131 PRELIMINARY; PRT; 11 AA.
AC O43131; Q9P8G6;
DT 01-JUN-1998 (TrEMBLrel. 06, Created)
DT 01-JUN-1998 (TrEMBLrel. 06, Last sequence update)
DT 01-MAR-2001 (TrEMBLrel. 16, Last annotation update)
DE TRPC polyprotein (Fragment).
GN TRPC.
OS *Aspergillus flavus*.
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
OC Eurotiales; Trichocomaceae; mitosporic Trichocomaceae; *Aspergillus*.
OX NCBI_TaxID=5059;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Various strains;
RX MEDLINE=98081883; PubMed=9419385;
RA Geiser D.M., Pitt J.I., Taylor J.W.;
RT "Cryptic speciation and recombination in the aflatoxin-producing
RT fungus *Aspergillus flavus*."
RL Proc. Natl. Acad. Sci. U.S.A. 95:388-393(1998).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=11-4;

RA Geiser D.M., Dorner J.W., Horn B.W., Taylor J.W.;
 RT "The phylogenetics of mycotoxin and sclerotium production in
 RT Aspergillus flavus and Aspergillus oryzae.";
 RL Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
 RN [3]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Various strains;
 RA Geiser D.M., Dorner J.W., Horn B.W., Taylor J.W.;
 RT "The phylogenetics of mycotoxin and sclerotium production in
 RT Aspergillus flavus and Aspergillus oryzae.";
 RL Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AF036867; AAC01702.1; -.
 DR EMBL; AF036851; AAC01686.1; -.
 DR EMBL; AF036852; AAC01687.1; -.
 DR EMBL; AF036853; AAC01688.1; -.
 DR EMBL; AF036854; AAC01689.1; -.
 DR EMBL; AF036855; AAC01690.1; -.
 DR EMBL; AF036856; AAC01691.1; -.
 DR EMBL; AF036858; AAC01693.1; -.
 DR EMBL; AF036859; AAC01694.1; -.
 DR EMBL; AF036860; AAC01695.1; -.
 DR EMBL; AF036861; AAC01696.1; -.
 DR EMBL; AF036862; AAC01697.1; -.
 DR EMBL; AF036863; AAC01698.1; -.
 DR EMBL; AF036864; AAC01699.1; -.
 DR EMBL; AF036865; AAC01700.1; -.
 DR EMBL; AF036866; AAC01701.1; -.
 DR EMBL; AF262378; AAF73005.1; -.
 DR EMBL; AF261878; AAG16152.1; -.
 DR EMBL; AF261863; AAG16137.1; -.
 DR EMBL; AF261864; AAG16138.1; -.
 DR EMBL; AF261866; AAG16140.1; -.
 DR EMBL; AF261867; AAG16141.1; -.
 DR EMBL; AF261868; AAG16142.1; -.
 DR EMBL; AF261869; AAG16143.1; -.
 DR EMBL; AF261871; AAG16145.1; -.
 DR EMBL; AF261873; AAG16147.1; -.
 DR EMBL; AF261874; AAG16148.1; -.
 KW Polyprotein.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1128 MW; 8FBEEBD3B2C72AB5 CRC64;

Query Match 27.3%; Score 3; DB 3; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+04;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGS 3
 |||
 Db 2 AGS 4

RESULT 5

Q9HDR8

ID Q9HDR8 PRELIMINARY; PRT; 11 AA.
 AC Q9HDR8;
 DT 01-MAR-2001 (TrEMBLrel. 16, Created)
 DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)

DT 01-MAR-2001 (TrEMBLrel. 16, Last annotation update)
 DE TrpC polyprotein (Fragment).
 GN TRPC.
 OS Aspergillus oryzae.
 OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
 OC Eurotiales; Trichocomaceae; mitosporic Trichocomaceae; Aspergillus.
 OX NCBI_TaxID=5062;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=NRRL_449;
 RA Geiser D.M., Dorner J.W., Horn B.W., Taylor J.W.;
 RT "The phylogenetics of mycotoxin and sclerotium production in
 RT Aspergillus flavus and Aspergillus oryzae."
 RL Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AF261876; AAG16150.1; -.
 KW Polyprotein.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1128 MW; 8FBEEBD3B2C72AB5 CRC64;

Query Match 27.3%; Score 3; DB 3; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+04;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGS 3
 |||
 Db 2 AGS 4

RESULT 6

Q9HDR7

ID Q9HDR7 PRELIMINARY; PRT; 11 AA.
 AC Q9HDR7;
 DT 01-MAR-2001 (TrEMBLrel. 16, Created)
 DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
 DT 01-MAR-2001 (TrEMBLrel. 16, Last annotation update)
 DE TrpC polyprotein (Fragment).
 GN TRPC.
 OS Aspergillus flavus.
 OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
 OC Eurotiales; Trichocomaceae; mitosporic Trichocomaceae; Aspergillus.
 OX NCBI_TaxID=5059;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=TX12_10_2S;
 RA Geiser D.M., Dorner J.W., Horn B.W., Taylor J.W.;
 RT "The phylogenetics of mycotoxin and sclerotium production in
 RT Aspergillus flavus and Aspergillus oryzae."
 RL Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AF261877; AAG16151.1; -.
 KW Polyprotein.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1114 MW; 8FBC3A63B2C72AB5 CRC64;

Query Match 27.3%; Score 3; DB 3; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+04;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGS 3
|||
Db 2 AGS 4

RESULT 7

O42762

ID O42762 PRELIMINARY; PRT; 11 AA.
AC O42762;
DT 01-JUN-1998 (TrEMBLrel. 06, Created)
DT 01-JUN-1998 (TrEMBLrel. 06, Last sequence update)
DT 01-NOV-1998 (TrEMBLrel. 08, Last annotation update)
DE TrpC polypeptide (Fragment).
GN TRPC.
OS *Aspergillus flavus*.
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
OC Eurotiales; Trichocomaceae; mitosporic Trichocomaceae; *Aspergillus*.
OX NCBI_TaxID=5059;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=5-1;
RX MEDLINE=98081883; PubMed=9419385;
RA Geiser D.M., Pitt J.I., Taylor J.W.;
RT "Cryptic speciation and recombination in the aflatoxin-producing
RT fungus *aspergillus flavus*.";
RL Proc. Natl. Acad. Sci. U.S.A. 95:388-393(1998).
DR EMBL; AF036857; AAC01692.1; -.
KW Polypeptide.
FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1142 MW; 8FBEEBD202C72AB5 CRC64;

Query Match 27.3%; Score 3; DB 3; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGS 3
|||
Db 2 AGS 4

RESULT 8

O43130

ID O43130 PRELIMINARY; PRT; 11 AA.
AC O43130;
DT 01-JUN-1998 (TrEMBLrel. 06, Created)
DT 01-JUN-1998 (TrEMBLrel. 06, Last sequence update)
DT 01-OCT-2001 (TrEMBLrel. 18, Last annotation update)
DE TRPC polypeptide (Fragment).
GN TRPC.
OS *Aspergillus parasiticus*.
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
OC Eurotiales; Trichocomaceae; mitosporic Trichocomaceae; *Aspergillus*.
OX NCBI_TaxID=5067;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CA3-01, and CA1-05;
RX MEDLINE=98081883; PubMed=9419385;

RA Geiser D.M., Pitt J.I., Taylor J.W.;
 RT "Cryptic speciation and recombination in the aflatoxin-producing
 RT fungus *Aspergillus flavus*.";
 RL Proc. Natl. Acad. Sci. U.S.A. 95:388-393(1998).
 DR EMBL; AF036870; AAC01705.1; -.
 DR EMBL; AF036869; AAC01704.1; -.
 KW Polyprotein.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1128 MW; 8FBEEBD3B2C72AB5 CRC64;

 Query Match 27.3%; Score 3; DB 3; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+04;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGS 3
 |||
 Db 2 AGS 4

RESULT 9
 Q9HDS3
 ID Q9HDS3 PRELIMINARY; PRT; 11 AA.
 AC Q9HDS3;
 DT 01-MAR-2001 (TrEMBLrel. 16, Created)
 DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
 DT 01-MAR-2001 (TrEMBLrel. 16, Last annotation update)
 DE TrpC polyprotein (Fragment).
 GN TRPC.
 OS *Aspergillus flavus*.
 OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
 OC Eurotiales; Trichocomaceae; mitosporic Trichocomaceae; *Aspergillus*.
 OX NCBI_TaxID=5059;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=A120;
 RA Geiser D.M., Dorner J.W., Horn B.W., Taylor J.W.;
 RT "The phylogenetics of mycotoxin and sclerotium production in
 RT *Aspergillus flavus* and *Aspergillus oryzae*.";
 RL Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AF261862; AAG16136.1; -.
 KW Polyprotein.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1139 MW; 8FBEEBD3BAE72AB5 CRC64;

 Query Match 27.3%; Score 3; DB 3; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+04;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGS 3
 |||
 Db 2 AGS 4

RESULT 10
 Q86D32
 ID Q86D32 PRELIMINARY; PRT; 11 AA.
 AC Q86D32;

DT 01-JUN-2003 (TrEMBLrel. 24, Created)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE Histone H1 (Fragment).
 OS Trypanosoma cruzi.
 OC Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae; Trypanosoma.
 OX NCBI_TaxID=5693;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Dm28c;
 RX MEDLINE=22557728; PubMed=12670512;
 RA Sturm N.R., Vargas N.S., Westenberger S.J., Zingales B.,
 RA Campbell D.A.;
 RT "Evidence for multiple hybrid groups in Trypanosoma cruzi.";
 RL Int. J. Parasitol. 33:269-279(2003).
 DR EMBL; AF545075; AAP21903.1; -.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1114 MW; CCC1B31E7772CDDD CRC64;

Query Match 27.3%; Score 3; DB 5; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+04;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 KKA 11
 |||
 Db 9 KKA 11

RESULT 11

Q86D31

ID Q86D31 PRELIMINARY; PRT; 11 AA.
 AC Q86D31;
 DT 01-JUN-2003 (TrEMBLrel. 24, Created)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE Histone H1 (Fragment).
 OS Trypanosoma cruzi.
 OC Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae; Trypanosoma.
 OX NCBI_TaxID=5693;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Sylvio X10;
 RX MEDLINE=22557728; PubMed=12670512;
 RA Sturm N.R., Vargas N.S., Westenberger S.J., Zingales B.,
 RA Campbell D.A.;
 RT "Evidence for multiple hybrid groups in Trypanosoma cruzi.";
 RL Int. J. Parasitol. 33:269-279(2003).
 DR EMBL; AF545076; AAP21906.1; -.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1174 MW; CCD1B21E7772CDDD CRC64;

Query Match 27.3%; Score 3; DB 5; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+04;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 KKA 11
 |||

RESULT 12

O77908

ID O77908 PRELIMINARY; PRT; 11 AA.
 AC O77908;
 DT 01-NOV-1998 (TrEMBLrel. 08, Created)
 DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
 DE MHC class II B locus 2 (Fragment).
 OS Oreochromis niloticus (Nile tilapia) (Tilapia nilotica).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
 OC Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Labroidae;
 OC Cichlidae; Oreochromis.
 OX NCBI_TaxID=8128;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=98315113; PubMed=9649539;
 RA Malaga-Trillo E., Zaleska-Rutczynska Z., McAndrew B., Vincek V.,
 RA Figueroa F., Sultmann H., Klein J.;
 RT "Linkage relationships and haplotype polymorphism among cichlid mhc
 RT class II B loci.";
 RL Genetics 149:1527-1537(1998).
 DR EMBL; AF050019; AAC41358.1; -.
 FT NON_TER 1 1
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1261 MW; 4346CE9A7EB69EB3 CRC64;

Query Match 27.3%; Score 3; DB 7; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+04;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SAV 5
 |||
 Db 9 SAV 11

RESULT 13

Q9QXM6

ID Q9QXM6 PRELIMINARY; PRT; 11 AA.
 AC Q9QXM6;
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE Glutamate receptor A (Fragment).
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Bass B.L., Aruscavage P.J.;
 RT "A phylogenetic analysis reveals an unusual sequence conservation
 RT within introns involved in RNA editing.";
 RL Submitted (NOV-1999) to the EMBL/GenBank/DDBJ databases.

DR EMBL; AF201342; AAF23954.1; -.
 DR GO; GO:0004872; F:receptor activity; IEA.
 KW Receptor.
 FT NON_TER 1 1
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1077 MW; C85710C5732771AD CRC64;

Query Match 27.3%; Score 3; DB 11; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+04;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GSA 4
 |||
 Db 8 GSA 10

RESULT 14

O68237

ID O68237 PRELIMINARY; PRT; 11 AA.
 AC O68237;
 DT 01-AUG-1998 (TrEMBLrel. 07, Created)
 DT 01-AUG-1998 (TrEMBLrel. 07, Last sequence update)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE Plasmid cp32-4, possible partition proteins (Fragment).
 OS *Borrelia burgdorferi* (Lyme disease spirochete).
 OG Plasmid cp32-4.
 OC Bacteria; Spirochaetes; Spirochaetales; Spirochaetaceae; *Borrelia*.
 OX NCBI_TaxID=139;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=B31;
 RX MEDLINE=98361033; PubMed=9695920;
 RA Stevenson B., Casjens S., Rosa P.;
 RT "Evidence of past recombination events among the genes encoding the
 RT Erp antigens of *Borrelia burgdorferi*."
 RL Microbiology 144:1869-1879(1998).
 DR EMBL; AF022481; AAC35449.1; -.
 DR GO; GO:0046821; C:extrachromosomal DNA; IEA.
 KW Plasmid.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1237 MW; 50E3B714D45B5DD7 CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LK 8
 ||
 Db 9 LK 10

RESULT 15

Q9R790

ID Q9R790 PRELIMINARY; PRT; 11 AA.
 AC Q9R790;
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)

DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE Outer surface protein C (Fragment).
 GN OSPC.
 OS *Borrelia garinii*.
 OC Bacteria; Spirochaetes; Spirochaetales; Spirochaetaceae; *Borrelia*.
 OX NCBI_TaxID=29519;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=G25;
 RX MEDLINE=97426044; PubMed=9282748;
 RA Tilly K., Casjens S., Stevenson B., Bono J.L., Samuels D.S., Hogan D.,
 RA Rosa P.;
 RT "he *Borrelia burgdorferi* circular plasmid cp26: conservation of
 RT plasmid structure and targeted inactivation of the ospC gene.";
 RL Mol. Microbiol. 25:361-374(1997).
 DR EMBL; U93700; AAC45535.1; -.
 DR GO; GO:0009279; C:external outer membrane (sensu Gram-negativ. . .; IEA.
 DR GO; GO:0003793; F:defense/immunity protein activity; IEA.
 DR GO; GO:0006952; P:defense response; IEA.
 DR InterPro; IPR001800; Lipoprotein_6.
 DR Pfam; PF01441; Lipoprotein_6; 1.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1250 MW; 0868D864C5B731A4 CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SA 4
 ||
 Db 7 SA 8

RESULT 16

Q8RKN1
 ID Q8RKN1 PRELIMINARY; PRT; 11 AA.
 AC Q8RKN1;
 DT 01-JUN-2002 (TrEMBLrel. 21, Created)
 DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
 DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
 DE Beta-lactamase CTX-M-9 (Fragment).
 GN BLACTX-M-9.
 OS *Escherichia coli*.
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
 OC Enterobacteriaceae; *Escherichia*.
 OX NCBI_TaxID=562;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=743-D;
 RA Sabate M., Navarro F., Miro E., Campoy S., Mirelis B., Barbe J.,
 RA Prats G.;
 RT "A novel complex sull-type integron in *Escherichia coli* carrying the
 RT bla(CTX-M-9) gene.";
 RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AY092058; AAM15718.1; -.
 FT NON_TER 1 1
 SQ SEQUENCE 11 AA; 1071 MW; C26BF418D050440D CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SA 4
||
Db 2 SA 3

RESULT 17

Q9L4F7

ID Q9L4F7 PRELIMINARY; PRT; 11 AA.
AC Q9L4F7;
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-MAR-2001 (TrEMBLrel. 16, Last annotation update)
DE Phosphatidylinositol-specific phospholipase C (PI-PLC)
DE (Fragment).
GN PLCA.
OS Bacillus cereus.
OC Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus.
OX NCBI_TaxID=1396;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC 14579 type strain;
RX MEDLINE=20055637; PubMed=10589720;
RA Okstad O., Gominet M., Purnelle B., Rose M., Lereclus D., Kolsto A.B.;
RT "Sequence analysis of three Bacillus cereus loci under P1cR-regulated
RT genes encoding degradative enzymes and enterotoxin."
RL Microbiology 145:3129-3138(1999).
DR EMBL; AJ243711; CAB69804.1; -.
FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1335 MW; 4277A30E20572333 CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KK 9
||
Db 4 KK 5

RESULT 18

Q8L2T4

ID Q8L2T4 PRELIMINARY; PRT; 11 AA.
AC Q8L2T4;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE Histidinol phosphatase (Fragment).
OS Neisseria meningitidis.
OC Bacteria; Proteobacteria; Betaproteobacteria; Neisseriales;
OC Neisseriaceae; Neisseria.
OX NCBI_TaxID=487;
RN [1]

RP SEQUENCE FROM N.A.
 RC STRAIN=126E;
 RX MEDLINE=22051050; PubMed=12055303;
 RA Zhu P., Klutch M.J., Bash M.C., Tsang R.S.W., Ng L.K., Tsai C.M.;
 RT "Genetic Diversity of Three Lgt Loci for Biosynthesis of
 RT Lipooligosaccharide (LOS) in Neisseria Species.";
 RL Microbiology 148:1833-1844(2002).
 DR EMBL; AF470685; AAM33538.1; -.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1273 MW; 01EC828D0AA72050 CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KL 7
 ||
 Db 2 KL 3

RESULT 19

Q9R5P3

ID Q9R5P3 PRELIMINARY; PRT; 11 AA.
 AC Q9R5P3;
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE SM2=NUCLEASE (Fragment).
 OS Serratia marcescens.
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
 OC Enterobacteriaceae; Serratia.
 OX NCBI_TaxID=615;
 RN [1]
 RP SEQUENCE.
 RX MEDLINE=92134331; PubMed=1663739;
 RA Bannikova G.E., Blagova E.V., Dementiev A.A., Morgunova E.Yu.,
 RA Mikchailov A.M., Shlyapnikov S.V., Varlamov V.P., Vainshtein B.K.;
 RT "Two isoforms of Serratia marcescens nuclease. Crystallization and
 RT preliminary X-ray investigation of the enzyme.";
 RL Biochem. Int. 24:813-822(1991).
 DR PIR; A27356; A27356.
 FT NON_TER 1 1
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1179 MW; 6DF18EE04AA045BB CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 AV 5
 ||
 Db 10 AV 11

RESULT 20

P77404

ID P77404 PRELIMINARY; PRT; 11 AA.

AC P77404;
 DT 01-FEB-1997 (TrEMBLrel. 02, Created)
 DT 01-FEB-1997 (TrEMBLrel. 02, Last sequence update)
 DT 01-NOV-1998 (TrEMBLrel. 08, Last annotation update)
 DE DNA sequence downstream of the ECOPRRI HSD locus (Fragment).
 GN HSDR.
 OS Escherichia coli.
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
 OC Enterobacteriaceae; Escherichia.
 OX NCBI_TaxID=562;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=97206151; PubMed=9157244;
 RA Tyndall C., Lehnher H., Sandmeier U., Kulik E., Bickle T.A.;
 RT "The type IC hsd loci of the enterobacteria are flanked by DNA with
 RT high homology to the phage P1 genome: implications for the evolution
 RT and spread of DNA restriction systems.";
 RL Mol. Microbiol. 23:729-736(1997).
 DR EMBL; X98145; CAA66840.1; -.
 DR EMBL; X98144; CAA66839.1; -.
 FT NON_TER 1 1
 SQ SEQUENCE 11 AA; 1259 MW; 714AB092A4072734 CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LK 8
 ||
 Db 9 LK 10

RESULT 21

Q93RM6
 ID Q93RM6 PRELIMINARY; PRT; 11 AA.
 AC Q93RM6;
 DT 01-DEC-2001 (TrEMBLrel. 19, Created)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
 DE Lipophilic protein affecting bacterial lysis and methicillin
 DE resistance (Fragment).
 OS Staphylococcus aureus.
 OC Bacteria; Firmicutes; Bacillales; Staphylococcus.
 OX NCBI_TaxID=1280;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=SRM551;
 RA Maki H.;
 RT "Upstream region of llm gene.";
 RL Submitted (JAN-1997) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AB000542; BAB62080.1; -.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1191 MW; 4AC763F4C2C72727 CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 AV 5
||
Db 8 AV 9

RESULT 22

P71228

ID P71228 PRELIMINARY; PRT; 11 AA.
AC P71228;
DT 01-FEB-1997 (TrEMBLrel. 02, Created)
DT 01-JUL-1997 (TrEMBLrel. 04, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Nitrate/nitrite sensor transmitter (Fragment).
GN NARQ.
OS Escherichia coli.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Escherichia.
OX NCBI_TaxID=562;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=K-12;
RX MEDLINE=92374842; PubMed=1508040;
RA Chiang R.C., Cavicchioli R., Gunsalus R.P.;
RT "Identification and characterization of narQ, a second nitrate sensor
RT for nitrate-dependent gene regulation in Escherichia coli.";
RL Mol. Microbiol. 6:1913-1923(1992).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=K-12;
RX MEDLINE=97113461; PubMed=8955321;
RA Cavicchioli R., Kolesnikow T., Chiang R.C., Gunsalus R.P.;
RT "Characterization of the aegA locus of Escherichia coli: control of
RT gene expression in response to anaerobiosis and nitrate.";
RL J. Bacteriol. 178:6968-6974(1996).
DR EMBL; L34011; AAB46943.1; -.
FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1200 MW; 52E1CFFCA2D77403 CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 VK 6
||
Db 3 VK 4

RESULT 23

Q9K332

ID Q9K332 PRELIMINARY; PRT; 11 AA.
AC Q9K332;
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)
DE Geh (Fragment).
GN GEH.

OS Staphylococcus aureus.
 OC Bacteria; Firmicutes; Bacillales; Staphylococcus.
 OX NCBI_TaxID=1280;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=VARIOUS STRAINS;
 RX MEDLINE=20187516; PubMed=10722640;
 RA Cramton S.E., Schnell N.F., Gotz F., Bruckner R.;
 RT "Identification of a new repetitive element in Staphylococcus
 RT aureus.";
 RL Infect. Immun. 68:2344-2348(2000).
 DR EMBL; AF195967; AAF60251.1; -.
 DR EMBL; AF195963; AAF60243.1; -.
 DR EMBL; AF195964; AAF60245.1; -.
 DR EMBL; AF195965; AAF60247.1; -.
 DR EMBL; AF195966; AAF60249.1; -.
 FT NON_TER 1 1
 SQ SEQUENCE 11 AA; 1262 MW; 4F978F86AAB1A723 CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KL 7
 ||
 Db 4 KL 5

RESULT 24

Q9RFZ2

ID Q9RFZ2 PRELIMINARY; PRT; 11 AA.
 AC Q9RFZ2;
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
 DE Fructose biphosphate aldolase (Fragment).
 GN FBA.
 OS Mycoplasma mycoides subsp. capri.
 OC Bacteria; Firmicutes; Mollicutes; Mycoplasmataceae; Mycoplasma.
 OX NCBI_TaxID=40477;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=PG3;
 RX MEDLINE=20193983; PubMed=10727835;
 RA Thiaucourt F., Lorenzon S., David A., Breard A.;
 RT "Phylogeny of the Mycoplasma mycoides cluster as shown by sequencing
 RT of a putative membrane protein gene.";
 RL Vet. Microbiol. 72:251-268(2000).
 DR EMBL; AF162998; AAF15255.1; -.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1371 MW; 50B0881A3331FB57 CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KL 7

Db ||
 3 KL 4

RESULT 25

P95518

ID P95518 PRELIMINARY; PRT; 11 AA.
AC P95518;
DT 01-MAY-1997 (TrEMBLrel. 03, Created)
DT 01-MAY-1997 (TrEMBLrel. 03, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE Ribosomal protein RpsA (Fragment).
GN RPSA.
OS Pasteurella haemolytica.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Pasteurellales;
OC Pasteurellaceae; Mannheimia.
OX NCBI_TaxID=75985;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=PHL101;
RX MEDLINE=97164347; PubMed=9011038;
RA Highlander S.K., Garza O., Brown B.J., Koby S., Oppenheim A.B.;
RT "Isolation and characterization of the integration host factor genes
RT of Pasteurella haemolytica."
RL FEMS Microbiol. Lett. 146:181-188(1997).
DR EMBL; U56139; AAC44845.1; -.
FT NON_TER 1 1
SQ SEQUENCE 11 AA; 1168 MW; 7A4BFD38D339CDDDB CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 KA 11
 ||
Db 7 KA 8

RESULT 26

Q47604

ID Q47604 PRELIMINARY; PRT; 11 AA.
AC Q47604;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE REase protein (Fragment).
GN REASE.
OS Escherichia coli.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Escherichia.
OX NCBI_TaxID=562;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=91139577; PubMed=1995588;
RA Tao T., Bourne J.C., Blumenthal R.M.;
RT "A family of regulatory genes associated with type II restriction-
RT modification systems.";

RL J. Bacteriol. 173:1367-1375(1991).
DR EMBL; M63621; AAA24560.1; -.
FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1296 MW; 3039A71A34472AB7 CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KL 7
||
Db 8 KL 9

RESULT 27

Q44237

ID Q44237 PRELIMINARY; PRT; 11 AA.
AC Q44237;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE Glutamine synthetase (Fragment).
GN GLNA.
OS Anabaena sp. (strain PCC 7120).
OC Bacteria; Cyanobacteria; Nostocales; Nostocaceae; Nostoc.
OX NCBI_TaxID=103690;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=PCC 7120;
RA Warner L.E., Ligon P.J., Stahel A.W., Curtis S.E.;
RT "The apcF gene of Anabaena sp. strain PCC 7120 is regulated by
RT nitrogen and the apcF and glnA promoters overlap."
RL Submitted (MAY-1995) to the EMBL/GenBank/DDBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=PCC 7120;
RA Scappino L.A.;
RL Submitted (FEB-1995) to the EMBL/GenBank/DDBJ databases.
DR EMBL; U21853; AAA65652.1; -.
FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1316 MW; 2000580E32CB06C7 CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LK 8
||
Db 8 LK 9

RESULT 28

Q9R872

ID Q9R872 PRELIMINARY; PRT; 11 AA.
AC Q9R872;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)

DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE Dihydrofolate reductase (Fragment).
 GN DFR1.
 OS Escherichia coli.
 OG Plasmid r483.
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
 OC Enterobacteriaceae; Escherichia.
 OX NCBI_TaxID=562;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TRANSPOSON=Tn7;
 RA Hansson K., Sundstrom L., Pelletier A., Roy P.H.;
 RT "Sequence and function of the second type of integron in Tn7."
 RL Submitted (SEP-1997) to the EMBL/GenBank/DDBJ databases.
 RN [2]
 RP SEQUENCE FROM N.A.
 RC TRANSPOSON=Tn7;
 RX MEDLINE=82220022; PubMed=6283361;
 RA Lichtenstein C., Brenner S.;
 RT "Unique insertion site of Tn7 in the E. coli chromosome."
 RL Nature 297:601-603(1982).
 RN [3]
 RP SEQUENCE FROM N.A.
 RC TRANSPOSON=Tn7;
 RX MEDLINE=83290694; PubMed=6411680;
 RA Simonsen C.C., Chen E.Y., Levinson A.D.;
 RT "Identification of the type I trimethoprim-resistant dihydrofolate
 RT reductase specified by the Escherichia coli R-plasmid R483: Comparison
 RT with procaryotic and eucaryotic dihydrofolate reductases."
 RL J. Bacteriol. 155:1001-1008(1983).
 RN [4]
 RP SEQUENCE FROM N.A.
 RC TRANSPOSON=Tn7;
 RX MEDLINE=83272957; PubMed=6308574;
 RA Fling M.E., Richards C.;
 RT "The nucleotide sequence of the trimethoprim-resistant dihydrofolate
 RT reductase gene harbored by Tn7."
 RL Nucleic Acids Res. 11:5147-5158(1983).
 DR EMBL; AJ001816; CAA05032.1; -.
 DR GO; GO:0046821; C:extrachromosomal DNA; IEA.
 KW Plasmid.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1221 MW; 92014864C2C69735 CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KL 7
 ||
 Db 2 KL 3

RESULT 29

Q9R446

ID Q9R446 PRELIMINARY; PRT; 11 AA.
 AC Q9R446;

DT 01-MAY-2000 (TrEMBLrel. 13, Created)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last annotation update)
 DE Carbamoyl-phosphate synthase subunit A (Fragment).
 GN CARA.
 OS Neisseria gonorrhoeae.
 OC Bacteria; Proteobacteria; Betaproteobacteria; Neisseriales;
 OC Neisseriaceae; Neisseria.
 OX NCBI_TaxID=485;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=MS11, and FA1090;
 RX MEDLINE=95291461; PubMed=7773412;
 RA Lawson F.S., Billowes F.M., Dillon J.A.;
 RT "Organization of carbamoyl-phosphate synthase genes in Neisseria
 RT gonorrhoeae includes a large, variable intergenic sequence which is
 RT also present in other Neisseria species."
 RL Microbiology 141:0-0(0).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=MS11, and FA1090;
 RA Brinkman F.S.L., Francis F.M., Dillon J.R.;
 RT "Complexity of the variable sequence between the carbamoyl-phosphate
 RT synthase genes of Neisseria species."
 RL Submitted (OCT-1997) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AF029363; AAC78453.1; -.
 DR EMBL; AF029362; AAC78452.1; -.
 FT NON_TER 1 1
 SQ SEQUENCE 11 AA; 1178 MW; 0C07A8E3DDD33694 CRC64;

 Query Match 18.2%; Score 2; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

 Qy 10 KA 11
 ||
 Db 6 KA 7

RESULT 30

Q8GMU3

ID Q8GMU3 PRELIMINARY; PRT; 11 AA.
 AC Q8GMU3;
 DT 01-MAR-2003 (TrEMBLrel. 23, Created)
 DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE Putative catalase isozyme (Fragment).
 GN KATA.
 OS Acinetobacter lwoffii.
 OG Plasmid pKLH202.
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales;
 OC Moraxellaceae; Acinetobacter.
 OX NCBI_TaxID=28090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=TC108;
 RA Kholodii G.Y., Yurieva O.V., Mindlin S.Z., Gorlenko Z.M.,

RA Nikiforov V.G.;
 RT "pKLH2-like aberrant transposons and possible mechanisms of their
 RT dissemination."
 RL Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AJ250245; CAC80800.1; -.
 DR GO; GO:0046821; C:extrachromosomal DNA; IEA.
 KW Plasmid.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1233 MW; 81A15757B333276A CRC64;

 Query Match 18.2%; Score 2; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KK 9
 ||
 Db 6 KK 7

RESULT 31

Q8GL24
 ID Q8GL24 PRELIMINARY; PRT; 11 AA.
 AC Q8GL24;
 DT 01-MAR-2003 (TrEMBLrel. 23, Created)
 DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE PF-50 protein (Fragment).
 GN PF-50.
 OS Borrelia burgdorferi (Lyme disease spirochete).
 OG Plasmid group cp32-6.
 OC Bacteria; Spirochaetes; Spirochaetales; Spirochaetaceae; Borrelia.
 OX NCBI_TaxID=139;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Sh-2-82;
 RA Stevenson B., Miller J.C.;
 RT "Comparative analyses of Borrelia burgdorferi erp genes and their cp32
 RT prophages: conservation amidst diversity."
 RL Submitted (AUG-2002) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AY142093; AAN17876.1; -.
 DR GO; GO:0046821; C:extrachromosomal DNA; IEA.
 KW Plasmid.
 FT NON_TER 1 1
 SQ SEQUENCE 11 AA; 1366 MW; 4E441D5330504373 CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LK 8
 ||
 Db 10 LK 11

RESULT 32

Q8GL19
 ID Q8GL19 PRELIMINARY; PRT; 11 AA.

AC Q8GL19;
 DT 01-MAR-2003 (TrEMBLrel. 23, Created)
 DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE PF-50 protein (Fragment).
 GN PF-50.
 OS *Borrelia burgdorferi* (Lyme disease spirochete).
 OG Plasmid group cp32-11.
 OC Bacteria; Spirochaetes; Spirochaetales; Spirochaetaceae; *Borrelia*.
 OX NCBI_TaxID=139;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Sh-2-82;
 RA Stevenson B., Miller J.C.;
 RT "Comparative analyses of *Borrelia burgdorferi* erp genes and their cp32
 RT prophages: conservation amidst diversity."
 RL Submitted (AUG-2002) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AY142096; AAN17880.1; -.
 DR GO; GO:0046821; C:extrachromosomal DNA; IEA.
 KW Plasmid.
 FT NON_TER 1 1
 SQ SEQUENCE 11 AA; 1366 MW; 4E441D5337204373 CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LK 8
 ||
 Db 7 LK 8

RESULT 33

P83537

ID P83537 PRELIMINARY; PRT; 11 AA.
 AC P83537;
 DT 01-JUN-2003 (TrEMBLrel. 24, Created)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE Unknown protein from 2D-page (Fragment).
 OS *Lactobacillus sanfranciscensis* (*Lactobacillus sanfrancisco*).
 OC Bacteria; Firmicutes; Lactobacillales; Lactobacillaceae;
 OC *Lactobacillus*.
 OX NCBI_TaxID=1625;
 RN [1]
 RP SEQUENCE, AND INDUCTION.
 RC STRAIN=DSM 20451;
 RX PubMed=12112860;
 RA Drews O., Weiss W., Reil G., Parlar H., Wait R., Goerg A.;
 RT "High pressure effects step-wise altered protein expression in
 RT *Lactobacillus sanfranciscensis*."
 RL Proteomics 2:765-774(2002).
 CC -!- INDUCTION: BY ELEVATED HYDROSTATIC PRESSURE.
 CC -!- MISCELLANEOUS: ON THE 2D-GEL THE DETERMINED MW OF THIS UNKNOWN
 CC PROTEIN IS: 65 KDA.
 FT NON_TER 1 1
 FT NON_TER 11 11

SQ SEQUENCE 11 AA; 1249 MW; D96C8231B771ADD9 CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3
||
Db 1 GS 2

RESULT 34

Q47569

ID Q47569 PRELIMINARY; PRT; 11 AA.
AC Q47569;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein (Fragment).
OS Escherichia coli.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Escherichia.
OX NCBI_TaxID=562;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=K-12;
RX MEDLINE=94162733; PubMed=7764507;
RA Yamada M., Yanai S., Talkuder A.;
RT "Analysis of products of the Escherichia coli genomic genes and
RT regulation of their expressions: an applicable procedure for genomic
RT analysis of other microorganisms.";
RL Biosci. Biotechnol. Biochem. 58:117-120(1994).
DR EMBL; D21156; BAA04692.1; -.
KW Hypothetical protein.
FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1322 MW; C0B8E40E37672732 CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LK 8
||
Db 8 LK 9

RESULT 35

Q7WUL8

ID Q7WUL8 PRELIMINARY; PRT; 11 AA.
AC Q7WUL8;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE PdtJ (Fragment).
GN PDTJ.
OS Pseudomonas putida.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales;

OC Pseudomonadaceae; Pseudomonas.
 OX NCBI_TaxID=303;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=DSM 3601;
 RA Lewis T.A., Leach L., Morales S.E., Austin P.R., Hartwell H.J.,
 RA Kaplan B., Forker C., Meyer J.-M.;
 RT "Physiological and molecular genetic evaluation of the dechlorination
 RT agent, pyridine-2,6-bis (monothiocarboxylic acid) (PDTC), as a
 RT secondary siderophore of Pseudomonas sp.";
 RL Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AY319946; AAQ01713.1; -.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1143 MW; C22A6E13A050587D CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AG 2
 ||
 Db 4 AG 5

RESULT 36

O42763

ID O42763 PRELIMINARY; PRT; 11 AA.
 AC O42763;
 DT 01-JUN-1998 (TrEMBLrel. 06, Created)
 DT 01-JUN-1998 (TrEMBLrel. 06, Last sequence update)
 DT 01-NOV-1998 (TrEMBLrel. 08, Last annotation update)
 DE TrpC polyprotein (Fragment).
 GN TRPC.
 OS Aspergillus oryzae.
 OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
 OC Eurotiales; Trichocomaceae; mitosporic Trichocomaceae; Aspergillus.
 OX NCBI_TaxID=5062;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=NRRL469;
 RX MEDLINE=98081883; PubMed=9419385;
 RA Geiser D.M., Pitt J.I., Taylor J.W.;
 RT "Cryptic speciation and recombination in the aflatoxin-producing
 RT fungus aspergillus flavus.";
 RL Proc. Natl. Acad. Sci. U.S.A. 95:388-393(1998).
 DR EMBL; AF036868; AAC01703.1; -.
 KW Polyprotein.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1162 MW; 8FA1D6C3F2C72AB5 CRC64;

Query Match 18.2%; Score 2; DB 3; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3
 ||
 Db 3 GS 4

RESULT 37

Q9UR95

ID Q9UR95 PRELIMINARY; PRT; 11 AA.
 AC Q9UR95;
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 01-JUN-2000 (TrEMBLrel. 14, Last annotation update)
 DE Heat shock protein 60 homolog (Fragment).
 OS Pichia angusta (Yeast) (Hansenula polymorpha).
 OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
 OC Saccharomycetales; Saccharomycetaceae; Pichia.
 OX NCBI_TaxID=4905;
 RN [1]
 RP SEQUENCE.
 RX MEDLINE=93223840; PubMed=8096822;
 RA Evers M.E., Huhse B., Titorenko V.I., Kunau W.H., Hartl F.U.,
 RA Harder W., Veenhuis M.;
 RT "Affinity purification of molecular chaperones of the yeast Hansenula
 RT polymorpha using immobilized denatured alcohol oxidase.";
 RL FEBS Lett. 321:32-36(1993).
 SQ SEQUENCE 11 AA; 1230 MW; 71872C1779C3372B CRC64;

Query Match 18.2%; Score 2; DB 3; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LK 8
 ||
 Db 5 LK 6

RESULT 38

Q9HFN8

ID Q9HFN8 PRELIMINARY; PRT; 11 AA.
 AC Q9HFN8;
 DT 01-MAR-2001 (TrEMBLrel. 16, Created)
 DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
 DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
 DE Acyl carrier protein (Fragment).
 GN ACP.
 OS Candida rugosa (Yeast) (Candida cylindracea).
 OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
 OC Saccharomycetales; mitosporic Saccharomycetales; Candida.
 OX NCBI_TaxID=5481;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Biasio W.;
 RL Thesis (2000), University of Vienna, Austria.
 DR EMBL; AJ279021; CAC08812.1; -.
 FT NON_TER 1 1
 SQ SEQUENCE 11 AA; 1274 MW; D2E4CC3976C40732 CRC64;

Query Match 18.2%; Score 2; DB 3; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 AV 5
||
Db 10 AV 11

RESULT 39

Q9URG1

ID Q9URG1 PRELIMINARY; PRT; 11 AA.
AC Q9URG1;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE Cytochrome C oxidase subunit 2 (Fragment).
OS Neurospora crassa.
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Sordariomycetes;
OC Sordariomycetidae; Sordariales; Sordariaceae; Neurospora.
OX NCBI_TaxID=5141;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=92035058; PubMed=1657411;
RA Lemire E.G., Percy J.A., Correia J.M., Crowther B.M., Nargang F.E.;
RT "Alteration of the cytochrome c oxidase subunit 2 gene in the [exn-5]
RT mutant of Neurospora crassa."
RL Curr. Genet. 20:121-127(1991).
FT NON_TER 1 1
FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1222 MW; 936B1558C7605DC5 CRC64;

Query Match 18.2%; Score 2; DB 3; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SA 4
||
Db 4 SA 5

RESULT 40

O60005

ID O60005 PRELIMINARY; PRT; 11 AA.
AC O60005;
DT 01-AUG-1998 (TrEMBLrel. 07, Created)
DT 01-AUG-1998 (TrEMBLrel. 07, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE TrpC (Fragment).
GN TRPC.
OS Aspergillus versicolor.
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
OC Eurotiales; Trichocomaceae; mitosporic Trichocomaceae; Aspergillus.
OX NCBI_TaxID=46472;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=NRRL 226;
RA Geiser D.M., Taylor J.W., Smith G.W., Ritchie K.B.;
RT "Aspergillus sydowii causing sea fan mortality."
RL Nature 0:0-0(1998).

DR EMBL; AF058967; AAC15743.1; -.
FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1142 MW; 8C71EBD3B2C72DC5 CRC64;

Query Match 18.2%; Score 2; DB 3; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SA 4
||
Db 4 SA 5

RESULT 41

O60007

ID O60007 PRELIMINARY; PRT; 11 AA.
AC O60007;
DT 01-AUG-1998 (TrEMBLrel. 07, Created)
DT 01-AUG-1998 (TrEMBLrel. 07, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE TrpC (Fragment).
GN TRPC.
OS Emericella violacea.
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
OC Eurotiales; Trichocomaceae; Emericella.
OX NCBI_TaxID=41738;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC 16813;
RA Geiser D.M., Taylor J.W., Smith G.W., Ritchie K.B.;
RT "Aspergillus sydowii causing sea fan mortality."
RL Nature 0:0-0(1998).
DR EMBL; AF058975; AAC15751.1; -.
FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1142 MW; 8C71EBD3B2C72DC5 CRC64;

Query Match 18.2%; Score 2; DB 3; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SA 4
||
Db 4 SA 5

RESULT 42

O60192

ID O60192 PRELIMINARY; PRT; 11 AA.
AC O60192;
DT 01-AUG-1998 (TrEMBLrel. 07, Created)
DT 01-AUG-1998 (TrEMBLrel. 07, Last sequence update)
DT 01-OCT-2001 (TrEMBLrel. 18, Last annotation update)
DE TRPC (Fragment).
GN TRPC.
OS Aspergillus sydowii.
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
OC Eurotiales; Trichocomaceae; mitosporic Trichocomaceae; Aspergillus.

OX NCBI_TaxID=75750;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=NRRL 249, H640, SA-25, SS-7, FK-11, and NRRL 244;
 RA Geiser D.M., Taylor J.W., Smith G.W., Ritchie K.B.;
 RL Nature 0:0-0(1998).
 DR EMBL; AF058974; AAC15750.1; -.
 DR EMBL; AF058968; AAC15744.1; -.
 DR EMBL; AF058969; AAC15745.1; -.
 DR EMBL; AF058970; AAC15746.1; -.
 DR EMBL; AF058971; AAC15747.1; -.
 DR EMBL; AF058973; AAC15749.1; -.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1142 MW; 8C71EBD3B2C72DC5 CRC64;

Query Match 18.2%; Score 2; DB 3; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SA 4
 ||
 Db 4 SA 5

RESULT 43

O60006

ID O60006 PRELIMINARY; PRT; 11 AA.
 AC O60006;
 DT 01-AUG-1998 (TrEMBLrel. 07, Created)
 DT 01-AUG-1998 (TrEMBLrel. 07, Last sequence update)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
 DE TrpC (Fragment).
 GN TRPC.
 OS Aspergillus sydowii.
 OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
 OC Eurotiales; Trichocomaceae; mitosporic Trichocomaceae; Aspergillus.
 OX NCBI_TaxID=75750;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=NRRL 242;
 RA Geiser D.M., Taylor J.W., Smith G.W., Ritchie K.B.;
 RT "Aspergillus sydowii causing sea fan mortality."
 RL Nature 0:0-0(1998).
 DR EMBL; AF058972; AAC15748.1; -.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1110 MW; 8C71F0C3F2C72DC5 CRC64;

Query Match 18.2%; Score 2; DB 3; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SA 4
 ||
 Db 4 SA 5

RESULT 44

Q9Y3G2

ID Q9Y3G2 PRELIMINARY; PRT; 11 AA.
AC Q9Y3G2;
DT 01-NOV-1999 (TrEMBLrel. 12, Created)
DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE LSFR2 protein (Fragment).
GN LSFR2.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=99299247; PubMed=10369878;
RA Gilley J., Fried M.;
RT "Extensive gene order differences within regions of conserved synteny
RT between the Fugu and human genomes: implications for chromosomal
RT evolution and the cloning of disease genes."
RL Hum. Mol. Genet. 8:1313-1320(1999).
DR EMBL; Y17456; CAB44349.1; -.
FT NON_TER 1 1
FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1342 MW; 68C5E5D7A8772324 CRC64;

Query Match 18.2%; Score 2; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KL 7
||
Db 5 KL 6

RESULT 45

O60761

ID O60761 PRELIMINARY; PRT; 11 AA.
AC O60761;
DT 01-AUG-1998 (TrEMBLrel. 07, Created)
DT 01-AUG-1998 (TrEMBLrel. 07, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE NPT-1 protein (Fragment).
GN NPT-1.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=98207718; PubMed=9545579;
RA Taketani Y., Miyamoto K., Chikamori M., Tanaka K., Yamamoto H.,
RA Tatsumi S., Morita K., Takeda E.;
RT "Characterization of the 5' flanking region of the human NPT-1
RT Na+/phosphate cotransporter gene."
RL Biochim. Biophys. Acta 1396:267-272(1998).
DR EMBL; D83236; BAA25645.1; -.
FT NON_TER 11 11

SQ SEQUENCE 11 AA; 1358 MW; 884E2D4E6734044A CRC64;

Query Match 18.2%; Score 2; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KK 9
||
Db 10 KK 11

RESULT 46

Q9H4H5

ID Q9H4H5 PRELIMINARY; PRT; 11 AA.
AC Q9H4H5;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DT 01-MAR-2002 (TrEMBLrel. 20, Last annotation update)
DE DJ661I20.2 (Novel helicase C-terminal domain and SNF2 N-terminal
DE domains containing protein) (Fragment).
GN DJ620E11.1.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Skuce C.;
RL Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.
DR EMBL; AL031669; CAC17164.2; -.
FT NON_TER 1 1
FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1420 MW; 5EB2C32A3326D053 CRC64;

Query Match 18.2%; Score 2; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 KK 9
||
Db 7 KK 8

RESULT 47

Q15997

ID Q15997 PRELIMINARY; PRT; 11 AA.
AC Q15997;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE RARA protein (Fragment).
GN RARA.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]

RP SEQUENCE FROM N.A.
 RX MEDLINE=93222087; PubMed=7682097;
 RA Dong S., Geng J.P., Tong J.H., Wu Y., Cai J.R., Sun G.L., Chen S.R.,
 RA Wang Z.Y., Larsen C.J., Berger R., et al;
 RT "Breakpoint clusters of the PML gene in acute promyelocytic leukemia:
 RT primary structure of the reciprocal products of the PML-RARA gene in a
 RT patient with t(15;17).";
 RL Genes Chromosomes Cancer 6:133-139(1993).
 DR EMBL; S57794; AAD13888.1; -.
 DR PIR; I54081; I54081.
 FT NON_TER 1 1
 SQ SEQUENCE 11 AA; 1277 MW; 33C70E22CDDDC417 CRC64;

Query Match 18.2%; Score 2; DB 4; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 AV 5
 ||
 Db 7 AV 8

RESULT 48

Q9UCP5

ID Q9UCP5 PRELIMINARY; PRT; 11 AA.
 AC Q9UCP5;
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE Aggrecan core protein (Fragment).
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE.
 RX MEDLINE=92235266; PubMed=1569188;
 RA Sandy J.D., Flannery C.R., Neame P.J., Lohmander L.S.;
 RL J. Clin. Invest. 89:1512-1516(1992).
 DR GO; GO:0005201; F:extracellular matrix structural constituent; TAS.
 DR GO; GO:0006508; P:proteolysis and peptidolysis; NAS.
 DR GO; GO:0001501; P:skeletal development; NAS.
 FT NON_TER 1 1
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1149 MW; 8FBFE8DFE72042D5 CRC64;

Query Match 18.2%; Score 2; DB 4; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3
 ||
 Db 3 GS 4

RESULT 49

Q16234

ID Q16234 PRELIMINARY; PRT; 11 AA.
AC Q16234;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE HuD protein (Fragment).
GN HUD.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=94349312; PubMed=8069866;
RA Sekido Y., Bader S.A., Carbone D.P., Johnson B.E., Minna J.D.;
RT "Molecular analysis of the HuD gene encoding a paraneoplastic
RT encephalomyelitis antigen in human lung cancer cell lines."
RL Cancer Res. 54:4988-4992(1994).
DR EMBL; S73887; AAD14142.1; -.
DR PIR; I52708; I52708.
FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1289 MW; 2EDCF20E204415A7 CRC64;

Query Match 18.2%; Score 2; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LK 8
||
Db 8 LK 9

RESULT 50

Q9C057

ID Q9C057 PRELIMINARY; PRT; 11 AA.
AC Q9C057;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)
DE HEX (Fragment).
GN HEX.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Oyama Y., Kurabayashi M., Nagai R., Shimomura Y., Sekiguchi K.;
RT "Human Hex 5'-flanking sequence."
RL Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases.
DR EMBL; AF182950; AAK12833.1; -.
FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1125 MW; 2644D7FE686761F7 CRC64;

Query Match 18.2%; Score 2; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AG 2
||
Db 10 AG 11

RESULT 51

Q8NFN9

ID Q8NFN9 PRELIMINARY; PRT; 11 AA.
AC Q8NFN9;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Corticotropin releasing hormone receptor 1 (Fragment).
GN CRHRL.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Parham K.L., Catalano R., Hillhouse E.W.;
RT "Identification of the Promoter Region of the Human Type 1 CRH
RT Receptor Gene.";
RL Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases.
DR EMBL; AF488558; AAM55213.1; -.
DR GO; GO:0004872; F:receptor activity; IEA.
KW Receptor.
FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1236 MW; ECEE030D0736C761 CRC64;

Query Match 18.2%; Score 2; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 VK 6
||
Db 10 VK 11

RESULT 52

Q8NI03

ID Q8NI03 PRELIMINARY; PRT; 11 AA.
AC Q8NI03;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE 25 hydroxyvitamin d3 1-alpha hydroxylase (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Ebert R., Schneider D., Jovanovic M., Adamski J., Jakob F.;
RL Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
DR EMBL; AF500480; AAM21669.1; -.

FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1298 MW; 82C14E84CB533731 CRC64;

Query Match 18.2%; Score 2; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LK 8
||
Db 5 LK 6

RESULT 53

Q8TDA8

ID Q8TDA8 PRELIMINARY; PRT; 11 AA.
AC Q8TDA8;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE Glutathione synthetase (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Cho Y.-W., Lee Y.-Y., Lim C.-J.;
RT "Cloning and characterization of glutathione synthetase gene from
RT human placenta DNA.";
RL Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases.
DR EMBL; AF485789; AAL91591.1; -.
FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1235 MW; 1CE28D1E35B86374 CRC64;

Query Match 18.2%; Score 2; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3
||
Db 6 GS 7

RESULT 54

Q9UC46

ID Q9UC46 PRELIMINARY; PRT; 11 AA.
AC Q9UC46;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Neutrophil inhibitor peptide, NIP=POLYMORPHONUCLEAR neutrophil
DE inhibitor peptide.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]

RP SEQUENCE.
RX MEDLINE=96326114; PubMed=8703476;
RA Cooper J.A.Jr., Culbreth R.R.;
RT "Characterization of a neutrophil inhibitor peptide harvested from
RT human bronchial lavage: homology to influenza A nucleoprotein.";
RL Am. J. Respir. Cell Mol. Biol. 15:207-215(1996).
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0030236; P:anti-inflammatory response; NAS.
SQ SEQUENCE 11 AA; 1262 MW; 951A1C3279C9DB45 CRC64;

Query Match 18.2%; Score 2; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3
||
Db 3 GS 4

RESULT 55

Q9UH72

ID Q9UH72 PRELIMINARY; PRT; 11 AA.
AC Q9UH72;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE V1-vascular vasopressin receptor AVPR1A (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Thibonnier M., Willard H.F., Jeunemaitre X.;
RT "Study of V1-vascular vasopressin receptor gene microsatellite
RT polymorphisms in human essential hypertension.";
RL Submitted (NOV-1999) to the EMBL/GenBank/DDBJ databases.
DR EMBL; AF208541; AAF18470.1; -.
DR GO; GO:0004872; F:receptor activity; IEA.
KW Receptor.
FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1071 MW; 8653B8E3B7687DC5 CRC64;

Query Match 18.2%; Score 2; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SA 4
||
Db 4 SA 5

RESULT 56

Q26092

ID Q26092 PRELIMINARY; PRT; 11 AA.
AC Q26092;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)

DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
 DE Sea StAR histone H2B gene 5'region (Fragment).
 OS *Pisaster ochraceus* (Sea star).
 OC Eukaryota; Metazoa; Echinodermata; Eleutherozoa; Asterozoa;
 OC Asteroidea; Forcipulatacea; Forcipulatida; Asteriidae; *Pisaster*.
 OX NCBI_TaxID=7612;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Sperm;
 RA Howell A.M., Cool D., Hewitt J., Ydenberg B., Smith M.J., Honda B.M.;
 RT "Organization and Unusual Expression of Histone Genes in the Sea Star
 RT *Pisaster ochraceus*.";
 RL J. Mol. Evol. 25:29-36(1987).
 DR EMBL; X05619; CAA29106.1; -.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1128 MW; 5173974A3865BDD3 CRC64;

Query Match 18.2%; Score 2; DB 5; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 KA 11
 ||
 Db 4 KA 5

RESULT 57

P82698

ID P82698 PRELIMINARY; PRT; 11 AA.
 AC P82698;
 DT 01-MAR-2001 (TrEMBLrel. 16, Created)
 DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE Periviscerokinin-1 (LEM-PVK-1).
 OS *Leucophaea maderae* (Madeira cockroach),
 OS *Nauphoeta cinerea* (Cinereous cockroach) (Gray cockroach),
 OS *Blaberus craniifer*,
 OS *Blaptica dubia*, and
 OS *Gromphadorina portentosa* (Cockroach).
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
 OC Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blaberoidea;
 OC Blaberidae; *Leucophaea*.
 OX NCBI_TaxID=6988, 6990, 6982, 132935, 36953;
 RN [1]
 RP SEQUENCE, FUNCTION, AND MASS SPECTROSCOPY.
 RC TISSUE=ABDOMINAL PERISYMPATHETIC ORGANS;
 RX MEDLINE=20307624; PubMed=10849006;
 RA Predel R., Kellner R., Baggerman G., Steinmetzer T., Schoofs L.;
 RT "Identification of novel periviscerokinins from single neurohaemal
 RT release sites in insects. MS/MS fragmentation complemented by Edman
 RT degradation.";
 RL Eur. J. Biochem. 267:3869-3873(2000).
 CC -!- FUNCTION: MEDIATES VISCERAL MUSCLE CONTRACTILE ACTIVITY
 CC (MYOTROPIC ACTIVITY).
 CC -!- MASS SPECTROMETRY: MW=1090.6; METHOD=MALDI.
 DR GO; GO:0007218; P:neuropeptide signaling pathway; IEA.

KW Neuropeptide; Amidation.
FT MOD_RES 11 11 AMIDATION.
SQ SEQUENCE 11 AA; 1091 MW; 2C2D80E2D7605728 CRC64;

Query Match 18.2%; Score 2; DB 5; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3
||
Db 1 GS 2

RESULT 58

P82699

ID P82699 PRELIMINARY; PRT; 11 AA.
AC P82699;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Periviscerokinin-2 (LEM-PVK-2).
OS Leucophaea maderae (Madeira cockroach),
OS Nauphoeta cinerea (Cinereous cockroach) (Gray cockroach),
OS Blaberus craniifer,
OS Blaptica dubia, and
OS Gromphadorina portentosa (Cockroach).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blaberoidea;
OC Blaberidae; Leucophaea.
OX NCBI_TaxID=6988, 6990, 6982, 132935, 36953;
RN [1]
RP SEQUENCE, FUNCTION, AND MASS SPECTROSCOPY.
RC TISSUE=ABDOMINAL PERISYMPATHETIC ORGANS;
RX MEDLINE=20307624; PubMed=10849006;
RA Predel R., Kellner R., Baggerman G., Steinmetzer T., Schoofs L.;
RT "Identification of novel periviscerokinins from single neurohaemal
RT release sites in insects. MS/MS fragmentation complemented by Edman
RT degradation.";
RL Eur. J. Biochem. 267:3869-3873(2000).
CC -!- FUNCTION: MEDIATES VISCERAL MUSCLE CONTRACTILE ACTIVITY
CC (MYOTROPIC ACTIVITY).
CC -!- MASS SPECTROMETRY: MW=1102.6; METHOD=MALDI.
DR GO; GO:0007218; P:neuropeptide signaling pathway; IEA.
KW Neuropeptide; Amidation.
FT MOD_RES 11 11 AMIDATION.
SQ SEQUENCE 11 AA; 1103 MW; 2F4D9FFD85B05728 CRC64;

Query Match 18.2%; Score 2; DB 5; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3
||
Db 1 GS 2

RESULT 59

P82700

ID P82700 PRELIMINARY; PRT; 11 AA.
AC P82700;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Periviscerokinin-3 (LEM-PVK-3).
OS Leucophaea maderae (Madeira cockroach),
OS Nauphoeta cinerea (Cinereous cockroach) (Gray cockroach),
OS Blaberus craniifer,
OS Blaptica dubia (Argentinian wood cockroach), and
OS Gromphadorina portentosa (Cockroach).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blaberoidea;
OC Blaberidae; Leucophaea.
OX NCBI_TaxID=6988, 6990, 6982, 132935, 36953;
RN [1]
RP SEQUENCE, FUNCTION, AND MASS SPECTROSCOPY.
RC TISSUE=ABDOMINAL PERISYMPATHETIC ORGANS;
RX MEDLINE=20307624; PubMed=10849006;
RA Predel R., Kellner R., Baggerman G., Steinmetzer T., Schoofs L.;
RT "Identification of novel periviscerokininins from single neurohaemal
RT release sites in insects. MS/MS fragmentation complemented by Edman
RT degradation.";
RL Eur. J. Biochem. 267:3869-3873(2000).
CC -!- FUNCTION: MEDIATES VISCERAL MUSCLE CONTRACTILE ACTIVITY
CC (MYOTROPIC ACTIVITY).
CC -!- MASS SPECTROMETRY: MW=1146.6; METHOD=MALDI.
DR GO; GO:0007218; P:neuropeptide signaling pathway; IEA.
KW Neuropeptide; Amidation.
FT MOD_RES 11 11 AMIDATION.
SQ SEQUENCE 11 AA; 1147 MW; 2F4D9FF2D7605698 CRC64;

Query Match 18.2%; Score 2; DB 5; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3
||
Db 1 GS 2

RESULT 60

Q95PX6

ID Q95PX6 PRELIMINARY; PRT; 11 AA.
AC Q95PX6;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein.
GN ZK1236.8.
OS Caenorhabditis elegans.
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;
OC Rhabditidae; Peloderinae; Caenorhabditis.
OX NCBI_TaxID=6239;
RN [1]
RP SEQUENCE FROM N.A.

RC STRAIN=Bristol N2;
 RX MEDLINE=99069613; PubMed=9851916;
 RA None;
 RT "Genome sequence of the nematode C. elegans: a platform for
 RT investigating biology. The C. elegans Sequencing Consortium.";
 RL Science 282:2012-2018(1998).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Bristol N2;
 RA Favello A.;
 RT "The sequence of C. elegans cosmid ZK1236.";
 RL Submitted (MAY-1993) to the EMBL/GenBank/DDBJ databases.
 RN [3]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Bristol N2;
 RA Waterston R.;
 RT "Direct Submission.";
 RL Submitted (OCT-2001) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; L13200; AAL11108.1; -.
 DR WormPep; ZK1236.8; CE29629.
 KW Hypothetical protein.
 SQ SEQUENCE 11 AA; 1304 MW; DFA3510A25A76322 CRC64;

Query Match 18.2%; Score 2; DB 5; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 VK 6
 ||
 Db 4 VK 5

RESULT 61

Q9BDC8

ID Q9BDC8 PRELIMINARY; PRT; 11 AA.
 AC Q9BDC8;
 DT 01-JUN-2001 (TrEMBLrel. 17, Created)
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE D2 dopamine receptor (Fragment).
 GN DRD2.
 OS Pongo pygmaeus (Orangutan).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pongo.
 OX NCBI_TaxID=9600;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Jaril, CP81a, Jari2, and CP81b;
 RX MEDLINE=20445696; PubMed=10993600;
 RA Deinard A.S., Kidd K.K.;
 RT "Evolution of a D2 Dopamine receptor intron within the great apes and
 RT humans.";
 RL DNA Seq. 8:289-301(1998).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Jaril, CP81a, Jari2, and CP81b;
 RA Deinard A.S., Kidd K.K.;

RL Submitted (JAN-2001) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AF333020; AAK29396.1; -.
 DR EMBL; AF333021; AAK29397.1; -.
 DR EMBL; AF333022; AAK29398.1; -.
 DR EMBL; AF333023; AAK29399.1; -.
 DR GO; GO:0004872; F:receptor activity; IEA.
 KW Receptor.
 FT NON_TER 1 1
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1145 MW; 9F46E75FEDD1E87E CRC64;

Query Match 18.2%; Score 2; DB 6; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 AV 5
 ||
 Db 9 AV 10

RESULT 62

Q95J20

ID Q95J20 PRELIMINARY; PRT; 11 AA.
 AC Q95J20;
 DT 01-DEC-2001 (TrEMBLrel. 19, Created)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
 DE Malic enzyme (Fragment).
 OS Eulemur fulvus albocollaris.
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Strepsirhini; Lemuridae; Eulemur.
 OX NCBI_TaxID=122224;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Wyner Y.M., Johnson S.E., DeSalle R.;
 RT "A genetic assessment of a red-fronted/white-collared lemur hybrid
 RT zone at Andringitra, Madagascar."
 RL Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AF258139; AAK53119.1; -.
 DR EMBL; AF258145; AAK53125.1; -.
 DR EMBL; AF258147; AAK53127.1; -.
 FT NON_TER 1 1
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1204 MW; C7CD492E66D9D2C9 CRC64;

Query Match 18.2%; Score 2; DB 6; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AG 2
 ||
 Db 9 AG 10

RESULT 63

Q9XSP7

ID Q9XSP7 PRELIMINARY; PRT; 11 AA.

AC Q9XSP7;
 DT 01-NOV-1999 (TrEMBLrel. 12, Created)
 DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
 DE Platelet-derived growth factor A chain (Fragment).
 GN PDGFA.
 OS Pygathrix nemaeus (Dove langur).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Cercopithecidae; Colobinae;
 OC Pygathrix.
 OX NCBI_TaxID=54133;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=20065871; PubMed=10598812;
 RA Bonthron D.T., Smith S.L., Campbell R.;
 RT "Complex patterns of intragenic polymorphism at the PDGFA locus."
 RL Hum. Genet. 105:452-459(1999).
 DR EMBL; AJ243282; CAB45924.1; -.
 FT NON_TER 1 1
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1345 MW; 7FB881F101E1E044 CRC64;

Query Match 18.2%; Score 2; DB 6; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 VK 6
 ||
 Db 10 VK 11

RESULT 64

Q9TTQ0

ID Q9TTQ0 PRELIMINARY; PRT; 11 AA.
 AC Q9TTQ0;
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE Alanine glyoxylate aminotransferase (EC 2.6.1.44) (Fragment).
 GN AGT.
 OS Gorilla gorilla (gorilla).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Gorilla.
 OX NCBI_TaxID=9593;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=20188798; PubMed=10723739;
 RA Holbrook J.D., Birdsey G.M., Yang Z., Bruford M.W., Danpure C.J.;
 RT "Molecular adaptation of alanine Glyoxylate aminotransferase targeting
 RT in primates."
 RL Mol. Biol. Evol. 17:387-400(2000).
 DR EMBL; AJ237887; CAB56788.1; -.
 DR GO; GO:0008453; F:alanine-glyoxylate transaminase activity; IEA.
 DR GO; GO:0016740; F:transferase activity; IEA.
 KW Aminotransferase; Transferase.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1193 MW; E9F82B8BC7272331 CRC64;

Query Match 18.2%; Score 2; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KL 7
||
Db 5 KL 6

RESULT 65

Q9XSP2

ID Q9XSP2 PRELIMINARY; PRT; 11 AA.
AC Q9XSP2;
DT 01-NOV-1999 (TrEMBLrel. 12, Created)
DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE Platelet-derived growth factor A chain (Fragment).
GN PDGFA.
OS Hylobates syndactylus (Siamang) (Symphalangus syndactylus).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hylobatidae; Hylobates.
OX NCBI_TaxID=9590;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=20065871; PubMed=10598812;
RA Bonthron D.T., Smith S.L., Campbell R.;
RT "Complex patterns of intragenic polymorphism at the PDGFA locus."
RL Hum. Genet. 105:452-459(1999).
DR EMBL; AJ243280; CAB45927.1; -.
FT NON_TER 1 1
FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1345 MW; 7FB881F101E1E044 CRC64;

Query Match 18.2%; Score 2; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 VK 6
||
Db 10 VK 11

RESULT 66

Q9BDQ9

ID Q9BDQ9 PRELIMINARY; PRT; 11 AA.
AC Q9BDQ9;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE D2 dopamine receptor (Fragment).
GN DRD2.
OS Gorilla gorilla (gorilla).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Gorilla.
OX NCBI_TaxID=9593;
RN [1]

RP SEQUENCE FROM N.A.
 RX MEDLINE=20445696; PubMed=10993600;
 RA Deinard A.S., Kidd K.K.;
 RT "Evolution of a D2 Dopamine receptor intron within the great apes and
 RT humans.";
 RL DNA Seq. 8:289-301(1998).
 RN [2]
 RP SEQUENCE FROM N.A.
 RA Deinard A.S., Kidd K.K.;
 RL Submitted (JAN-2001) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AF333010; AAK29386.1; -.
 DR GO; GO:0004872; F:receptor activity; IEA.
 KW Receptor.
 FT NON_TER 1 1
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1145 MW; 9F46E75FEDD1E87E CRC64;

Query Match 18.2%; Score 2; DB 6; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 AV 5
 ||
 Db 9 AV 10

RESULT 67

Q95NB6

ID Q95NB6 PRELIMINARY; PRT; 11 AA.
 AC Q95NB6;
 DT 01-DEC-2001 (TrEMBLrel. 19, Created)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
 DE Malic enzyme (Fragment).
 OS Eulemur fulvus rufus.
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Strepsirhini; Lemnidae; Eulemur.
 OX NCBI_TaxID=47179;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Wyner Y.M., Johnson S.E., DeSalle R.;
 RT "A genetic assessment of a red-fronted/white-collared lemur hybrid
 RT zone at Andringitra, Madagascar.";
 RL Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AF258148; AAK53128.1; -.
 FT NON_TER 1 1
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1204 MW; C7CD492E66D9D2C9 CRC64;

Query Match 18.2%; Score 2; DB 6; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AG 2
 ||
 Db 9 AG 10

RESULT 68

Q9XSP5

ID Q9XSP5 PRELIMINARY; PRT; 11 AA.
 AC Q9XSP5;
 DT 01-NOV-1999 (TrEMBLrel. 12, Created)
 DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
 DE Platelet-derived growth factor A chain (Fragment).
 GN PDGFA.
 OS Pan troglodytes (Chimpanzee).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pan.
 OX NCBI_TaxID=9598;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=20065871; PubMed=10598812;
 RA Bonthron D.T., Smith S.L., Campbell R.;
 RT "Complex patterns of intragenic polymorphism at the PDGFA locus."
 RL Hum. Genet. 105:452-459(1999).
 DR EMBL; AJ243277; CAB45926.1; -.
 FT NON_TER 1 1
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1331 MW; 7FB881F101E1F2D4 CRC64;

Query Match 18.2%; Score 2; DB 6; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 VK 6
 ||
 Db 10 VK 11

RESULT 69

Q95J19

ID Q95J19 PRELIMINARY; PRT; 11 AA.
 AC Q95J19;
 DT 01-DEC-2001 (TrEMBLrel. 19, Created)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
 DE Malic enzyme (Fragment).
 OS Eulemur fulvus (brown lemur).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Strepsirhini; Lemnidae; Eulemur.
 OX NCBI_TaxID=13515;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Wyner Y.M., Johnson S.E., DeSalle R.;
 RT "A genetic assessment of a red-fronted/white-collared lemur hybrid
 zone at Andringitra, Madagascar."
 RL Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AF258163; AAK53143.1; -.
 DR EMBL; AF258170; AAK53150.1; -.
 DR EMBL; AF258171; AAK53151.1; -.
 DR EMBL; AF258173; AAK53153.1; -.
 DR EMBL; AF258175; AAK53155.1; -.

DR EMBL; AF258178; AAK53158.1; -.
 DR EMBL; AF258179; AAK53159.1; -.
 DR EMBL; AF258181; AAK53161.1; -.
 DR EMBL; AF258182; AAK53162.1; -.
 FT NON_TER 1 1
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1204 MW; C7CD492E66D9D2C9 CRC64;

Query Match 18.2%; Score 2; DB 6; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AG 2
 ||
 Db 9 AG 10

RESULT 70

Q9TQSO

ID Q9TQSO PRELIMINARY; PRT; 11 AA.
 AC Q9TQSO;
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last annotation update)
 DE C-KIT (Fragment).
 GN KIT.
 OS Bos taurus (Bovine).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovoidea;
 OC Bovidae; Bovinae; Bos.
 OX NCBI_TaxID=9913;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Olsen H.G., Vage D.I., Lien S., Klun gland H.;
 RT "A polymorphism in the bovine c-kit gene."
 RL Submitted (JUN-1999) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AJ243424; CAB60775.1; -.
 DR EMBL; AJ243060; CAB60774.1; -.
 FT NON_TER 1 1
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1126 MW; DD785FF8A2D2D772 CRC64;

Query Match 18.2%; Score 2; DB 6; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 KA 11
 ||
 Db 2 KA 3

RESULT 71

Q9BDD0

ID Q9BDD0 PRELIMINARY; PRT; 11 AA.
 AC Q9BDD0;
 DT 01-JUN-2001 (TrEMBLrel. 17, Created)
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)

DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE D2 dopamine receptor (Fragment).
 GN DRD2.
 OS Pan troglodytes (Chimpanzee).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pan.
 OX NCBI_TaxID=9598;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Various strains;
 RX MEDLINE=20445696; PubMed=10993600;
 RA Deinard A.S., Kidd K.K.;
 RT "Evolution of a D2 Dopamine receptor intron within the great apes and
 RT humans.";
 RL DNA Seq. 8:289-301(1998).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Various strains;
 RA Deinard A.S., Kidd K.K.;
 RL Submitted (JAN-2001) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AF333011; AAK29387.1; -.
 DR EMBL; AF333012; AAK29388.1; -.
 DR EMBL; AF333013; AAK29389.1; -.
 DR EMBL; AF333015; AAK29391.1; -.
 DR EMBL; AF333016; AAK29392.1; -.
 DR EMBL; AF333017; AAK29393.1; -.
 DR EMBL; AF333018; AAK29394.1; -.
 DR EMBL; AF333019; AAK29395.1; -.
 DR GO; GO:0004872; F:receptor activity; IEA.
 KW Receptor.
 FT NON_TER 1 1
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1145 MW; 9F46E75FEDD1E87E CRC64;

 Query Match 18.2%; Score 2; DB 6; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

 Qy 4 AV 5
 ||
 Db 9 AV 10

RESULT 72

Q9XSP8

ID Q9XSP8 PRELIMINARY; PRT; 11 AA.
 AC Q9XSP8;
 DT 01-NOV-1999 (TrEMBLrel. 12, Created)
 DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
 DE Platelet-derived growth factor A chain (Fragment).
 GN PDGFA.
 OS Presbytis johnii.
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Cercopithecidae; Colobinae;
 OC Presbytis.
 OX NCBI_TaxID=98375;

RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=20065871; PubMed=10598812;
 RA Bonthron D.T., Smith S.L., Campbell R.;
 RT "Complex patterns of intragenic polymorphism at the PDGFA locus."
 RL Hum. Genet. 105:452-459(1999).
 DR EMBL; AJ243281; CAB46013.1; -.
 FT NON_TER 1 1
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1345 MW; 7FB881F101E1E044 CRC64;

Query Match 18.2%; Score 2; DB 6; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 VK 6
 ||
 Db 10 VK 11

RESULT 73

Q9XSP6

ID Q9XSP6 PRELIMINARY; PRT; 11 AA.
 AC Q9XSP6;
 DT 01-NOV-1999 (TrEMBLrel. 12, Created)
 DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
 DE Platelet-derived growth factor A chain (Fragment).
 GN PDGFA.
 OS Pongo pygmaeus (Orangutan).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pongo.
 OX NCBI_TaxID=9600;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=20065871; PubMed=10598812;
 RA Bonthron D.T., Smith S.L., Campbell R.;
 RT "Complex patterns of intragenic polymorphism at the PDGFA locus."
 RL Hum. Genet. 105:452-459(1999).
 DR EMBL; AJ243279; CAB45925.1; -.
 FT NON_TER 1 1
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1345 MW; 7FB881F101E1E044 CRC64;

Query Match 18.2%; Score 2; DB 6; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 VK 6
 ||
 Db 10 VK 11

RESULT 74

Q9BDC9

ID Q9BDC9 PRELIMINARY; PRT; 11 AA.
 AC Q9BDC9;

DT 01-JUN-2001 (TrEMBLrel. 17, Created)
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
 DE D2 dopamine receptor (Fragment).
 GN DRD2.
 OS Pan paniscus (Pygmy chimpanzee) (Bonobo).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pan.
 OX NCBI_TaxID=9597;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Jimmy;
 RX MEDLINE=20445696; PubMed=10993600;
 RA Deinard A.S., Kidd K.K.;
 RT "Evolution of a D2 Dopamine receptor intron within the great apes and
 RT humans.";
 RL DNA Seq. 8:289-301(1998).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Jimmy;
 RA Deinard A.S., Kidd K.K.;
 RL Submitted (JAN-2001) to the EMBL/GenBank/DDBJ databases.
 RN [3]
 RP SEQUENCE FROM N.A.
 RA Deinard A.S., Kidd K.K.;
 RL Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AF333014; AAK29390.1; -.
 DR EMBL; AF358821; AAK29457.1; -.
 DR GO; GO:0004872; F:receptor activity; IEA.
 KW Receptor.
 FT NON_TER 1 1
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1145 MW; 9F46E75FEDD1E87E CRC64;

 Query Match 18.2%; Score 2; DB 6; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.5e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

 Qy 4 AV 5
 ||
 Db 9 AV 10

RESULT 75

Q9XSQ4

ID Q9XSQ4 PRELIMINARY; PRT; 11 AA.
 AC Q9XSQ4;
 DT 01-NOV-1999 (TrEMBLrel. 12, Created)
 DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
 DE Platelet-derived growth factor A chain (Fragment).
 GN PDGFA.
 OS Gorilla gorilla (gorilla).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Gorilla.
 OX NCBI_TaxID=9593;
 RN [1]

RP SEQUENCE FROM N.A.
RX MEDLINE=20065871; PubMed=10598812;
RA Bonthron D.T., Smith S.L., Campbell R.;
RT "Complex patterns of intragenic polymorphism at the PDGFA locus."
RL Hum. Genet. 105:452-459(1999).
DR EMBL; AJ243278; CAB45916.1; -.
FT NON_TER 1 1
FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1331 MW; 7FB881F101E1F2D4 CRC64;

Query Match 18.2%; Score 2; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 VK 6
||
Db 10 VK 11

Search completed: April 8, 2004, 15:46:04
Job time : 28.7692 secs

OM protein - protein search, using sw model

Run on: April 8, 2004, 15:30:07 ; Search time 5.15385 Seconds
(without alignments)
111.135 Million cell updates/sec

Title: US-09-787-443A-4
Perfect score: 11
Sequence: 1 AGSAVKLKKKA 11

Scoring table: OLIGO
Gapop 60.0 , Gapext 60.0

Searched: 141681 seqs, 52070155 residues

Word size : 0

Total number of hits satisfying chosen parameters: 70

Minimum DB seq length: 11
Maximum DB seq length: 11

Post-processing: Listing first 100 summaries

Database : SwissProt_42:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	%		DB	ID	Description
		Query Match	Length			
1	3	27.3	11	1	OAIF_SARBU	P83518 sarcophaga
2	2	18.2	11	1	BRK_MEGFL	P12797 megascolia
3	2	18.2	11	1	CA41_LITCI	P82091 litoria cit
4	2	18.2	11	1	CA42_LITCI	P82092 litoria cit
5	2	18.2	11	1	COXA_CANFA	P99501 canis famil
6	2	18.2	11	1	CSI5_BACSU	P81095 bacillus su
7	2	18.2	11	1	CXL1_CONMR	P58807 conus marmo
8	2	18.2	11	1	LPW_THETH	P05624 thermus the
9	2	18.2	11	1	MHBI_KLEPN	P80580 klebsiella
10	2	18.2	11	1	MORN_HUMAN	P01163 homo sapien
11	2	18.2	11	1	NUHM_CANFA	P49820 canis famil
12	2	18.2	11	1	PQQC_PSEFL	P55173 pseudomonas
13	2	18.2	11	1	Q2OA_COMTE	P80464 comamonas t
14	2	18.2	11	1	RS30_ONCMY	P83328 oncorhynchu
15	1	9.1	11	1	ANGT_CRIGE	P09037 crinia geor
16	1	9.1	11	1	ASL1_BACSE	P83146 bacteroides
17	1	9.1	11	1	ASL2_BACSE	P83147 bacteroides

18	1	9.1	11	1	BPP3_BOTIN	P30423	bothrops in
19	1	9.1	11	1	BPP4_BOTIN	P30424	bothrops in
20	1	9.1	11	1	BPPB_AGKHA	P01021	agkistrodon
21	1	9.1	11	1	BPP_AGKHP	P04562	agkistrodon
22	1	9.1	11	1	CA21_LITCI	P82087	litoria cit
23	1	9.1	11	1	CA22_LITCI	P82088	litoria cit
24	1	9.1	11	1	CA31_LITCI	P82089	litoria cit
25	1	9.1	11	1	CA32_LITCI	P82090	litoria cit
26	1	9.1	11	1	CEP1_ACHFU	P22790	achatina fu
27	1	9.1	11	1	CORZ_PERAM	P11496	periplaneta
28	1	9.1	11	1	CX5B_CONAL	P58849	conus aulic
29	1	9.1	11	1	EFG_CLOPA	P81350	clostridium
30	1	9.1	11	1	ES1_RAT	P56571	rattus norv
31	1	9.1	11	1	FAR6_PENMO	P83321	penaeus mon
32	1	9.1	11	1	FAR9_CALVO	P41864	calliphora
33	1	9.1	11	1	HS70_PINPS	P81672	pinus pinas
34	1	9.1	11	1	LADD_ONCMY	P81018	oncorhynchu
35	1	9.1	11	1	LSK1_LEUMA	P04428	leucophaea
36	1	9.1	11	1	LSKP_PERAM	P36885	periplaneta
37	1	9.1	11	1	MLG_THETS	P41989	theromyzon
38	1	9.1	11	1	NXSN_PSETE	P59072	pseudonaja
39	1	9.1	11	1	PKC1_CARMO	P82684	carausius m
40	1	9.1	11	1	PVK1_PERAM	P41837	periplaneta
41	1	9.1	11	1	RANC_RANPI	P08951	rana pipien
42	1	9.1	11	1	RE41_LITRU	P82074	litoria rub
43	1	9.1	11	1	RR2_CONAM	P42341	conopholis
44	1	9.1	11	1	RRPL_CHAV	P13179	chandipura
45	1	9.1	11	1	T2P1_PROVU	P31031	proteus vul
46	1	9.1	11	1	TIN4_HOPTI	P82654	hoplobatrac
47	1	9.1	11	1	TKC2_CALVO	P41518	calliphora
48	1	9.1	11	1	TKN1_PSEGU	P42986	pseudophryn
49	1	9.1	11	1	TKN1_UPEIN	P82026	uperoleia i
50	1	9.1	11	1	TKN1_UPERU	P08612	uperoleia r
51	1	9.1	11	1	TKN2_PSEGU	P42987	pseudophryn
52	1	9.1	11	1	TKN2_UPERU	P08616	uperoleia r
53	1	9.1	11	1	TKN3_PSEGU	P42988	pseudophryn
54	1	9.1	11	1	TKN4_PSEGU	P42989	pseudophryn
55	1	9.1	11	1	TKN5_PSEGU	P42990	pseudophryn
56	1	9.1	11	1	TKNA_CHICK	P19850	gallus gall
57	1	9.1	11	1	TKNA_GADMO	P28498	gadus morhu
58	1	9.1	11	1	TKNA_HORSE	P01290	equus cabal
59	1	9.1	11	1	TKNA_ONCMY	P28499	oncorhynchu
60	1	9.1	11	1	TKNA_RANCA	P22688	rana catesb
61	1	9.1	11	1	TKNA_RANRI	P29207	rana ridibu
62	1	9.1	11	1	TKNA_SCYCA	P41333	scyliorhinu
63	1	9.1	11	1	TKND_RANCA	P22691	rana catesb
64	1	9.1	11	1	TKN_ELEMO	P01293	eledone mos
65	1	9.1	11	1	TKN_PHYFU	P08615	physalaemus
66	1	9.1	11	1	UF05_MOUSE	P38643	mus musculu
67	1	9.1	11	1	ULAG_HUMAN	P31933	homo sapien
68	1	9.1	11	1	UXB2_YEAST	P99013	saccharomyc
69	0	0.0	11	1	CX5A_CONAL	P58848	conus aulic
70	0	0.0	11	1	TIN1_HOPTI	P82651	hoplobatrac

ALIGNMENTS

RESULT 1

OAIF_SARBU

ID OAIF_SARBU STANDARD; PRT; 11 AA.
AC P83518;
DT 10-OCT-2003 (Rel. 42, Created)
DT 10-OCT-2003 (Rel. 42, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Ovary-derived ACE interactive factor (Neb-ODAIF) [Contains: Neb-ODAIF(1-9); Neb-ODAIF(1-7)].
OS Sarcophaga bullata (Grey flesh fly) (Neobellieria bullata).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha; Oestroidea;
OC Sarcophagidae; Sarcophaga.
OX NCBI_TaxID=7385;
RN [1]
RP SEQUENCE, SYNTHESIS, CHARACTERIZATION, AND MASS SPECTROMETRY.
RC TISSUE=Ovary;
RX MEDLINE=22272747; PubMed=12383874;
RA Vandingenen A., Hens K., Baggerman G., Macours N., Schoofs L.,
RA De Loof A., Huybrechts R.;
RT "Isolation and characterization of an angiotensin converting enzyme
RT substrate from vitellogenic ovaries of Neobellieria bullata.";
RL Peptides 23:1853-1863(2002).
CC -!- FUNCTION: Substrate for angiotensin converting enzyme (ACE) in
CC vitro.
CC -!- PTM: ACE hydrolyzes Neb-ODAIF by sequentially cleaving off two C-
CC terminal dipeptides.
CC -!- MASS SPECTROMETRY: MW=1312.7; METHOD=MALDI; RANGE=1-11.
CC -!- SIMILARITY: To the N-terminal part of insect vitellogenins.
FT PEPTIDE 1 11 NEB-ODAIF.
FT PEPTIDE 1 9 NEB-ODAIF(1-9).
FT PEPTIDE 1 7 NEB-ODAIF(1-7).
SQ SEQUENCE 11 AA; 1314 MW; 4E114BB566C5A763 CRC64;

Query Match 27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.8e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KLK 8
|||
Db 2 KLK 4

RESULT 2

BRK_MEGFL

ID BRK_MEGFL STANDARD; PRT; 11 AA.
AC P12797;
DT 01-OCT-1989 (Rel. 12, Created)
DT 01-OCT-1989 (Rel. 12, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Megascoliakinin ([Thr6]bradykinin-Lys-Ala) [Contains: Bradykinin-like
DE peptide ([Thr6]bradykinin)].
OS Megascolia flavifrons (Garden dagger wasp) (Solitary wasp).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Hymenoptera; Apocrita; Aculeata; Vespoidea;
OC Scoliidae; Megascolia.

OX NCBI_TaxID=7437;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Venom;
 RX MEDLINE=87293024; PubMed=3617088;
 RA Yasuhara T., Mantel P., Nakajima T., Piek T.;
 RT "Two kinins isolated from an extract of the venom reservoirs of the
 RT solitary wasp *Megascolia flavifrons*.";
 RL Toxicon 25:527-535(1987).
 RN [2]
 RP SEQUENCE.
 RC TISSUE=Venom;
 RA Nakajima T., Piek T., Yashuara T., Mantel P.;
 RT "Two kinins isolated from the venom of *Megascolia flavifrons*.";
 RL Toxicon 26:34-34(1988).
 CC -!- FUNCTION: Both proteins have bradykinin-like, although lower
 CC activities (e.g. smooth muscle contraction).
 CC -!- SUBCELLULAR LOCATION: Secreted; wasp venom reservoirs.
 CC -!- SIMILARITY: Belongs to the bradykinin family.
 DR PIR; B26744; B26744.
 DR GO; GO:0005615; C:extracellular space; IDA.
 DR GO; GO:0045776; P:negative regulation of blood pressure; ISS.
 DR GO; GO:0045987; P:positive regulation of smooth muscle contra. . .; TAS.
 KW Bradykinin; Vasodilator.
 FT PEPTIDE 1 11 MEGASCOLIAKININ.
 FT PEPTIDE 1 9 BRADYKININ-LIKE PEPTIDE.
 SQ SEQUENCE 11 AA; 1273 MW; 33867393D771A9C8 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.8e+04;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 KA 11
 ||
 Db 10 KA 11

RESULT 3

CA41_LITCI
 ID CA41_LITCI STANDARD; PRT; 11 AA.
 AC P82091;
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Caerulein 4.1/4.1Y4.
 OS Litoria citropa (Australian blue mountains tree frog).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Hylidae;
 OC Pelodryadinae; Litoria.
 OX NCBI_TaxID=94770;
 RN [1]
 RP SEQUENCE, AND MASS SPECTROMETRY.
 RC TISSUE=Skin secretion;
 RX MEDLINE=20057701; PubMed=10589099;
 RA Wabnitz P.A., Bowie J.H., Tyler M.J.;
 RT "Caerulein-like peptides from the skin glands of the Australian blue
 RT mountains tree frog *Litoria citropa*. Part 1. Sequence determination

RT using electrospray mass spectrometry.";
 RL Rapid Commun. Mass Spectrom. 13:2498-2502(1999).
 CC -!- FUNCTION: Hypotensive neuropeptide (Probable).
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- TISSUE SPECIFICITY: Skin dorsal glands.
 CC -!- PTM: Isoform 4.1Y4 differs from isoform 4.1 in not being
 CC sulfated.
 CC -!- MASS SPECTROMETRY: MW=1388; METHOD=Electrospray.
 CC -!- SIMILARITY: Belongs to the gastrin/cholecystokinin family.
 DR InterPro; IPR001651; Gastrin.
 DR PROSITE; PS00259; GASTRIN; FALSE_NEG.
 KW Amphibian defense peptide; Hypotensive agent; Amidation; Sulfation;
 KW Pyrrolidone carboxylic acid.
 FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
 FT MOD_RES 4 4 SULFATION.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1328 MW; 10DAB7C4F5B861BB CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.8e+04;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3
 ||
 Db 6 GS 7

RESULT 4

CA42_LITCI

ID CA42_LITCI STANDARD; PRT; 11 AA.
 AC P82092;
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Caerulein 4.2/4.2Y4.
 OS Litoria citropa (Australian blue mountains tree frog).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Hylidae;
 OC Pelodyadinae; Litoria.
 OX NCBI_TaxID=94770;
 RN [1]
 RP SEQUENCE, AND MASS SPECTROMETRY.
 RC TISSUE=Skin secretion;
 RX MEDLINE=20057701; PubMed=10589099;
 RA Wabnitz P.A., Bowie J.H., Tyler M.J.;
 RT "Caerulein-like peptides from the skin glands of the Australian blue
 RT mountains tree frog Litoria citropa. Part 1. Sequence determination
 RT using electrospray mass spectrometry.";
 RL Rapid Commun. Mass Spectrom. 13:2498-2502(1999).
 CC -!- FUNCTION: Hypotensive neuropeptide (Probable).
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- TISSUE SPECIFICITY: Skin dorsal glands.
 CC -!- PTM: Isoform 4.2Y4 differs from isoform 4.2 in not being
 CC sulfated.
 CC -!- MASS SPECTROMETRY: MW=1404; METHOD=Electrospray.
 CC -!- SIMILARITY: Belongs to the gastrin/cholecystokinin family.
 DR InterPro; IPR001651; Gastrin.

DR PROSITE; PS00259; GASTRIN; FALSE_NEG.
 KW Amphibian defense peptide; Hypotensive agent; Amidation; Sulfation;
 KW Pyrrolidone carboxylic acid.
 FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
 FT MOD_RES 4 4 SULFATION.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1344 MW; 10DAB894F5B861BB CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.8e+04;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3
 ||
 Db 6 GS 7

RESULT 5

COXA_CANFA
 ID COXA_CANFA STANDARD; PRT; 11 AA.
 AC P99501;
 DT 15-JUL-1998 (Rel. 36, Created)
 DT 15-JUL-1998 (Rel. 36, Last sequence update)
 DT 30-MAY-2000 (Rel. 39, Last annotation update)
 DE Cytochrome c oxidase polypeptide Va (EC 1.9.3.1) (Fragment).
 GN COX5A.
 OS Canis familiaris (Dog).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
 OX NCBI_TaxID=9615;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Heart;
 RX MEDLINE=98163340; PubMed=9504812;
 RA Dunn M.J., Corbett J.M., Wheeler C.H.;
 RT "HSC-2DPAGE and the two-dimensional gel electrophoresis database of
 RT dog heart proteins."
 RL Electrophoresis 18:2795-2802(1997).
 CC -!- FUNCTION: This is the heme A-containing chain of cytochrome c
 CC oxidase, the terminal oxidase in mitochondrial electron transport.
 CC -!- CATALYTIC ACTIVITY: 4 ferrocytochrome c + O(2) = 4 ferricytochrome
 CC c + 2 H(2)O.
 CC -!- SUBCELLULAR LOCATION: Mitochondrial inner membrane.
 CC -!- SIMILARITY: Belongs to the cytochrome c oxidase Va family.
 DR HSC-2DPAGE; P99501; DOG.
 DR InterPro; IPR003204; Cyt_c_ox5A.
 DR Pfam; PF02284; COX5A; 1.
 KW Oxidoreductase; Heme; Mitochondrion; Inner membrane.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1274 MW; 910B35C5B1AB11F5 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.8e+04;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3
 ||

Db

3 GS 4

RESULT 6

CSI5_BACSU

ID CSI5_BACSU STANDARD; PRT; 11 AA.
AC P81095;
DT 15-JUL-1998 (Rel. 36, Created)
DT 15-JUL-1998 (Rel. 36, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Cold shock protein CSI5 (11 kDa cold shock protein) (Fragment).
OS Bacillus subtilis.
OC Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus.
OX NCBI_TaxID=1423;
RN [1]
RP SEQUENCE.
RC STRAIN=168 / JH642;
RA Graumann P.L., Schmid R., Marahiel M.A.;
RL Submitted (OCT-1997) to Swiss-Prot.
RN [2]
RP CHARACTERIZATION.
RC STRAIN=168 / JH642;
RX MEDLINE=96345629; PubMed=8755892;
RA Graumann P., Schroeder K., Schmid R., Marahiel M.A.;
RT "Cold shock stress-induced proteins in Bacillus subtilis."
RL J. Bacteriol. 178:4611-4619(1996).
CC -!- SUBCELLULAR LOCATION: Cytoplasmic.
CC -!- INDUCTION: In response to low temperature.
CC -!- CAUTION: Could not be found in the genome of B.subtilis 168.
FT NON TER 11 11
SQ SEQUENCE 11 AA; 1360 MW; 15F6ECEE6322C330 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.8e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 VK 6
||
Db 6 VK 7

RESULT 7

CXL1_CONMR

ID CXL1_CONMR STANDARD; PRT; 11 AA.
AC P58807;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Lambda-conotoxin CMrVIA.
OS Conus marmoreus (Marble cone).
OC Eukaryota; Metazoa; Mollusca; Gastropoda; Orthogastropoda;
OC Apogastropoda; Caenogastropoda; Sorbeoconcha; Hypsogastropoda;
OC Neogastropoda; Conoidea; Conidae; Conus.
OX NCBI_TaxID=42752;
RN [1]
RP SEQUENCE, SYNTHESIS, AND MASS SPECTROMETRY.
RC TISSUE=Venom;

```

RX  MEDLINE=20564325; PubMed=10988292;
RA  Balaji R.A., Ohtake A., Sato K., Gopalakrishnakone P., Kini R.M.,
RA  Seow K.T., Bay B.-H.;
RT  "Lambda-conotoxins, a new family of conotoxins with unique disulfide
RT  pattern and protein folding. Isolation and characterization from the
RT  venom of Conus marmoreus.";
RL  J. Biol. Chem. 275:39516-39522(2000).
CC  -!- FUNCTION: Inhibits the neuronal noradrenaline transporter.
CC  -!- SUBCELLULAR LOCATION: Secreted.
CC  -!- TISSUE SPECIFICITY: Expressed by the venom duct.
CC  -!- MASS SPECTROMETRY: MW=1237.93; MW_ERR=0.21; METHOD=Electrospray.
CC  -!- SIMILARITY: Belongs to the chi/lambda-conotoxin family.
KW  Neurotoxin; Toxin; Hydroxylation.
FT  DISULFID      2      11
FT  DISULFID      3       8
FT  MOD_RES       10     10      HYDROXYLATION.
SQ  SEQUENCE     11 AA;  1226 MW;  277AAC60B7232B58 CRC64;

Query Match          18.2%; Score 2; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.8e+04;
Matches      2; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

Qy          6 KL 7
           ||
Db          6 KL 7

```

RESULT 8

```

LPW_THETH
ID  LPW THETH          STANDARD;          PRT;      11 AA.
AC  P05624;
DT  01-NOV-1988 (Rel. 09, Created)
DT  01-NOV-1988 (Rel. 09, Last sequence update)
DT  30-MAY-2000 (Rel. 39, Last annotation update)
DE  Trp operon leader peptide.
GN  TRPL.
OS  Thermus thermophilus.
OC  Bacteria; Deinococcus-Thermus; Deinococci; Thermales; Thermaceae;
OC  Thermus.
OX  NCBI_TaxID=274;
RN  [1]
RP  SEQUENCE FROM N.A.
RC  STRAIN=HB8 / ATCC 27634;
RX  MEDLINE=89000781; PubMed=2844259;
RA  Sato S., Nakada Y., Kanaya S., Tanaka T.;
RT  "Molecular cloning and nucleotide sequence of Thermus thermophilus
RT  HB8 trpE and trpG.";
RL  Biochim. Biophys. Acta 950:303-312(1988).
CC  -!- FUNCTION: THIS PROTEIN IS INVOLVED IN CONTROL OF THE BIOSYNTHESIS
CC  OF TRYPTOPHAN.
CC  -----
CC  This SWISS-PROT entry is copyright. It is produced through a collaboration
CC  between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC  the European Bioinformatics Institute. There are no restrictions on its
CC  use by non-profit institutions as long as its content is in no way
CC  modified and this statement is not removed. Usage by and for commercial
CC  entities requires a license agreement (See http://www.isb-sib.ch/announce/

```

CC or send an email to license@isb-sib.ch).

CC

DR EMBL; X07744; CAA30565.1; -.

KW Tryptophan biosynthesis; Leader peptide.

SQ SEQUENCE 11 AA; 1228 MW; 364B295A772DC5A7 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.8e+04;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SA 4

||

Db 5 SA 6

RESULT 9

MHBI_KLEPN

ID MHBI_KLEPN STANDARD; PRT; 11 AA.

AC P80580;

DT 01-OCT-1996 (Rel. 34, Created)

DT 01-OCT-1996 (Rel. 34, Last sequence update)

DT 01-NOV-1997 (Rel. 35, Last annotation update)

DE Maleylpyruvate isomerase (EC 5.2.1.4) (Fragment).

GN MHBI.

OS Klebsiella pneumoniae.

OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;

OC Enterobacteriaceae; Klebsiella.

OX NCBI_TaxID=573;

RN [1]

RP SEQUENCE.

RX MEDLINE=96349117; PubMed=8760924;

RA Robson N.D., Parrott S., Cooper R.A.;

RT "In vitro formation of a catabolic plasmid carrying Klebsiella

pneumoniae DNA that allows growth of Escherichia coli K-12 on 3-

RT hydroxybenzoate.";

RL Microbiology 142:2115-2120(1996).

CC -!- CATALYTIC ACTIVITY: 3-maleylpyruvate = 3-fumarylpyruvate.

KW Isomerase.

FT NON_TER 11 11

SQ SEQUENCE 11 AA; 1387 MW; 1EE0E2DD49C9D5AB CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.8e+04;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 KL 7

||

Db 2 KL 3

RESULT 10

MORN_HUMAN

ID MORN_HUMAN STANDARD; PRT; 11 AA.

AC P01163;

DT 21-JUL-1986 (Rel. 01, Created)

DT 21-JUL-1986 (Rel. 01, Last sequence update)

DT 28-FEB-2003 (Rel. 41, Last annotation update)

DE Morphogenetic neuropeptide (Head activator) (HA).
 OS Homo sapiens (Human),
 OS Rattus norvegicus (Rat),
 OS Bos taurus (Bovine),
 OS Anthopleura elegantissima (Sea anemone), and
 OS Hydra attenuata (Hydra) (Hydra vulgaris).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606, 10116, 9913, 6110, 6087;
 RN [1]
 RP SEQUENCE.
 RC SPECIES=Human, Rat, and Bovine;
 RX MEDLINE=82035850; PubMed=7290191;
 RA Bodenmuller H., Schaller H.C.;
 RT "Conserved amino acid sequence of a neuropeptide, the head activator,
 RT from coelenterates to humans.";
 RL Nature 293:579-580(1981).
 RN [2]
 RP SEQUENCE.
 RC SPECIES=A.elegantissima, and H.attenuata;
 RA Schaller H.C., Bodenmuller H.;
 RT "Isolation and amino acid sequence of a morphogenetic peptide from
 RT hydra.";
 RL Proc. Natl. Acad. Sci. U.S.A. 78:7000-7004(1981).
 RN [3]
 RP SYNTHESIS.
 RX MEDLINE=82050803; PubMed=7297679;
 RA Birr C., Zachmann B., Bodenmuller H., Schaller H.C.;
 RT "Synthesis of a new neuropeptide, the head activator from hydra.";
 RL FEBS Lett. 131:317-321(1981).
 RN [4]
 RP FUNCTION.
 RX MEDLINE=90059923; PubMed=2583101;
 RA Schaller H.C., Druffel-Augustin S., Dubel S.;
 RT "Head activator acts as an autocrine growth factor for NH15-CA2 cells
 RT in the G2/mitosis transition.";
 RL EMBO J. 8:3311-3318(1989).
 CC -!- FUNCTION: HA acts as an autocrine growth factor for neural cells
 CC in the G2/mitosis transition.
 CC -!- CAUTION: This peptide was first isolated from nerve cells of hydra
 CC and was called head activator by the authors, because it induced
 CC head-specific growth and differentiation in this animal. It has
 CC been found in mammalian intestine and hypothalamus.
 DR PIR; A01427; YHRT.
 DR PIR; A93900; YHXAE.
 DR PIR; B01427; YHHU.
 DR PIR; B93900; YHJFHY.
 DR PIR; C01427; YHBO.
 DR GK; P01163; -.
 KW Growth factor; Cell cycle; Mitosis; Pyrrolidone carboxylic acid.
 FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
 SQ SEQUENCE 11 AA; 1142 MW; 37927417C325B878 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.8e+04;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3
 ||
 Db 5 GS 6

RESULT 11

NUHM_CANFA

ID NUHM_CANFA STANDARD; PRT; 11 AA.
 AC P49820;
 DT 01-OCT-1996 (Rel. 34, Created)
 DT 15-JUL-1998 (Rel. 36, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE NADH-ubiquinone oxidoreductase 24 kDa subunit (EC 1.6.5.3)
 DE (EC 1.6.99.3) (Fragment).
 GN NDUFV2.
 OS Canis familiaris (Dog).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
 OX NCBI_TaxID=9615;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Heart;
 RX MEDLINE=98163340; PubMed=9504812;
 RA Dunn M.J., Corbett J.M., Wheeler C.H.;
 RT "HSC-2DPAGE and the two-dimensional gel electrophoresis database of
 RT dog heart proteins.";
 RL Electrophoresis 18:2795-2802(1997).
 CC -!- FUNCTION: TRANSFER OF ELECTRONS FROM NADH TO THE RESPIRATORY
 CC CHAIN. THE IMMEDIATE ELECTRON ACCEPTOR FOR THE ENZYME IS BELIEVED
 CC TO BE UBIQUINONE. COMPONENT OF THE FLAVOPROTEIN-SULFUR (FP)
 CC FRAGMENT OF THE ENZYME.
 CC -!- CATALYTIC ACTIVITY: NADH + ubiquinone = NAD(+) + ubiquinol.
 CC -!- CATALYTIC ACTIVITY: NADH + acceptor = NAD(+) + reduced acceptor.
 CC -!- COFACTOR: Binds 1 2Fe-2S cluster (Potential).
 CC -!- SUBUNIT: Mammalian complex I is composed of 45 different subunits.
 CC -!- SUBCELLULAR LOCATION: Matrix and cytoplasmic side of the
 CC mitochondrial inner membrane.
 CC -!- SIMILARITY: Belongs to the complex I 24 kDa subunit family.
 DR HSC-2DPAGE; P49820; DOG.
 DR InterPro; IPR002023; Cmplx1_24kDa.
 DR PROSITE; PS01099; COMPLEX1_24K; PARTIAL.
 KW Oxidoreductase; NAD; Ubiquinone; Mitochondrion; Metal-binding;
 KW Iron-sulfur; Iron; 2Fe-2S.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1099 MW; 267F5369C9C72DD8 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.8e+04;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AG 2
 ||
 Db 2 AG 3

RESULT 12

PQQC_PSEFL

ID PQQC_PSEFL STANDARD; PRT; 11 AA.
AC P55173;
DT 01-OCT-1996 (Rel. 34, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Coenzyme PQQ synthesis protein C (Pyrroloquinoline quinone
DE biosynthesis protein C) (Fragment).
GN PQQC.
OS Pseudomonas fluorescens.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales;
OC Pseudomonadaceae; Pseudomonas.
OX NCBI_TaxID=294;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CHA0;
RX MEDLINE=96064397; PubMed=8526497;
RA Schnider U., Keel C., Defago G., Haas D.;
RT "Tn5-directed cloning of pqq genes from Pseudomonas fluorescens CHA0:
RT mutational inactivation of the genes results in overproduction of the
RT antibiotic pyoluteorin.";
RL Appl. Environ. Microbiol. 61:3856-3864(1995).
CC -!- PATHWAY: Pyrroloquinoline quinone (PQQ) biosynthesis.
CC -!- SIMILARITY: Belongs to the pqqC family.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; X87299; CAA60734.1; -.
DR PIR; S58244; S58244.
DR HAMAP; MF_00654; -; 1.
KW PQQ biosynthesis.
FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1182 MW; 89DF46E4C5B73771 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.8e+04;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SA 4
||
Db 7 SA 8

RESULT 13

Q2OA_COMTE

ID Q2OA_COMTE STANDARD; PRT; 11 AA.
AC P80464;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Quinoline 2-oxidoreductase, alpha chain (EC 1.3.99.17) (Fragment).
OS Comamonas testosteroni (Pseudomonas testosteroni).

OC Bacteria; Proteobacteria; Betaproteobacteria; Burkholderiales;
 OC Comamonadaceae; Comamonas.
 OX NCBI_TaxID=285;
 RN [1]
 RP SEQUENCE.
 RC STRAIN=63;
 RX MEDLINE=96035889; PubMed=7556204;
 RA Schach S., Tshisuaka B., Fetzner S., Lingens F.;
 RT "Quinoline 2-oxidoreductase and 2-oxo-1,2-dihydroquinoline 5,6-
 RT dioxygenase from Comamonas testosteroni 63. The first two enzymes in
 RT quinoline and 3-methylquinoline degradation.";
 RL Eur. J. Biochem. 232:536-544(1995).
 CC -!- FUNCTION: Converts (3-methyl-)-quinoline to (3-methyl-)2-oxo-
 CC 1,2-dihydroquinoline.
 CC -!- CATALYTIC ACTIVITY: Quinoline + acceptor + H(2)O = isoquinolin-
 CC 1(2H)-one + reduced acceptor.
 CC -!- COFACTOR: FAD, molybdenum and iron-sulfur.
 CC -!- PATHWAY: Degradation of quinoline and (3-methyl-)quinoline; first
 CC step.
 CC -!- SUBUNIT: Heterohexamer of two alpha chains, two beta chains, and
 CC two gamma chains (Probable).
 DR PIR; S66606; S66606.
 KW Oxidoreductase; Flavoprotein; FAD; Molybdenum.
 FT NON TER 11 11
 SQ SEQUENCE 11 AA; 1213 MW; 869094322B1DC2CA CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.8e+04;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LK 8
 ||
 Db 8 LK 9

RESULT 14

RS30_ONCMY

ID RS30_ONCMY STANDARD; PRT; 11 AA.
 AC P83328;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE 40S ribosomal protein S30 (Fragment).
 GN FAU.
 OS Oncorhynchus mykiss (Rainbow trout) (Salmo gairdneri).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei;
 OC Protacanthopterygii; Salmoniformes; Salmonidae; Oncorhynchus.
 OX NCBI_TaxID=8022;
 RN [1]
 RP SEQUENCE, FUNCTION, AND MASS SPECTROMETRY.
 RC TISSUE=Skin mucus;
 RX MEDLINE=22142142; PubMed=12147245;
 RA Fernandes J.M.O., Smith V.J.;
 RT "A novel antimicrobial function for a ribosomal peptide from rainbow
 RT trout skin.";
 RL Biochem. Biophys. Res. Commun. 296:167-171(2002).

CC -!- FUNCTION: Has antibacterial activity against Gram-positive
 CC bacteria.
 CC -!- MASS SPECTROMETRY: MW=6676.6; METHOD=MALDI.
 CC -!- SIMILARITY: Belongs to the S30E family of ribosomal proteins.
 KW Ribosomal protein; Antibiotic.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1123 MW; 2312AB630DD735B8 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.8e+04;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 GS 3
 ||
 Db 4 GS 5

RESULT 15

ANGT_CRIGE

ID ANGT_CRIGE STANDARD; PRT; 11 AA.
 AC P09037;
 DT 01-NOV-1988 (Rel. 09, Created)
 DT 01-NOV-1988 (Rel. 09, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Crinia-angiotensin II.
 OS Crinia georgiana (Quacking frog).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Myobatrachidae;
 OC Myobatrachinae; Crinia.
 OX NCBI_TaxID=8374;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Skin secretion;
 RX MEDLINE=80024575; PubMed=488254;
 RA Erspamer V., Melchiorri P., Nakajima T., Yasuhara T., Endean R.;
 RT "Amino acid composition and sequence of crinia-angiotensin, an
 RT angiotensin II-like endecapeptide from the skin of the Australian
 RT frog Crinia georgiana."
 RL Experientia 35:1132-1133(1979).
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- TISSUE SPECIFICITY: Skin.
 DR PIR; S07207; S07207.
 KW Vasoconstrictor.
 SQ SEQUENCE 11 AA; 1271 MW; 8A0921F7DB50440A CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 A 1
 |
 Db 1 A 1

RESULT 16

ASL1_BACSE

ID ASL1_BACSE STANDARD; PRT; 11 AA.

AC P83146;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Acharan sulfate lyase 1 (EC 4.2.2.-) (Fragment).
 OS Bacteroides stercoris.
 OC Bacteria; Bacteroidetes; Bacteroides (class); Bacteroidales;
 OC Bacteroidaceae; Bacteroides.
 OX NCBI_TaxID=46506;
 RN [1]
 RP SEQUENCE, FUNCTION, ENZYME REGULATION, AND SUBUNIT.
 RC STRAIN=HJ-15;
 RX MEDLINE=21223019; PubMed=11322884;
 RA Kim B.-T., Hong S.-W., Kim W.-S., Kim Y.S., Kim D.-H.;
 RT "Purification and characterization of acharan sulfate lyases, two
 RT novel heparinases, from Bacteroides stercoris HJ-15."
 RL Eur. J. Biochem. 268:2635-2641(2001).
 CC -!- FUNCTION: Degrades acharan sulfate and, to a lesser extent,
 CC heparin and heparan sulfate.
 CC -!- ENZYME REGULATION: Inhibited by cupric ion, nitrogen and cobalt.
 CC Activated by reducing agents, such as DL-dithiothreitol and 2-
 CC mercaptoethanol.
 CC -!- SUBUNIT: Monomer.
 CC -!- PTM: The N-terminus is blocked.
 CC -!- MISCELLANEOUS: Has an isoelectric point of 8.6. Its optimum pH is
 CC 7.2 and optimum temperature 45 degrees Celsius.
 KW Lyase; Heparin-binding.
 FT NON_TER 1 1
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1395 MW; 01B2DAA241E865AB CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 S 3
 |
 Db 5 S 5

RESULT 17

ASL2_BACSE

ID ASL2_BACSE STANDARD; PRT; 11 AA.
 AC P83147;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Acharan sulfate lyase 2 (EC 4.2.2.-) (Fragment).
 OS Bacteroides stercoris.
 OC Bacteria; Bacteroidetes; Bacteroides (class); Bacteroidales;
 OC Bacteroidaceae; Bacteroides.
 OX NCBI_TaxID=46506;
 RN [1]
 RP SEQUENCE, FUNCTION, ENZYME REGULATION, AND SUBUNIT.
 RC STRAIN=HJ-15;
 RX MEDLINE=21223019; PubMed=11322884;
 RA Kim B.-T., Hong S.-W., Kim W.-S., Kim Y.S., Kim D.-H.;

RT "Purification and characterization of acharan sulfate lyases, two
 RT novel heparinases, from *Bacteroides stercoris* HJ-15.";
 RL Eur. J. Biochem. 268:2635-2641(2001).
 CC -!- FUNCTION: Degrades acharan sulfate and, to a lesser extent,
 CC heparin and heparan sulfate.
 CC -!- ENZYME REGULATION: Inhibited by cupric ion, nitrogen and lead.
 CC Activated by reducing agents, such as DL-dithiothreitol and 2-
 CC mercaptoethanol.
 CC -!- SUBUNIT: Monomer.
 CC -!- PTM: The N-terminus is blocked.
 CC -!- MISCELLANEOUS: Has an isoelectric point of 8.6. Its optimum pH is
 CC 7.2 and optimum temperature 45 degrees Celsius.
 KW Lyase; Heparin-binding.
 FT NON_TER 1 1
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1195 MW; D79D897C7AA451AD CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 A 1
 |
 Db 4 A 4

RESULT 18

BPP3 BOTIN

ID BPP3 BOTIN STANDARD; PRT; 11 AA.
 AC P30423;
 DT 01-APR-1993 (Rel. 25, Created)
 DT 01-FEB-1994 (Rel. 28, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Bradykinin-potentiating peptide S4,3,2 (10C) (Angiotensin-converting
 DE enzyme inhibitor).
 OS Bothrops insularis (Island jararaca) (Queimada jararaca).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Lepidosauria; Squamata; Scleroglossa; Serpentes; Colubroidea;
 OC Viperidae; Crotalinae; Bothrops.
 OX NCBI_TaxID=8723;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Venom;
 RX MEDLINE=90351557; PubMed=2386615;
 RA Cintra A.C.O., Vieira C.A., Giglio J.R.;
 RT "Primary structure and biological activity of bradykinin potentiating
 RT peptides from *Bothrops insularis* snake venom."
 RL J. Protein Chem. 9:221-227(1990).
 CC -!- FUNCTION: This peptide both inhibits the activity of the
 CC angiotensin-converting enzyme and enhances the action of
 CC bradykinin by inhibiting the kinases that inactivate it.
 CC It acts as an indirect hypotensive agent.
 DR PIR; C37196; C37196.
 KW Hypotensive agent; Pyrrolidone carboxylic acid.
 FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
 SQ SEQUENCE 11 AA; 1199 MW; 20B25813C7741777 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 L 7
|
Db 2 L 2

RESULT 19

BPP4_BOTIN

ID BPP4_BOTIN STANDARD; PRT; 11 AA.
AC P30424;
DT 01-APR-1993 (Rel. 25, Created)
DT 01-FEB-1994 (Rel. 28, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Bradykinin-potentiating peptide S4,1,2 (Angiotensin-converting
DE enzyme inhibitor).
OS Bothrops insularis (Island jararaca) (Queimada jararaca).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Lepidosauria; Squamata; Scleroglossa; Serpentes; Colubroidea;
OC Viperidae; Crotalinae; Bothrops.
OX NCBI_TaxID=8723;
RN [1]
RP SEQUENCE.
RC TISSUE=Venom;
RX MEDLINE=90351557; PubMed=2386615;
RA Cintra A.C.O., Vieira C.A., Giglio J.R.;
RT "Primary structure and biological activity of bradykinin potentiating
RT peptides from Bothrops insularis snake venom."
RL J. Protein Chem. 9:221-227(1990).
CC -!- FUNCTION: This peptide both inhibits the activity of the
CC angiotensin-converting enzyme and enhances the action of
CC bradykinin by inhibiting the kinases that inactivate it.
CC It acts as an indirect hypotensive agent.
DR PIR; D37196; D37196.
KW Hypotensive agent; Pyrrolidone carboxylic acid.
FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
SQ SEQUENCE 11 AA; 1143 MW; 20BBBF13C7741777 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 G 2
|
Db 2 G 2

RESULT 20

BPPB_AGKHA

ID BPPB_AGKHA STANDARD; PRT; 11 AA.
AC P01021;
DT 21-JUL-1986 (Rel. 01, Created)
DT 01-FEB-1994 (Rel. 28, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Bradykinin-potentiating peptide B (Angiotensin-converting

DE enzyme inhibitor).

OS Agkistrodon halys blomhoffii (Mamushi) (Gloydus blomhoffii).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Lepidosauria; Squamata; Scleroglossa; Serpentes; Colubroidea;

OC Viperidae; Crotalinae; Gloydus.

OX NCBI_TaxID=242054;

RN [1]

RP SEQUENCE.

RC TISSUE=Venom;

RA Kato H., Suzuki T.;

RT "Amino acid sequence of bradykinin-potentiating peptide isolated from

RT the venom of Agkistrodon halys blomhoffii.";

RL Proc. Jpn. Acad., B, Phys. Biol. Sci. 46:176-181(1970).

CC -!- FUNCTION: This peptide both inhibits the activity of the

CC angiotensin-converting enzyme and enhances the action of

CC bradykinin by inhibiting the kinases that inactivate it.

CC It acts as an indirect hypotensive agent.

DR PIR; A01254; XASNBA.

KW Hypotensive agent; Pyrrolidone carboxylic acid.

FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.

SQ SEQUENCE 11 AA; 1199 MW; 295CBF0627741777 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.1e+05;

Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 G 2

|

Db 2 G 2

RESULT 21

BPP_AGKHP

ID BPP_AGKHP STANDARD; PRT; 11 AA.

AC P04562;

DT 13-AUG-1987 (Rel. 05, Created)

DT 01-FEB-1994 (Rel. 28, Last sequence update)

DT 28-FEB-2003 (Rel. 41, Last annotation update)

DE Bradykinin-potentiating peptide (Angiotensin-converting

DE enzyme inhibitor).

OS Agkistrodon halys pallas (Chinese water moccasin) (Gloydus halys

OS pallas).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Lepidosauria; Squamata; Scleroglossa; Serpentes; Colubroidea;

OC Viperidae; Crotalinae; Gloydus.

OX NCBI_TaxID=8714;

RN [1]

RP SEQUENCE.

RC TISSUE=Venom;

RX MEDLINE=86177022; PubMed=3008123;

RA Chi C.-W., Wang S.-Z., Xu L.-G., Wang M.-Y., Lo S.-S., Huang W.-D.;

RT "Structure-function studies on the bradykinin potentiating peptide

RT from Chinese snake venom (Agkistrodon halys pallas).";

RL Peptides 6 Suppl. 3:339-342(1985).

CC -!- FUNCTION: This peptide both inhibits the activity of the

CC angiotensin-converting enzyme and enhances the action of

CC bradykinin by inhibiting the kinases that inactivate it.

CC It acts as an indirect hypotensive agent.
 DR PIR; JC0002; XAVIBH.
 KW Hypotensive agent; Pyrrolidone carboxylic acid.
 FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
 SQ SEQUENCE 11 AA; 1112 MW; 30BABF1277686777 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 G 2
 |
 Db 2 G 2

RESULT 22

CA21_LITCI

ID CA21_LITCI STANDARD; PRT; 11 AA.
 AC P82087;
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Caerulein 2.1/2.1Y4.
 OS Litoria citropa (Australian blue mountains tree frog).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hylloidea; Hylidae;
 OC Pelodyadinae; Litoria.
 OX NCBI_TaxID=94770;
 RN [1]
 RP SEQUENCE, AND MASS SPECTROMETRY.
 RC TISSUE=Skin secretion;
 RX MEDLINE=20057701; PubMed=10589099;
 RA Wabnitz P.A., Bowie J.H., Tyler M.J.;
 RT "Caerulein-like peptides from the skin glands of the Australian blue
 RT montains tree frog Litoria citropa. Part 1. Sequence determination
 RT using electrospray mass spectrometry."
 RL Rapid Commun. Mass Spectrom. 13:2498-2502(1999).
 CC -!- FUNCTION: Hypotensive neuropeptide (Probable).
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- TISSUE SPECIFICITY: Skin dorsal glands.
 CC -!- PTM: Isoform 2.1Y4 differs from isoform 2.1 in not being
 CC sulfated.
 CC -!- MASS SPECTROMETRY: MW=1372; METHOD=Electrospray.
 CC -!- SIMILARITY: Belongs to the gastrin/cholecystokinin family.
 DR InterPro; IPR001651; Gastrin.
 DR PROSITE; PS00259; GASTRIN; FALSE_NEG.
 KW Amphibian defense peptide; Hypotensive agent; Amidation; Sulfation;
 KW Pyrrolidone carboxylic acid.
 FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
 FT MOD_RES 4 4 SULFATION.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1312 MW; 10DAB7C4EDD861BB CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 G 2
|
Db 6 G 6

RESULT 23

CA22_LITCI

ID CA22_LITCI STANDARD; PRT; 11 AA.
AC P82088;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Caerulein 2.2/2.2Y4.
OS Litoria citropa (Australian blue mountains tree frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Hylidae;
OC Pelodyadinae; Litoria.
OX NCBI_TaxID=94770;
RN [1]
RP SEQUENCE, AND MASS SPECTROMETRY.
RC TISSUE=Skin secretion;
RX MEDLINE=20057701; PubMed=10589099;
RA Wabnitz P.A., Bowie J.H., Tyler M.J.;
RT "Caerulein-like peptides from the skin glands of the Australian blue
RT mountains tree frog Litoria citropa. Part 1. Sequence determination
RT using electrospray mass spectrometry."
RL Rapid Commun. Mass Spectrom. 13:2498-2502(1999).
CC -!- FUNCTION: Hypotensive neuropeptide (Probable).
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- TISSUE SPECIFICITY: Skin dorsal glands.
CC -!- PTM: Isoform 2.2Y4 differs from isoform 2.2 in not being
CC sulfated.
CC -!- MASS SPECTROMETRY: MW=1388; METHOD=Electrospray.
CC -!- SIMILARITY: Belongs to the gastrin/cholecystokinin family.
DR InterPro; IPR001651; Gastrin.
DR PROSITE; PS00259; GASTRIN; FALSE_NEG.
KW Amphibian defense peptide; Hypotensive agent; Amidation; Sulfation;
KW Pyrrolidone carboxylic acid.
FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
FT MOD_RES 4 4 SULFATION.
FT MOD_RES 11 11 AMIDATION.
SQ SEQUENCE 11 AA; 1328 MW; 10DAB894EDD861BB CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 G 2
|
Db 6 G 6

RESULT 24

CA31_LITCI

ID CA31_LITCI STANDARD; PRT; 11 AA.
AC P82089;
DT 16-OCT-2001 (Rel. 40, Created)

DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Caerulein 3.1/3.1Y4.
 OS Litoria citropa (Australian blue mountains tree frog).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Hylidae;
 OC Pelodyadinae; Litoria.
 OX NCBI_TaxID=94770;
 RN [1]
 RP SEQUENCE, AND MASS SPECTROMETRY.
 RC TISSUE=Skin secretion;
 RX MEDLINE=20057701; PubMed=10589099;
 RA Wabnitz P.A., Bowie J.H., Tyler M.J.;
 RT "Caerulein-like peptides from the skin glands of the Australian blue
 RT mountains tree frog Litoria citropa. Part 1. Sequence determination
 RT using electrospray mass spectrometry."
 RL Rapid Commun. Mass Spectrom. 13:2498-2502(1999).
 CC -!- FUNCTION: Hypotensive neuropeptide (Probable).
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- TISSUE SPECIFICITY: Skin dorsal glands.
 CC -!- PTM: Isoform 3.1Y4 differs from isoform 3.1 in not being
 CC sulfated.
 CC -!- MASS SPECTROMETRY: MW=1407; METHOD=Electrospray.
 CC -!- SIMILARITY: Belongs to the gastrin/cholecystokinin family.
 DR InterPro; IPR001651; Gastrin.
 DR PROSITE; PS00259; GASTRIN; FALSE_NEG.
 KW Amphibian defense peptide; Hypotensive agent; Amidation; Sulfation;
 KW Pyrrolidone carboxylic acid.
 FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
 FT MOD_RES 4 4 SULFATION.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1347 MW; 10DAB7D67861A86B CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 G 2
 |
 Db 5 G 5

RESULT 25

CA32_LITCI
 ID CA32_LITCI STANDARD; PRT; 11 AA.
 AC P82090;
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Caerulein 3.2/3.2Y4.
 OS Litoria citropa (Australian blue mountains tree frog).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Hylidae;
 OC Pelodyadinae; Litoria.
 OX NCBI_TaxID=94770;
 RN [1]
 RP SEQUENCE, AND MASS SPECTROMETRY.

RC TISSUE=Skin secretion;
 RX MEDLINE=20057701; PubMed=10589099;
 RA Wabnitz P.A., Bowie J.H., Tyler M.J.;
 RT "Caerulein-like peptides from the skin glands of the Australian blue
 RT montains tree frog *Litoria citropa*. Part 1. Sequence determination
 RT using electrospray mass spectrometry."
 RL Rapid Commun. Mass Spectrom. 13:2498-2502(1999).
 CC -!- FUNCTION: Hypotensive neuropeptide (Probable).
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- TISSUE SPECIFICITY: Skin dorsal glands.
 CC -!- PTM: Isoform 3.2Y4 differs from isoform 3.2 in not being
 CC sulfated.
 CC -!- MASS SPECTROMETRY: MW=1423; METHOD=Electrospray.
 CC -!- SIMILARITY: Belongs to the gastrin/cholecystokinin family.
 DR InterPro; IPR001651; Gastrin.
 DR PROSITE; PS00259; GASTRIN; FALSE_NEG.
 KW Amphibian defense peptide; Hypotensive agent; Amidation; Sulfation;
 KW Pyrrolidone carboxylic acid.
 FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
 FT MOD_RES 4 4 SULFATION.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1363 MW; 10DAB8867861A86B CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 G 2
 |
 Db 5 G 5

RESULT 26

CEPl_ACHFU
 ID CEPl_ACHFU STANDARD; PRT; 11 AA.
 AC P22790;
 DT 01-AUG-1991 (Rel. 19, Created)
 DT 01-AUG-1991 (Rel. 19, Last sequence update)
 DT 01-DEC-1992 (Rel. 24, Last annotation update)
 DE Cardio-excitatory peptide-1 (ACEP-1).
 OS Achatina fulica (Giant African snail).
 OC Eukaryota; Metazoa; Mollusca; Gastropoda; Pulmonata; Stylommatophora;
 OC Sigmurethra; Achatinoidea; Achatinidae; Achatina.
 OX NCBI_TaxID=6530;
 RN [1]
 RP SEQUENCE.
 RC STRAIN=Ferussac; TISSUE=Heart atrium;
 RX MEDLINE=90211261; PubMed=2322251;
 RA Fujimoto K., Ohta N., Yoshida M., Kubota I., Muneoka Y., Kobayashi M.;
 RT "A novel cardio-excitatory peptide isolated from the atria of the
 RT African giant snail, *Achatina fulica*."
 RL Biochem. Biophys. Res. Commun. 167:777-783(1990).
 CC -!- FUNCTION: Potentiates the beat of the ventricle, and has also
 CC excitatory actions on the penis retractor muscle, the buccal
 CC muscle and the identified neurons controlling the buccal muscle
 CC movement of achatina.
 CC -!- SIMILARITY: TO POSSIBLE PEPTIDE L5 FROM APLYSIA.

DR PIR; A34662; A34662.
KW Hormone; Amidation.
FT MOD_RES 11 11 AMIDATION.
SQ SEQUENCE 11 AA; 1305 MW; 82D6D5B9C7741365 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 S 3
|
Db 1 S 1

RESULT 27

CORZ_PERAM

ID CORZ_PERAM STANDARD; PRT; 11 AA.
AC P11496;
DT 01-OCT-1989 (Rel. 12, Created)
DT 01-FEB-1994 (Rel. 28, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Corazonin.
OS Periplaneta americana (American cockroach).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blattoidea;
OC Blattidae; Periplaneta.
OX NCBI_TaxID=6978;
RN [1]
RP SEQUENCE.
RC TISSUE=Corpora cardiaca;
RX MEDLINE=89325572; PubMed=2753132;
RA Veenstra J.A.;
RT "Isolation and structure of corazonin, a cardioactive peptide from
RT the American cockroach.";
RL FEBS Lett. 250:231-234(1989).
CC -!- FUNCTION: Cardioactive peptide. Corazonin is probably involved
CC in the physiological regulation of the heart beat.
CC -!- SUBCELLULAR LOCATION: Secreted.
DR PIR; S05002; S05002.
KW Neuropeptide; Amidation; Pyrrolidone carboxylic acid.
FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
FT MOD_RES 11 11 AMIDATION.
SQ SEQUENCE 11 AA; 1387 MW; C7CFF32D6415AB46 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 S 3
|
Db 6 S 6

RESULT 28

CX5B_CONAL

ID CX5B_CONAL STANDARD; PRT; 11 AA.
AC P58849;

DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 15-MAR-2004 (Rel. 43, Last annotation update)
 DE Conotoxin au5b.
 OS Conus aulicus (Court cone).
 OC Eukaryota; Metazoa; Mollusca; Gastropoda; Orthogastropoda;
 OC Apogastropoda; Caenogastropoda; Sorbeoconcha; Hypsogastropoda;
 OC Neogastropoda; Conoidea; Conidae; Conus.
 OX NCBI_TaxID=89437;
 RN [1]
 RP SEQUENCE, AND MASS SPECTROMETRY.
 RC TISSUE=Venom;
 RX MEDLINE=99452958; PubMed=10521453;
 RA Walker C.S., Steel D., Jacobsen R.B., Lirazan M.B., Cruz L.J.,
 RA Hooper D., Shetty R., DelaCruz R.C., Nielsen J.S., Zhou L.M.,
 RA Bandyopadhyay P., Craig A.G., Olivera B.M.;
 RT "The T-superfamily of conotoxins."
 RL J. Biol. Chem. 274:30664-30671(1999).
 RN [2]
 RP ERRATUM.
 RA Walker C.S., Steel D., Jacobsen R.B., Lirazan M.B., Cruz L.J.,
 RA Hooper D., Shetty R., DelaCruz R.C., Nielsen J.S., Zhou L.M.,
 RA Bandyopadhyay P., Craig A.G., Olivera B.M.;
 RL J. Biol. Chem. 274:36030-36030(1999).
 CC -!- FUNCTION: Causes dorsal fins drooping in fish. No effect is
 CC observed when injected into mice (By similarity).
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- TISSUE SPECIFICITY: Expressed by the venom duct.
 CC -!- MASS SPECTROMETRY: MW=1388.6; METHOD=LSIMS.
 CC -!- SIMILARITY: Belongs to the conotoxin T-superfamily.
 DR PIR; B59146; B59146.
 KW Toxin.
 FT DISULFID 2 9
 FT DISULFID 3 10
 SQ SEQUENCE 11 AA; 1393 MW; 21A36775440042D7 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 V 5
 |
 Db 5 V 5

RESULT 29
 EFG_CLOPA
 ID EFG_CLOPA STANDARD; PRT; 11 AA.
 AC P81350;
 DT 15-JUL-1998 (Rel. 36, Created)
 DT 15-JUL-1998 (Rel. 36, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Elongation factor G (EF-G) (CP 5) (Fragment).
 GN FUSA.
 OS Clostridium pasteurianum.
 OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;
 OC Clostridium.

OX NCBI_TaxID=1501;
 RN [1]
 RP SEQUENCE.
 RC STRAIN=W5;
 RX MEDLINE=98291870; PubMed=9629918;
 RA Flengsrud R., Skjeldal L.;
 RT "Two-dimensional gel electrophoresis separation and N-terminal
 RT sequence analysis of proteins from Clostridium pasteurianum W5.";
 RL Electrophoresis 19:802-806(1998).
 CC -!- FUNCTION: This protein promotes the GTP-dependent translocation of
 CC the nascent protein chain from the A-site to the P-site of the
 CC ribosome.
 CC -!- SUBCELLULAR LOCATION: Cytoplasmic.
 CC -!- SIMILARITY: Belongs to the GTP-binding elongation factor family.
 CC EF-G/EF-2 subfamily.
 DR InterPro; IPR000795; EF_GTPbind.
 DR PROSITE; PS00301; EFACTOR_GTP; PARTIAL.
 KW Elongation factor; Protein biosynthesis; GTP-binding.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1337 MW; 412E71F1D9C33B17 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 K 6
 |
 Db 1 K 1

RESULT 30

ES1_RAT
 ID ES1_RAT STANDARD; PRT; 11 AA.
 AC P56571;
 DT 15-DEC-1998 (Rel. 37, Created)
 DT 15-DEC-1998 (Rel. 37, Last sequence update)
 DT 15-MAR-2004 (Rel. 43, Last annotation update)
 DE ES1 protein, mitochondrial (Fragment).
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 OX NCBI_TaxID=10116;
 RN [1]
 RP SEQUENCE.
 RC STRAIN=Wistar; TISSUE=Heart;
 RA Li X.-P., Pleissner K.-P., Scheler C., Regitz-Zagrosek V., Salikov J.,
 RA Jungblut P.R.;
 RL Submitted (SEP-1998) to Swiss-Prot.
 CC -!- SUBCELLULAR LOCATION: Mitochondrial (Potential).
 CC -!- MISCELLANEOUS: By 2D-PAGE, the determined pI of this protein (spot
 CC P2) is: 8.9, its MW is: 25 kDa.
 CC -!- SIMILARITY: BELONGS TO THE ES1 FAMILY.
 KW Mitochondrion.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1142 MW; D862272D32C72DC2 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.1e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 A 1
|
Db 2 A 2

RESULT 31

FAR6_PENMO

ID FAR6_PENMO STANDARD; PRT; 11 AA.
AC P83321;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE FMRFamide-like neuropeptide FLP6 (DGRTPALRLRF-amide).
OS Penaeus monodon (Penoeid shrimp).
OC Eukaryota; Metazoa; Arthropoda; Crustacea; Malacostraca;
OC Eumalacostraca; Eucarida; Decapoda; Dendrobranchiata; Penaeoidea;
OC Penaeidae; Penaeus.
OX NCBI_TaxID=6687;
RN [1]
RP SEQUENCE, AND MASS SPECTROMETRY.
RC TISSUE=Eyestalk;
RX MEDLINE=21956277; PubMed=11959015;
RA Sithigorngul P., Pupuem J., Krungkasem C., Longyant S.,
RA Chaivisuthangkura P., Sithigorngul W., Petsom A.;
RT "Seven novel FMRFamide-like neuropeptide sequences from the eyestalk
RT of the giant tiger prawn Penaeus monodon."
RL Comp. Biochem. Physiol. 131B:325-337(2002).
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- MASS SPECTROMETRY: MW=1301.8; METHOD=MALDI.
CC -!- SIMILARITY: Belongs to the FARP (FMRFamide related peptide)
CC family.
DR GO; GO:0007218; P:neuropeptide signaling pathway; TAS.
KW Neuropeptide; Amidation.
FT MOD RES 11 11 AMIDATION.
SQ SEQUENCE 11 AA; 1301 MW; 9A19C860072DC771 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 G 2
|
Db 2 G 2

RESULT 32

FAR9_CALVO

ID FAR9_CALVO STANDARD; PRT; 11 AA.
AC P41864;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 01-NOV-1995 (Rel. 32, Last annotation update)
DE CalliFMRFamide 9.
OS Calliphora vomitoria (Blue blowfly).

OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
 OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha; Oestroidea;
 OC Calliphoridae; Calliphora.
 OX NCBI_TaxID=27454;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Thoracic ganglion;
 RX MEDLINE=92196111; PubMed=1549595;
 RA Duve H., Johnsen A.H., Sewell J.C., Scott A.G., Orchard I.,
 RA Rehfeld J.F., Thorpe A.;
 RT "Isolation, structure, and activity of -Phe-Met-Arg-Phe-NH2
 RT neuropeptides (designated calliFMRFamides) from the blowfly
 RT Calliphora vomitoria.";
 RL Proc. Natl. Acad. Sci. U.S.A. 89:2326-2330(1992).
 CC -!- SIMILARITY: Belongs to the FARP (FMRFamide related peptide)
 CC family.
 DR PIR; I41978; I41978.
 KW Neuropeptide; Amidation.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1359 MW; 8160CE46CAA44321 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 S 3
 |
 Db 1 S 1

RESULT 33

HS70_PINPS

ID HS70_PINPS STANDARD; PRT; 11 AA.
 AC P81672;
 DT 15-JUL-1999 (Rel. 38, Created)
 DT 15-JUL-1999 (Rel. 38, Last sequence update)
 DT 15-MAR-2004 (Rel. 43, Last annotation update)
 DE Heat shock 70 kDa protein (Fragment).
 OS Pinus pinaster (Maritime pine).
 OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 OC Spermatophyta; Coniferopsida; Coniferales; Pinaceae; Pinus.
 OX NCBI_TaxID=71647;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Needle;
 RX MEDLINE=99274088; PubMed=10344291;
 RA Costa P., Pionneau C., Bauw G., Dubos C., Bahrman N., Kremer A.,
 RA Frigerio J.-M., Plomion C.;
 RT "Separation and characterization of needle and xylem maritime pine
 RT proteins.";
 RL Electrophoresis 20:1098-1108(1999).
 CC -!- MISCELLANEOUS: On the 2D-gel the determined pI of this protein
 CC (spot N164) is: 5.4, its MW is: 73 kDa.
 CC -!- SIMILARITY: Belongs to the heat shock protein 70 family.
 KW ATP-binding; Heat shock; Multigene family.
 FT NON_TER 1 1
 FT NON_TER 11 11

SQ SEQUENCE 11 AA; 1228 MW; 037C1BE8DAA44DD0 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 V 5
|
Db 1 V 1

RESULT 34

LADD_ONCMY

ID LADD_ONCMY STANDARD; PRT; 11 AA.
AC P81018;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 15-DEC-1998 (Rel. 37, Last annotation update)
DE Ladderlectin (Fragment).
OS Oncorhynchus mykiss (Rainbow trout) (Salmo gairdneri).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei;
OC Protacanthopterygii; Salmoniformes; Salmonidae; Oncorhynchus.
OX NCBI_TaxID=8022;
RN [1]
RP SEQUENCE.
RC TISSUE=Blood;
RX MEDLINE=97293418; PubMed=9149391;
RA Jensen L.E., Thiel S., Petersen T.E., Jensenuis J.C.;
RT "A rainbow trout lectin with multimeric structure."
RL Comp. Biochem. Physiol. 116B:385-390(1997).
CC -!- FUNCTION: Lectin that binds sepharose.
CC -!- COFACTOR: Calcium is essential for sepharose binding.
CC -!- SUBUNIT: Multimeric.
KW Lectin; Calcium.
FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1163 MW; 0B26227FF6D45404 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 A 1
|
Db 1 A 1

RESULT 35

LSK1_LEUMA

ID LSK1_LEUMA STANDARD; PRT; 11 AA.
AC P04428;
DT 13-AUG-1987 (Rel. 05, Created)
DT 13-AUG-1987 (Rel. 05, Last sequence update)
DT 15-MAR-2004 (Rel. 43, Last annotation update)
DE Leucosulfakinin-I (LSK-I).
OS Leucophaea maderae (Madeira cockroach).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;

OC Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blaberoidea;
 OC Blaberidae; Leucophaea.
 OX NCBI_TaxID=6988;
 RN [1]
 RP SEQUENCE.
 RX MEDLINE=86315858; PubMed=3749893;
 RA Nachman R.J., Holman G.M., Haddon W.F., Ling N.;
 RT "Leucosulfakinin, a sulfated insect neuropeptide with homology to
 RT gastrin and cholecystokinin.";
 RL Science 234:71-73(1986).
 CC -!- FUNCTION: Change the frequency and amplitude of contractions of
 CC the hingat. Inhibits muscle contraction of hindgut.
 CC -!- SIMILARITY: Belongs to the gastrin/cholecystokinin family.
 DR PIR; A01622; GMROL.
 DR InterPro; IPR001651; Gastrin.
 DR PROSITE; PS00259; GASTRIN; 1.
 KW Hormone; Amidation; Sulfation.
 FT MOD_RES 6 6 SULFATION.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1459 MW; 7E4E0680E86B5AAB CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 G 2
 |
 Db 7 G 7

RESULT 36

LSKP_PERAM

ID LSKP_PERAM STANDARD; PRT; 11 AA.
 AC P36885;
 DT 01-JUN-1994 (Rel. 29, Created)
 DT 01-JUN-1994 (Rel. 29, Last sequence update)
 DT 01-FEB-1996 (Rel. 33, Last annotation update)
 DE Perisulfakinin (Pea-SK-I).
 OS Periplaneta americana (American cockroach).
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
 OC Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blattoidea;
 OC Blattidae; Periplaneta.
 OX NCBI_TaxID=6978;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Corpora cardiaca;
 RX MEDLINE=90137190; PubMed=2615921;
 RA Veenstra J.A.;
 RT "Isolation and structure of two gastrin/CCK-like neuropeptides from
 RT the American cockroach homologous to the leucosulfakinins.";
 RL Neuropeptides 14:145-149(1989).
 CC -!- FUNCTION: Stimulates hindgut contractions.
 CC -!- SIMILARITY: Belongs to the gastrin/cholecystokinin family.
 DR PIR; A60656; A60656.
 DR InterPro; IPR001651; Gastrin.
 DR PROSITE; PS00259; GASTRIN; 1.
 KW Hormone; Amidation; Sulfation.

FT MOD_RES 6 6 SULFATION.
FT MOD_RES 11 11 AMIDATION.
SQ SEQUENCE 11 AA; 1445 MW; 8B4E0680E86B5AAA CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 G 2
|
Db 7 G 7

RESULT 37

MLG THETS

ID MLG_THETS STANDARD; PRT; 11 AA.
AC P41989;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Melanotropin gamma (Gamma-melanocyte stimulating hormone) (Gamma-MSH).
OS Theromyzon tessulatum (Leech).
OC Eukaryota; Metazoa; Annelida; Clitellata; Hirudinida; Hirudinea;
OC Rhynchobdellida; Glossiphoniidae; Theromyzon.
OX NCBI_TaxID=13286;
RN [1]
RP SEQUENCE.
RC TISSUE=Brain;
RX MEDLINE=94298944; PubMed=8026574;
RA Salzet M., Wattez C., Bulet P., Malecha J.;
RT "Isolation and structural characterization of a novel peptide related
RT to gamma-melanocyte stimulating hormone from the brain of the leech
RT Theromyzon tessulatum.";
RL FEBS Lett. 348:102-106(1994).
CC -!- SIMILARITY: Belongs to the POMC family.
DR PIR; S45698; S45698.
KW Hormone; Amidation.
FT MOD_RES 11 11 AMIDATION.
SQ SEQUENCE 11 AA; 1486 MW; 2DB8FACE6409C1E8 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 V 5
|
Db 2 V 2

RESULT 38

NXSN PSETE

ID NXSN_PSETE STANDARD; PRT; 11 AA.
AC P59072;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Short neurotoxin N1 (Alpha neurotoxin) (Fragment).

OS Pseudonaja textilis (Eastern brown snake).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Lepidosauria; Squamata; Scleroglossa; Serpentes; Colubroidea;
 OC Elapidae; Acanthophiinae; Pseudonaja.
 OX NCBI_TaxID=8673;
 RN [1]
 RP SEQUENCE, AND MASS SPECTROMETRY.
 RC TISSUE=Venom;
 RX MEDLINE=99449602; PubMed=10518793;
 RA Gong N.L., Armugam A., Jeyaseelan K.;
 RT "Postsynaptic short-chain neurotoxins from Pseudonaja textilis: cDNA
 RT cloning, expression and protein characterization.";
 RL Eur. J. Biochem. 265:982-989(1999).
 CC -!- FUNCTION: Lethal neurotoxin, binds and inhibits nicotinic
 CC acetylcholine receptors (nAChR).
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- TISSUE SPECIFICITY: Expressed by the venom gland.
 CC -!- MASS SPECTROMETRY: MW=6236; METHOD=Electrospray.
 CC -!- MISCELLANEOUS: LD(50) is 0.84 mg/kg by intravenous injection.
 CC -!- SIMILARITY: Belongs to the snake toxin family.
 DR InterPro; IPR003571; Snake_toxin.
 DR PROSITE; PS00272; SNAKE_TOXIN; PARTIAL.
 KW Toxin; Neurotoxin; Postsynaptic neurotoxin;
 KW Acetylcholine receptor inhibitor; Multigene family.
 FT UNSURE 3 3
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1319 MW; 0D1EF0C81B58732B CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.le+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 L 7
 |
 Db 1 L 1

RESULT 39

PKC1_CARMO
 ID PKC1_CARMO STANDARD; PRT; 11 AA.
 AC P82684;
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 16-OCT-2001 (Rel. 40, Last annotation update)
 DE Pyrokinin-1 (Cam-PK-1) (FXPRL-Amide).
 OS Carausius morosus (Indian stick insect).
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
 OC Neoptera; Orthopteroidea; Phasmatodea; Euphasmida; Phasmatoidea;
 OC Heteronemiidae; Carausius.
 OX NCBI_TaxID=7022;
 RN [1]
 RP SEQUENCE, FUNCTION, AND MASS SPECTROMETRY.
 RC TISSUE=Corpora cardiaca;
 RA Predel R., Kellner R., Gaede G.;
 RT "Myotropic neuropeptides from the retrocerebral complex of the stick
 RT insect, Carausius morosus (Phasmatodea: Lonchodidae).";
 RL Eur. J. Entomol. 96:275-278(1999).

CC -!- FUNCTION: Mediates visceral muscle contractile activity (myotropic
 CC activity).
 CC -!- MASS SPECTROMETRY: MW=1235; METHOD=MALDI.
 CC -!- SIMILARITY: Belongs to the pyrokinin family.
 DR InterPro; IPR001484; Pyrokinin.
 DR PROSITE; PS00539; PYROKININ; FALSE_NEG.
 KW Neuropeptide; Amidation; Pyrokinin.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1236 MW; 2BFA5225BB46C1A8 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 G 2
 |
 Db 3 G 3

RESULT 40

PVK1_PERAM

ID PVK1_PERAM STANDARD; PRT; 11 AA.
 AC P41837;
 DT 01-NOV-1995 (Rel. 32, Created)
 DT 01-NOV-1995 (Rel. 32, Last sequence update)
 DT 16-OCT-2001 (Rel. 40, Last annotation update)
 DE Periviscerokinin-1 (Pea-PVK-1).
 OS Periplaneta americana (American cockroach).
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
 OC Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blattoidea;
 OC Blattidae; Periplaneta.
 OX NCBI_TaxID=6978;
 RN [1]
 RP SEQUENCE, AND SYNTHESIS.
 RC TISSUE=Abdominal perisymphathetic organs;
 RX MEDLINE=95232021; PubMed=7716075;
 RA Predel R., Linde D., Rapus J., Vettermann S., Penzlin H.;
 RT "Periviscerokinin (Pea-PVK): a novel myotropic neuropeptide from the
 RT perisymphathetic organs of the American cockroach."
 RL Peptides 16:61-66(1995).
 CC -!- FUNCTION: MYOACTIVE PEPTIDE; HAS EXCITORY ACTIONS ON THE
 CC HYPERNEURAL MUSCLE.
 KW Neuropeptide; Amidation.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1114 MW; 39DB5419D7605728 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 G 2
 |
 Db 1 G 1

RESULT 41

RANC_RANPI

ID RANC_RANPI STANDARD; PRT; 11 AA.
AC P08951;
DT 01-NOV-1988 (Rel. 09, Created)
DT 01-NOV-1988 (Rel. 09, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Ranatensin-C.
OS Rana pipiens (Northern leopard frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Neobatrachia; Ranoidea; Ranidae; Rana.
OX NCBI_TaxID=8404;
RN [1]
RP SEQUENCE.
RC TISSUE=Skin secretion;
RX MEDLINE=84131098; PubMed=6141890;
RA Nakajima T.;
RL Unpublished results, cited by:
RL Erspamer V., Erspamer G.F., Mazzanti G., Endean R.;
RL Comp. Biochem. Physiol. 77C:99-108(1984).
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- TISSUE SPECIFICITY: Skin.
CC -!- SIMILARITY: Belongs to the bombesin/neuromedin B/ranatensin
CC family.
DR InterPro; IPR000874; Bombesin.
DR Pfam; PF02044; Bombesin; 1.
DR PROSITE; PS00257; BOMBESIN; 1.
KW Amphibian defense peptide; Bombesin family; Amidation.
FT MOD_RES 11 11 AMIDATION.
SQ SEQUENCE 11 AA; 1304 MW; D6C9885A61ADC366 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 A 1
|
Db 6 A 6

RESULT 42

RE41_LITRU
ID RE41_LITRU STANDARD; PRT; 11 AA.
AC P82074;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Rubellidin 4.1.
OS Litoria rubella (Desert tree frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Hylidae;
OC Pelodyadinae; Litoria.
OX NCBI_TaxID=104895;
RN [1]
RP SEQUENCE, AND MASS SPECTROMETRY.
RC TISSUE=Skin secretion;
RA Steinborner S.T., Wabnitz P.A., Waugh R.J., Bowie J.H., Gao C.,
RA Tyler M.J., Wallace J.C.;
RT "The structure of new peptides from the Australian red tree frog

RT 'Litoria rubella'. The skin peptide profile as a probe for the study
 RT of evolutionary trends of amphibians.";
 RL Aust. J. Chem. 49:955-963(1996).
 CC -!- FUNCTION: Shows neither neuropeptide activity nor antibiotic
 CC activity.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- TISSUE SPECIFICITY: Expressed by the skin dorsal glands.
 CC -!- MASS SPECTROMETRY: MW=1039; METHOD=FAB.
 KW Amphibian defense peptide; Amidation.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1040 MW; 84ED5CBC2877205A CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 G 2
 |
 Db 1 G 1

RESULT 43

RR2_CONAM

ID RR2_CONAM STANDARD; PRT; 11 AA.
 AC P42341;
 DT 01-NOV-1995 (Rel. 32, Created)
 DT 01-NOV-1995 (Rel. 32, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Chloroplast 30S ribosomal protein S2 (Fragment).
 GN RPS2.
 OS Conopholis americana (Squawroot).
 OG Chloroplast.
 OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; asterids;
 OC lamids; Lamiales; Orobanchaceae; Orobancheae; Conopholis.
 OX NCBI_TaxID=4179;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=92145776; PubMed=1723664;
 RA Taylor G., Wolfe K.H., Morden C.W., Depamphilis C.W., Palmer J.D.;
 RT "Lack of a functional plastid tRNA(Cys) gene is associated with loss
 RT of photosynthesis in a lineage of parasitic plants.";
 RL Curr. Genet. 20:515-518(1991).
 CC -!- SIMILARITY: Belongs to the S2P family of ribosomal proteins.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; X64567; CAA45868.1; -.
 DR PIR; S32575; S32575.
 DR HAMAP; MF_00291; -, 1.
 DR InterPro; IPR001865; Ribosomal_S2.

DR PROSITE; PS00962; RIBOSOMAL_S2_1; PARTIAL.
 DR PROSITE; PS00963; RIBOSOMAL_S2_2; PARTIAL.
 KW Ribosomal protein; Chloroplast.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1497 MW; 76CD719954536B44 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 L 7
 |
 Db 10 L 10

RESULT 44

RRPL_CHAV

ID RRPL_CHAV STANDARD; PRT; 11 AA.
 AC P13179;
 DT 01-JAN-1990 (Rel. 13, Created)
 DT 01-JAN-1990 (Rel. 13, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE RNA polymerase beta subunit (EC 2.7.7.48) (Large structural protein)
 DE (L protein) (Fragment).
 GN L.
 OS Chandipura virus (strain I653514).
 OC Viruses; ssRNA negative-strand viruses; Mononegavirales;
 OC Rhabdoviridae; Vesiculovirus.
 OX NCBI_TaxID=11273;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=89299473; PubMed=2741347;
 RA Masters P.S., Bhella R.S., Butcher M., Patel B., Ghosh H.P.,
 RA Banerjee A.K.;
 RT "Structure and expression of the glycoprotein gene of Chandipura
 RT virus."
 RL Virology 171:285-290(1989).
 CC -!- FUNCTION: THIS PROTEIN IS PROBABLY A COMPONENT OF THE ACTIVE
 CC POLYMERASE. IT MAY FUNCTION IN RNA SYNTHESIS, CAPPING, AS WELL AS
 CC METHYLATION OF CAPS, AND POLY(A) SYNTHESIS.
 CC -!- CATALYTIC ACTIVITY: N nucleoside triphosphate = N diphosphate +
 CC {RNA}(N).
 CC -!- SUBUNIT: THOUGHT TO FORM A TRANSCRIPTION COMPLEX WITH THE
 CC NUCLEOCAPSID (N) PROTEIN.
 CC -!- SIMILARITY: WITH THE L PROTEIN OF OTHER RHABDOVIRUSES AND
 CC PARAMYXOVIRUSES.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; J04350; AAA42917.1; -.
 KW Transferase; RNA-directed RNA polymerase.

FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1189 MW; 0335D6E3AAB2D764 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 L 7
|
Db 3 L 3

RESULT 45

T2P1_PROVU

ID T2P1_PROVU STANDARD; PRT; 11 AA.
AC P31031;
DT 01-JUL-1993 (Rel. 26, Created)
DT 01-JUL-1993 (Rel. 26, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Type II restriction enzyme PvuI (EC 3.1.21.4) (Endonuclease PvuI)
DE (R.PvuI) (Fragment).
GN PVUIR.
OS Proteus vulgaris.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Proteus.
OX NCBI_TaxID=585;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC 13315;
RX MEDLINE=93087186; PubMed=1454536;
RA Smith M.D., Longo M., Gerard G.F., Chatterjee D.K.;
RT "Cloning and characterization of genes for the PvuI restriction and
RT modification system."
RL Nucleic Acids Res. 20:5743-5747(1992).
CC -!- FUNCTION: RECOGNIZES THE DOUBLE-STRANDED SEQUENCE CGATCG AND
CC CLEAVES AFTER T-4.
CC -!- CATALYTIC ACTIVITY: Endonucleolytic cleavage of DNA to give
CC specific double-stranded fragments with terminal 5'-phosphates.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; L04163; AAA25660.1; -.
DR PIR; S35490; S35490.
DR REBASE; 1541; PvuI.
KW Restriction system; Hydrolase; Nuclease; Endonuclease.
FT NON_TER 1 1
SQ SEQUENCE 11 AA; 1300 MW; 9F0CDE7955B72B1A CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 S 3
 |
Db 2 S 2

RESULT 46

TIN4_HOPTI

ID TIN4_HOPTI STANDARD; PRT; 11 AA.
AC P82654;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Tigerinin-4.
OS Hoplobatrachus tigerinus (Indian bull frog) (Rana tigerina).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Neobatrachia; Ranoidea; Ranidae;
OC Hoplobatrachus.
OX NCBI_TaxID=103373;
RN [1]
RP SEQUENCE, FUNCTION, MASS SPECTROMETRY, AND DISULFIDE BONDS.
RC TISSUE=Skin secretion;
RX PubMed=11031261;
RA Purna Sai K., Jaganadham M.V., Vairamani M., Raju N.P.,
RA Devi A.S., Nagaraj R., Sitaram N.;
RT "Tigerinins: novel antimicrobial peptides from the Indian frog Rana
RT tigerina.";
RL J. Biol. Chem. 276:2701-2707(2001).
CC -!- FUNCTION: Antibacterial activity against B.subtilis, E.coli,
CC S.aureus, M.luteus, P.putida and S.cerevisiae.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- TISSUE SPECIFICITY: Skin.
CC -!- MASS SPECTROMETRY: MW=1247; METHOD=MALDI.
KW Amphibian defense peptide; Antibiotic.
FT DISULFID 3 11
SQ SEQUENCE 11 AA; 1248 MW; 117D8EFD37605DCB CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 V 5
 |
Db 2 V 2

RESULT 47

TKC2_CALVO

ID TKC2_CALVO STANDARD; PRT; 11 AA.
AC P41518;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Callitachykinin II.
OS Calliphora vomitoria (Blue blowfly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha; Oestroidea;

OC Calliphoridae; Calliphora.
 OX NCBI_TaxID=27454;
 RN [1]
 RP SEQUENCE, AND SYNTHESIS.
 RX MEDLINE=95075727; PubMed=7984492;
 RA Lundquist C.T., Clottens F.L., Holman G.M., Nichols R., Nachman R.J.,
 RA Naessel D.R.;
 RT "Callitachykinin I and II, two novel myotropic peptides isolated from
 RT the blowfly, Calliphora vomitoria, that have resemblances to
 RT tachykinins.";
 RL Peptides 15:761-768(1994).
 CC -!- FUNCTION: Myoactive peptide.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- SIMILARITY: SOME SIMILARITY TO TACHYKININS.
 KW Tachykinin; Neuropeptide; Amidation.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1103 MW; 15D7E3F9C9CDD444 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 G 2
 |
 Db 1 G 1

RESULT 48

TKN1_PSEGU

ID TKN1_PSEGU STANDARD; PRT; 11 AA.
 AC P42986;
 DT 01-NOV-1995 (Rel. 32, Created)
 DT 01-NOV-1995 (Rel. 32, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Kassinin-like peptide K-I (PG-KI).
 OS Pseudophryne guentheri (Guenther's toadlet).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Myobatrachidae;
 OC Myobatrachinae; Pseudophryne.
 OX NCBI_TaxID=30349;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Skin secretion;
 RX MEDLINE=90287814; PubMed=2356157;
 RA Simmaco M., Severini C., de Biase D., Barra D., Bossa F.,
 RA Roberts J.D., Melchiorri P., Erspamer V.;
 RT "Six novel tachykinin- and bombesin-related peptides from the skin of
 RT the Australian frog Pseudophryne guntheri.";
 RL Peptides 11:299-304(1990).
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,
 CC evoke behavioral responses, are potent vasodilators and
 CC secretagogues, and contract (directly or indirectly) many smooth
 CC muscles.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- TISSUE SPECIFICITY: Skin.
 CC -!- SIMILARITY: Belongs to the tachykinin family.
 DR PIR; B60409; B60409.

DR InterPro; IPR002040; Tachy_Neurokinin.
 DR InterPro; IPR008215; Tachykinin.
 DR Pfam; PF02202; Tachykinin; 1.
 DR SMART; SM00203; TK; 1.
 DR PROSITE; PS00267; TACHYKININ; 1.
 KW Amphibian defense peptide; Tachykinin; Neuropeptide; Amidation;
 KW Pyrrolidone carboxylic acid.
 FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1269 MW; 3DBA7C37C9CB1AB7 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 G 2
 |
 Db 9 G 9

RESULT 49

TKN1_UPEIN

ID TKN1_UPEIN STANDARD; PRT; 11 AA.
 AC P82026;
 DT 30-MAY-2000 (Rel. 39, Created)
 DT 30-MAY-2000 (Rel. 39, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Uperin 1.1.
 OS Uperoleia inundata (Floodplain toadlet).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Myobatrachidae;
 OC Myobatrachinae; Uperoleia.
 OX NCBI_TaxID=104953;
 RN [1]
 RP SEQUENCE, AND MASS SPECTROMETRY.
 RC TISSUE=Skin secretion;
 RA Bradford A.M., Raftery M.J., Bowie J.H., Tyler M.J., Wallace J.C.,
 RA Adams G.W., Severini C.;
 RT "Novel uperin peptides from the dorsal glands of the australian
 RT floodplain toadlet Uperoleia inundata.";
 RL Aust. J. Chem. 49:475-484(1996).
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,
 CC evoke behavioral responses, are potent vasodilators and
 CC secretagogues, and contract (directly or indirectly) many smooth
 CC muscles.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- TISSUE SPECIFICITY: Skin dorsal glands.
 CC -!- MASS SPECTROMETRY: MW=1208; METHOD=FAB.
 CC -!- SIMILARITY: Belongs to the tachykinin family.
 DR InterPro; IPR002040; Tachy_Neurokinin.
 DR Pfam; PF02202; Tachykinin; 1.
 DR PROSITE; PS00267; TACHYKININ; 1.
 KW Amphibian defense peptide; Tachykinin; Neuropeptide; Amidation;
 KW Pyrrolidone carboxylic acid.
 FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1226 MW; 3293693E59CDD457 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 A 1
|
Db 2 A 2

RESULT 50:

TKN1_UPERU

ID TKN1_UPERU STANDARD; PRT; 11 AA.
AC P08612;
DT 01-AUG-1988 (Rel. 08, Created)
DT 01-FEB-1994 (Rel. 28, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Uperolein.
OS Uperoleia rugosa (Wrinkled toadlet).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Myobatrachidae;
OC Myobatrachinae; Uperoleia.
OX NCBI_TaxID=8368;
RN [1]
RP SEQUENCE.
RC TISSUE=Skin secretion;
RX MEDLINE=75131227; PubMed=1120493;
RA Anastasi A., Erspamer V., Endean R.;
RT "Structure of uperolein, a physalaemin-like endecapeptide occurring
RT in the skin of Uperoleia rugosa and Uperoleia marmorata.";
RL Experientia 31:394-395(1975).
CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,
CC evoke behavioral responses, are potent vasodilators and
CC secretagogues, and contract (directly or indirectly) many smooth
CC muscles.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- TISSUE SPECIFICITY: Skin.
CC -!- SIMILARITY: Belongs to the tachykinin family.
DR InterPro; IPR002040; Tachy_Neurokinin.
DR InterPro; IPR008215; Tachykinin.
DR Pfam; PF02202; Tachykinin; 1.
DR SMART; SM00203; TK; 1.
DR PROSITE; PS00267; TACHYKININ; 1.
KW Amphibian defense peptide; Tachykinin; Neuropeptide; Amidation;
KW Pyrrolidone carboxylic acid.
FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
FT MOD_RES 11 11 AMIDATION.
SQ SEQUENCE 11 AA; 1252 MW; 32867C3E59CDD457 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 A 1
|
Db 6 A 6

RESULT 51

TKN2_PSEGU

ID TKN2_PSEGU STANDARD; PRT; 11 AA.
 AC P42987;
 DT 01-NOV-1995 (Rel. 32, Created)
 DT 01-NOV-1995 (Rel. 32, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Kassinin-like peptide K-II (PG-KII).
 OS Pseudophryne guentheri (Guenther's toadlet).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hylaidea; Myobatrachidae;
 OC Myobatrachinae; Pseudophryne.
 OX NCBI_TaxID=30349;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Skin secretion;
 RX MEDLINE=90287814; PubMed=2356157;
 RA Simmaco M., Severini C., de Biase D., Barra D., Bossa F.,
 RA Roberts J.D., Melchiorri P., Erspamer V.;
 RT "Six novel tachykinin- and bombesin-related peptides from the skin of
 RT the Australian frog Pseudophryne guentheri.";
 RL Peptides 11:299-304(1990).
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,
 CC evoke behavioral responses, are potent vasodilators and
 CC secretagogues, and contract (directly or indirectly) many smooth
 CC muscles.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- TISSUE SPECIFICITY: Skin.
 CC -!- SIMILARITY: Belongs to the tachykinin family.
 DR PIR; C60409; C60409.
 DR InterPro; IPR002040; Tachy_Neurokinin.
 DR InterPro; IPR008215; Tachykinin.
 DR Pfam; PF02202; Tachykinin; 1.
 DR SMART; SM00203; TK; 1.
 DR PROSITE; PS00267; TACHYKININ; 1.
 KW Amphibian defense peptide; Tachykinin; Neuropeptide; Amidation;
 KW Pyrrolidone carboxylic acid.
 FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1246 MW; 3A247C37C9CB1AB7 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 G 2
 |
 Db 9 G 9

RESULT 52

TKN2_UPERU

ID TKN2_UPERU STANDARD; PRT; 11 AA.
 AC P08616;
 DT 01-AUG-1988 (Rel. 08, Created)
 DT 01-FEB-1994 (Rel. 28, Last sequence update)

DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Rugosauperolein II ([Lys5,Thr6]physalaemin).
 OS Uperoleia rugosa (Wrinkled toadlet).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Myobatrachidae;
 OC Myobatrachinae; Uperoleia.
 OX NCBI_TaxID=8368;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Skin secretion;
 RX MEDLINE=80223080; PubMed=7389029;
 RA Nakajima T., Yasuhara T., Erspamer V., Erspamer G.F., Negri L.;
 RT "Physalaemin- and bombesin-like peptides in the skin of the
 RT Australian leptodactylid frog Uperoleia rugosa.";
 RL Chem. Pharm. Bull. 28:689-695(1980).
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,
 CC evoke behavioral responses, are potent vasodilators and
 CC secretagogues, and contract (directly or indirectly) many smooth
 CC muscles.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- TISSUE SPECIFICITY: Skin.
 CC -!- SIMILARITY: Belongs to the tachykinin family.
 DR InterPro; IPR002040; Tachy_Neurokinin.
 DR Pfam; PF02202; Tachykinin; 1.
 DR PROSITE; PS00267; TACHYKININ; 1.
 KW Amphibian defense peptide; Tachykinin; Neuropeptide; Amidation;
 KW Pyrrolidone carboxylic acid.
 FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1270 MW; 3293693E59D1A327 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 A 1
 |
 Db 2 A 2

RESULT 53

TKN3_PSEGU
 ID TKN3_PSEGU STANDARD; PRT; 11 AA.
 AC P42988;
 DT 01-NOV-1995 (Rel. 32, Created)
 DT 01-NOV-1995 (Rel. 32, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Kassinin-like peptide K-III (PG-KIII).
 OS Pseudophryne guentheri (Guenther's toadlet).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Myobatrachidae;
 OC Myobatrachinae; Pseudophryne.
 OX NCBI_TaxID=30349;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Skin secretion;
 RX MEDLINE=90287814; PubMed=2356157;

RA Simmaco M., Severini C., de Biase D., Barra D., Bossa F.,
 RA Roberts J.D., Melchiorri P., Erspamer V.;
 RT "Six novel tachykinin- and bombesin-related peptides from the skin of
 RT the Australian frog *Pseudophryne guntheri*.";
 RL Peptides 11:299-304(1990).
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,
 CC evoke behavioral responses, are potent vasodilators and
 CC secretagogues, and contract (directly or indirectly) many smooth
 CC muscles.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- TISSUE SPECIFICITY: Skin.
 CC -!- SIMILARITY: Belongs to the tachykinin family.
 DR PIR; D60409; D60409.
 DR InterPro; IPR002040; Tachy_Neurokinin.
 DR InterPro; IPR008215; Tachykinin.
 DR Pfam; PF02202; Tachykinin; 1.
 DR SMART; SM00203; TK; 1.
 DR PROSITE; PS00267; TACHYKININ; 1.
 KW Amphibian defense peptide; Tachykinin; Neuropeptide; Amidation;
 KW Pyrrolidone carboxylic acid.
 FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1268 MW; 3DBA7C37C9CB1457 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 G 2
 |
 Db 9 G 9

RESULT 54

TKN4_PSEGU

ID TKN4_PSEGU STANDARD; PRT; 11 AA.
 AC P42989;
 DT 01-NOV-1995 (Rel. 32, Created)
 DT 01-NOV-1995 (Rel. 32, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Substance P-like peptide I (PG-SPI).
 OS *Pseudophryne guentheri* (Guenther's toadlet).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Myobatrachidae;
 OC Myobatrachinae; *Pseudophryne*.
 OX NCBI_TaxID=30349;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Skin secretion;
 RX MEDLINE=90287814; PubMed=2356157;
 RA Simmaco M., Severini C., de Biase D., Barra D., Bossa F.,
 RA Roberts J.D., Melchiorri P., Erspamer V.;
 RT "Six novel tachykinin- and bombesin-related peptides from the skin of
 RT the Australian frog *Pseudophryne guntheri*.";
 RL Peptides 11:299-304(1990).
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,
 CC evoke behavioral responses, are potent vasodilators and

CC secretagogues, and contract (directly or indirectly) many smooth
 CC muscles.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- TISSUE SPECIFICITY: Skin.
 CC -!- SIMILARITY: Belongs to the tachykinin family.
 DR PIR; E60409; E60409.
 DR InterPro; IPR002040; Tachy_Neurokinin.
 DR InterPro; IPR008215; Tachykinin.
 DR Pfam; PF02202; Tachykinin; 1.
 DR SMART; SM00203; TK; 1.
 DR PROSITE; PS00267; TACHYKININ; 1.
 KW Amphibian defense peptide; Tachykinin; Neuropeptide; Amidation;
 KW Pyrrolidone carboxylic acid.
 FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1294 MW; 3A247C2CC9CB1AB7 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 G 2
 |
 Db 9 G 9

RESULT 55

TKN5_PSEGU

ID TKN5_PSEGU STANDARD; PRT; 11 AA.
 AC P42990;
 DT 01-NOV-1995 (Rel. 32, Created)
 DT 01-NOV-1995 (Rel. 32, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Substance P-like peptide II (PG-SPII).
 OS Pseudophryne guentheri (Guenther's toadlet).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Myobatrachidae;
 OC Myobatrachinae; Pseudophryne.
 OX NCBI_TaxID=30349;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Skin secretion;
 RX MEDLINE=90287814; PubMed=2356157;
 RA Simmaco M., Severini C., de Biase D., Barra D., Bossa F.,
 RA Roberts J.D., Melchiorri P., Erspamer V.;
 RT "Six novel tachykinin- and bombesin-related peptides from the skin of
 RT the Australian frog Pseudophryne guentheri."
 RL Peptides 11:299-304(1990).
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,
 CC evoke behavioral responses, are potent vasodilators and
 CC secretagogues, and contract (directly or indirectly) many smooth
 CC muscles.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- TISSUE SPECIFICITY: Skin.
 CC -!- SIMILARITY: Belongs to the tachykinin family.
 DR PIR; F60409; F60409.
 DR InterPro; IPR002040; Tachy_Neurokinin.

DR InterPro; IPR008215; Tachykinin.
 DR Pfam; PF02202; Tachykinin; 1.
 DR SMART; SM00203; TK; 1.
 DR PROSITE; PS00267; TACHYKININ; 1.
 KW Amphibian defense peptide; Tachykinin; Neuropeptide; Amidation;
 KW Pyrrolidone carboxylic acid.
 FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1293 MW; 3A247C2CC9CB1457 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 G 2
 |
 Db 9 G 9

RESULT 56

TKNA_CHICK

ID TKNA_CHICK STANDARD; PRT; 11 AA.
 AC P19850;
 DT 01-FEB-1991 (Rel. 17, Created)
 DT 01-FEB-1991 (Rel. 17, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Substance P.
 OS Gallus gallus (Chicken).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
 OC Gallus.
 OX NCBI_TaxID=9031;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Intestine;
 RX MEDLINE=88204263; PubMed=2452461;
 RA Conlon J.M., Katsoulis S., Schmidt W.E., Thim L.;
 RT "[Arg3]substance P and neurokinin A from chicken small intestine."
 RL Regul. Pept. 20:171-180(1988).
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,
 CC evoke behavioral responses, are potent vasodilators and
 CC secretagogues, and contract (directly or indirectly) many smooth
 CC muscles.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- SIMILARITY: Belongs to the tachykinin family.
 DR PIR; JN0023; JN0023.
 DR InterPro; IPR002040; Tachy_Neurokinin.
 DR Pfam; PF02202; Tachykinin; 1.
 DR PROSITE; PS00267; TACHYKININ; 1.
 KW Tachykinin; Neuropeptide; Amidation; Neurotransmitter.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1377 MW; 21487FE3C9D6C6C7 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 G 2
 |
Db 9 G 9

RESULT 57

TKNA_GADMO

ID TKNA_GADMO STANDARD; PRT; 11 AA.
AC P28498;
DT 01-DEC-1992 (Rel. 24, Created)
DT 01-DEC-1992 (Rel. 24, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Substance P.
OS Gadus morhua (Atlantic cod).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
OC Acanthomorpha; Paracanthopterygii; Gadiformes; Gadidae; Gadus.
OX NCBI_TaxID=8049;
RN [1]
RP SEQUENCE.
RC TISSUE=Brain;
RX MEDLINE=92298992; PubMed=1376687;
RA Jensen J., Conlon J.M.;
RT "Substance-P-related and neurokinin-A-related peptides from the brain
RT of the cod and trout."
RL Eur. J. Biochem. 206:659-664(1992).
CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,
CC evoke behavioral responses, are potent vasodilators and
CC secretagogues, and contract (directly or indirectly) many smooth
CC muscles.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- SIMILARITY: Belongs to the tachykinin family.
DR PIR; S23306; S23306.
DR InterPro; IPR002040; Tachy_Neurokinin.
DR InterPro; IPR008215; Tachykinin.
DR Pfam; PF02202; Tachykinin; 1.
DR SMART; SM00203; TK; 1.
DR PROSITE; PS00267; TACHYKININ; 1.
KW Tachykinin; Neuropeptide; Amidation; Neurotransmitter.
FT MOD_RES 11 11 AMIDATION (BY SIMILARITY).
SQ SEQUENCE 11 AA; 1315 MW; 214860D759D6C6C7 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 K 6
 |
Db 1 K 1

RESULT 58

TKNA_HORSE

ID TKNA_HORSE STANDARD; PRT; 11 AA.
AC P01290;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)

DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Substance P.
 GN TAC1 OR NKNA OR TAC2 OR NKA.
 OS Equus caballus (Horse), and
 OS Cavia porcellus (Guinea pig).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Perissodactyla; Equidae; Equus.
 OX NCBI_TaxID=9796, 10141;
 RN [1]
 RP SEQUENCE.
 RC SPECIES=Horse;
 RA Studer R.O., Trzeciak A., Lergier W.;
 RT "Isolation and amino-acid sequence of substance P from horse
 RT intestine.";
 RL Helv. Chim. Acta 56:860-866(1973).
 RN [2]
 RP SEQUENCE.
 RC SPECIES=C.porcellus;
 RX MEDLINE=90044685; PubMed=2478925;
 RA Murphy R.;
 RT "Primary amino acid sequence of guinea-pig substance P.";
 RL Neuropeptides 14:105-110(1989).
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,
 CC evoke behavioral responses, are potent vasodilators and
 CC secretagogues, and contract (directly or indirectly) many smooth
 CC muscles.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- SIMILARITY: Belongs to the tachykinin family.
 DR PIR; A01558; SPHO.
 DR PIR; A60654; A60654.
 DR InterPro; IPR002040; Tachy_Neurokinin.
 DR InterPro; IPR008215; Tachykinin.
 DR Pfam; PF02202; Tachykinin; 1.
 DR SMART; SM00203; TK; 1.
 DR PROSITE; PS00267; TACHYKININ; 1.
 KW Tachykinin; Neuropeptide; Amidation; Neurotransmitter.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1349 MW; 3E757FE3C9D6C6C7 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 K 6
 |
 Db 3 K 3

RESULT 59

TKNA_ONCMY

ID TKNA_ONCMY STANDARD; PRT; 11 AA.

AC P28499;

DT 01-DEC-1992 (Rel. 24, Created)

DT 01-DEC-1992 (Rel. 24, Last sequence update)

DT 10-OCT-2003 (Rel. 42, Last annotation update)

DE Substance P.

OS Oncorhynchus mykiss (Rainbow trout) (Salmo gairdneri).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei;
 OC Protacanthopterygii; Salmoniformes; Salmonidae; Oncorhynchus.
 OX NCBI_TaxID=8022;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Brain;
 RX MEDLINE=92298992; PubMed=1376687;
 RA Jensen J., Conlon J.M.;
 RT "Substance-P-related and neurokinin-A-related peptides from the brain
 RT of the cod and trout."
 RL Eur. J. Biochem. 206:659-664(1992).
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,
 CC evoke behavioral responses, are potent vasodilators and
 CC secretagogues, and contract (directly or indirectly) many smooth
 CC muscles.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- SIMILARITY: Belongs to the tachykinin family.
 DR PIR; S23308; S23308.
 DR InterPro; IPR002040; Tachy_Neurokinin.
 DR InterPro; IPR008215; Tachykinin.
 DR Pfam; PF02202; Tachykinin; 1.
 DR SMART; SM00203; TK; 1.
 DR PROSITE; PS00267; TACHYKININ; 1.
 KW Tachykinin; Neuropeptide; Amidation; Neurotransmitter.
 FT MOD_RES 11 11 AMIDATION (BY SIMILARITY).
 SQ SEQUENCE 11 AA; 1358 MW; 214860DEC9D6D1F7 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 K 6
 |
 Db 1 K 1

RESULT 60

TKNA_RANCA

ID TKNA_RANCA STANDARD; PRT; 11 AA.
 AC P22688;
 DT 01-AUG-1991 (Rel. 19, Created)
 DT 01-AUG-1991 (Rel. 19, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Ranatachykinin A (RTK A).
 OS Rana catesbeiana (Bull frog).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Amphibia; Batrachia; Anura; Neobatrachia; Ranoidea; Ranidae; Rana.
 OX NCBI_TaxID=8400;
 RN [1]
 RP SEQUENCE, AND SYNTHESIS.
 RC TISSUE=Brain, and Intestine;
 RX MEDLINE=91254337; PubMed=2043143;
 RA Kozawa H., Hino J., Minamino N., Kangawa K., Matsuo H.;
 RT "Isolation of four novel tachykinins from frog (Rana catesbeiana)
 RT brain and intestine."
 RL Biochem. Biophys. Res. Commun. 177:588-595(1991).

RN [2]
 RP SEQUENCE.
 RC TISSUE=Intestine;
 RX MEDLINE=94023216; PubMed=8210506;
 RA Kangawa K., Kozawa H., Hino J., Minamino N., Matsuo H.;
 RT "Four novel tachykinins in frog (*Rana catesbeiana*) brain and
 RT intestine.";
 RL Regul. Pept. 46:81-88(1993).
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,
 CC evoke behavioral responses, are potent vasodilators and
 CC secretagogues, and contract (directly or indirectly) many smooth
 CC muscles.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- SIMILARITY: Belongs to the tachykinin family.
 DR PIR; A61033; A61033.
 DR InterPro; IPR002040; Tachy_Neurokinin.
 DR InterPro; IPR008215; Tachykinin.
 DR Pfam; PF02202; Tachykinin; 1.
 DR SMART; SM00203; TK; 1.
 DR PROSITE; PS00267; TACHYKININ; 1.
 KW Tachykinin; Neuropeptide; Amidation.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1311 MW; 200D60CC59D40AB7 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 K 6
 |
 Db 1 K 1

RESULT 61

TKNA_RANRI
 ID TKNA_RANRI STANDARD; PRT; 11 AA.
 AC P29207;
 DT 01-DEC-1992 (Rel. 24, Created)
 DT 01-DEC-1992 (Rel. 24, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Ranakinin (Substance-P-related peptide).
 OS *Rana ridibunda* (Laughing frog) (Marsh frog).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Amphibia; Batrachia; Anura; Neobatrachia; Ranoidea; Ranidae; *Rana*.
 OX NCBI_TaxID=8406;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Brain;
 RX MEDLINE=92044543; PubMed=1658233;
 RA O'Harte F., Burcher E., Lovas S., Smith D.D., Vaudry H., Conlon J.M.;
 RT "Ranakinin: a novel NK1 tachykinin receptor agonist isolated with
 RT neurokinin B from the brain of the frog *Rana ridibunda*.";
 RL J. Neurochem. 57:2086-2091(1991).
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,
 CC evoke behavioral responses, are potent vasodilators and
 CC secretagogues, and contract (directly or indirectly) many smooth
 CC muscles.

CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- SIMILARITY: Belongs to the tachykinin family.
 DR InterPro; IPR002040; Tachy_Neurokinin.
 DR InterPro; IPR008215; Tachykinin.
 DR Pfam; PF02202; Tachykinin; 1.
 DR SMART; SM00203; TK; 1.
 DR PROSITE; PS00267; TACHYKININ; 1.
 KW Tachykinin; Neuropeptide; Amidation.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1352 MW; 3A2460CC59D40B07 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 K 6
 |
 Db 1 K 1

RESULT 62

TKNA_SCYCA

ID TKNA_SCYCA STANDARD; PRT; 11 AA.
 AC P41333;
 DT 01-FEB-1995 (Rel. 31, Created)
 DT 01-FEB-1995 (Rel. 31, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Substance P.
 OS Scyliorhinus canicula (Spotted dogfish) (Spotted catshark).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Chondrichthyes;
 OC Elasmobranchii; Galeomorphii; Galeoidea; Carcharhiniformes;
 OC Scyliorhinidae; Scyliorhinus.
 OX NCBI_TaxID=7830;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Brain;
 RX MEDLINE=93292508; PubMed=7685693;
 RA Waugh D., Wang Y., Hazon N., Balment R.J., Conlon J.M.;
 RT "Primary structures and biological activities of substance-P-related
 RT peptides from the brain of the dogfish, Scyliorhinus canicula.";
 RL Eur. J. Biochem. 214:469-474(1993).
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,
 CC evoke behavioral responses, are potent vasodilators and
 CC secretagogues, and contract (directly or indirectly) many smooth
 CC muscles.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- SIMILARITY: Belongs to the tachykinin family.
 DR PIR; S33300; S33300.
 DR InterPro; IPR002040; Tachy_Neurokinin.
 DR PROSITE; PS00267; TACHYKININ; 1.
 KW Tachykinin; Neuropeptide; Amidation; Neurotransmitter.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1278 MW; 214860DEC9D6D867 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 K 6
 |
Db 1 K 1

RESULT 63

TKND_RANCA

ID TKND_RANCA STANDARD; PRT; 11 AA.
AC P22691;
DT 01-AUG-1991 (Rel. 19, Created)
DT 01-AUG-1991 (Rel. 19, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Ranatachykinin D (RTK D).
OS Rana catesbeiana (Bull frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Neobatrachia; Ranoidea; Ranidae; Rana.
OX NCBI_TaxID=8400;
RN [1]
RP SEQUENCE, AND SYNTHESIS.
RC TISSUE=Intestine;
RX MEDLINE=91254337; PubMed=2043143;
RA Kozawa H., Hino J., Minamino N., Kangawa K., Matsuo H.;
RT "Isolation of four novel tachykinins from frog (Rana catesbeiana)
RT brain and intestine.";
RL Biochem. Biophys. Res. Commun. 177:588-595(1991).
RN [2]
RP SEQUENCE.
RC TISSUE=Intestine;
RX MEDLINE=94023216; PubMed=8210506;
RA Kangawa K., Kozawa H., Hino J., Minamino N., Matsuo H.;
RT "Four novel tachykinins in frog (Rana catesbeiana) brain and
RT intestine.";
RL Regul. Pept. 46:81-88(1993).
CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,
CC evoke behavioral responses, are potent vasodilators and
CC secretagogues, and contract (directly or indirectly) many smooth
CC muscles.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- SIMILARITY: Belongs to the tachykinin family.
DR PIR; D61033; D61033.
DR InterPro; IPR002040; Tachy_Neurokinin.
DR PROSITE; PS00267; TACHYKININ; FALSE_NEG.
KW Tachykinin; Neuropeptide; Amidation.
FT MOD_RES 11 11 AMIDATION.
SQ SEQUENCE 11 AA; 1350 MW; 3A34256C59D40B07 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 K 6
 |
Db 1 K 1

RESULT 64

TKN_ELEMO

ID TKN_ELEMO STANDARD; PRT; 11 AA.
 AC P01293;
 DT 21-JUL-1986 (Rel. 01, Created)
 DT 01-FEB-1994 (Rel. 28, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Eledoisin.
 OS Eledone moschata (Musky octopus) (Ozaena moschata), and
 OS Eledone cirrhosa (Curled octopus) (Ozaena cirrosa).
 OC Eukaryota; Metazoa; Mollusca; Cephalopoda; Coleoidea; Neocoleoidea;
 OC Octopodiformes; Octopoda; Incirrata; Octopodidae; Eledone.
 OX NCBI_TaxID=6641, 102876;
 RN [1]
 RP SEQUENCE.
 RA Anastasi A., Erspamer V.;
 RT "The isolation and amino acid sequence of eledoisin, the active
 RT endecapeptide of the posterior salivary glands of Eledone.";
 RL Arch. Biochem. Biophys. 101:56-65(1963).
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,
 CC evoke behavioral responses, are potent vasodilators and
 CC secretagogues, and contract (directly or indirectly) many smooth
 CC muscles.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- TISSUE SPECIFICITY: Skin.
 CC -!- SIMILARITY: Belongs to the tachykinin family.
 DR PIR; A01561; EOOC.
 DR PIR; B01561; EOCC.
 DR PDB; 1MXQ; 18-FEB-03.
 DR InterPro; IPR002040; Tachy_Neurokinin.
 DR PROSITE; PS00267; TACHYKININ; 1.
 KW Tachykinin; Neuropeptide; Amidation; Pyrrolidone carboxylic acid;
 KW 3D-structure.
 FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1206 MW; 570D7C2559CDDAA3 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 S 3
 |
 Db 3 S 3

RESULT 65

TKN_PHYFU

ID TKN_PHYFU STANDARD; PRT; 11 AA.
 AC P08615;
 DT 01-AUG-1988 (Rel. 08, Created)
 DT 01-FEB-1994 (Rel. 28, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Physalaemin.
 OS Physalaemus fuscumaculatus (Neotropical frog).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Leptodactylidae;
 OC Leptodactylinae; Physalaemus.

OX NCBI_TaxID=8378;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Skin secretion;
 RX MEDLINE=66076612; PubMed=5857249;
 RA Erspamer V., Anastasi A., Bertaccini G., Cei J.M.;
 RT "Structure and pharmacological actions of physalaemin, the main
 RT active polypeptide of the skin of *Physalaemus fuscumaculatus*.";
 RL Experientia 20:489-490(1964).
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,
 CC evoke behavioral responses, are potent vasodilators and
 CC secretagogues, and contract (directly or indirectly) many smooth
 CC muscles.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- TISSUE SPECIFICITY: Skin.
 CC -!- SIMILARITY: Belongs to the tachykinin family.
 DR PIR; S07201; S07201.
 DR InterPro; IPR002040; Tachy_Neurokinin.
 DR Pfam; PF02202; Tachykinin; 1.
 DR PROSITE; PS00267; TACHYKININ; 1.
 KW Amphibian defense peptide; Tachykinin; Neuropeptide; Amidation;
 KW Pyrrolidone carboxylic acid.
 FT MOD_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1283 MW; 3293693E59C33457 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 A 1
 |
 Db 2 A 2

RESULT 66

UF05_MOUSE

ID UF05_MOUSE STANDARD; PRT; 11 AA.
 AC P38643;
 DT 01-OCT-1994 (Rel. 30, Created)
 DT 01-OCT-1994 (Rel. 30, Last sequence update)
 DT 15-MAR-2004 (Rel. 43, Last annotation update)
 DE Unknown protein from 2D-page of fibroblasts (P48) (Fragment).
 OS *Mus musculus* (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Fibroblast;
 RX MEDLINE=95009907; PubMed=7523108;
 RA Merrick B.A., Patterson R.M., Wichter L.L., He C., Selkirk J.K.;
 RT "Separation and sequencing of familiar and novel murine proteins
 RT using preparative two-dimensional gel electrophoresis.";
 RL Electrophoresis 15:735-745(1994).
 CC -!- MISCELLANEOUS: On the 2D-gel the determined pI of this unknown
 CC protein is: 5.5, its MW is: 48 kDa.

FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1328 MW; E54835E5CAAABAFa CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 K 6
|
Db 1 K 1

RESULT 67

ULAG_HUMAN

ID ULAG_HUMAN STANDARD; PRT; 11 AA.
AC P31933;
DT 01-JUL-1993 (Rel. 26, Created)
DT 01-JUL-1993 (Rel. 26, Last sequence update)
DT 15-MAR-2004 (Rel. 43, Last annotation update)
DE Unknown protein from 2D-page of liver tissue (Spot 118) (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE.
RC TISSUE=Liver;
RX MEDLINE=94147969; PubMed=8313870;
RA Hughes G.J., Frutiger S., Paquet N., Pasquali C., Sanchez J.-C.,
RA Tissot J.-D., Bairoch A., Appel R.D., Hochstrasser D.F.;
RT "Human liver protein map: update 1993."
RL Electrophoresis 14:1216-1222(1993).
CC -!- MISCELLANEOUS: On the 2D-gel the determined pI of this unknown
CC protein is: 5.5, its MW is: 34 kDa.
DR SWISS-2DPAGE; P31933; HUMAN.
DR Siena-2DPAGE; P31933; -.
FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1219 MW; EDABD37F272DDB0A CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+05;
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 A 1
|
Db 6 A 6

RESULT 68

UXB2_YEAST

ID UXB2_YEAST STANDARD; PRT; 11 AA.
AC P99013;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 15-MAR-2004 (Rel. 43, Last annotation update)
DE Unknown protein from 2D-page (Spot 2D-000K2F) (Fragment).
OS Saccharomyces cerevisiae (Baker's yeast).

OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
 OC Saccharomycetales; Saccharomycetaceae; Saccharomyces.
 OX NCBI_TaxID=4932;
 RN [1]
 RP SEQUENCE.
 RC STRAIN=X2180-1A;
 RA Sanchez J.-C., Golaz O., Schaller D., Morch F., Frutiger S.,
 RA Hughes G.J., Appel R.D., Deshusses J., Hochstrasser D.F.;
 RL Submitted (AUG-1995) to Swiss-Prot.
 CC -!- MISCELLANEOUS: On the 2D-gel the determined pI of this unknown
 CC protein is: 6.20, its MW is: 9.2 kDa.
 DR SWISS-2DPAGE; P99013; YEAST.
 FT NON_TER 11 11
 SQ SEQUENCE 11 AA; 1328 MW; EC38021C0DCB42DA CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 V 5
 |
 Db 2 V 2

RESULT 69

CX5A_CONAL

ID CX5A_CONAL STANDARD; PRT; 11 AA.
 AC P58848;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 15-MAR-2004 (Rel. 43, Last annotation update)
 DE Conotoxin au5a.
 OS Conus aulicus (Court cone).
 OC Eukaryota; Metazoa; Mollusca; Gastropoda; Orthogastropoda;
 OC Apogastropoda; Caenogastropoda; Sorbeoconcha; Hypsogastropoda;
 OC Neogastropoda; Conoidea; Conidae; Conus.
 OX NCBI_TaxID=89437;
 RN [1]
 RP SEQUENCE, SYNTHESIS, AND MASS SPECTROMETRY.
 RC TISSUE=Venom;
 RX MEDLINE=99452958; PubMed=10521453;
 RA Walker C.S., Steel D., Jacobsen R.B., Lirazan M.B., Cruz L.J.,
 RA Hooper D., Shetty R., DelaCruz R.C., Nielsen J.S., Zhou L.M.,
 RA Bandyopadhyay P., Craig A.G., Olivera B.M.;
 RT "The T-superfamily of conotoxins."
 RL J. Biol. Chem. 274:30664-30671(1999).
 RN [2]
 RP ERRATUM.
 RA Walker C.S., Steel D., Jacobsen R.B., Lirazan M.B., Cruz L.J.,
 RA Hooper D., Shetty R., DelaCruz R.C., Nielsen J.S., Zhou L.M.,
 RA Bandyopadhyay P., Craig A.G., Olivera B.M.;
 RL J. Biol. Chem. 274:36030-36030(1999).
 CC -!- FUNCTION: Causes dorsal fins drooping in fish. No effect is
 CC observed when injected into mice.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- TISSUE SPECIFICITY: Expressed by the venom duct.
 CC -!- MASS SPECTROMETRY: MW=1436.6; METHOD=LSIMS.

CC -!- SIMILARITY: Belongs to the conotoxin T-superfamily.
 DR PIR; A59146; A59146.
 KW Toxin.
 FT DISULFID 2 9
 FT DISULFID 3 10
 SQ SEQUENCE 11 AA; 1441 MW; 21A36775440059D7 CRC64;

Query Match 0.0%; Score 0; DB 1; Length 11;
 Best Local Similarity 0.0%; Pred. No. 1.4e+05;
 Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 A 1

Db 1 F 1

RESULT 70

TIN1_HOPTI

ID TIN1_HOPTI STANDARD; PRT; 11 AA.
 AC P82651;
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 15-MAR-2004 (Rel. 43, Last annotation update)
 DE Tigerinin-1.
 OS Hoplobatrachus tigerinus (Indian bull frog) (Rana tigerina).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Amphibia; Batrachia; Anura; Neobatrachia; Ranoidea; Ranidae;
 OC Hoplobatrachus.
 OX NCBI_TaxID=103373;
 RN [1]
 RP SEQUENCE, FUNCTION, MASS SPECTROMETRY, AND DISULFIDE BONDS.
 RC TISSUE=Skin secretion;
 RX PubMed=11031261;
 RA Purna Sai K., Jaganadham M.V., Vairamani M., Raju N.P.,
 RA Devi A.S., Nagaraj R., Sitaram N.;
 RT "Tigerinins: novel antimicrobial peptides from the Indian frog Rana
 RT tigerina.";
 RL J. Biol. Chem. 276:2701-2707(2001).
 CC -!- FUNCTION: Antibacterial activity against B.subtilis, E.coli,
 CC S.aureus, M.luteus, P.putida and S.cerevisiae.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- TISSUE SPECIFICITY: Skin.
 CC -!- MASS SPECTROMETRY: MW=1342; METHOD=MALDI.
 KW Amphibian defense peptide; Antibiotic; Fungicide; Amidation.
 FT DISULFID 2 10
 FT MOD_RES 11 11 AMIDATION.
 SQ SEQUENCE 11 AA; 1344 MW; A2087DC960476056 CRC64;

Query Match 0.0%; Score 0; DB 1; Length 11;
 Best Local Similarity 0.0%; Pred. No. 1.4e+05;
 Matches 0; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 A 1

Db 1 F 1

Search completed: April 8, 2004, 15:47:19
Job time : 5.15385 secs